

BioMed Realty Trust Inc
Form 10-K
February 10, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K

ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2013

Commission File Number: 1-32261 (BioMed Realty Trust, Inc.)
000-54089 (BioMed Realty, L.P.)
BIOMED REALTY TRUST, INC.
BIOMED REALTY, L.P.
(Exact name of registrant as specified in its charter)

Maryland
(State or other jurisdiction of
incorporation or organization)

20-1142292 (BioMed Realty Trust, Inc.)
20-1320636 (BioMed Realty, L.P.)
(I.R.S. Employer Identification No.)

17190 Bernardo Center Drive
San Diego, California
(Address of Principal Executive Offices)
(858) 485-9840

92128
(Zip Code)

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

| | Title of Each Class | Name of Each Exchange on Which Registered |
|---------------------------|--------------------------------|---|
| BioMed Realty Trust, Inc. | Common Stock, \$0.01 Par Value | New York Stock Exchange |
| BioMed Realty, L.P. | None | None |

Securities registered pursuant to Section 12(g) of the Act:

| | |
|---------------------------|------|
| BioMed Realty Trust, Inc. | None |
| BioMed Realty, L.P. | None |

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act of 1933.

| | |
|---------------------------|--|
| BioMed Realty Trust, Inc. | Yes <input type="checkbox"/> No <input type="checkbox"/> |
| BioMed Realty, L.P. | Yes <input type="checkbox"/> No <input type="checkbox"/> |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

BioMed Realty Trust, Inc. Yes No
 BioMed Realty, L.P. Yes No

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

BioMed Realty Trust, Inc. Yes No
 BioMed Realty, L.P. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

BioMed Realty Trust, Inc. Yes No
 BioMed Realty, L.P. Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

| | | | |
|--|---|---|---|
| BioMed Realty Trust, Inc.: | | | |
| Large accelerated filer <input checked="" type="radio"/> | Accelerated filer <input type="radio"/> | Non-accelerated filer <input type="radio"/> (Do not check if a smaller reporting company) | Smaller reporting company <input type="radio"/> |
| BioMed Realty, L.P.: | | | |
| Large accelerated filer <input type="radio"/> | Accelerated filer <input type="radio"/> | Non-accelerated filer <input checked="" type="radio"/> (Do not check if a smaller reporting company) | Smaller reporting company <input type="radio"/> |

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

BioMed Realty Trust, Inc. Yes No
 BioMed Realty, L.P. Yes No

The aggregate market value of the 190,667,947 shares of common stock of BioMed Realty Trust, Inc. held by non-affiliates of the registrant was \$3,857,212,568 based upon the last reported sale price of \$20.23 per share on the New York Stock Exchange on June 28, 2013, the last business day of its most recently completed second quarter. The number of outstanding shares of BioMed Realty Trust, Inc.'s common stock, par value \$0.01 per share, as of February 7, 2014 was 192,571,286.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of BioMed Realty Trust, Inc.'s Proxy Statement with respect to its 2014 Annual Meeting of Stockholders to be filed not later than 120 days after the end of the registrant's fiscal year are incorporated by reference into Part III hereof.

Table of Contents

EXPLANATORY NOTE

This report combines the annual reports on Form 10-K for the year ended December 31, 2013 of BioMed Realty Trust, Inc., a Maryland corporation, and BioMed Realty, L.P., a Maryland limited partnership of which BioMed Realty Trust, Inc. is the parent company and general partner. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our” or “our company” refer to BioMed Realty Trust, Inc. together with its consolidated subsidiaries, including BioMed Realty, L.P. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “our operating partnership” or “the operating partnership” refer to BioMed Realty, L.P. together with its consolidated subsidiaries.

BioMed Realty Trust, Inc. operates as a real estate investment trust, or REIT, and is the general partner of BioMed Realty, L.P. As of December 31, 2013, BioMed Realty Trust, Inc. owned an approximate 97.3% partnership interest and other limited partners, including some of our directors, executive officers and their affiliates, owned the remaining 2.7% partnership interest (including long term incentive plan units) in BioMed Realty, L.P. As the sole general partner of BioMed Realty, L.P., BioMed Realty Trust, Inc. has the full, exclusive and complete responsibility for the operating partnership’s day-to-day management and control.

There are a few differences between our company and our operating partnership, which are reflected in the disclosure in this report. We believe it is important to understand the differences between our company and our operating partnership in the context of how BioMed Realty Trust, Inc. and BioMed Realty, L.P. operate as an interrelated consolidated company. BioMed Realty Trust, Inc. is a REIT, whose only material asset is its ownership of partnership interests of BioMed Realty, L.P. As a result, BioMed Realty Trust, Inc. does not conduct business itself, other than acting as the sole general partner of BioMed Realty, L.P., issuing public equity from time to time and guaranteeing certain debt of BioMed Realty, L.P. BioMed Realty Trust, Inc. itself does not hold any indebtedness but guarantees some of the secured and unsecured debt of BioMed Realty, L.P. BioMed Realty, L.P. holds substantially all the assets of the company and holds the ownership interests in the company’s joint ventures. BioMed Realty, L.P. conducts the operations of the business and is structured as a partnership with no publicly-traded equity. Except for net proceeds from public equity issuances by BioMed Realty Trust, Inc., which are generally contributed to BioMed Realty, L.P. in exchange for partnership units, BioMed Realty, L.P. generates the capital required by the company’s business through BioMed Realty, L.P.’s operations, by BioMed Realty, L.P.’s direct or indirect incurrence of indebtedness or through the issuance of partnership units.

Noncontrolling interests and stockholders’ equity and partners’ capital are the main areas of difference between the consolidated financial statements of BioMed Realty Trust, Inc. and those of BioMed Realty, L.P. The operating partnership and long term incentive plan units in BioMed Realty, L.P. that are not owned by BioMed Realty Trust, Inc. are accounted for as partners’ capital in BioMed Realty, L.P.’s financial statements and as noncontrolling interests in BioMed Realty Trust, Inc.’s financial statements. The noncontrolling interests in BioMed Realty, L.P.’s financial statements include the interests of joint venture partners. The noncontrolling interests in BioMed Realty Trust, Inc.’s financial statements include the same noncontrolling interests at the BioMed Realty, L.P. level as well as the limited partnership unitholders of BioMed Realty, L.P., not including BioMed Realty Trust, Inc. The differences between stockholders’ equity and partners’ capital result from the differences in the equity issued at the BioMed Realty Trust, Inc. and BioMed Realty, L.P. levels.

We believe combining the annual reports on Form 10-K of BioMed Realty Trust, Inc. and BioMed Realty, L.P. into this single report:

- better reflects how management and the analyst community view the business as a single operating unit,
 - enhances investor understanding of our company by enabling them to view the business as a whole and in the same manner as management,
 - is more efficient for our company and results in savings in time, effort and expense, and
 - is more efficient for investors by reducing duplicative disclosure and providing a single document for their review.
- To help investors understand the significant differences between our company and our operating partnership, this report presents the following separate sections for each of BioMed Realty Trust, Inc. and BioMed Realty, L.P.:
- consolidated financial statements,
 - the following notes to the consolidated financial statements:

Equity / Partners' Capital,
Debt, and

2

Table of Contents

Earnings Per Share / Unit,

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities, and Liquidity and Capital Resources in Management's Discussion and Analysis of Financial Condition and Results of Operations.

This report also includes separate Item 9A. Controls and Procedures sections and separate Exhibit 31 and 32 certifications for each of BioMed Realty Trust, Inc. and BioMed Realty, L.P. in order to establish that the Chief Executive Officer and the Chief Financial Officer of BioMed Realty Trust, Inc. have made the requisite certifications and BioMed Realty Trust, Inc. and BioMed Realty, L.P. are compliant with Rule 13a-15 or Rule 15d-15 of the Securities Exchange Act of 1934 and 18 U.S.C. §1350.

BIOMED REALTY TRUST, INC. AND BIOMED REALTY, L.P.

FORM 10-K - ANNUAL REPORT
FOR THE YEAR ENDED DECEMBER 31, 2013
TABLE OF CONTENTS

| | Page |
|--|------------|
| <u>PART I</u> | |
| <u>Item 1 Business</u> | <u>5</u> |
| <u>Item 1A Risk Factors</u> | <u>13</u> |
| <u>Item 1B Unresolved Staff Comments</u> | <u>31</u> |
| <u>Item 2 Properties</u> | <u>31</u> |
| <u>Item 3 Legal Proceedings</u> | <u>36</u> |
| <u>Item 4 Mine Safety Disclosures</u> | <u>37</u> |
| <u>PART II</u> | |
| <u>Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u> | <u>37</u> |
| <u>Item 6 Selected Financial Data</u> | <u>39</u> |
| <u>Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>41</u> |
| <u>Item 7A Quantitative and Qualitative Disclosures About Market Risk</u> | <u>64</u> |
| <u>Item 8 Financial Statements and Supplementary Data</u> | <u>67</u> |
| <u>Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u> | <u>126</u> |
| <u>Item 9A Controls and Procedures</u> | <u>126</u> |
| <u>Item 9B Other Information</u> | <u>129</u> |
| <u>PART III</u> | |
| <u>Item 10 Directors, Executive Officers and Corporate Governance</u> | <u>130</u> |
| <u>Item 11 Executive Compensation</u> | <u>130</u> |
| <u>Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u> | <u>130</u> |
| <u>Item 13 Certain Relationships and Related Transactions, and Director Independence</u> | <u>130</u> |

Item 14 Principal Accountant Fees and Services

130

PART IV

Item 15 Exhibits and Financial Statement Schedules

130

4

Table of Contents

PART I

ITEM 1. BUSINESS

Forward-Looking Statements

We make statements in this report that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act). In particular, statements pertaining to our capital resources, portfolio performance and results of operations contain forward-looking statements. Likewise, our statements regarding anticipated growth in our funds from operations and anticipated market conditions, demographics and results of operations are forward-looking statements. Forward-looking statements involve numerous risks and uncertainties, and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise, and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). You can identify forward-looking statements by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates” or the negative of these words and phrases or similar words or phrases. You can also identify forward-looking statements by discussions of strategy, plans or intentions. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

- adverse economic or real estate developments in the life science industry or in our target markets, including the inability of our tenants to obtain funding to run their businesses,
- our dependence on significant tenants,
- our failure to obtain necessary outside financing on favorable terms or at all, including the continued availability of our unsecured line of credit,
- general economic conditions, including downturns in the foreign, domestic and local economies,
- changes in interest rates and foreign currency exchange rates,
- volatility in financial and securities markets,
- defaults on or non-renewal of leases by tenants,
- our inability to compete effectively,
- increased operating costs,
- our inability to successfully complete real estate acquisitions, developments and dispositions,
- risks and uncertainties affecting property development and construction,
- risks associated with tax credits, grants and other subsidies to fund development activities,
- our failure to effectively manage our growth and expansion into new markets or to successfully operate acquired properties and companies,
- our ownership of properties outside of the United States that subject us to different and potentially greater risks than those associated with our domestic operations,
- risks associated with our investments in loans, including borrower defaults and potential principal losses,
- reductions in asset valuations and related impairment charges,
- the loss of services of one or more of our executive officers,
- BioMed Realty Trust, Inc.’s failure to qualify or continue to qualify as a REIT,

Table of Contents

our failure to maintain our investment grade corporate credit ratings or a downgrade in our investment grade corporate credit ratings from one or more of the rating agencies,
 government approvals, actions and initiatives, including the need for compliance with environmental requirements,
 the effects of earthquakes and other natural disasters,
 lack of or insufficient amounts of insurance, and
 changes in real estate, zoning and other laws and increases in real property tax rates.

While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a further discussion of these and other factors that could impact our future results, performance or transactions, see the section below entitled “Item 1A. Risk Factors.”

General

We own, acquire, develop, redevelop, lease and manage laboratory and office space for the life science industry. Our tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. Our properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania, North Carolina, Seattle, and Cambridge (United Kingdom). BioMed Realty Trust, Inc., a Maryland corporation, and BioMed Realty, L.P., a Maryland limited partnership, were formed on April 30, 2004 and commenced operations on August 11, 2004, after completing BioMed Realty Trust, Inc.’s initial public offering. BioMed Realty Trust, Inc. operates as a REIT for federal income tax purposes. BioMed Realty, L.P. is the entity through which BioMed Realty Trust, Inc. conducts its business and owns its assets. At December 31, 2013, we owned or had interests in properties comprising approximately 16.3 million rentable square feet.

Our senior management team has significant experience in the real estate industry, principally focusing on properties designed for life science tenants. We operate as a fully integrated, self-administered and self-managed REIT, providing property management, leasing, development and administrative services to our properties. As of February 6, 2014, we had 235 employees.

Our principal offices are located at 17190 Bernardo Center Drive, San Diego, California 92128. Our telephone number at that location is (858) 485-9840. Our website is located at www.biomedrealty.com. We make available through our website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Sections 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission. You can also access on our website our Code of Business Conduct and Ethics, Corporate Governance Guidelines, Audit Committee Charter, Compensation Committee Charter, and Nominating and Corporate Governance Committee Charter.

2013 Highlights**Financial Results**

| | Year Ended December 31, | | | Percent Increase | |
|---|---------------------------------------|-----------|-----------|------------------|---|
| | 2013 | 2012 | Increase | | |
| | (in thousands, except per share data) | | | | |
| FFFO - diluted | \$295,711 | \$219,662 | \$76,049 | 34.6 | % |
| FFFO per share - diluted | \$1.49 | \$1.31 | \$0.18 | 13.7 | % |
| Same property net operating income - cash basis | \$355,532 | \$332,235 | \$23,297 | 7.0 | % |
| Total revenues | \$637,314 | \$518,167 | \$119,147 | 23.0 | % |
| Rental revenues | \$445,980 | \$392,628 | \$53,352 | 13.6 | % |

For definitions and discussion of same property net operating income - cash basis and core funds from operations, or CFFO, see the section below entitled “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Leasing

Table of Contents

During the year ended December 31, 2013, we executed 120 leasing transactions representing approximately 2.3 million square feet, including 75 new leases totaling approximately 1.4 million square feet and 45 leases which were amended to extend their terms totaling 839,114 square feet. As of December 31, 2013, our total operating portfolio was 91.4% leased on a weighted-average basis to 296 tenants. Significant transactions included:

| Property | Market | Tenant | Square Feet |
|---|--------------------------|--|-------------|
| New Leases | | | |
| 320 Bent Street | Boston | Momenta Pharmaceuticals | 105,000 |
| 320 Charles Street | Boston | The Broad Institute | 100,000 |
| 650 E. Kendall Street (Kendall B) | Boston | Biomeasure Incorporated | 63,000 |
| 320 Bent Street | Boston | Moderna Therapeutics | 44,000 |
| 60 Hampshire Street | Boston | iZotope | 36,000 |
| 210 Broadway | Boston | GiN Hubs | 16,000 |
| 650 E. Kendall Street (Kendall B) | Boston | ArtScience Labs | 13,000 |
| Vassar Street | Boston | Preceres | 10,000 |
| University of Maryland BioPark II | Maryland | Catholic Health Initiatives Center | 11,000 |
| Landmark at Eastview III | New York / New Jersey | Regeneron Pharmaceuticals | 297,000 |
| Landmark at Eastview | New York / New Jersey | Regeneron Pharmaceuticals | 29,000 |
| Landmark at Eastview | New York / New Jersey | Profectus BioSciences | 10,000 |
| Piedmont Triad Research - Wake 90 | North Carolina | Forsyth Technical Community College | 24,000 |
| Piedmont Triad Research - Wake 90 | North Carolina | Young Men's Christian Association | 10,000 |
| Wateridge Circle | San Diego | Genalyte | 29,000 |
| Wateridge Circle | San Diego | Inovio Pharmaceuticals | 27,000 |
| Road to the Cure | San Diego | Human Longevity | 11,000 |
| Science Center at Oyster Point (180) | San Francisco | Life Technologies | 116,000 |
| Science Center at Oyster Point (200) | San Francisco | Life Technologies | 89,000 |
| Dumbarton Circle | San Francisco | Asterias Biotherapeutics | 44,000 |
| Pacific Industrial Center | San Francisco | Theranos | 33,000 |
| Pacific Research Center North | San Francisco | Risk Management Solutions | 31,000 |
| Kaiser Drive | San Francisco | Arstasis | 21,000 |
| Pacific Research Center North | San Francisco | Tegile Systems | 19,000 |
| Pacific Research Center North | San Francisco | Infosys Limited | 18,000 |
| Pacific Research Center North | San Francisco | Cellscape Corporation | 9,000 |
| Monte Villa Parkway | Seattle | Bristol-Myers Squibb | 30,000 |
| 217th Place | Seattle | Sarepta Therapeutics | 11,000 |
| Heritage @ 4240 | University Related/Other | Cambridge Innovation Center | 32,000 |
| Renewals, Amendments or Extensions | | | |
| 21 Erie Street | Boston | Metabolix | 28,000 |
| Coolidge Avenue | Boston | Blend Therapeutics | 16,000 |
| Coolidge Avenue | Boston | Wolfe Laboratories | 13,000 |
| 50 West Watkins Mill Road | Maryland | Johnson Controls | 20,000 |
| Landmark at Eastview | New York / New Jersey | Regeneron Pharmaceuticals | 361,000 |
| Landmark at Eastview | New York / New Jersey | Momentive Performance Materials | 62,000 |
| Weston Parkway | North Carolina | Fujifilm Diosynth Biotechnologies U.S.A. | 31,000 |

Table of Contents

| | | | |
|--|--------------------------|---------------------------------------|--------|
| Phoenixville Pike | Pennsylvania | TetraLogic Pharmaceuticals | 12,000 |
| Wateridge Circle | San Diego | Genomatica | 29,000 |
| San Diego Science Center | San Diego | Tocagen | 14,000 |
| Bridgeview Technology Park I | San Francisco | MedImmune | 24,000 |
| 4320 Forest Park Avenue | University Related/Other | The Washington University | 58,000 |
| BRDG Park at Danforth Plant Science Center | University Related/Other | Monsanto Company | 28,000 |
| Innovation Research Park at ODU I | University Related/Other | EVMS Academic Physicians and Surgeons | 16,000 |
| BRDG Park at Danforth Plant Science Center | University Related/Other | Akermin | 12,000 |

Acquisitions

During 2013, we acquired over 2.9 million rentable square feet of laboratory and office space, which was 83.5% leased at acquisition on a weighted-average basis, and approximately 580,000 square feet of development potential for approximately \$842.6 million, excluding transaction costs:

| Property | Market | Closing Date | Rentable Square Feet(1) | Investment (In thousands) | Percent Leased at Acquisition | |
|----------------------------------|---------------|-------------------|-------------------------|------------------------------|-------------------------------|---|
| Woodside Technology Park | San Francisco | February 28, 2013 | 255,650 | \$87,000 | 100 | % |
| The Campus at Lincoln Centre (2) | San Francisco | March 20, 2013 | — | 37,000 | n/a | |
| Wexford Science & Technology (3) | Various | May 31, 2013 | 2,555,174 | 669,100 | 81.2 | % |
| 320 Charles Street (4) | Boston | June 18, 2013 | 99,513 | 49,518 | 100 | % |
| Total / weighted-average | | | 2,910,337 | \$842,618 | 83.5 | % |

(1) Rentable square feet at time of acquisition.

(2) Includes approximately 280,000 square feet of development potential.

(3) Includes approximately 935,000 square feet in development and approximately 300,000 square feet of development potential. Investment includes the issuance of 5,568,227 shares of common stock of BioMed Realty Trust, Inc. and 336,960 operating partnership units of BioMed Realty, L.P. to the sellers as part of the consideration for the merger.

(4) Investment includes the issuance of 2,034,211 operating partnership units of BioMed Realty, L.P. to the seller as part of the consideration for the acquisition.

We also acquired properties with approximately 274,000 and 300,000 square feet of pre-development and development potential, respectively, for approximately \$13.4 million.

Financings

Significant financing activities during 2013 included the following:

Entered into an amended and restated credit agreement, or the Amended and Restated Credit Facility, which provides for aggregate borrowings of up to \$1.25 billion, consisting of a \$900.0 million revolving line of credit and a \$350.0 million Term Loan due 2018, with a maturity date of March 24, 2018.

Entered into interest rate swap agreements that effectively fix the interest rate on \$200.0 million of the Term Loan due 2018 at 2.2% for three years, subject to adjustments based on our credit ratings.

Issued 14,605,000 shares of BioMed Realty Trust, Inc.'s common stock for net proceeds of approximately \$287.0 million. The net proceeds were utilized to fund the acquisition of the Woodside Technology Park property, to fund a portion of the redemption of BioMed Realty Trust, Inc.'s Series A preferred stock, to repay a portion of the outstanding indebtedness under our unsecured line of credit and for other general corporate and working capital purposes.

Table of Contents

Redeemed all 7,920,000 outstanding shares of BioMed Realty Trust, Inc.'s Series A preferred stock for approximately \$198.0 million.

Issued 17,250,000 shares of BioMed Realty Trust, Inc.'s common stock for net proceeds of approximately \$354.1 million. The net proceeds were utilized to fund a portion of the purchase price in connection with the acquisition of Wexford Science & Technology, LLC and related entities, which we collectively refer to as Wexford, to repay a portion of the outstanding indebtedness under our unsecured line of credit and for other general corporate and working capital purposes.

Issued 5,568,227 shares of common stock of BioMed Realty Trust, Inc. and 336,960 operating partnership units of BioMed Realty, L.P. to the sellers as part of the consideration for our acquisition of Wexford.

Issued 2,034,211 operating partnership units of BioMed Realty, L.P. to fund a portion of the purchase price of our acquisition of the 320 Charles Street property.

Repaid approximately \$105.9 million in mortgage notes with a weighted-average interest rate of 1.22%.

Ended the fourth quarter with a debt to total gross assets ratio of 39.4%.

Senior Management and Board of Directors

During 2013, we continued to enhance the depth and breadth of our senior management team with the following additions and promotions:

James R. Berens joined as President of Wexford in May 2013.

Daniel C. Cramer joined as Senior Vice President, Development of Wexford in May 2013.

Sandy N. Weeks joined as Senior Vice President and General Counsel of Wexford in May 2013.

James W. Cullinan joined as Vice President, Marketing in October 2013.

Dr. William R. Brody, President of the Salk Institute for Biological Studies, joined our board of directors in December 2013, increasing the size of the board to nine members.

Denis J. Sullivan was promoted to Vice President, Acquisitions in February 2013.

Common Stock Dividends

During 2013, we declared aggregate dividends on BioMed Realty Trust, Inc.'s common stock of \$0.955 per common share, representing an 8.5% increase over common stock dividends declared in 2012.

OP Unit Distributions

During 2013, we declared aggregate distributions on BioMed Realty, L.P.'s operating partnership units and long-term incentive plan units (individually referred to as LTIP units, and collectively with the operating partnership units referred to as OP units) of \$0.955 per OP unit, representing an 8.5% increase over aggregate distributions for OP units declared in 2012.

Growth Strategy

Our success and future growth potential are based upon the real estate opportunities within the life science industry. Our growth strategy is designed to meet the sizable demand and specialized requirements of life science tenants by leveraging the knowledge and expertise of a management team focused on serving this large and growing industry. Our internal growth strategy includes:

negotiating leases with contractual rental rate increases in order to provide predictable and consistent earnings growth, creating strong relationships with our tenants to enable us to identify and capitalize on opportunities to renew or extend existing leases or to provide expansion space,

redeveloping currently owned non-laboratory space into higher yielding laboratory facilities, and

9

Table of Contents

developing new laboratory and office space on land we have acquired for development.

Our external growth strategy includes:

- acquiring, subject to our rigorous underwriting standards, well-located properties leased to high-quality life science tenants with attractive in-place yields and long-term growth potential,
- investing in properties with leasing opportunities, capitalizing on our industry relationships to enter into new leases, and
- investing in redevelopment and development projects, capitalizing on our development platform that we believe will serve as an additional catalyst for future growth.

Target Markets

Our target markets - Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania, North Carolina, Seattle, Cambridge (United Kingdom) and research parks near or adjacent to universities - have emerged as the primary hubs for research, development and production in the life science industry. Each of these markets benefits from the presence of mature life science companies, which provide scale and stability to the market, as well as academic and university environments and government entities to contribute innovation, research, personnel and capital to the private sector. In addition, the clustered research environments within these target markets typically provide a high quality of life for the research professionals and a fertile ground for new life science ideas and ventures.

Positive Life Science Industry Trends

We expect continued long-term growth in the life science industry due to several factors:

- the aging of the U.S. population resulting from the transition of baby boomers to senior citizens, which has increased the demand for new drugs and health care treatment alternatives to extend, improve and enhance their quality of life,
- the high level of research and development expenditures, as represented by a Battelle and R&D Magazine forecast indicating that global research and development spending will grow by 3.8%, or \$60.0 billion, to \$1.6 trillion in 2014, and
- escalating health care costs, which drive the demand for better drugs, less expensive treatments and more services in an attempt to manage such costs.

We are uniquely positioned to benefit from these favorable long-term dynamics through the demand for space for research, development and production by our life science industry tenants.

Experienced Management

We have created and continue to develop a premier life science real estate-oriented management team, dedicated to maximizing current and long-term returns for our stockholders. Our executive team, including Alan D. Gold, our company's Chief Executive Officer and Chairman, has acquired, developed, financed, owned, leased or managed in excess of \$7.0 billion in life science real estate. Through this experience, our management team has established extensive industry relationships among life science tenants, property owners and real estate brokers. In addition, our experienced independent board members provide management with a broad range of knowledge in real estate, the sciences, life science company operations, and large public company finance and management.

Regulation

General

Our properties are subject to various laws, ordinances and regulations, including regulations relating to common areas. We believe that we have the necessary permits and approvals to operate each of our properties.

Americans with Disabilities Act

Our properties must comply with Title III of the Americans with Disabilities Act, or ADA, to the extent that such properties are "public accommodations" as defined by the ADA. The ADA may require removal of structural barriers to access by persons with disabilities in certain public areas of our properties where such removal is readily achievable. We believe that our properties are in substantial compliance with the ADA and that we will not be required to make substantial capital expenditures to address the requirements of the ADA. The tenants are generally responsible for any additional amounts required to conform their

Table of Contents

construction projects to the ADA. However, noncompliance with the ADA could result in imposition of fines or an award of damages to private litigants. The obligation to make readily achievable accommodations is an ongoing one, and we will continue to assess our properties and to make alterations as appropriate in this respect.

Environmental Matters

Under various federal, state and local environmental laws and regulations, a current or previous owner, operator or tenant of real estate may be required to investigate and remediate releases or threats of releases of hazardous or toxic substances or petroleum products at such property, and may be held liable for property damage, personal injury damages and investigation, clean-up and monitoring costs incurred in connection with the actual or threatened contamination. Such laws typically impose clean-up responsibility and liability without regard to fault, or whether the owner, operator or tenant knew of or caused the presence of the contamination. The liability under such laws may be joint and several for the full amount of the investigation, clean-up and monitoring costs incurred or to be incurred or actions to be undertaken, although a party held jointly and severally liable may obtain contributions from the other identified, solvent, responsible parties of their fair share toward these costs. These costs may be substantial, and can exceed the value of the property. The presence of contamination, or the failure to properly remediate contamination, on a property may adversely affect the ability of the owner, operator or tenant to sell or rent that property or to borrow using such property as collateral, and may adversely impact our investment in that property.

Federal asbestos regulations and certain state laws and regulations require building owners and those exercising control over a building's management to identify and warn, via signs, labels or other notices, of potential hazards posed by the actual or potential presence of asbestos-containing materials, or ACMs, in their building. The regulations also set forth employee training, record-keeping and due diligence requirements pertaining to ACMs and potential ACMs. Significant fines can be assessed for violating these regulations. Building owners and those exercising control over a building's management may be subject to an increased risk of personal injury lawsuits by workers and others exposed to ACMs and potential ACMs as a result of these regulations. The regulations may affect the value of a building containing ACMs and potential ACMs in which we have invested. Federal, state and local laws and regulations also govern the removal, encapsulation, disturbance, handling and/or disposal of ACMs and potential ACMs when such materials are in poor condition or in the event of construction, remodeling, renovation or demolition of a building. Such laws may impose liability for improper handling or a release to the environment of ACMs and potential ACMs and may provide for fines to, and for third parties to seek recovery from, owners or operators of real properties for personal injury or improper work exposure associated with ACMs and potential ACMs. See "Risk Factors - Risks Related to the Real Estate Industry - We could incur significant costs related to governmental regulation and private litigation over environmental matters involving asbestos-containing materials, which could adversely affect our operations, the value of our properties, and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders" under Item 1A. below.

Federal, state and local environmental laws and regulations also require removing or upgrading certain underground storage tanks and regulate the discharge of storm water, wastewater and other pollutants; the emission of air pollutants; the generation, management and disposal of hazardous or toxic chemicals, substances or wastes; and workplace health and safety. Life science industry tenants, including certain of our tenants, engage in various research and development activities involving the controlled use of hazardous materials, chemicals, biological and radioactive compounds. Some of our tenants, particularly those in the biotechnology, life sciences and technology manufacturing industries, routinely handle hazardous substances and wastes as part of their operations at our properties, including acetonitrile, alcohol, ammonia, argon, batteries, carbon dioxide, chemical solvents, cryogenic gases, dichlorophenol, diesel fuel for emergency generators, fluorine, hydrocarbons, hydrogen, medical waste, methane, naturalyte acid, neon, nitrogen, nitrous oxide, oxygen, radioactive material and tetrahydrofuran. Many of these compounds and materials are used in the experiments, clinical trials, research and development and light manufacturing efforts conducted by our tenants. Although we believe that the tenants' activities involving such materials comply in all material respects with applicable laws and regulations, the risk of contamination or injury from these materials cannot be completely eliminated. In the event of such contamination or injury, we could be held liable for any damages that result, and any such liability could exceed our resources and our environmental remediation insurance coverage. Licensing requirements governing use of radioactive materials by tenants may also restrict the use of or ability to

transfer space in buildings we own. See “Risk Factors - Risks Related to the Real Estate Industry - We could incur significant costs related to government regulation and private litigation over environmental matters involving the presence, discharge or threat of discharge of hazardous or toxic substances, which could adversely affect our operations, the value of our properties, and our ability to make distributions to BioMed Realty, L.P.’s unitholders or BioMed Realty Trust, Inc.’s stockholders” under Item 1A. below.

In addition, our leases generally provide that (1) the tenant is responsible for all environmental liabilities relating to the tenant’s operations, (2) we are indemnified for such liabilities and (3) the tenant must comply with all environmental laws and regulations. Such a contractual arrangement, however, does not eliminate our statutory liability or preclude claims against us by governmental authorities or persons who are not parties to such an arrangement. Noncompliance with environmental or health and safety requirements may also result in the need to cease or alter operations at a property, which could affect the financial health of a

Table of Contents

tenant and its ability to make lease payments. In addition, if there is a violation of such a requirement in connection with a tenant's operations, it is possible that we, as the owner of the property, could be held accountable by governmental authorities (or other injured parties) for such violation and could be required to correct the violation and pay related fines. In certain situations, we have agreed to indemnify tenants for conditions preceding their lease term, or that do not result from their operations.

Prior to closing any property acquisition, we obtain environmental assessments in a manner we believe prudent in order to attempt to identify potential environmental concerns at such properties. These assessments are carried out in accordance with an appropriate level of due diligence and generally include a physical site inspection, a review of relevant federal, state and local environmental and health agency database records, one or more interviews with appropriate site-related personnel, review of the property's chain of title and review of historic aerial photographs and other information on past uses of the property. We may also conduct limited subsurface investigations and test for substances of concern where the results of the first phase of the environmental assessments or other information indicate possible contamination or where our consultants recommend such procedures.

While we may purchase our properties on an "as is" basis, most of our purchase contracts contain an environmental contingency clause, which permits us to reject a property because of any environmental hazard at such property. We receive environmental reports on all prospective properties.

We believe that our properties comply in all material respects with all federal and state regulations regarding hazardous or toxic substances and other environmental matters.

Insurance

We carry commercial general liability, "all-risk" property insurance (subject to policy terms, conditions, limitations and exclusions), including fire and extended coverage, terrorism and loss of rental income insurance covering all of our properties under a blanket portfolio policy, with the exception of property insurance on our McKellar Court property in San Diego and 9911 Belward Campus Drive and Shady Grove Road properties in Maryland, which is carried directly by the tenants in accordance with the terms of their respective leases, and builders' risk policies or equivalent course of construction coverage for any projects under construction. In addition, we carry workers' compensation coverage for injury to our employees. We believe the policy specifications and insured limits are adequate given the relative risk of loss, cost of the coverage and standard industry practice. We also carry environmental insurance for our properties. This insurance, subject to certain exclusions and deductibles, covers the cost to remediate environmental damage caused by unintentional future spills or the historic presence of previously undiscovered hazardous substances, as well as third-party bodily injury and property damage claims related to the release of hazardous substances. We intend to carry similar insurance with respect to future acquisitions as appropriate. A substantial portion of our properties are located in areas subject to earthquake loss, such as San Diego and San Francisco, California and Seattle, Washington. Although we presently carry earthquake insurance on our properties, the amount of earthquake insurance coverage we carry may not be sufficient to fully cover losses from earthquakes. In addition, we may discontinue earthquake, terrorism, windstorm or other insurance, or may elect not to procure such insurance, on some or all of our properties in the future if the cost of the premiums for any of these policies exceeds, in our judgment, the value of the coverage discounted for the risk of loss. See "Risk Factors - Risks Related to the Real Estate Industry - Uninsured and underinsured losses could adversely affect our operating results and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders" under Item 1A. below.

Competition

We face competition from various entities for investment opportunities in properties for life science tenants, including other REITs, such as health care REITs and suburban office property REITs, pension funds, insurance companies, investment funds and companies, partnerships, and developers. Because properties designed for life science tenants typically contain improvements that are specific to tenants operating in the life science industry, we believe that we will be able to maximize returns on investments as a result of:

- our expertise in understanding the real estate needs of life science industry tenants,
- our ability to identify, acquire and develop properties with generic laboratory infrastructure that appeal to a wide range of life science industry tenants, and

our expertise in identifying and evaluating life science industry tenants.

However, some of our competitors have greater financial resources than we do and may be able to accept more risks, including risks with respect to the creditworthiness of a tenant or the geographic proximity of its investments. In the future, competition from these entities may reduce the number of suitable investment opportunities offered to us or increase the bargaining power of

12

Table of Contents

property owners seeking to sell. Further, as a result of their greater resources, those entities may have more flexibility than we do in their ability to offer rental concessions to attract tenants. These concessions could put pressure on our ability to maintain or raise rents and could adversely affect our ability to attract or retain tenants. Additionally, our ability to compete depends upon, among other factors, trends of the national and local economies, investment alternatives, financial condition and operating results of current and prospective tenants, availability and cost of capital, construction and renovation costs, taxes, governmental regulations, legislation and population trends.

Foreign Operations

Assets and liabilities of subsidiaries outside the United States with non-U.S. dollar functional currencies are translated into U.S. dollars using exchange rates as of the balance sheet dates. Income and expenses are translated using the average exchange rates for the reporting period. Foreign currency translation adjustments are recorded as a component of other comprehensive income. For the years ended December 31, 2013, and 2012 total revenues from properties outside the United States were \$18.2 million and \$10.3 million, respectively, which represented 2.9% and 2.0%, respectively, of our total revenues during the same period. Our net investments in properties outside the United States were \$190.2 million and \$188.8 million at December 31, 2013 and December 31, 2012, respectively. Prior to 2012, we did not engage in any foreign operations or derive any revenue from foreign sources.

ITEM IA. RISK FACTORS

For purposes of this section, the term “stockholders” means the holders of shares of BioMed Realty Trust, Inc.’s common stock and preferred stock and the term “unitholders” means the holders of BioMed Realty, L.P.’s OP units and preferred units.

Risks Related to Our Properties, Our Business and Our Growth Strategy

Because we lease our properties to a limited number of tenants, and to the extent we depend on a limited number of tenants in the future, the inability of any single tenant to make its lease payments could adversely affect our business and our ability to make distributions to BioMed Realty, L.P.’s unitholders or BioMed Realty Trust, Inc.’s stockholders. As of December 31, 2013, we had 309 tenants in our portfolio of 16.3 million square feet. Our tenant Human Genome Sciences, Inc., a wholly-owned subsidiary of GlaxoSmithKline plc, represented 8.8% of our annualized base rent, and 6.5% of our total leased rentable square footage as of December 31, 2013. There can be no assurance that any tenant will be able to make timely rental payments or avoid defaulting under its lease. If a tenant defaults, we may experience delays in enforcing our rights as landlord and may incur substantial costs in protecting our investment. Our revenue and cash flow, and consequently our ability to make distributions to BioMed Realty, L.P.’s unitholders and BioMed Realty Trust, Inc.’s stockholders, could be materially adversely affected if any of our significant tenants were to become bankrupt or insolvent, suffer a downturn in their business, curtail or suspend their operations, or fail to renew their leases at all or renew on terms less favorable to us than their current terms.

Life science entities, which comprise the vast majority of our tenant base, face high levels of regulation, expense and uncertainty that may adversely affect their ability to pay us rent and consequently adversely affect our business.

Life science entities comprise the vast majority of our tenant base and, as a result, adverse conditions affecting the life science industry will more adversely affect our business, and thus our ability to make distributions to BioMed Realty, L.P.’s unitholders and BioMed Realty Trust, Inc.’s stockholders, than if our business strategy included a more diverse tenant base. Life science industry tenants, particularly those involved in developing and marketing drugs and drug delivery technologies, fail from time to time as a result of various factors. Many of these factors are particular to the life science industry. For example:

Our tenants require significant outlays of funds for the research and development and clinical testing of their products and technologies and many of them have a history of recurring losses. The economic environment in recent years has significantly impacted the ability of these companies to access the capital markets, including both equity financing through public offerings and debt financing. The pace of venture capital funding has also declined from previous levels, further restricting access to capital for these companies. In addition, state and federal government budgets have been negatively impacted by the recent economic environment and, as a result certain programs, including grants

related to biotechnology research and development, may be at risk of being eliminated or cut back significantly. If private investors, the government, public markets or other sources of funding are unavailable to support such development, a tenant's business may fail.

The research and development, clinical testing, manufacture and marketing of some of our tenants' products require federal, state and foreign regulatory approvals. The approval process is typically long, expensive and uncertain. Even if our tenants

Table of Contents

have sufficient funds to seek approvals, one or all of their products may fail to obtain the required regulatory approvals on a timely basis or at all. Furthermore, our tenants may only have a small number of products under development. If one product fails to receive the required approvals at any stage of development, it could significantly adversely affect our tenant's entire business and its ability to pay rent.

Our tenants may be unable to adequately protect their intellectual property under patent, copyright or trade secret laws. Failure to do so could jeopardize their ability to profit from their efforts and to protect their products from competition.

Collaborative relationships with other life science entities may be crucial to the development, manufacturing, distribution or marketing of our tenants' products. If these other entities fail to fulfill their obligations under these collaborative arrangements, our tenants' businesses will suffer.

Legislation to reform the U.S. healthcare system, including regulations and legislation relating to the recently enacted Affordable Care Act, may include government intervention in product pricing and other changes that adversely affect reimbursement for our tenants' marketable products. In addition, sales of many of our tenants' marketable products are dependent, in large part, on the availability and extent of reimbursement from government health administration authorities, private health insurers and other organizations. Changes in government regulations, price controls or third-party payors' reimbursement policies may reduce reimbursement for our tenants' marketable products and adversely impact our tenants' businesses.

We cannot assure you that our tenants in the life science industry will be successful in their businesses. If our tenants' businesses are adversely affected, they may default on their obligations to third parties, including their obligations to pay rent or pay for tenant improvements relating to space they lease, which could adversely affect our financial condition, results of operations and cash flow.

The bankruptcy of a tenant may adversely affect the income produced by and the value of our properties.

The bankruptcy or insolvency of a tenant may adversely affect the income produced by our properties. If any tenant becomes a debtor in a case under the Bankruptcy Code, we cannot evict the tenant solely because of the bankruptcy. The bankruptcy court also might authorize the tenant to reject and terminate its lease with us, which would generally result in any unpaid, pre-bankruptcy rent being treated as an unsecured claim. An unsecured claim may be paid only to the extent that funds are available and only in the same percentage as is paid to all other holders of unsecured claims. In addition, our claim against the tenant for unpaid, future rent would be subject to a statutory cap equal to the greater of (1) one year of rent or (2) 15% of the remaining rent on the lease (not to exceed three years of rent). This cap might be substantially less than the remaining rent actually owed under the lease. Additionally, a bankruptcy court may require us to turn over to the estate all or a portion of any deposits, amounts in escrow, or prepaid rents. Our claim for unpaid, pre-bankruptcy rent, our lease termination damages and claims relating to damages for which we hold deposits or other amounts that we were forced to repay would likely not be paid in full. During the years ended December 31, 2013 and 2012, we incurred approximately \$324,000 and \$522,000, respectively, of rental operations expense related to early lease terminations and tenant receivables that were deemed to be uncollectible due to tenants that filed for bankruptcy at the time of lease termination or shortly thereafter.

We may fail to obtain the financial results expected from the properties we acquire, develop or renovate, making them unprofitable or less profitable than we had expected, or operate new properties successfully, which could harm our financial condition and ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

We continue to evaluate the market for available properties and may acquire office, laboratory and other properties when opportunities exist. We also may develop or substantially renovate office and other properties. Acquisition, development and renovation activities are subject to significant risks, including:

- we may spend more time or money than we budget to improve or renovate acquired properties or to develop new properties,
- we may be unable to quickly and efficiently integrate new properties, particularly if we acquire portfolios of properties, into our existing operations,
- market and economic conditions may result in higher than expected vacancy rates and lower than expected rental rates,

- we may face higher operating costs than we anticipated for properties that we acquire, develop or renovate, including insurance premiums, utilities, real estate taxes and costs of complying with changes in governmental regulations,
- we may face higher requirements for capital improvements than we anticipated for properties that we acquire, develop or renovate, particularly in older structures,
- we may fail to retain tenants that have pre-leased our properties under development if we do not complete the construction of these properties in a timely manner or to the tenants' specifications,
- we have a limited history in conducting ground-up construction activities,

Table of Contents

- if we develop properties, we may encounter delays or refusals in obtaining all necessary zoning, land use, building, occupancy and other required governmental permits and authorizations,
- acquired and developed properties may have defects we do not discover through our inspection processes, including latent defects that may not reveal themselves until many years after we put a property in service, and
- we may acquire land, properties or entities owning properties, which are subject to liabilities and for which, in the case of unknown liabilities, we may have limited or no recourse.

The realization of any of the above risks could significantly and adversely affect our financial condition, results of operations, cash flow, per share trading price of our securities, ability to satisfy our debt service obligations and ability to pay distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

Because particular upgrades are required for life science tenants, improvements to our properties involve greater expenditures than traditional office space, which costs may not be covered by the rents our tenants pay.

The improvements generally required for our properties' infrastructure are more costly than for other property types. Typical infrastructural improvements include the following:

- reinforced concrete floors,
- upgraded roof structures for greater load capacity,
- increased floor-to-ceiling clear heights,
- heavy-duty HVAC systems,
- enhanced environmental control technology,
- significantly upgraded electrical, gas and plumbing infrastructure, and
- laboratory benchwork.

We cannot assure you that our tenants will pay higher rents on our properties than tenants in traditional office space or that the rents paid will cover the additional costs of upgrading the properties.

Because of the unique and specific improvements required for our life science tenants, we may be required to incur substantial renovation costs to make our properties suitable for other life science tenants or other office tenants, which could adversely affect our operating performance.

We acquire or develop properties that include laboratory space and other features that we believe are generally desirable for life science industry tenants. However, different life science industry tenants may require different features in their properties, depending on each tenant's particular focus within the life science industry. If a current tenant is unable to pay rent and vacates a property, we may incur substantial expenditures to modify the property before we are able to re-lease the space to another life science industry tenant. This could hurt our operating performance and the value of your investment. Also, if the property needs to be renovated to accommodate multiple tenants, we may incur substantial expenditures before we are able to re-lease the space.

Additionally, our properties may not be suitable for lease to traditional office tenants without significant expenditures or renovations. Accordingly, any downturn in the life science industry may have a substantial negative impact on our properties' values.

Our success depends on key personnel with extensive experience dealing with the real estate needs of life science tenants, and the loss of these key personnel could threaten our ability to operate our business successfully.

Our future success depends, to a significant extent, on the continued services of our management team. In particular, we depend on the efforts of Alan D. Gold, our Chairman and Chief Executive Officer, R. Kent Griffin, Jr., our President and Chief Operating Officer, Greg N. Lubushkin, our Chief Financial Officer, Gary A. Kreitzer, our Executive Vice President, and Matthew G. McDevitt, our Executive Vice President, Real Estate. Among the reasons that Messrs. Gold, Griffin, Lubushkin, Kreitzer and McDevitt are important to our success are that they have extensive real estate and finance experience, and strong reputations within the life science industry. Our management team has developed informal relationships through past business dealings with numerous members of the scientific community, life science investors, current and prospective life science industry tenants and real estate brokers. We expect that their reputations will continue to attract business and investment opportunities before the active marketing of properties and will assist us in negotiations with lenders, existing and potential tenants, and industry personnel. If we lost their services, our relationships with such lenders, existing and prospective tenants, and industry personnel could suffer. We do not have employment agreements with any of our executive officers.

Table of Contents

We may not be successful in acquiring and integrating properties or companies that meet our investment criteria, which may impede our growth.

In addition to properties consisting of 2.3 million rentable square feet of laboratory and office space we acquired in connection with our initial public offering in August 2004, as of December 31, 2013, we had acquired or had acquired an interest in properties consisting of an additional 14.0 million rentable square feet of laboratory and office space (net of property dispositions). We continue to evaluate the market of available properties and may acquire properties when strategic opportunities exist. Changing market conditions, including competition from others, may diminish our opportunities for acquiring a desired property on favorable terms or at all. Even if we enter into agreements for the acquisition of properties, these agreements are subject to customary conditions to closing, including completion of due diligence investigations to our satisfaction. We also may be unable to obtain financing on favorable terms (or at all), including continued access to our unsecured line of credit, which may be necessary or desirable to fund property acquisitions. We may not be able to quickly and efficiently integrate any properties that we acquire into our organization and manage and lease the new properties in a way that allows us to realize the financial returns that we expect. In addition, we may incur unanticipated costs to make necessary improvements or renovations to acquired properties. Furthermore, our efforts to integrate new property acquisitions may divert management's attention away from or cause disruptions to the operations at our existing properties.

In May 2013, we completed a merger with Wexford, a real estate company with approximately 1.6 million square feet of rentable laboratory and office space and approximately 935,000 square feet of rentable space under development at the time of close, and may acquire other companies in the future. Acquisitions of companies present risks that are in addition to the property-specific risks identified above, including risks associated with our ability to integrate the operations or information technology of acquired companies, maintain consistent standards, controls, policies and procedures and retain key employees.

If we fail to successfully acquire new properties or companies or integrate them into our portfolio, or if newly acquired properties or companies fail to perform as we expect, our results of operations, financial condition and ability to pay distributions could suffer.

The geographic concentration of our properties in Boston, California and Maryland makes our business particularly vulnerable to adverse conditions affecting these markets.

As of December 31, 2013, our Boston properties represented 34.0% of our annualized base rent and 22.2% of our total leased square footage. As of December 31, 2013, our California properties located in San Francisco and San Diego represented 23.1% of our annualized base rent and 29.6% of our total leased square footage. As of December 31, 2013, our Maryland properties represented 13.8% of our annualized base rent and 13.1% of our total leased square footage. Because of this concentration in three geographic regions, we are particularly vulnerable to adverse conditions affecting Boston, California and Maryland, including general economic conditions, increased competition, a downturn in the local life science industry, real estate conditions, terrorist attacks, earthquakes and wildfires and other natural disasters occurring in these regions. In addition, we cannot assure you that these markets will continue to grow or remain favorable to the life science industry. The performance of the life science industry and the economy in general in these geographic markets may affect occupancy, market rental rates and expenses, and thus may affect our performance and the value of our properties. We are also subject to greater risk of loss from earthquakes or wildfires because of our properties' concentration in California. The close proximity of our properties in San Francisco to a fault line makes them more vulnerable to earthquakes than properties in many other parts of the country. Likewise, the increased risk of wildfires may make the properties we own in the San Diego area more vulnerable to fire damage or destruction than properties in many other parts of the country.

Our tax indemnification and debt maintenance obligations require us to make payments if we sell certain properties or repay certain debt, which could limit our operating flexibility.

In our formation transactions, Messrs. Gold and Kreitzer and certain other individuals contributed properties to our operating partnership. If we were to dispose of these contributed assets in a taxable transaction, Messrs. Gold and Kreitzer and the other contributors of those assets could suffer adverse tax consequences. In connection with these contribution transactions, we agreed to indemnify Messrs. Gold and Kreitzer and one other contributor against such adverse tax consequences through August 11, 2014, the ten-year anniversary of the contribution. The tax

indemnification provisions were not negotiated in an arm's length transaction but were determined by our management team. We have also agreed to use reasonable best efforts consistent with our fiduciary duties to maintain at least \$8.0 million of debt during the same period, some of which must be property specific, that these three contributors can guarantee in order to defer any taxable gain they may incur if our operating partnership repays existing debt. These tax indemnification and debt maintenance obligations may affect the way in which we conduct our business. During such period, these obligations may impact the timing and circumstances under which we sell the contributed properties or interests in entities holding the properties. For example, these tax indemnification payments could effectively reduce or eliminate any gain we might otherwise realize upon the sale or other disposition of the related properties. Accordingly, even if market conditions

Table of Contents

might otherwise dictate that it would be desirable to dispose of these properties, the existence of the tax indemnification obligations could result in a decision to retain the properties in our portfolio to avoid having to pay the tax indemnity payments. The existence of the debt maintenance obligations could require us to maintain debt at a higher level than we might otherwise choose. Higher debt levels could adversely affect our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

While we may seek to enter into tax-efficient joint ventures with third-party investors, we currently have no intention of disposing of these properties or interests in entities holding the properties in transactions that would trigger our tax indemnification obligations. The involuntary condemnation of one or more of these properties during the indemnification period could, however, trigger the tax indemnification obligations described above. The tax indemnity would equal the amount of the federal and state income tax liability the contributor would incur with respect to the gain allocated to the contributor. The calculation of the indemnity payment would not be reduced due to the time value of money or the time remaining within the indemnification period. The terms of the contribution agreements also require us to gross up the tax indemnity payment for the amount of income taxes due as a result of the tax indemnity payment. Messrs. Gold and Kreitzer are potential recipients of these indemnification payments. Because of these potential payments their personal interests may diverge from those of BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

Risks Related to the Real Estate Industry

Our performance and value are subject to risks associated with the ownership and operation of real estate assets and with factors affecting the real estate industry.

Our ability to make expected distributions to BioMed Realty, L.P.'s unitholders and BioMed Realty Trust, Inc.'s stockholders depends on our ability to generate revenues in excess of expenses, our scheduled principal payments on debt and our capital expenditure requirements. Events and conditions that are beyond our control may decrease our cash available for distribution and the value of our properties. These events include:

- local oversupply, increased competition or reduced demand for life science office and laboratory space,
- inability to collect rent from tenants,
- vacancies or our inability to rent space on favorable terms,
- potential changes in U.S. accounting standards regarding leases making leasing of our properties less attractive to tenants,
- increased operating costs, including insurance premiums, utilities and real estate taxes,
- the ongoing need for capital improvements, particularly in older structures,
- unanticipated delays in the completion of our development or redevelopment projects,
- costs of complying with changes in governmental regulations, including usage, zoning, environmental and tax laws,
- the relative illiquidity of real estate investments,
- changing submarket demographics, and
- civil unrest, acts of war and natural disasters, including earthquakes, floods and fires, which may result in uninsured and underinsured losses.

In addition, we could experience a general decline in rents or an increased incidence of defaults under existing leases if any of the following occur:

- future periods of economic slowdown or recession,
- rising interest rates,
- declining demand for real estate, or
- the public perception that any of these events may occur.

Any of these events could adversely affect our financial condition, results of operations, cash flow, per share trading price of BioMed Realty Trust, Inc.'s common stock, ability to satisfy our debt service obligations and ability to pay distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

Significant competition may decrease or prevent increases in our properties' occupancy and rental rates and may reduce our investment opportunities.

We face competition from various entities for investment opportunities in properties for life science tenants, including other REITs, such as health care REITs and suburban office property REITs, pension funds, insurance companies,

investment funds and companies, partnerships, and developers. Many of these entities have substantially greater financial resources than we do and may

Table of Contents

be able to accept more risk than we can prudently manage, including risks with respect to the creditworthiness of a tenant or the geographic location of its investments. In the future, competition from these entities may reduce the number of suitable investment opportunities offered to us or increase the bargaining power of property owners seeking to sell. Further, as a result of their greater resources, those entities may have more flexibility than we do in their ability to offer rental concessions to attract tenants. This could put pressure on our ability to maintain or raise rents and could adversely affect our ability to attract or retain tenants. As a result, our financial condition, results of operations, cash flow, per share trading price of BioMed Realty Trust, Inc.'s common stock, ability to satisfy our debt service obligations and ability to pay distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders may be adversely affected.

Illiquidity of real estate investments may make it difficult for us to sell properties in response to market conditions and could harm our financial condition and ability to make distributions.

Equity real estate investments are relatively illiquid and therefore will tend to limit our ability to vary our portfolio promptly in response to changing economic or other conditions. To the extent the properties are not subject to triple-net leases, some significant expenditures such as real estate taxes and maintenance costs are generally not reduced when circumstances cause a reduction in income from the investment. Should these events occur, our income and funds available for distribution could be adversely affected. If any of the parking leases or licenses associated with our Cambridge portfolio were to expire, or if we were unable to assign these leases to a buyer, it would be more difficult for us to sell these properties and would adversely affect our ability to retain current tenants or attract new tenants at these properties. In addition, as a REIT, BioMed Realty Trust, Inc. may be subject to a 100% tax on net income derived from the sale of property considered to be held primarily for sale to customers in the ordinary course of our business. We may seek to avoid this tax by complying with certain safe harbor rules that generally limit the number of properties we may sell in a given year, the aggregate expenditures made on such properties prior to their disposition, and how long we retain such properties before disposing of them. However, we can provide no assurance that we will always be able to comply with these safe harbors. If compliance is possible, the safe harbor rules may restrict our ability to sell assets in the future and achieve liquidity that may be necessary to fund distributions.

Declining real estate valuations and impairment charges could adversely affect our earnings and financial condition. We review the carrying value of our properties when circumstances, such as adverse market conditions (including conditions resulting from the ongoing challenges facing the U.S. and U.K. economies), indicate potential impairment may exist. We base our review on an estimate of the future undiscounted cash flows (excluding interest charges) expected to result from the property's use and eventual disposition. We consider factors such as future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. If our evaluation indicates that we may be unable to recover the carrying value of a property, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair-value of the property. These losses have a direct impact on our net income because recording an impairment loss results in an immediate negative adjustment to net income. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. A worsening real estate market may cause us to reevaluate the assumptions used in our impairment analysis. Although we generally plan to own and operate our existing portfolio of properties over the long term, our ability and/or our intent with regard to the operation of our properties may change to dictate an earlier sale date, and an impairment loss may be recognized in connection with such a proposed sale to reduce the property to the lower of the carrying amount or fair-value less costs to sell. Such impairment charges could be material, and could adversely affect our financial condition, results of operations and per share trading price of BioMed Realty Trust, Inc.'s common stock.

We may be unable to renew leases, lease vacant space or re-lease space as leases expire, which could adversely affect our business and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

If we cannot renew leases, we may be unable to re-lease our properties at rates equal to or above the current rate. Even if we can renew leases, tenants may be able to negotiate lower rates as a result of market conditions. Market conditions may also hinder our ability to lease vacant space in newly developed or redeveloped properties. In addition, we may enter into or acquire leases for properties that are specially suited to the needs of a particular tenant. Such

properties may require renovations, tenant improvements or other concessions in order to lease them to other tenants if the initial leases terminate. Any of these factors could adversely impact our financial condition, results of operations, cash flow, per share trading price of BioMed Realty Trust, Inc.'s common stock, our ability to satisfy our debt service obligations and our ability to pay distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

Changes in accounting pronouncements could adversely affect our operating results, in addition to the reported financial performance of our tenants.

Table of Contents

Accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Uncertainties posed by various initiatives of accounting standard-setting by the Financial Accounting Standards Board and the Securities and Exchange Commission, which create and interpret applicable accounting standards for U.S. companies, may change the financial accounting and reporting standards or their interpretation and application of these standards that govern the preparation of our financial statements. Proposed changes include, but are not limited to, changes in lease accounting and the adoption of accounting standards likely to require the increased use of “fair-value” measures.

These changes could have a material impact on our reported financial condition and results of operations. In some cases, we could be required to apply a new or revised standard retroactively, resulting in potentially material restatements of prior period financial statements. Similarly, these changes could have a material impact on our tenants’ reported financial condition or results of operations or could affect our tenants’ preferences regarding leasing real estate, lease structuring and terms of future leases.

Uninsured and underinsured losses could adversely affect our operating results and our ability to make distributions to BioMed Realty, L.P.’s unitholders or BioMed Realty Trust, Inc.’s stockholders.

We carry commercial general liability, “all-risk” property insurance (subject to policy terms, conditions, limitations and exclusions), including fire and extended coverage, terrorism and loss of rental income insurance, covering all of our properties under a blanket portfolio policy, with the exception of property insurance on our McKellar Court, Belward Campus Drive and Shady Grove Road locations, which is carried directly by the tenants in accordance with the terms of their respective leases, and builders’ risk policies or equivalent course of construction coverage for any projects under construction. In addition, we carry workers’ compensation coverage for injury to our employees. We also carry environmental insurance for our properties. This insurance, subject to certain exclusions and deductibles, covers the cost to remediate environmental damage caused by unintentional future spills or the historic presence of previously undiscovered hazardous substances, as well as third-party bodily injury and property damage claims related to the release of hazardous substances. We intend to carry similar insurance with respect to future acquisitions as appropriate. A substantial portion of our properties are located in areas subject to earthquake loss, such as San Diego and San Francisco, California and Seattle, Washington. Although we presently carry earthquake insurance on our properties, the amount of earthquake insurance coverage we carry may not be sufficient to fully cover losses from earthquakes. In addition, we may discontinue earthquake, terrorism, windstorm or other insurance, or may elect not to procure such insurance, on some or all of our properties in the future if the cost of the premiums for any of these policies exceeds, in our judgment, the value of the coverage discounted for the risk of loss.

If we experience a loss that is uninsured or that exceeds policy limits, we could lose the capital invested in the damaged properties as well as the anticipated future cash flows from those properties. In addition, if the damaged properties are subject to recourse indebtedness, we would continue to be liable for the indebtedness, even if these properties were irreparably damaged.

The financial condition of one or more of these insurance companies could significantly deteriorate to the point that they may be unable to pay future insurance claims. This risk has increased as a result of the economic environment in recent years and periodic disruptions in the financial markets. The inability of any of these insurance companies to pay future claims under our policies may adversely affect our financial condition and results of operations.

We could incur significant costs related to government regulation and private litigation over environmental matters involving the presence, discharge or threat of discharge of hazardous or toxic substances, which could adversely affect our operations, the value of our properties, and our ability to make distributions to BioMed Realty, L.P.’s unitholders or BioMed Realty Trust, Inc.’s stockholders.

Our properties may be subject to environmental liabilities. Under various federal, state and local laws, a current or previous owner, operator or tenant of real estate can face liability for environmental contamination created by the presence, discharge or threat of discharge of hazardous or toxic substances. Liabilities can include the cost to investigate, clean up and monitor the actual or threatened contamination and damages caused by the contamination (or threatened contamination). Environmental laws typically impose such liability on the current owner regardless of:

- the owner’s knowledge of the contamination,
- the timing of the contamination,

the cause of the contamination, or
the party responsible for the contamination.

The liability under such laws may be strict, joint and several, meaning that we may be liable regardless of whether we knew of, or were responsible for, the presence of the contaminants, and the government entity or private party may seek recovery of the entire amount from us even if there are other responsible parties. Liabilities associated with environmental conditions may be

19

Table of Contents

significant and can sometimes exceed the value of the affected property. The presence of hazardous substances on a property may adversely affect our ability to sell or rent that property or to borrow using that property as collateral. Some of our properties have had contamination in the past that required cleanup. In most cases, we believe the contamination has been effectively remediated, and that any remaining contamination either does not require remediation or that the costs associated with such remediation will not be material to us. However, we cannot guarantee that additional contamination will not be discovered in the future or any identified contamination will not continue to pose a threat to the environment or that we will not have continued liability in connection with such prior contamination. Our Kendall Street properties, in Cambridge, Massachusetts, are located on the site of a former manufactured gas plant. Various remedial actions were performed on these properties, including soil stabilization to control the spread of oil and hazardous materials in the soil. Another of our properties, Elliott Avenue, has known soil contamination beneath a portion of the building located on the property. Based on environmental consultant reports, management does not believe any remediation of the Elliott Avenue property would be required unless major structural changes were made to the building that resulted in the soil becoming exposed. In addition, the remediation of certain environmental conditions were performed at off-site parcels located in Cambridge, Massachusetts, which was an assumed obligation of PREI II LLC, one of our joint ventures with Prudential Real Estate Investors or PREI. We do not expect these matters to materially adversely affect such properties' value or the cash flows related to such properties, but we can provide no assurances to that effect.

Environmental laws also:

- may require the removal or upgrade of underground storage tanks,
- regulate the discharge of storm water, wastewater and other pollutants,
- regulate air pollutant emissions,
- regulate hazardous materials generation, management and disposal, and
- regulate workplace health and safety.

Life science industry tenants, our primary tenant industry focus, frequently use hazardous materials, chemicals, heavy metals, and biological and radioactive compounds. Our tenants' controlled use of these materials subjects us and our tenants to laws that govern using, manufacturing, storing, handling and disposing of such materials and certain byproducts of those materials. We are unaware of any of our existing tenants violating applicable laws and regulations, but we and our tenants cannot completely eliminate the risk of contamination or injury from these materials. If our properties become contaminated, or if a party is injured, we could be held liable for any damages that result. Such liability could exceed our resources and any environmental remediation insurance coverage we have, which could adversely affect our operations, the value of our properties, and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders. Licensing requirements governing use of radioactive materials by tenants may also restrict the use of or ability to transfer space in buildings we own. We could incur significant costs related to governmental regulation and private litigation over environmental matters involving asbestos-containing materials, which could adversely affect our operations, the value of our properties, and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders. Environmental laws also govern the presence, maintenance and removal of ACMs and may impose fines and penalties, including orders prohibiting the use of the affected property by us or our tenants, if we fail to comply with these requirements. Failure to comply with these laws, or even the presence of ACMs, may expose us to third-party liability. Some of our properties contain ACMs, and we could be liable for such fines or penalties, as described above in "Item 1. Business - Regulation - Environmental Matters."

Our properties may contain or develop harmful mold, which could lead to liability for adverse health effects and costs of remediating the problem, which could adversely affect the value of the affected property and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

When excessive moisture accumulates in buildings or on building materials, mold growth may occur, particularly if the moisture problem remains undiscovered or is not addressed over a period of time. Some molds may produce airborne toxins or irritants. Concern about indoor exposure to mold has been increasing because exposure to mold may cause a variety of adverse health effects and symptoms, including allergic or other reactions. As a result, the presence of significant mold at any of our properties could require us to undertake a costly remediation program to

contain or remove the mold from the affected property. In addition, the presence of significant mold could expose us to liability to our tenants, their or our employees, and others if property damage or health concerns arise. Compliance with the Americans with Disabilities Act (ADA) and similar laws may require us to make significant unanticipated expenditures.

Table of Contents

All of our properties are required to comply with the ADA. The ADA requires that all public accommodations must meet federal requirements related to access and use by disabled persons. Although we believe that our properties substantially comply with present requirements of the ADA, we have not conducted an audit of all of such properties to determine compliance. If one or more properties are not in compliance with the ADA, then we would be required to bring the non-compliant properties into compliance. Compliance with the ADA could require removing access barriers. Non-compliance could result in imposition of fines by the U.S. government or an award of damages and/or attorneys' fees to private litigants, or both. Additional federal, state and local laws also may require us to modify properties or could restrict our ability to renovate properties. Complying with the ADA or other legislation could be very expensive. If we incur substantial costs to comply with such laws, our financial condition, results of operations, cash flow, per share trading price of BioMed Realty Trust, Inc.'s common stock, our ability to satisfy our debt service obligations and our ability to pay distributions to BioMed Realty, L.P.'s unitholders and BioMed Realty Trust, Inc.'s stockholders could be adversely affected.

We may incur significant unexpected costs to comply with fire, safety and other regulations, which could adversely impact our financial condition, results of operations, and ability to make distributions.

Our properties are subject to various federal, state and local regulatory requirements, such as state and local fire and safety requirements, building codes and land use regulations. Failure to comply with these requirements could subject us to governmental fines or private litigant damage awards. In addition, we do not know whether existing requirements will change or whether future requirements, including any requirements that may emerge from pending or future climate change legislation, will require us to make significant unanticipated expenditures that will adversely impact our financial condition, results of operations, cash flow, the per share trading price of BioMed Realty Trust, Inc.'s common stock, our ability to satisfy our debt service obligations and our ability to pay distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

Risks Related to Our Capital Structure

A downgrade in our investment grade credit rating could materially adversely affect our business and financial condition.

There can be no assurance that we will be able to maintain our current credit ratings. Any downgrades in terms of ratings or outlook by either or both of the rating agencies could have a material adverse impact on our cost and availability of capital, which could in turn have a material adverse impact on our financial condition, results of operations and liquidity and a material adverse effect on the market price of BioMed Realty Trust, Inc.'s common stock.

Debt obligations expose us to increased risk of property losses and may have adverse consequences on our business operations and our ability to make distributions.

We have used and will continue to use debt to finance property acquisitions. Our use of debt may have adverse consequences, including the following:

We may not be able to refinance or extend our existing debt. If we cannot repay, refinance or extend our debt at maturity, in addition to our failure to repay our debt, we may be unable to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders at expected levels or at all.

Even if we are able to refinance or extend our existing debt, the terms of any refinancing or extension may not be as favorable as the terms of our existing debt. If the refinancing involves a higher interest rate, it could adversely affect our cash flow and ability to make distributions to unitholders and stockholders.

Required payments of principal and interest may be greater than our cash flow from operations.

We may be forced to dispose of one or more of our properties, possibly on disadvantageous terms, to make payments on our debt.

One or more lenders under our \$900.0 million unsecured line of credit could refuse to fund their financing commitment to us or could fail, and we may not be able to replace the financing commitment of any such lenders on favorable terms, or at all.

If we default on our debt obligations, the lenders or mortgagees may foreclose on our properties that secure those loans. Further, if we default under a mortgage loan, we will automatically be in default on any other loan that has cross-default provisions, and we may lose the properties securing all of these loans.

A foreclosure on one of our properties will be treated as a sale of the property for a purchase price equal to the outstanding balance of the secured debt. If the outstanding balance of the secured debt exceeds our tax basis in the property, we would recognize taxable income on foreclosure without realizing any accompanying cash proceeds to pay the tax (or to make distributions based on REIT taxable income).

Table of Contents

As of December 31, 2013, we had outstanding mortgage indebtedness of approximately \$698.0 million, excluding approximately \$11.3 million of debt premium; \$180.0 million of outstanding aggregate principal amount of the Exchangeable Senior Notes due 2030, or the Exchangeable Senior Notes; \$400.0 million of outstanding aggregate principal amount of the Unsecured Senior Notes due 2016, or the Notes due 2016, excluding approximately \$1.2 million of debt discount; \$250.0 million of outstanding aggregate principal amount of the Unsecured Senior Notes due 2020, or the Notes due 2020, excluding approximately \$1.8 million of debt discount; \$250.0 million of outstanding aggregate principal amount of the Unsecured Senior Notes due 2022, or the Notes due 2022, excluding approximately \$1.9 million of debt discount; approximately \$408.8 million in outstanding borrowings under our senior unsecured term loan facility, or the Unsecured Senior Term Loan; \$478.0 million in outstanding borrowings under our Amended and Restated Credit Facility, consisting of \$128.0 million in outstanding borrowings under the \$900.0 million revolving line of credit component and \$350.0 million outstanding aggregate principal amount under the term loan component; and \$29.2 million of borrowings under a mortgage note and secured loan representing our proportionate share of indebtedness in our unconsolidated partnerships. We expect to incur additional debt in connection with future acquisitions and development. Our organizational documents do not limit the amount or percentage of debt that we may incur. As of December 31, 2013, the principal payments due for our consolidated indebtedness were \$341.4 million in 2014, \$30.0 million in 2015 and \$566.5 million in 2016. Our consolidated indebtedness that matures in 2014 includes a mortgage secured by our Center for Life Science | Boston property. Given recent economic conditions, ongoing challenges impacting the global financial system, and changes in governmental monetary and fiscal policies, we may be unable to refinance these obligations when due or may incur significantly higher borrowing costs to refinance these obligations, which may negatively affect our ability to conduct operations.

Disruptions in the financial markets and the downturn of the broader U.S. economy could affect our ability to obtain debt financing on reasonable terms, or at all, and have other adverse effects on us.

In recent years, the U.S. credit markets have experienced significant dislocations and liquidity disruptions. These circumstances have materially impacted liquidity in the debt markets, and in certain cases have resulted in the unavailability of certain types of debt financing. Uncertainty in the credit markets may negatively impact our ability to access additional debt financing or to refinance existing debt maturities on reasonable terms (or at all), which may negatively affect our ability to conduct operations, make acquisitions and fund current and future development and redevelopment projects. In addition, if the financial position of the lenders under our unsecured line of credit worsened they could default on their obligations to make available to us the funds under that facility. A prolonged downturn in the credit markets may cause us to seek alternative sources of potentially less attractive financing, and may require us to adjust our business plan accordingly. In addition, these factors could make it more difficult for us to sell properties or adversely affect the price we receive for properties that we do sell, as prospective buyers may experience increased costs of debt financing or difficulties in obtaining debt financing. Adverse events in the credit markets could also have an adverse effect on other financial markets in the United States and globally, including the stock markets, which could make it more difficult or costly for us to raise capital through the issuance of common stock, preferred stock or other equity securities.

Reduced access to liquidity could have a negative impact on the U.S. economy, affecting consumer confidence and spending and negatively impacting the volume and pricing of real estate transactions. If there were a downturn in the national economy, the value of our properties, as well as the income we receive from our properties, could be adversely affected.

Disruptions in the financial markets could also have other adverse effects on us or the economy generally, which could adversely affect our ability to service our debt obligations and our ability to pay distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

Increases in interest rates could increase the amount of our debt payments, adversely affecting our ability to service our debt obligations and pay distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

Interest we pay reduces cash available for payments with respect to distributions. In addition, our unsecured line of credit, a portion of our Term Loan due 2017, a portion of our Term Loan due 2018, the outstanding balance of a mortgage secured by a property in Pennsylvania and our proportionate share of the outstanding balance of the PREI

joint ventures' secured construction loan bear interest at variable rates, and we may incur additional variable rate debt in the future. To the extent that our variable rate debt is not adequately hedged, increases in interest rates would increase our interest costs. These increased interest costs would reduce our cash flows and our ability to make payments with respect to distributions to BioMed Realty, L.P.'s unitholders and BioMed Realty Trust, Inc.'s stockholders. In addition, if we need to repay existing debt during a period of rising interest rates, we could be required to liquidate one or more of our investments in properties at times that may not permit realization of the maximum return on such investments.

In recent years, extraordinary monetary policy actions of the U.S. Federal Reserve and other central banking institutions were taken with the purpose of creating and maintaining a low interest rate environment, including the utilization of quantitative easing. Changes in the Federal Reserve's and other central banks' monetary policy positions, including but not limited to an elimination of quantitative easing over time, or market expectation of such changes, may result in significantly higher long-term interest rates,

Table of Contents

the transition to which may also be abrupt. Such a transition may, among other things, reduce the availability and/or increase the costs of obtaining new debt and refinancing existing indebtedness, result in a decrease in the value of our real estate, and negatively impact the market price of BioMed Realty Trust, Inc.'s common stock.

The terms governing our Amended and Restated Credit Facility, Notes due 2016, Notes due 2020 and Notes due 2022 include restrictive covenants relating to our operations, which could limit our ability to respond to changing market conditions and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

The terms of our Amended and Restated Credit Facility impose restrictions on us that affect our distribution and operating policies and our ability to incur additional debt, including financial covenants relating to the minimum amounts of net worth, fixed charge coverage, unsecured debt service coverage, overall leverage and unsecured leverage ratios, the maximum amount of secured indebtedness and certain investment limitations. The indentures governing the Notes due 2016, the Notes due 2020 and the Notes due 2022 also contain financial and operating covenants that, among other things, restrict our ability to take specific actions, even if we believe them to be in our best interest, including restrictions on our ability to (1) consummate a merger, consolidation or sale of all or substantially all of our assets and (2) incur additional secured and unsecured indebtedness.

The covenants relating to our Amended and Restated Credit Facility, the Notes due 2016, the Notes due 2020 and the Notes due 2022 may adversely affect our flexibility and our ability to achieve our operating plans. Our ability to comply with these covenants and other provisions relating to our Amended and Restated Credit Facility and the indentures governing the Notes due 2016, the Notes due 2020 and the Notes due 2022 may be affected by changes in our operating and financial performance, changes in general business and economic conditions, adverse regulatory developments or other events adversely impacting us. The breach of any of these covenants could result in a default under our indebtedness, which could cause those and other obligations to become due and payable. If any of our indebtedness is accelerated, we may not be able to repay it, pursue our business plan or make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders.

If we fail to obtain external sources of capital, which is outside of our control, we may be unable to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders, maintain our REIT qualification, or fund growth.

In order to maintain BioMed Realty Trust, Inc.'s qualification as a REIT and to avoid incurring a nondeductible excise tax, we are required, among other things, to distribute annually at least 90% of BioMed Realty Trust, Inc.'s REIT taxable income, excluding any net capital gain. In addition, we will be subject to income tax at regular corporate rates to the extent that we distribute less than 100% of BioMed Realty Trust, Inc.'s net taxable income, including any net capital gains. Because of these distribution requirements, we may not be able to fund future capital needs, including any necessary acquisition financing, from operating cash flow. Consequently, we rely on third-party sources to fund our capital needs. We may not be able to obtain financings on favorable terms or at all. Our access to third-party sources of capital depends, in part, on:

- general market conditions
- the market's perception of our growth potential,
- with respect to acquisition financing, the market's perception of the value of the properties to be acquired,
 - our current debt levels,
- our current and expected future earnings,
- our cash flow and cash distributions, and
- the market price of BioMed Realty Trust, Inc.'s common stock.

Our inability to obtain capital from third-party sources will adversely affect our business and limit our growth. Without sufficient capital, we may not be able to acquire or develop properties when strategic opportunities exist, satisfy our debt service obligations or make the cash distributions to BioMed Realty Trust, Inc.'s stockholders necessary to maintain our qualification as a REIT.

We have and may continue to engage in hedging transactions, which can limit our gains and increase exposure to losses.

We have and may continue to enter into hedging transactions to protect us from the effects of interest rate fluctuations on floating-rate debt. Our hedging transactions may include entering into interest rate swap agreements or interest rate cap or floor agreements, or other interest rate exchange contracts. Hedging activities may not have the desired beneficial impact on our results of operations or financial condition. No hedging activity can completely insulate us from the risks associated with changes in interest rates. Moreover, interest rate hedging could fail to protect us or adversely affect us because, among other things:

23

Table of Contents

• Available interest rate hedging may not correspond directly with the interest rate risk for which we seek protection.

• The duration or the amount of the hedge may not match the duration or amount of the related liability.

• The party owing money in the hedging transaction may default on its obligation to pay.

• The credit quality of the party owing money on the hedge may be downgraded to such an extent that it impairs our ability to sell or assign our side of the hedging transaction.

The value of derivatives used for hedging may be adjusted from time to time in accordance with accounting rules to reflect changes in fair-value. Downward adjustments, or “mark-to-market losses,” would reduce our stockholders’ equity.

Hedging involves risk and typically involves costs, including transaction costs, that may reduce our overall returns on our investments. These costs increase as the period covered by the hedging increases and during periods of rising and volatile interest rates. These costs will also limit the amount of cash available for distribution to stockholders. We generally intend to hedge as much of the interest rate risk as management determines is in our best interests given the cost of such hedging transactions. The REIT qualification rules may limit our ability to enter into hedging transactions by requiring us to limit our income from hedges. If we are unable to hedge effectively because of the REIT rules, we will face greater interest rate exposure than may be commercially prudent.

We are subject to risks associated with tax credits, grants and other subsidies utilized to partially fund construction activities.

We are a party from time to time to certain contractual arrangements established with the intent to receive the benefits of historic tax credits, new market tax credits, tax increment financings, grants and other subsidies, which we have utilized and intend to continue to utilize to fund a portion of the development costs at certain of our properties. Risks associated with these arrangements include, among others:

• non-compliance with applicable laws, regulations and contractual provisions could result in projected benefits not being realized, and, with regard to historic tax credits and new market tax credits, require a refund or reduction of capital contributions from the investor that is a party to that transaction;

• counterparty credit risks and funding risks, including, for example, the reliance in part on increasing real estate values to repay investors in tax increment financing transactions;

• changes in government rules that eliminate, reduce or otherwise adversely affect our ability to qualify for the benefits of these arrangements; and

• potential increases in federal income taxes on taxable income at regular corporate tax rates for certain arrangements where we are required to utilize a taxable REIT subsidiary.

Our inability to effectively utilize tax credits, grants and other subsidies to partially fund construction activities, or any required refund or reduction of capital contributions in connection with tax credit financing, could adversely affect our business and limit our growth.

Risks Related to Our Organizational Structure

BioMed Realty, L.P.’s Partnership Agreement, BioMed Realty Trust, Inc.’s charter and Maryland law contain provisions that may delay, defer or prevent a change of control transaction and may prevent stockholders from receiving a premium for their shares.

The limited partners of the operating partnership have limited approval rights, which may prevent BioMed Realty Trust, Inc. from completing a change of control transaction. BioMed Realty Trust, Inc., as the general partner of the operating partnership, may not withdraw as general partner or transfer its general partnership interest in the operating partnership without the consent of limited partners holding more than 50% of the operating partnership units held by all limited partners (excluding any limited partners owned or controlled by BioMed Realty Trust, Inc.). In addition, except in certain circumstances, BioMed Realty Trust, Inc., as general partner of the operating partnership, may not engage in a merger, consolidation, or other combination or the sale of all or substantially all of its assets or such similar transaction, without the consent of the partners holding more than 50% of all outstanding common operating partnership units, including the units held by BioMed Realty Trust, Inc., as more fully set forth in the partnership agreement of the operating partnership. The right of the limited partners to vote on these transactions could limit our ability to complete a change of control transaction that might otherwise be in the best interests of BioMed Realty, L.P.’s unitholders and BioMed Realty Trust, Inc.’s stockholders.

BioMed Realty Trust, Inc.'s charter contains ownership limits that may delay, defer or prevent a change of control transaction. BioMed Realty Trust, Inc.'s charter, with certain exceptions, authorizes BioMed Realty Trust, Inc.'s directors to take such actions as are necessary and desirable to preserve its qualification as a REIT. Unless exempted by its board of directors, no

Table of Contents

person may own more than 9.8% of the value of BioMed Realty Trust, Inc.'s outstanding shares of capital stock or more than 9.8% in value or number (whichever is more restrictive) of the outstanding shares of its common stock. The board may not grant such an exemption to a person whose ownership in excess of 9.8% of BioMed Realty Trust, Inc.'s outstanding shares would result in BioMed Realty Trust, Inc.'s failure to qualify as a REIT. These restrictions on transferability and ownership will not apply if BioMed Realty Trust, Inc.'s board of directors determines that it is no longer in BioMed Realty Trust, Inc.'s best interests to qualify as a REIT. The ownership limit may delay or impede a transaction or a change of control that might involve a premium price for BioMed Realty Trust, Inc.'s common stock or otherwise be in the best interests of its stockholders.

BioMed Realty Trust, Inc. could authorize and issue stock without stockholder approval that may delay, defer or prevent a change of control transaction. BioMed Realty Trust, Inc.'s charter authorizes it to issue additional authorized but unissued shares of its common stock or preferred stock. In addition, BioMed Realty Trust, Inc.'s board of directors may classify or reclassify any unissued shares of BioMed Realty Trust, Inc.'s common stock or preferred stock and may set the preferences, rights and other terms of the classified or reclassified shares. The board may also, without stockholder approval, amend BioMed Realty Trust, Inc.'s charter to increase or decrease the authorized number of shares of BioMed Realty Trust, Inc.'s common stock or preferred stock that it may issue. The board of directors could establish a class or series of common stock or preferred stock that could, depending on the terms of such class or series, delay, defer or prevent a transaction or a change of control that might involve a premium price for BioMed Realty Trust, Inc.'s common stock or otherwise be in the best interests of its stockholders.

Certain provisions of Maryland law could delay, defer or prevent a change of control transaction. Certain provisions of the Maryland General Corporation Law, or the MGCL, may have the effect of inhibiting a third party from making a proposal to acquire us or of impeding a change of control. In some cases, such an acquisition or change of control could provide BioMed Realty Trust, Inc.'s stockholders with the opportunity to realize a premium over the then-prevailing market price of their shares. These MGCL provisions include:

“business combination” provisions that, subject to limitations, prohibit certain business combinations between us and an “interested stockholder” or an affiliate of an interested stockholder for certain periods. An “interested stockholder” is generally any person who beneficially owns 10% or more of the voting power of BioMed Realty Trust, Inc.'s outstanding voting shares or an affiliate or associate of ours who, at any time within the two-year period immediately prior to the date in question, was the beneficial owner of 10% or more of the voting power of BioMed Realty Trust, Inc.'s then outstanding stock. A person is not an interested stockholder under the statute if the board of directors approved in advance the transaction by which he otherwise would have become an interested stockholder. Business combinations with an interested stockholder are prohibited for five years after the most recent date on which the stockholder becomes an interested stockholder. After that period, the MGCL imposes two super-majority voting requirements on such business combinations, and

“control share” provisions that provide that holders of “control shares” of BioMed Realty Trust, Inc. acquired in a “control share acquisition” have no voting rights except to the extent approved by a vote of two-thirds of the votes entitled to be cast on the matter (excluding interested shares). “Control shares” are voting shares that, when aggregated with all other shares owned by the stockholder or in respect of which the stockholder is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), entitle the stockholder to exercise one of three increasing ranges of voting power in electing directors. A “control share acquisition” is the direct or indirect acquisition of ownership or control of “control shares.”

In the case of the business combination provisions of the MGCL, we opted out by resolution of BioMed Realty Trust, Inc.'s board of directors with respect to any business combination between us and any person provided such business combination is first approved by BioMed Realty Trust, Inc.'s board of directors (including a majority of directors who are not affiliates or associates of such person). In the case of the control share provisions of the MGCL, we opted out pursuant to a provision in BioMed Realty Trust, Inc.'s bylaws. However, BioMed Realty Trust, Inc.'s board of directors may by resolution elect to opt in to the business combination provisions of the MGCL. Further, we may opt in to the control share provisions of the MGCL in the future by amending BioMed Realty Trust, Inc.'s bylaws, which BioMed Realty Trust, Inc.'s board of directors can do without stockholder approval.

The partnership agreement of BioMed Realty, L.P., Maryland law, and BioMed Realty Trust, Inc.'s charter and bylaws also contain other provisions that may delay, defer or prevent a transaction or a change of control that might involve a premium price for BioMed Realty Trust, Inc.'s common stock or otherwise be in the best interests of its stockholders. Changes to our investing and financing strategies could increase the risk we default under our debt obligations or could harm our business and results of operations.

Our organizational documents do not limit the amount or percentage of debt that we may incur, nor do they limit the types of properties we may acquire or develop. Changes to our investing and financing strategies could expose us to greater credit risk and interest rate risk and could also result in a more leveraged balance sheet. These factors could result in an increase in our debt

Table of Contents

service and could adversely affect our cash flow and our ability to make distributions to BioMed Realty, L.P.'s unitholders or BioMed Realty Trust, Inc.'s stockholders. Higher leverage also increases the risk we could default on our debt.

We may invest in properties with other entities, and our lack of sole decision-making authority or reliance on a co-venturer's financial condition could make these joint venture investments risky.

We have in the past and may continue in the future to co-invest with third parties through partnerships, joint ventures or other entities. We may acquire non-controlling interests or share responsibility for managing the affairs of a property, partnership, joint venture or other entity. In such events, we would not be in a position to exercise sole decision-making authority regarding the property or entity. Investments in entities may, under certain circumstances, involve risks not present were a third party not involved. These risks include the possibility that partners or co-venturers:

- might become bankrupt or fail to fund their share of required capital contributions,

- may have economic or other business interests or goals that are inconsistent with our business interests or goals, and

- may be in a position to take actions contrary to our policies or objectives.

Such investments may also have the potential risk of impasses on decisions, such as a sale, because neither we nor the partner or co-venturer would have full control over the partnership or joint venture. Disputes between us and partners or co-venturers may result in litigation or arbitration that would increase our expenses and prevent our officers and/or directors from focusing their time and effort on our business. In addition, we may in certain circumstances be liable for the actions of our third-party partners or co-venturers if:

- we structure a joint venture or conduct business in a manner that is deemed to be a general partnership with a third party, in which case we could be liable for the acts of that third party,

- third-party managers incur debt or other liabilities on behalf of a joint venture which the joint venture is unable to pay,

- and the joint venture agreement provides for capital calls, in which case we could be liable to make contributions as set forth in any such joint venture agreement, or

- we agree to cross-default provisions or to cross-collateralize our properties with the properties in a joint venture, in

- which case we could face liability if there is a default relating to those properties in the joint venture or the obligations relating to those properties.

We have had investments in joint ventures with PREI since 2007. While we, as managing member, are authorized to carry out the day-to-day management of the business and affairs of the PREI joint ventures, PREI's prior written consent is required for certain decisions, including decisions relating to financing, budgeting and the sale or pledge of interests in the properties owned by the PREI joint ventures.

Risks Related to BioMed Realty Trust, Inc.'s REIT Status

BioMed Realty Trust, Inc.'s failure to qualify as a REIT under the Code would result in significant adverse tax consequences to us and would adversely affect our business.

We believe that we have operated and intend to continue operating in a manner intended to allow BioMed Realty Trust, Inc. to qualify as a REIT for federal income tax purposes under the Internal Revenue Code of 1986, as amended, or the Code. Qualification as a REIT involves the application of highly technical and complex Code provisions for which there are only limited judicial and administrative interpretations. The fact that we hold substantially all of our assets through our operating partnership further complicates the application of the REIT requirements. Even a seemingly minor technical or inadvertent mistake could jeopardize BioMed Realty Trust, Inc.'s REIT status. BioMed Realty Trust, Inc.'s REIT status depends upon various factual matters and circumstances that may not be entirely within our control. For example, in order for BioMed Realty Trust, Inc. to qualify as a REIT, at least 95% of our gross income in any year must be derived from qualifying sources, and we must satisfy a number of requirements regarding the composition of our assets. Also, BioMed Realty Trust, Inc. must make distributions to stockholders aggregating annually at least 90% of BioMed Realty Trust, Inc.'s REIT taxable income, excluding net capital gains. In addition, new legislation, regulations, administrative interpretations or court decisions, each of which could have retroactive effect, may make it more difficult or impossible for BioMed Realty Trust, Inc. to qualify as a REIT, or could reduce the desirability of an investment in a REIT relative to other investments. We have not requested and do not plan to request a ruling from the IRS that BioMed Realty Trust, Inc. qualifies as a REIT, and the statements

in this report are not binding on the IRS or any court. Accordingly, we cannot be certain that BioMed Realty Trust, Inc. has qualified or will continue to qualify as a REIT.

If BioMed Realty Trust, Inc. fails to qualify as a REIT in any taxable year, we will face serious adverse tax consequences that would substantially reduce the funds available to make payments of principal and interest on the debt securities we issue and for distribution to BioMed Realty Trust, Inc.'s stockholders. If BioMed Realty Trust, Inc. fails to qualify as a REIT:

Table of Contents

we would not be allowed to deduct distributions to stockholders in computing our taxable income and would be subject to federal income tax at regular corporate rates, we could also be subject to the federal alternative minimum tax and possibly increased state and local taxes, and unless we are entitled to relief under applicable statutory provisions, BioMed Realty Trust, Inc. could not elect to be taxed as a REIT for four taxable years following the year in which BioMed Realty Trust, Inc. was disqualified. In addition, if BioMed Realty Trust, Inc. fails to qualify as a REIT, we will not be required to make distributions to stockholders; however, distributions to BioMed Realty Trust, Inc.'s stockholders would be subject to tax as corporate dividends to the extent of our current and accumulated earnings and profits. As a result of all these factors, BioMed Realty Trust, Inc.'s failure to qualify as a REIT could impair our ability to expand our business and raise capital and would adversely affect the value of BioMed Realty Trust, Inc.'s common stock.

To maintain BioMed Realty Trust, Inc.'s REIT status, we may be forced to borrow funds during unfavorable market conditions to make distributions to BioMed Realty Trust, Inc.'s stockholders.

For BioMed Realty Trust, Inc. to qualify as a REIT, we generally must distribute to BioMed Realty Trust, Inc.'s stockholders at least 90% of our REIT taxable income each year, determined by excluding any net capital gain, and we will be subject to regular corporate income taxes to the extent that we distribute less than 100% of our REIT taxable income each year. In addition, we will be subject to a 4% nondeductible excise tax on the amount, if any, by which distributions paid by us in any calendar year are less than the sum of 85% of our ordinary income, 95% of our capital gain net income and 100% of our undistributed income from prior years. To maintain BioMed Realty Trust, Inc.'s REIT status and avoid the payment of income and excise taxes we may need to borrow funds to meet the REIT distribution requirements. These borrowing needs could result from:

- differences in timing between the actual receipt of cash and inclusion of income for federal income tax purposes,
- the effect of non-deductible capital expenditures,
- the creation of reserves, or
- required debt or amortization payments.

We may need to borrow funds at times when the then-prevailing market conditions are not favorable for borrowing. These borrowings could increase our costs or reduce our equity and adversely affect the value of BioMed Realty Trust, Inc.'s common stock.

To maintain BioMed Realty Trust, Inc.'s REIT status, we may be forced to forego otherwise attractive opportunities. For BioMed Realty Trust, Inc. to qualify as a REIT, we must satisfy tests concerning, among other things, the sources of our income, the nature and diversification of our assets, the amounts we distribute to BioMed Realty Trust, Inc.'s stockholders and the ownership of BioMed Realty Trust, Inc.'s stock. We may be required to make distributions to BioMed Realty Trust, Inc.'s stockholders at times when it would be more advantageous to reinvest cash in our business or when we do not have funds readily available for distribution. Thus, compliance with the REIT requirements may hinder our ability to operate solely on the basis of maximizing profits.

Risks Related to the Ownership of BioMed Realty Trust, Inc. Stock

The market price and trading volume of BioMed Realty Trust, Inc.'s common stock may be volatile.

The market price of BioMed Realty Trust, Inc.'s common stock has recently been, and may continue to be, volatile. In addition, the trading volume in BioMed Realty Trust, Inc.'s common stock may fluctuate and cause significant price variations to occur. We cannot assure you that the market price of BioMed Realty Trust, Inc.'s common stock will not fluctuate or decline significantly in the future.

Some of the factors that could negatively affect BioMed Realty Trust, Inc.'s share price or result in fluctuations in the price or trading volume of BioMed Realty Trust, Inc.'s common stock include:

- actual or anticipated variations in our quarterly operating results or distributions,
- changes in our funds from operations or earnings estimates,
- publication of research reports about us or the real estate industry,
- increases in market interest rates that lead purchasers of BioMed Realty Trust, Inc.'s shares to demand a higher yield,
- changes in market valuations of similar companies,
- adverse market reaction to any additional debt we incur or acquisitions we make in the future,

Table of Contents

• additions or departures of key management personnel,
• actions by institutional stockholders,
• speculation in the press or investment community,
• the realization of any of the other risk factors presented in this report, and
• general market and economic conditions.

Broad market fluctuations could negatively impact the market price of BioMed Realty Trust, Inc.'s common stock.

The stock market has experienced continuing significant price and volume fluctuations that have affected the market price of the securities of many companies in industries similar or related to ours and that have been unrelated to these companies' operating performance. These broad market fluctuations could reduce the market price of BioMed Realty Trust, Inc.'s common stock. Furthermore, our operating results and prospects may be below the expectations of public market analysts and investors or may be lower than those of companies with comparable market capitalizations. Either of these factors could lead to a material decline in the market price of BioMed Realty Trust, Inc.'s common stock.

Market interest rates may have an adverse effect on the market price of BioMed Realty Trust, Inc.'s common stock.

One of the factors that will influence the price of BioMed Realty Trust, Inc.'s common stock will be the dividend yield on such stock (as a percentage of the price of the stock) relative to market interest rates. An increase in market interest rates may lead prospective purchasers of BioMed Realty Trust, Inc.'s common stock to expect a higher dividend yield, and higher interest rates would likely increase our borrowing costs and potentially decrease funds available for distribution. Thus, higher market interest rates could cause the market price of BioMed Realty Trust, Inc.'s common stock to fall.

Our distributions to unitholders and stockholders may decline at any time.

We may not continue our current level of distributions to unitholders and stockholders. BioMed Realty Trust, Inc.'s board of directors will determine future distributions based on a number of factors, including:

• cash available for distribution,
• operating results,
• our financial condition, especially in relation to our anticipated future capital needs,
• then current expansion plans,
• the distribution requirements for REITs under the Code, and
• other factors our board deems relevant.

In April 2009, in an effort to maintain financial flexibility in light of the capital markets environment, we reset our annual dividend rate on shares of BioMed Realty Trust, Inc.'s common stock and the annual distribution rate on BioMed Realty, L.P.'s OP units to \$0.44 per share or unit, starting in the second quarter of 2009. We subsequently increased these rates periodically and most recently declared dividends and distributions equal to an annualized rate of \$1.00 per share or unit, starting in the fourth quarter of 2013. The decision to declare and pay dividends on shares of BioMed Realty Trust, Inc.'s common stock or distributions to BioMed Realty, L.P.'s OP units in the future, as well as the timing, amount and composition of any such future dividends, will be at the sole discretion of BioMed Realty Trust, Inc.'s board of directors in light of conditions then existing, including our earnings, financial condition, capital requirements, debt maturities, the availability of debt and equity capital, applicable REIT and legal restrictions and the general overall economic conditions and other factors. Any change in our dividend policy could have a material adverse effect on the market price of BioMed Realty Trust, Inc.'s common stock.

The number of shares of BioMed Realty Trust, Inc.'s common stock available for future sale could adversely affect the market price of BioMed Realty Trust, Inc.'s common stock.

We cannot predict whether future issuances of shares of BioMed Realty Trust, Inc.'s common stock or the availability of shares for resale in the open market will decrease the market price of BioMed Realty Trust, Inc.'s common stock. As of December 31, 2013, 192,115,002 shares of BioMed Realty Trust, Inc.'s common stock were issued and outstanding, as well as BioMed Realty L.P.'s operating partnership units and LTIP units which may be exchanged for 5,083,400 and 332,574 shares of BioMed Realty Trust, Inc.'s common stock, respectively, based on the number of shares of common stock, operating partnership units and LTIP units outstanding as of December 31, 2013. In addition, as of December 31, 2013, we had reserved an additional 6,217,404 shares of common stock for future issuance under our incentive award plan, and 10,405,224 shares potentially issuable upon exchange of the Exchangeable Senior Notes

(based on the exchange rate as of December 31, 2013). Sales of substantial amounts of shares of BioMed Realty Trust, Inc.'s common stock in the public market, or upon exchange of operating partnership units, LTIP units,

Table of Contents

or the Exchangeable Senior Notes, or the perception that such sales might occur, could adversely affect the market price of BioMed Realty Trust, Inc.'s common stock.

Furthermore, under the rules adopted by the Securities and Exchange Commission regarding registration and offering procedures, if we meet the definition of a "well-known seasoned issuer" under Rule 405 of the Securities Act, we are permitted to file an automatic shelf registration statement that will be immediately effective upon filing. On August 31, 2012, we filed such an automatic shelf registration statement which may permit us, from time to time, to offer and sell debt securities, common stock, preferred stock, warrants and other securities to the extent necessary or advisable to meet our liquidity needs.

Any of the following could have an adverse effect on the market price of BioMed Realty Trust, Inc.'s common stock:

- the exchange of operating partnership units, LTIP units or the Exchangeable Senior Notes,

- additional grants of LTIP units, restricted stock or other securities to our directors, executive officers and other employees under our incentive award plan,

- issuances of preferred stock with liquidation or distribution preferences, and

- other issuances of BioMed Realty Trust, Inc.'s common stock.

Additionally, the existence of operating partnership units, LTIP units or the Exchangeable Senior Notes and shares of BioMed Realty Trust, Inc.'s common stock reserved for issuance upon exchange of operating partnership units, LTIP units or the Exchangeable Senior Notes and under our incentive award plan may adversely affect the terms upon which we may be able to obtain additional capital through the sale of equity securities. In addition, future sales of shares of BioMed Realty Trust, Inc.'s common stock may be dilutive to existing stockholders.

From time to time we also may issue shares of BioMed Realty Trust, Inc.'s common stock or BioMed Realty, L.P. operating partnership units in connection with property, portfolio or business acquisitions. We may grant additional demand or piggyback registration rights in connection with these issuances. Sales of substantial amounts of BioMed Realty Trust, Inc.'s common stock, or the perception that these sales could occur, may adversely affect the prevailing market price of BioMed Realty Trust, Inc.'s common stock or may adversely affect the terms upon which we may be able to obtain additional capital through the sale of equity securities.

Risks Related to International Operations

Our ownership of Granta Park in the United Kingdom and future activities outside the United States may subject us to risks different from and potentially greater than those associated with our domestic operations.

In June 2012, we acquired Granta Park, comprising eleven laboratory and office buildings and a total of approximately 472,200 square feet of space, as well as approximately 138,400 square feet of development and expansion rights, in Cambridge, United Kingdom. The purchase price for the property was £126.8 million, or approximately \$196.0 million (based on the exchange rate in effect as of June 8, 2012), excluding transaction costs. In addition to Granta Park, in the future we may underwrite and acquire other properties or interests in real estate related entities in international markets that are new to us. Our international investments, consisting only of Granta Park, constituted 3.1% of our total gross assets as of December 31, 2013.

International development, ownership and operating activities involve risks that are different from and potentially greater than those we face with respect to our domestic properties and operations. These risks include but are not limited to:

-

our limited knowledge of and relationships with sellers, tenants, contractors, suppliers or other parties in these markets,

• challenges in managing and integrating international operations, development and redevelopment, including difficulty in hiring qualified management, sales and construction personnel and service providers in a timely fashion,

• changes in foreign political, regulatory and economic conditions, including regionally, nationally and locally,

• challenges of complying with a wide variety of foreign laws and regulations, including those relating to real estate, corporate governance, operations, taxes, employment and legal proceedings,

Table of Contents

- establishing effective controls and procedures to regulate the operations of new offices and to monitor compliance with U.S. laws and regulations such as the Foreign Corrupt Practices Act and similar foreign laws and regulations,

- adverse effects of changes in exchange rates for foreign currencies,

- challenges with respect to the repatriation of foreign earnings,

- differences in lending practices, and

- differences in languages, cultures and time zones.

The realization of any of these risks could have an adverse impact on our results of operations and financial condition.

We are subject to risks from potential fluctuations in exchange rates between the U.S. dollar and foreign currencies.

We acquired Granta Park in June 2012, and may acquire additional properties in the United Kingdom or in other countries where the U.S. dollar is not the local currency. As a result, we are subject to international currency risk from the potential fluctuations in exchange rates between the U.S. dollar and the local currency. A significant decrease in the value of the British pound or other currencies in countries where we may have an investment could materially affect our results of operations. We may attempt to mitigate such effects by borrowing in the local foreign currency in which we invest and, under certain circumstances, by hedging exchange rate fluctuations; however, access to capital may be more restricted, or unavailable on favorable terms or at all, in certain locations, and we cannot assure you that our efforts will successfully neutralize all international currency risks. In addition, any international currency gain recognized with respect to changes in exchange rates may not qualify under the 75% gross income test or the 95% gross income test that we must satisfy annually in order to qualify and maintain our status as a REIT.

Risks Related to Our Other Investments

We face risks associated with our investment in a construction loan secured by a property under development and future investments in loans, including a failure of an underlying property to perform to expectations and potential principal losses on our investment.

In May 2012, we purchased a \$255.0 million interest in a \$355.0 million construction loan, or the Construction Loan, secured by first priority mortgages on the properties owned and under development by the borrower located in Boston, Massachusetts, and may make similar investments in the future. We began funding the Construction Loan in monthly draws starting in the fourth quarter of 2012 and expect to fund the full balance of the Construction Loan by the third quarter of 2014. We face risks associated with our investment in the Construction Loan and other similar investments that we may undertake in the future, including the following:

- A loan may become non-performing or sub-performing for a variety of reasons outside of our control, including, without limitation, because the underlying property is too highly leveraged, the borrower falls upon financial distress or the property fails to perform as expected, resulting in the borrower being unable to meet its debt service obligations to us.

- A non-performing or sub-performing loan may require a substantial amount of workout negotiations and/or restructuring, which may divert the attention of our management from other activities and entail, among other things, a substantial reduction in the interest rate, capitalization of interest payments and a substantial write-down of the principal of the loan.

-

If we find it necessary or desirable to foreclose on one or more loans we acquire, the foreclosure process may be lengthy and expensive, with an uncertain outcome, and the underlying property's value may deteriorate as a result.

As is the case with our investment in the Construction Loan, we may co-invest in mortgage loans with other investors. As a result, we may lack sole decision-making authority, rely on co-investors' financial condition and/or have disputes between us and other co-investors. In addition, such co-investors may become bankrupt or fail to fund their share of required capital contributions, have economic or other business interests or goals that are inconsistent with our business interests or goals, or take actions contrary to our policies or objectives.

The realization of any of these risks could have an adverse impact on our results of operations and financial condition.

External factors may adversely impact the valuation of our investments in publicly traded companies, privately held companies and venture capital funds.

Table of Contents

We hold investments in certain publicly traded companies, privately held companies and venture capital funds primarily involved in the life science industry. The valuation of these investments is affected by many external factors beyond our control, including, but not limited to, market prices, economic conditions, prospects for favorable or unfavorable clinical trial results, the availability of financing sources, legislative developments, new product initiatives and new collaborative agreements. Unfavorable developments with respect to any of these factors may have an adverse impact on the valuation of our investments.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

Existing Portfolio

At December 31, 2013, we owned or had interests in a portfolio of properties with an aggregate of approximately 16.3 million rentable square feet.

The following reflects the classification of our properties between stabilized properties (operating properties in which more than 90% of the rentable square footage is under lease), lease up properties (operating properties in which less than 90% of the rentable square footage is under lease), development properties (properties that are currently under development through ground up construction), redevelopment properties (properties that are currently being prepared for their intended use), pre-development properties (development properties that are engaged in activities related to planning, entitlement, or other preparations for future construction), unconsolidated partnership properties (properties which we partially own, but are not included in our consolidated financial statements) and development potential (representing management's estimates of rentable square footage if development of these properties was undertaken) at December 31, 2013:

| | Gross Book Value (In thousands) | Buildings | Rentable Square Feet | Weighted- Average Leased (1) | |
|--------------------------------------|---------------------------------------|-----------|-------------------------|------------------------------------|---|
| Stabilized | \$4,116,424 | 115 | 9,544,945 | 99.1 | % |
| Lease up | 1,447,689 | 60 | 5,554,641 | 69.6 | % |
| Total operating portfolio | 5,564,113 | 175 | 15,099,586 | 91.4 | % |
| Development | 95,479 | 4 | 694,305 | 59.2 | % |
| Redevelopment | 31,944 | 2 | 146,000 | 97.6 | % |
| Unconsolidated partnership portfolio | 32,069 | 3 | 355,080 | 77.3 | % |
| Pre-development | 106,999 | — | 1,057,000 | — | |
| Development potential | 204,945 | — | 3,866,000 | — | |
| Total portfolio | \$6,035,549 | 184 | 21,217,971 | | |

(1) Calculated based on gross book value for each asset multiplied by the percentage leased.

Our total portfolio by market at December 31, 2013 was as follows:

Table of Contents

| Market | Leased Square Feet | Current (1) | | | Expiration (2) | | |
|---|--------------------|-------------------------------------|---------------------------------|---------------------------------------|-------------------------------------|---------------------------------|---------------------------------------|
| | | Annualized Base Rent (In thousands) | Percent of Annualized Base Rent | Annualized Base Rent per Leased Sq Ft | Annualized Base Rent (In thousands) | Percent of Annualized Base Rent | Annualized Base Rent per Leased Sq Ft |
| Boston | 3,175,494 | \$ 175,937 | 34.0 | % \$ 55.40 | \$ 190,347 | 31.4 | % \$ 59.94 |
| Maryland | 1,875,757 | 71,177 | 13.8 | % 37.95 | 87,273 | 14.4 | % 46.53 |
| San Diego | 1,794,360 | 60,133 | 11.6 | % 33.51 | 74,975 | 12.4 | % 41.78 |
| San Francisco | 2,441,023 | 59,248 | 11.5 | % 24.27 | 72,090 | 11.9 | % 29.53 |
| New York / New Jersey | 1,518,705 | 53,568 | 10.4 | % 35.27 | 66,641 | 11.0 | % 43.88 |
| Pennsylvania | 949,904 | 24,102 | 4.7 | % 25.37 | 28,333 | 4.7 | % 29.83 |
| Cambridge, UK | 470,015 | 17,572 | 3.4 | % 37.39 | 17,572 | 2.9 | % 37.39 |
| North Carolina | 771,467 | 13,369 | 2.6 | % 17.33 | 17,363 | 2.9 | % 22.51 |
| Seattle | 265,142 | 11,622 | 2.2 | % 43.83 | 14,556 | 2.4 | % 54.90 |
| University Related - Other | 1,058,335 | 30,492 | 5.8 | % 28.81 | 37,184 | 6.0 | % 35.13 |
| Total portfolio / weighted- average | 14,320,202 | \$ 517,220 | 100.0 | % \$ 36.12 | \$ 606,334 | 100.0 | % \$ 42.34 |

(1) Current annualized base rent is the monthly contractual rent as of the period end, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.

(2) Annualized base rent at expiration is the monthly contractual rent as of date of expiration of the applicable lease (not including any extension option(s)), multiplied by 12 months.

Properties we owned, or had an ownership interest in, at December 31, 2013 were as follows:

| Property | Rentable Square Feet | Percent Leased | |
|------------------------------------|----------------------|----------------|---|
| Boston | | | |
| Albany Street | 75,003 | 100.0 | % |
| 320 Bent Street | 195,198 | 100.0 | % |
| 301 Binney Street | 417,290 | 96.7 | % |
| 301 Binney Street Garage | 503 Stalls | 99.8 | % |
| 210 Broadway | 64,812 | 100.0 | % |
| Center for Life Science Boston | 704,159 | 98.9 | % |
| Charles Street | 47,912 | 100.0 | % |
| 320 Charles Street | 99,513 | 100.0 | % |
| Coolidge Avenue | 37,684 | 91.8 | % |
| 21 Erie Street | 48,627 | 100.0 | % |
| 40 Erie Street | 100,854 | 100.0 | % |
| 47 Erie Street Parking Structure | 447 Stalls | 100.0 | % |
| Fresh Pond Research Park | 90,702 | 98.3 | % |
| 50 Hampshire Street | 183,052 | 100.0 | % |
| 60 Hampshire Street (1) | 41,257 | 86.5 | % |
| Kendall Crossing Apartments | 37 Apts. | 91.2 | % |
| 450 Kendall Street (Kendall G) (2) | 63,000 | — | |

Table of Contents

| | | | |
|---------------------------------------|------------|-------|---|
| 500 Kendall Street (Kendall D) | 349,325 | 98.5 | % |
| 675 W. Kendall Street (Kendall A) | 302,919 | 100.0 | % |
| Sidney Street | 191,904 | 100.0 | % |
| Vassar Street | 60,845 | 100.0 | % |
| Maryland | | | |
| Beckley Street | 77,225 | 100.0 | % |
| 9900 Belward Campus Drive | 49,317 | 65.3 | % |
| 9901 Belward Campus Drive | 57,152 | 99.9 | % |
| 9911 Belward Campus Drive | 289,912 | 100.0 | % |
| 9920 Belward Campus Drive | 51,181 | 100.0 | % |
| 9704 Medical Center Drive | 122,600 | 100.0 | % |
| 9708-9714 Medical Center Drive | 92,124 | 17.4 | % |
| 1701 / 1711 Research Blvd (1) | 104,743 | 100.0 | % |
| Shady Grove Road | 635,058 | 100.0 | % |
| Tributary Street | 91,592 | 100.0 | % |
| University of Maryland BioPark I | 75,517 | 100.0 | % |
| University of Maryland BioPark II | 235,333 | 93.5 | % |
| University of Maryland BioPark Garage | 638 Stalls | 96.0 | % |
| 50 West Watkins Mill Road | 57,410 | 34.8 | % |
| 55 / 65 West Watkins Mill Road | 82,405 | 100.0 | % |
| San Diego | | | |
| Balboa Avenue | 35,344 | 100.0 | % |
| Bernardo Center Drive | 61,286 | 100.0 | % |
| Coast 9 | 162,074 | 82.3 | % |
| 4570 Executive Drive | 125,219 | 85.3 | % |
| Faraday Avenue | 28,704 | 100.0 | % |
| Gazelle Court | 176,000 | 100.0 | % |
| 3525 John Hopkins Court | 48,306 | 100.0 | % |
| 3545-3575 John Hopkins Court | 72,192 | 84.7 | % |
| 6114-6154 Nancy Ridge Drive | 196,557 | 100.0 | % |
| 6122-6126 Nancy Ridge Drive | 68,000 | 100.0 | % |
| 6828 Nancy Ridge Drive | 42,138 | 42.0 | % |
| Pacific Center Boulevard | 66,745 | 100.0 | % |
| Road to the Cure | 67,998 | 89.6 | % |
| San Diego Science Center | 105,364 | 81.3 | % |
| 10240 Science Center Drive | 49,347 | 100.0 | % |
| 10255 Science Center Drive | 53,740 | 100.0 | % |
| Sorrento Plaza | 31,184 | 100.0 | % |
| Sorrento Valley Boulevard | 54,924 | — | |
| 11388 Sorrento Valley Road | 35,940 | 100.0 | % |
| Summers Ridge | — | 100.0 | % |
| Torreyana Road | 81,204 | 100.0 | % |
| 9865 Towne Centre Drive | 94,866 | 100.0 | % |
| 9885 Towne Centre Drive | 104,870 | 100.0 | % |
| Waples Street | 50,055 | 43.9 | % |
| Wateridge Circle | 106,490 | 95.6 | % |

Table of Contents

| | | | |
|------------------------------------|---------|-------|---|
| San Francisco | | | |
| Ardentech Court | 55,588 | 100.0 | % |
| Ardenwood Venture (3) | 72,500 | 83.2 | % |
| Bayshore Boulevard | 183,344 | 100.0 | % |
| Bridgeview Technology Park I | 201,567 | 52.9 | % |
| Bridgeview Technology Park II | 50,400 | 57.0 | % |
| 550 Broadway Street | 71,239 | 100.0 | % |
| Dumbarton Circle | 44,000 | 100.0 | % |
| Gateway Business Park | 176,503 | 82.2 | % |
| Industrial Road | 175,144 | 100.0 | % |
| Kaiser Drive | 87,953 | 81.0 | % |
| Pacific Industrial Center | 305,026 | 82.7 | % |
| Pacific Research Center North | 661,245 | 79.2 | % |
| Pacific Research Center South | 423,246 | 62.3 | % |
| Science Center at Oyster Point | 204,887 | 100.0 | % |
| Woodside Technology Park | 255,650 | 100.0 | % |
| New York / New Jersey | | | |
| Ardsley Park | 160,500 | 100.0 | % |
| Graphics Drive | 72,300 | 64.2 | % |
| Landmark at Eastview | 800,671 | 81.7 | % |
| Landmark at Eastview II | 360,520 | 100.0 | % |
| Landmark at Eastview III (2) | 297,000 | 100.0 | % |
| One Research Way | 49,421 | — | |
| Pennsylvania | | | |
| George Patterson Boulevard | 71,500 | 100.0 | % |
| Hershey Center of Applied Research | 80,867 | 87.7 | % |
| King of Prussia | 374,387 | 100.0 | % |
| 3711 Market Street (4) | 154,793 | 94.5 | % |
| 3737 Market Street (2) (5) | 334,305 | 55.2 | % |
| Phoenixville Pike | 104,400 | 37.5 | % |
| Spring Mill Drive | 76,561 | 82.5 | % |
| 900 Uniqema Boulevard | 11,293 | — | |
| 1000 Uniqema Boulevard | 59,821 | — | |
| Cambridge, UK | | | |
| Granta Park | 472,234 | 99.5 | % |
| North Carolina | | | |
| Paramount Parkway | 61,603 | 100.0 | % |
| Patriot Drive | 48,394 | 83.8 | % |
| Piedmont Triad Research - Wake 90 | 475,742 | 83.4 | % |
| Wake Forest Biotech Place | 242,000 | 100.0 | % |
| Weston Parkway | 30,589 | 100.0 | % |
| Seattle | | | |
| Elliott Avenue | 151,194 | 56.0 | % |
| 530 Fairview Avenue | 96,305 | 100.0 | % |
| Monte Villa Parkway | 51,000 | 59.2 | % |
| 217th Place | 67,799 | 79.7 | % |

Table of Contents

| | | | |
|--|--------------|-------|---|
| University Related - Other | | | |
| BRDG Park at Danforth Plant Science Center (6) | 109,731 | 83.1 | % |
| 4320 Forest Park Avenue (6) | 152,664 | 100.0 | % |
| Heritage @ 4240 (6) | 183,842 | 60.6 | % |
| Innovation Research Park at ODU I (7) | 95,634 | 90.0 | % |
| Innovation Research Park at ODU II (7) | 95,670 | 74.9 | % |
| Trade Centre Avenue (8) | 78,023 | 100.0 | % |
| University of Miami Life Science & Technology Park (9) | 258,680 | 73.2 | % |
| University Tech Park at IIT (10) | 128,000 | 100.0 | % |
| Walnut Street (11) | 149,984 | 100.0 | % |
| Total Consolidated Portfolio / Weighted-Average | 15,939,891 | 88.1 | % |
| Unconsolidated Portfolio: | | | |
| McKellar Court (12) | 72,863 | 100.0 | % |
| 650 E. Kendall Street (Kendall B) (13) | 282,217 | 71.5 | % |
| 350 E. Kendall Street Garage (Kendall F) (13) | 1,409 Stalls | 100.0 | % |
| Total Portfolio / Weighted-Average | 16,294,971 | 87.9 | % |

(1) The property was under redevelopment at December 31, 2013.

(2) The property was under development at December 31, 2013.

(3) We own an 87.5% membership interest in the limited liability company that owns this property.

(4) We own a 60% membership interest in the limited liability company that owns this property.

(5) We own a 68% membership interest in the limited liability company that owns this property.

(6) Located in St. Louis, Missouri.

(7) Located in Norfolk, Virginia.

(8) Located in Longmont, Colorado.

(9) Located in Miami, Florida.

(10) Located in Chicago, Illinois.

(11) Located in Boulder, Colorado.

We own the general partnership interest in the limited partnership that owns the McKellar Court property, which

(12) entitles us to 75% of the extraordinary cash flows after repayment of the partners' capital contributions and 22% of the operating cash flows. The property is located in San Diego, California.

(13) We are a member of the limited liability companies that own a portfolio of properties in Cambridge, Massachusetts, which entitles us to approximately 20% of the operating cash flows.

Tenant Information

As of December 31, 2013, our consolidated and unconsolidated properties were leased to 309 tenants, and we estimate that 83% of our annualized base rent was derived from tenants that were research institutions or public companies or their subsidiaries. The following is a summary of our ten largest tenants based on percentage of our annualized base rent as of December 31, 2013:

Table of Contents

| Tenant | Leased Square Feet | Annualized Base Rent Current (1) (In thousands) | Annualized Base Rent per Leased Sq Ft Current | Percent of Annualized Base Rent Current Total Portfolio | Lease Expiration |
|--|--------------------|--|---|---|------------------|
| GlaxoSmithKline plc (2) | 924,970 | \$45,373 | \$49.05 | 8.8 | % June 2026 |
| Regeneron Pharmaceuticals, Inc. (3) | 1,001,718 | 40,079 | 40.01 | 7.7 | % Multiple |
| Vertex Pharmaceuticals Incorporated (4) | 685,286 | 36,401 | 53.12 | 7.0 | % Multiple |
| Beth Israel Deaconess Medical Center, Inc. | 362,364 | 26,823 | 74.02 | 5.2 | % July 2023 |
| Sanofi (5) | 418,003 | 22,857 | 54.68 | 4.4 | % Multiple |
| Ironwood Pharmaceuticals, Inc. | 303,259 | 15,340 | 50.58 | 3.0 | % February 2018 |
| Children's Hospital Corporation (6) | 200,081 | 14,459 | 72.27 | 2.8 | % May 2023 |
| Janssen Biotech, Inc. (Johnson & Johnson) | 374,387 | 9,267 | 24.75 | 1.8 | % April 2014 |
| Bristol-Myers Squibb (7) | 270,047 | 9,108 | 33.73 | 1.8 | % Multiple |
| MedImmune, Inc. (8) | 245,808 | 8,669 | 35.27 | 1.7 | % Multiple |
| Total / weighted-average (9) | 4,785,923 | \$228,376 | \$47.72 | 44.2 | % |

Based on current annualized base rent. Current annualized base rent is the monthly contractual rent as of the (1) current period end, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by 12 months.

(2) The tenant is Human Genome Sciences, a wholly-owned subsidiary of GlaxoSmithKline plc.

(3) On April 3, 2013, we entered into a build-to-suit agreement to construct two new buildings pre-leased to Regeneron for a 15-year term totaling approximately 297,000 square feet at Landmark at Eastview. 2,833 square feet expire July 2015, 312,525 square feet expire July 2024 and 686,360 square feet expire July 2029.

(4) 81,204 square feet are leased to a subsidiary of Vertex Pharmaceuticals Incorporated. 292,758 square feet expire January 2016, 20,608 square feet expire May 2017, 290,716 square feet expire May 2018, and 81,204 square feet expire January 2019.

(5) 343,000 square feet expire August 2018 and 75,003 square feet expire October 2018.

(6) This tenant guarantees rent on 49,866 square feet leased at the Center for Life Science Boston.

(7) 77,539 square feet expire February 2015, 29,218 square feet expire April 2018, 133,123 square feet expire December 2022 and 30,167 square feet expire April 2024.

(8) 46,013 square feet expire December 2015, 39,505 square feet expire January 2021 and 160,290 square feet expire December 2021.

(9) Without regard to any early lease terminations and/or renewal options.

Lease Terms

Our leases are typically structured for terms of five to 15 years, with extension options, and include a fixed rental rate with scheduled annual escalations. From time to time, we offer rent concessions to new tenants, including periods of free rent or contractual rent discounted from prevailing market rates. Any decision to offer a rent concession, however, is made on a case-by-case basis after taking into account factors such as anticipated lease terms, general and local market conditions, local practices and tenant characteristics. Approximately 95.4% of current annualized base rent at December 31, 2013 was earned from triple-net leases. Triple-net leases are those in which tenants pay not only base rent, but also some or all real estate taxes and operating expenses of the leased property. Current annualized base rent

is the monthly contractual rent as of the current quarter ended, or if rent has not yet commenced, the first monthly rent payment due at each rent commencement date, multiplied by twelve months. Tenants typically reimburse us for the full direct cost, without regard to a base year or expense stop, for use of lighting, heating and air conditioning, and certain capital improvements necessary to maintain the property in its original condition. We are generally responsible for structural repairs.

ITEM 3. LEGAL PROCEEDINGS

36

Table of Contents

Although we are involved in legal proceedings arising in the ordinary course of business, we are not currently a party to any legal proceedings nor is any legal proceeding threatened against us that we believe would have a material adverse effect on our financial position, results of operations or liquidity.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES (BIOMED REALTY TRUST, INC.)

BioMed Realty Trust, Inc.'s common stock has been listed on the New York Stock Exchange, or NYSE, under the symbol "BMR" since August 6, 2004. On February 6, 2014, the reported closing sale price per share for BioMed Realty Trust, Inc.'s common stock on the NYSE was \$19.79 and there were approximately 482 holders of record. The following table sets forth, for the periods indicated, the high, low and last sale prices in dollars on the NYSE for our common stock and the distributions we declared per share.

| Period | High | Low | Last | Cash Dividend per Common Share |
|---------------------|---------|---------|---------|-----------------------------------|
| First Quarter 2012 | \$19.65 | \$17.72 | \$18.98 | \$0.215 |
| Second Quarter 2012 | \$20.30 | \$17.52 | \$18.68 | \$0.215 |
| Third Quarter 2012 | \$19.94 | \$18.10 | \$18.72 | \$0.215 |
| Fourth Quarter 2012 | \$19.68 | \$18.19 | \$19.33 | \$0.235 |
| First Quarter 2013 | \$22.30 | \$19.47 | \$21.60 | \$0.235 |
| Second Quarter 2013 | \$23.13 | \$18.55 | \$20.23 | \$0.235 |
| Third Quarter 2013 | \$21.62 | \$17.90 | \$18.59 | \$0.235 |
| Fourth Quarter 2013 | \$20.56 | \$17.97 | \$18.12 | \$0.250 |

Information about our equity compensation plans is incorporated by reference in Item 12 of Part III of this annual report on Form 10-K.

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities (BioMed Realty, L.P.)

There is no established public trading market for BioMed Realty, L.P.'s OP units. As of February 6, 2014, there were 26 holders of record of BioMed Realty, L.P.'s OP units, including BioMed Realty Trust, Inc. The following table sets forth, for the periods indicated, the distributions we declared with respect to BioMed Realty, L.P.'s OP units for the periods indicated.

| Period | Cash Distribution per Unit |
|---------------------|-------------------------------|
| First Quarter 2012 | \$0.215 |
| Second Quarter 2012 | \$0.215 |
| Third Quarter 2012 | \$0.215 |
| Fourth Quarter 2012 | \$0.235 |
| First Quarter 2013 | \$0.235 |
| Second Quarter 2013 | \$0.235 |
| Third Quarter 2013 | \$0.235 |
| Fourth Quarter 2013 | \$0.250 |

Table of Contents

As of December 31, 2013, (1) there were 197,198,402 operating partnership units and 332,574 LTIP units outstanding, (2) there were no operating partnership units subject to outstanding options or warrants to purchase, (3) there were no securities convertible into BioMed Realty, L.P.'s operating partnership units and (4) there were no operating partnership units that have been, or are proposed to be, publicly offered by us. As of December 31, 2013, there were 156,928,002 operating partnership units which could be sold pursuant to Rule 144 under the Securities Act, subject to other restrictions on transfer in the securities laws or in BioMed Realty, L.P.'s partnership agreement. Currently, pursuant to the terms of BioMed Realty, L.P.'s partnership agreement, any transfer of OP units by the limited partners, except to us, as general partner, to an affiliate of the transferring limited partner, to other original limited partners, to immediate family members of the transferring limited partner, to a trust for the benefit of a charitable beneficiary, or to a lending institution as collateral for a bona fide loan, subject to specified limitations, will be subject to a right of first refusal by us and must be made only to "accredited investors" as defined under Rule 501 of the Securities Act.

We intend to continue to declare quarterly distributions on BioMed Realty, L.P.'s OP units and BioMed Realty Trust, Inc.'s common stock. The actual amount and timing of future distributions will be at the discretion of BioMed Realty Trust, Inc.'s board of directors and will depend upon our financial condition in addition to the requirements of the Code, and no assurance can be given as to the amounts or timing of future distributions. In addition, our Amended and Restated Credit Facility and the indentures governing the Notes due 2016, the Notes due 2020 and the Notes due 2022 contain financial covenants which may limit our ability to pay distributions to BioMed Realty, L.P.'s unitholders and BioMed Realty Trust, Inc.'s common stockholders. We do not anticipate that our ability to pay distributions will be impaired by the terms of our Amended and Restated Credit Facility, or the indentures governing the Notes due 2016, the Notes due 2020 and the Notes due 2022. However, there can be no assurances in that regard.

Sales of Unregistered Equity Securities (BioMed Realty Trust, Inc.)

None.

Sales of Unregistered Equity Securities (BioMed Realty, L.P.)

During the three months ended December 31, 2013, BioMed Realty Trust, Inc. issued, net of forfeitures, an aggregate of 8,253 shares of its common stock in connection with restricted stock awards under its incentive award plan for no cash consideration. For each share of common stock issued by BioMed Realty Trust, Inc. in connection with such an award, BioMed Realty, L.P. issued a restricted operating partnership unit to BioMed Realty Trust, Inc., in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. During the three months ended December 31, 2013, BioMed Realty, L.P. issued an aggregate of 8,253 restricted operating partnership units to BioMed Realty Trust, Inc., as required by BioMed Realty, L.P.'s partnership agreement.

Stock Performance Graph

The following graph shows a comparison from December 31, 2008 to December 31, 2013 of cumulative total shareholder return, calculated on a dividend reinvested basis, for BioMed Realty Trust, Inc., the S&P 500 Stock Index, or the S&P 500, and the National Association of Real Estate Investment Trusts, Inc. Equity REIT Total Return Index, or the Industry Index, which includes all tax-qualified equity REITs listed on the NYSE. The graph assumes \$100 was invested in each of BioMed Realty Trust, Inc.'s common stock, the S&P 500 and the Industry Index on December 31, 2008. Data points on the graph are annual. Note that historic stock price performance is not necessarily indicative of future stock price performance.

Table of Contents

Source: SNL Financial LC

ITEM 6. SELECTED FINANCIAL DATA

The following tables set forth selected consolidated financial and operating data on an historical basis for BioMed Realty Trust, Inc. and BioMed Realty, L.P. The following data should be read in conjunction with our financial statements and notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included below in this report. Certain prior year amounts have been reclassified to conform to the current year presentation.

BIOMED REALTY TRUST, INC.

(Dollars in thousands, except share data)

| | Years Ended December 31, | | | | |
|-------------------------------|--------------------------|-----------|-----------|-----------|-----------|
| | 2013 | 2012 | 2011 | 2010 | 2009 |
| Statements of Operations: | | | | | |
| Revenues: | | | | | |
| Total revenues | \$637,314 | \$518,167 | \$438,200 | \$383,629 | \$358,193 |
| Expenses: | | | | | |
| Rental operations | 184,073 | 152,219 | 128,146 | 111,900 | 104,246 |
| Depreciation and amortization | 245,000 | 196,844 | 142,319 | 114,788 | 109,007 |
| General and administrative | 44,175 | 38,025 | 30,966 | 25,901 | 22,455 |
| Acquisition-related expenses | 5,282 | 13,077 | 1,099 | 3,053 | 464 |
| Total expenses | 478,530 | 400,165 | 302,530 | 255,642 | 236,172 |
| Income from operations | 158,784 | 118,002 | 135,670 | 127,987 | 122,021 |

Table of Contents

| | | | | | | |
|--|-------------|-------------|-------------|-------------|-------------|---|
| Equity in net loss of unconsolidated partnerships | (905 |) (1,389 |) (2,489 |) (1,645 |) (2,390 |) |
| Interest expense, net | (107,727 |) (99,608 |) (89,181 |) (86,073 |) (64,690 |) |
| Other (expense) / income | (2,943 |) (872 |) (1,760 |) (2,658 |) 3,467 |) |
| Income from continuing operations | 47,209 | 16,133 | 42,240 | 37,611 | 58,408 | |
| (Loss) / income from discontinued operations | — | (4,370 |) 474 | 1,703 | 1,782 | |
| Net income | 47,209 | 11,763 | 42,714 | 39,314 | 60,190 | |
| Net (income) / loss attributable to noncontrolling interests | (565 |) 62 | (525 |) (498 |) (1,468 |) |
| Net income attributable to the Company | 46,644 | 11,825 | 42,189 | 38,816 | 58,722 | |
| Preferred stock dividends | (2,393 |) (14,603 |) (16,033 |) (16,963 |) (16,963 |) |
| Cost on redemption of preferred stock | (6,531 |) — | (165 |) — | — |) |
| Net income / (loss) available to common stockholders | \$37,720 | \$(2,778 |) \$25,991 | \$21,853 | \$41,759 | |
| Income from continuing operations per share available to stockholders: | | | | | | |
| Basic and diluted earnings per share | \$0.20 | \$— | \$0.19 | \$0.17 | \$0.43 | |
| Net income / (loss) per share available to common stockholders: | | | | | | |
| Basic and diluted earnings per share | \$0.20 | \$(0.03 |) \$0.19 | \$0.19 | \$0.45 | |
| Weighted-average shares outstanding: | | | | | | |
| Basic | 182,043,391 | 152,752,086 | 132,625,915 | 112,698,704 | 91,011,123 | |
| Diluted | 186,397,022 | 155,700,387 | 135,609,843 | 115,718,199 | 91,851,002 | |
| Cash dividends declared per common share | \$0.96 | \$0.88 | \$0.80 | \$0.63 | \$0.70 | |
| Cash dividends declared per preferred share | \$0.30 | \$1.84 | \$1.84 | \$1.84 | \$1.84 | |
| Balance Sheet Data (at period end): | | | | | | |
| Investments in real estate, net | \$5,217,902 | \$4,319,716 | \$3,950,246 | \$3,536,114 | \$2,971,767 | |
| Total assets | 5,972,601 | 4,834,479 | 4,428,545 | 3,959,754 | 3,283,274 | |
| Total indebtedness | 2,671,193 | 2,169,285 | 1,681,425 | 1,497,465 | 1,361,805 | |
| Total liabilities | 2,985,576 | 2,349,938 | 1,816,349 | 1,646,858 | 1,459,342 | |
| Total equity | 2,987,025 | 2,484,541 | 2,612,196 | 2,312,896 | 1,823,932 | |
| Other Data: | | | | | | |
| Cash flows provided by / (used in): | | | | | | |
| Operating activities | 279,789 | 238,235 | 175,031 | 161,895 | 144,128 | |
| Investing activities | (833,219 |) (537,982 |) (604,331 |) (710,986 |) (156,666 |) |
| Financing activities | 568,576 | 303,285 | 424,244 | 550,636 | 11,038 | |

BIOMED REALTY, L.P.

(Dollars in thousands, except unit data)

| | Years Ended December 31, | | | | |
|---------------------------|--------------------------|-----------|-----------|-----------|-----------|
| | 2013 | 2012 | 2011 | 2010 | 2009 |
| Statements of Operations: | | | | | |
| Revenues: | | | | | |
| Total revenues | \$637,314 | \$518,167 | \$438,200 | \$383,629 | \$358,193 |
| Expenses: | | | | | |

| | | | | | |
|-------------------|---------|---------|---------|---------|---------|
| Rental operations | 184,073 | 152,219 | 128,146 | 111,900 | 104,246 |
|-------------------|---------|---------|---------|---------|---------|

40

Table of Contents

| | | | | | |
|--|-------------|-------------|-------------|-------------|-------------|
| Depreciation and amortization | 245,000 | 196,844 | 142,319 | 114,788 | 109,007 |
| General and administrative | 44,175 | 38,025 | 30,966 | 25,901 | 22,455 |
| Acquisition-related expenses | 5,282 | 13,077 | 1,099 | 3,053 | 464 |
| Total expenses | 478,530 | 400,165 | 302,530 | 255,642 | 236,172 |
| Income from operations | 158,784 | 118,002 | 135,670 | 127,987 | 122,021 |
| Equity in net loss of unconsolidated partnerships | (905 |) (1,389 |) (2,489 |) (1,645 |) (2,390 |
| Interest expense, net | (107,727 |) (99,608 |) (89,181 |) (86,073 |) (64,690 |
| Other (expense) / income | (2,943 |) (872 |) (1,760 |) (2,658 |) 3,467 |
| Income from continuing operations | 47,209 | 16,133 | 42,240 | 37,611 | 58,408 |
| (Loss) / income from discontinued operations | — | (4,370 |) 474 | 1,703 | 1,782 |
| Net income | 47,209 | 11,763 | 42,714 | 39,314 | 60,190 |
| Net loss attributable to noncontrolling interests | 254 | 8 | 44 | 48 | 64 |
| Net income attributable to the operating partnership | 47,463 | 11,771 | 42,758 | 39,362 | 60,254 |
| Preferred unit dividends | (2,393 |) (14,603 |) (16,033 |) (16,963 |) (16,963 |
| Cost on redemption of preferred units | (6,531 |) — | (165 |) — | — |
| Net income / (loss) available to the operating partnership | \$38,539 | \$(2,832 |) \$26,560 | \$22,399 | \$43,291 |
| Income from continuing operations per unit available to unitholders: | | | | | |
| Basic and diluted earnings per unit | \$0.20 | \$— | \$0.19 | \$0.17 | \$0.43 |
| Net income / (loss) per unit available to unitholders: | | | | | |
| Basic and diluted earnings per unit | \$0.20 | \$(0.03 |) \$0.19 | \$0.19 | \$0.45 |
| Weighted-average units outstanding: | | | | | |
| Basic | 186,333,292 | 155,670,931 | 135,549,934 | 115,572,569 | 94,005,382 |
| Diluted | 186,396,309 | 155,670,931 | 135,549,934 | 115,572,569 | 94,005,382 |
| Cash distributions declared per unit | \$0.96 | \$0.88 | \$0.80 | \$0.63 | \$0.70 |
| Cash distributions declared per preferred unit | \$0.30 | \$1.84 | \$1.84 | \$1.84 | \$1.84 |
| Balance Sheet Data (at period end): | | | | | |
| Investments in real estate, net | \$5,217,902 | \$4,319,716 | \$3,950,246 | \$3,536,114 | \$2,971,767 |
| Total assets | 5,972,601 | 4,834,479 | 4,428,545 | 3,959,754 | 3,283,274 |
| Total indebtedness | 2,671,193 | 2,169,285 | 1,681,425 | 1,497,465 | 1,361,805 |
| Total liabilities | 2,985,576 | 2,349,938 | 1,816,349 | 1,646,858 | 1,459,342 |
| Total capital | 2,987,025 | 2,484,541 | 2,612,196 | 2,312,896 | 1,823,932 |
| Other Data: | | | | | |
| Cash flows provided by / (used in): | | | | | |
| Operating activities | 279,789 | 238,235 | 175,031 | 161,895 | 144,128 |
| Investing activities | (833,219 |) (537,982 |) (604,331 |) (710,986 |) (156,666 |
| Financing activities | 568,576 | 303,285 | 424,244 | 550,636 | 11,038 |

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this report. We make statements in this section that are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section above entitled “Item 1. Business — Forward-Looking Statements.” Certain risk factors may cause our actual results, performance or achievements to differ materially from

Table of Contents

those expressed or implied by the following discussion. For a discussion of such risk factors, see the section above entitled “Item 1A. Risk Factors.”

Overview

As used herein, the terms “we,” “us,” “our” or the “Company” refer to BioMed Realty Trust, Inc., a Maryland corporation, and any of our subsidiaries, including BioMed Realty, L.P., a Maryland limited partnership of which BioMed Realty Trust, Inc. is the parent company and general partner, which may be referred to herein as the “operating partnership.” BioMed Realty Trust, Inc. conducts its business and owns its assets through the operating partnership and operates as a fully integrated, self-administered and self-managed REIT. The operating partnership is focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. Our tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. Our properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Francisco, San Diego, Maryland, North Carolina, New York/New Jersey, Pennsylvania, Seattle and Cambridge (United Kingdom).

We were formed on April 30, 2004 and completed BioMed Realty Trust, Inc.’s initial public offering on August 11, 2004.

At December 31, 2013, we owned or had interests in a portfolio of properties with an aggregate of approximately 16.3 million rentable square feet.

| | Gross Book Value (In thousands) | Buildings | Rentable Square Feet | Weighted- Average Leased % (1) | |
|--------------------------------------|---------------------------------------|-----------|-------------------------|--------------------------------------|---|
| Stabilized | \$4,116,424 | 115 | 9,544,945 | 99.1 | % |
| Lease up | 1,447,689 | 60 | 5,554,641 | 69.6 | % |
| Total operating portfolio | 5,564,113 | 175 | 15,099,586 | 91.4 | % |
| Development | 95,479 | 4 | 694,305 | 59.2 | % |
| Redevelopment | 31,944 | 2 | 146,000 | 97.6 | % |
| Unconsolidated partnership portfolio | 32,069 | 3 | 355,080 | 77.3 | % |
| Pre-development | 106,999 | — | 1,057,000 | — | |
| Development potential | 204,945 | — | 3,866,000 | — | |
| Total portfolio | \$6,035,549 | 184 | 21,217,971 | | |

(1) Calculated based on gross book value for each asset multiplied by the percentage leased.

Factors Which May Influence Future Operations

Our long-term corporate strategy is to continue to focus on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. As of December 31, 2013, our total operating portfolio was 91.4% leased on a weighted-average basis to 296 tenants. As of December 31, 2012, our total operating portfolio was 92.1% leased on a weighted-average basis to 209 tenants. The decrease in our total operating portfolio leased percentage and increase in number of tenants were primarily due to our acquisitions completed in 2013, which were 83.5% leased on a weighted-average basis at acquisition.

Our leasing strategy for 2014 focuses on leasing vacant space, negotiating renewals for leases scheduled to expire during the year, and identifying new tenants or existing tenants seeking additional space to occupy the spaces for which we are unable to negotiate such renewals. We may proceed with additional new developments and acquisitions, as real estate and capital market conditions permit. As of December 31, 2013, leases representing 5.7% of our leased square feet were scheduled to expire during 2014. The success of our leasing and development strategy depends on, among other things, general economic conditions, real estate market conditions and life science industry trends in our target markets in the United States and the United Kingdom.

As a result of changing market conditions and the recent economic recession, we believe that the fair-values of some of our properties may have declined below their respective carrying values. However, to the extent that a property has a substantial remaining estimated useful life and management does not believe that the property will be disposed of

prior to the end of its useful life, it would be unusual for undiscounted cash flows to be insufficient to recover the property's carrying value. We presently have the ability and intent to continue to own and operate our existing portfolio of properties and estimated undiscounted future cash flows from the operation of the properties are expected to be sufficient to recover the carrying value of each property. Accordingly,

42

Table of Contents

we do not believe that the carrying value of any of our properties is impaired. If our ability and/or our intent with regard to the operation of our properties otherwise dictate an earlier sale date, an impairment loss may be recognized to reduce the property to fair-value and such loss could be material.

Lease Expirations

The following is a summary of lease expirations over the next ten calendar years for leases in place at December 31, 2013. This table assumes that none of the tenants exercise renewal options or early termination rights, if any, at or prior to the scheduled expirations:

| Year of Lease Expiration | Leased Square Feet | Percent of Leased Square Feet | Current Annualized Base Rent (In thousands) | Percent of Current Annualized Base Rent | Current Annualized Base Rent per Leased Square Feet |
|------------------------------------|--------------------|-------------------------------|---|---|---|
| Month-to-month | 10,080 | 0.1 | % \$300 | 0.1 | % \$29.76 |
| 2014 | 815,540 | 5.7 | % 27,453 | 5.4 | % 33.66 |
| 2015 | 661,717 | 4.6 | % 20,243 | 3.9 | % 30.59 |
| 2016 | 1,176,148 | 8.2 | % 45,268 | 8.8 | % 38.49 |
| 2017 | 649,002 | 4.5 | % 19,245 | 3.7 | % 29.65 |
| 2018 | 1,827,585 | 12.8 | % 81,440 | 15.7 | % 44.56 |
| 2019 | 944,668 | 6.6 | % 27,870 | 5.4 | % 29.50 |
| 2020 | 879,603 | 6.1 | % 30,436 | 5.9 | % 34.60 |
| 2021 | 638,284 | 4.5 | % 19,352 | 3.7 | % 30.32 |
| 2022 | 785,347 | 5.5 | % 18,691 | 3.6 | % 23.80 |
| 2023 | 1,117,505 | 7.8 | % 55,152 | 10.7 | % 49.35 |
| Thereafter | 4,814,723 | 33.6 | % 171,770 | 33.1 | % 35.68 |
| Total Portfolio / Weighted-Average | 14,320,202 | 100.0 | % \$517,220 | 100.0 | % \$36.12 |

The success of our leasing and development strategy will be dependent upon the general economic conditions and more specifically real estate market conditions and life science industry trends in the United States and in our target markets of Boston, San Francisco, San Diego, Maryland, North Carolina, New York/New Jersey, Pennsylvania, Seattle, Cambridge (United Kingdom) and research parks near or adjacent to universities. We cannot give any assurance that leases will be renewed or that available space will be released at rental rates equal to or above the current contractual rental rates or at all.

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to use judgment in the application of accounting policies, including making estimates and assumptions. We base our estimates on historical experience and on various other assumptions believed to be reasonable under the circumstances. These judgments affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions had been different, it is possible that different accounting policies would have been applied resulting in a different presentation of our financial statements. On an ongoing basis, we evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current information. Below is a discussion of accounting policies that we consider critical in that they address the most material parts of our financial statements, require complex judgment in their application or require estimates about matters that are inherently uncertain.

Revenue Recognition, Operating Expenses and Lease Terminations

We commence revenue recognition on our leases based on a number of factors. In most cases, revenue recognition under a lease begins when the lessee takes possession of or controls the physical use of the leased asset. Generally, this occurs on the lease commencement date. In determining what constitutes the leased asset, we evaluate whether we or the lessee is the owner, for accounting purposes, of the tenant improvements. If we are the owner, for accounting purposes, of the tenant improvements, then

43

Table of Contents

the leased asset is the finished space and revenue recognition begins when the lessee takes possession of the finished space, typically when the improvements are substantially complete. If we conclude that we are not the owner, for accounting purposes, of the tenant improvements (the lessee is the owner), then the leased asset is the unimproved space and any tenant improvement allowances funded under the lease are treated as lease incentives, which reduce revenue recognized on a straight-line basis over the remaining non-cancelable term of the respective lease. In these circumstances, we begin revenue recognition when the lessee takes possession of the unimproved space for the lessee to construct improvements. The determination of who is the owner, for accounting purposes, of the tenant improvements determines the nature of the leased asset and when revenue recognition under a lease begins. We consider a number of different factors to evaluate whether we or the lessee is the owner of the tenant improvements for accounting purposes. These factors include:

- whether the lease stipulates how and on what a tenant improvement allowance may be spent;
- whether the tenant or landlord retain legal title to the improvements;
- the uniqueness of the improvements;
- the expected economic life of the tenant improvements relative to the length of the lease;
- the responsible party for construction cost overruns; and
- who constructs or directs the construction of the improvements.

The determination of who owns the tenant improvements, for accounting purposes, is subject to significant judgment. In making that determination we consider all of the above factors. However, no one factor is determinative in reaching a conclusion.

All leases are classified as operating leases and minimum rents are recognized on a straight-line basis over the term of the related lease. The excess of rents recognized over amounts contractually due pursuant to the underlying leases is included in accrued straight-line rents on the accompanying consolidated balance sheets and contractually due but unpaid rents are included in accounts receivable. Existing leases at acquired properties are reviewed at the time of acquisition to determine if contractual rents are above or below current market rents for the acquired property. An identifiable lease intangible asset or liability is recorded based on the present value (using a discount rate that reflects the risks associated with the acquired leases) of the difference between (1) the contractual amounts to be paid pursuant to the in-place leases and (2) our estimate of the fair market lease rates for the corresponding in-place leases at acquisition, measured over a period equal to the remaining non-cancelable term of the leases and any fixed rate renewal periods. The capitalized above-market lease values are amortized as a reduction of rental income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values are amortized as an increase to rental income over the remaining non-cancelable terms of the respective leases. If a lease were to be terminated or if termination were determined to be likely (e.g., in the case of a tenant bankruptcy) prior to its contractual expiration, amortization of the related unamortized above or below market lease intangible would be accelerated and such amounts written off.

Rental operations expenses, consisting of real estate taxes, insurance and common area maintenance costs, are subject to recovery from tenants under the terms of our lease agreements. Amounts recovered are dependent on several factors, including occupancy and lease terms. Revenues are recognized in the period the expenses are incurred. The reimbursements are recorded in revenues as tenant recoveries, and the expenses are recorded in rental operations expenses, as the Company is generally the primary obligor with respect to purchasing goods and services from third-party suppliers, has discretion in selecting the supplier and bears the credit risk.

On an ongoing basis, we evaluate the recoverability of tenant balances, including rents receivable, straight-line rents receivable, tenant improvements, deferred leasing costs and any acquisition intangibles. When it is determined that the recoverability of tenant balances is not probable, an allowance for expected losses related to tenant receivables, including straight-line rents receivable is recorded as a charge to earnings. Upon the termination of a lease, the amortization of tenant improvements, deferred leasing costs and acquisition intangible assets and liabilities is accelerated to the expected termination date as a charge to their respective line items and tenant receivables are written off as a reduction of the allowance in the period in which the balance is deemed to be no longer collectible. For financial reporting purposes, a lease is treated as terminated upon a tenant filing for bankruptcy, when a space is abandoned and a tenant ceases rent payments, or when other circumstances indicate that termination of a tenant's lease

is probable (e.g., eviction). Lease termination fees are recognized in other revenue when the related leases are canceled, the amounts to be received are fixed and determinable and collectability is assured, and when we have no continuing obligation to provide services to such former tenants.

Investments in Partnerships and Limited Liability Companies

Table of Contents

We evaluate our investments in limited liability companies and partnerships to determine whether such entities may be a variable interest entity, or VIE, and, if a VIE, whether we are the primary beneficiary. Generally, an entity is determined to be a VIE when either (1) the equity investors (if any) lack one or more of the essential characteristics of a controlling financial interest, (2) the equity investment at risk is insufficient to finance that entity's activities without additional subordinated financial support or (3) the equity investors have voting rights that are not proportionate to their economic interests and the activities of the entity involve or are conducted on behalf of an investor with a disproportionately small voting interest. The primary beneficiary is the entity that has both (1) the power to direct matters that most significantly impact the VIE's economic performance and (2) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. We consider a variety of factors in identifying the entity that holds the power to direct matters that most significantly impact the VIE's economic performance including, but not limited to, the ability to direct financing, leasing, construction and other operating decisions and activities. In addition, we consider the rights of other investors to participate in policy making decisions, to replace or remove the manager of the entity and to liquidate or sell the entity. The obligation to absorb losses and the right to receive benefits when a reporting entity is affiliated with a VIE must be based on ownership, contractual, and/or other pecuniary interests in that VIE. We have determined that we are the primary beneficiary in five VIEs (excluding certain VIEs through our ownership of Wexford), consisting of single-tenant properties in which the tenant has a fixed-price purchase option, which are consolidated and reflected in the accompanying consolidated financial statements.

If the above conditions do not apply, we consider whether a general partner or managing member controls a limited partnership or limited liability company, respectively. The general partner in a limited partnership or managing member in a limited liability company is presumed to control that limited partnership or limited liability company, as applicable. The presumption may be overcome if the limited partners or members have either (1) the substantive ability to dissolve the limited partnership or limited liability company, as applicable, or otherwise remove the general partner or managing member, as applicable, without cause or (2) substantive participating rights, which provide the limited partners or members with the ability to effectively participate in significant decisions that would be expected to be made in the ordinary course of the limited partnership's or limited liability company's business, as applicable, and thereby preclude the general partner or managing member from exercising unilateral control over the partnership or limited liability company, as applicable. If these criteria are met and we are the general partner or the managing member, as applicable, the consolidation of the partnership or limited liability company is required.

Except for investments that are consolidated, we account for investments in entities over which we exercise significant influence, but do not control, under the equity method of accounting. These investments are recorded initially at cost and subsequently adjusted for equity in earnings and cash contributions and distributions. Under the equity method of accounting, our net equity in the investment is reflected in the consolidated balance sheets and its share of net income or loss is included in our consolidated statements of income.

On a periodic basis, management assesses whether there are any indicators that the carrying value of our investments in unconsolidated partnerships or limited liability companies may be impaired on a more than temporary basis. An investment is impaired only if management's estimate of the fair-value of the investment is less than the carrying value of the investment on a more than temporary basis. To the extent impairment has occurred, the loss is measured as the excess of the carrying value of the investment over the fair-value of the investment. Management does not believe that the value of any of our unconsolidated investments in partnerships or limited liability companies was impaired as of December 31, 2013.

We are also a party to certain VIEs through our ownership of Wexford, which are described in further detail in Note 11 of the Notes to Consolidated Financial Statements included elsewhere herein.

Impairment of Investments in Real Estate

When circumstances such as adverse market conditions indicate a possible impairment of the value of a property, we review the recoverability of the property's carrying value. The review of recoverability is based on an estimate of the future undiscounted cash flows (excluding interest charges) expected to result from the long-lived asset's use and eventual disposition. These cash flows consider factors such as expected future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. If impairment exists due to the

inability to recover the carrying value of a long-lived asset, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair-value of the property. We are required to make subjective assessments as to whether there are impairments in the values of our investments in long-lived assets. These assessments have a direct impact on our net income because recording an impairment loss results in an immediate negative adjustment to net income. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. Although our strategy is to hold our properties over the long-term, if our strategy changes or market conditions otherwise dictate an earlier sale date, an impairment loss may be recognized to reduce the property to fair-value and such loss could be material. If we determine that impairment has occurred, the affected assets must be reduced to their fair-value.

Table of Contents

Assets and Liabilities Measured at Fair-Value

We measure financial instruments and other items at fair-value where required under GAAP, but have elected not to measure any additional financial instruments and other items at fair-value as permitted under fair-value option accounting guidance.

Fair-value measurement is determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair-value measurements, there is a fair-value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair-value measurement is based on inputs from different levels of the fair-value hierarchy, the level in the fair-value hierarchy within which the entire fair-value measurement falls is based on the lowest level input that is significant to the fair-value measurement in its entirety. Our assessment of the significance of a particular input to the fair-value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

We have used interest rate swaps to manage our interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair-values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash receipts (or payments) and the discounted expected variable cash payments (or receipts). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the respective counterparty's nonperformance risk in the fair-value measurements. In adjusting the fair-value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts, and guarantees.

Derivative Instruments

We record all derivatives on the consolidated balance sheets at fair-value. In determining the fair-value of our derivatives, we consider our credit risk and that of our counterparties. These counterparties are generally larger financial institutions engaged in providing a variety of financial services. These institutions generally face similar risks regarding adverse changes in market and economic conditions, including, but not limited to, fluctuations in interest rates, exchange rates, equity and commodity prices and credit spreads. The ongoing disruptions in the financial markets have heightened the risks to these institutions. While management believes that our counterparties will meet their obligations under the derivative contracts, it is possible that defaults may occur.

The accounting for changes in the fair-value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair-value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair-value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair-value of the hedged asset or liability that are

attributable to the hedged risk in a fair-value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. We may enter into derivative contracts that are intended to economically hedge certain of our risks, even though hedge accounting does not apply or we elect not to apply hedge accounting.

For derivatives designated as cash flow hedges, the effective portion of changes in the fair-value of the derivative is initially reported in other comprehensive income (outside of earnings) and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings. If charges relating to the hedged transaction are being deferred pursuant to redevelopment or development activities, the effective portion of changes in the fair-value of the derivative are also deferred in other comprehensive income, and are amortized to the income statement once the deferred charges from the hedged transaction begin again to affect earnings. The ineffective portion of changes in the fair-value of the derivative is recognized directly in earnings. We assess the

Table of Contents

effectiveness of each hedging relationship by comparing the changes in cash flows of the derivative hedging instrument with the changes in cash flows of the designated hedged item or transaction. For derivatives that are not classified as hedges, changes in the fair-value of the derivative are recognized directly in earnings in the period in which the change occurs.

We are exposed to certain risks arising from both our business operations and economic conditions. We principally manage our exposures to a wide variety of business and operational risks through management of our core business activities. We manage economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of our debt funding and the use of derivative financial instruments. Specifically, we enter into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known or expected cash amounts, the value of which are determined by interest rates. Our derivative financial instruments are used to manage differences in the amount, timing, and duration of our known or expected cash receipts and our known or expected cash payments principally related to our investments and borrowings.

Our primary objective in using derivatives is to add stability to interest expense and to manage our exposure to interest rate movements or other identified risks. To accomplish this objective, we primarily use interest rate swaps as part of our interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for making fixed-rate payments over the life of the agreements without exchange of the underlying principal amount. During the years ended December 31, 2013, 2012 and 2011, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt and future variability in the interest-related cash flows from forecasted issuances of debt (see Note 9 of the Notes to Consolidated Financial Statements included elsewhere herein). We formally document the hedging relationships for all derivative instruments, have historically accounted for our interest rate swap agreements as cash flow hedges, and do not use derivatives for trading or speculative purposes.

Results of Operations

Leasing Activity

During the year ended December 31, 2013, we executed 120 leasing transactions representing 2.3 million square feet, including 75 new leases totaling approximately 1.4 million square feet and 45 leases amended to extend their terms totaling 839,114 square feet. The following table summarizes our leasing activity, including leasing activity in our unconsolidated portfolio, during the year ended December 31, 2013:

| | Leased Square Feet | Current annualized base rent per leased square foot (1) | Current annualized base rent per leased square foot - GAAP basis (2) |
|--|--------------------|---|--|
| Leased square feet as of December 31, 2012 | 11,549,607 | | |
| Acquisitions | 2,428,965 | \$25.31 | \$29.53 |
| Dispositions | (27,750) | 10.56 | 10.70 |
| Expirations | (1,542,313) | 38.69 | 37.67 |
| Terminations | (333,835) | 42.02 | 43.74 |
| Pre-leased delivery | 452,110 | 36.54 | 41.58 |
| Renewals, amendments, and extensions | 839,114 | 36.87 | 37.84 |
| New leases - first generation (3) | 712,636 | 30.98 | 32.52 |
| New leases - second generation (4) | 241,668 | 35.10 | 36.75 |
| Leased square feet as of December 31, 2013 | 14,320,202 | | |
| Pre-leased square feet as of December 31, 2012 | 71,011 | | |
| Pre-leased acquisitions | 13,373 | \$18.00 | \$20.29 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | |
|--|----------|---------|-------|
| Pre-leased new leases - second generation (4) | 470,273 | 38.63 | 39.97 |
| Pre-leased delivery | (452,110 |) 36.54 | 41.58 |
| Pre-leased square feet as of December 31, 2013 | 102,547 | | |

Current annualized base rent per leased square foot is the monthly contractual rent per leased square foot as of the (1) period end, or if rent has not yet commenced, the first monthly rent payment per leased square foot due at each rent commencement date, multiplied by 12 months.

47

Table of Contents

Current annualized base rent per leased square foot - GAAP basis is the monthly contractual rent per square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per square foot due at each rent commencement date, multiplied by 12 months (as adjusted for straight line rent, fair-value lease revenue and lease incentive revenue).

Leases on space which, in management's evaluation, require significant improvements to prepare or condition the premises for its intended purpose or enhance the value of the property. This generally includes capital expenditures for development, redevelopment or repositioning a property.

(4) Leases which are not considered by management to be first generation leases.

The following table summarizes our leasing activity and associated leasing costs for the year ended December 31, 2013:

| | Number of leases | Square feet | Tenant improvement costs per square foot | Lease commission costs per square foot | Tenant concession costs per square foot (1) |
|--|------------------|-------------|--|--|---|
| Renewals, amendments, and extensions (2) | 45 | 839,114 | \$4.34 | \$3.05 | \$0.84 |
| New leases - first generation | 40 | 712,636 | 83.99 | 9.86 | 16.42 |
| New leases - second generation | 35 | 711,941 | 28.52 | 12.17 | 3.52 |
| Total / weighted-average | 120 | 2,263,691 | \$37.02 | \$8.06 | \$6.59 |

(1) Includes both rent concessions due to free or discounted rent periods and lease incentives paid to tenants.

(2) Renewals, amendments and extensions were leased at a weighted-average current annualized base rent of \$37.84 per square foot, representing an increase of 3.8% over the previously expiring rents on a GAAP basis.

Development/Redevelopment Activity

The following table summarizes our consolidated properties under development or redevelopment at December 31, 2013 (dollars in thousands):

| Property | Rentable Square Feet | Percent Leased | Investment to Date (1) | Estimated Total Investment (2) | Estimated In-Service Date (3) |
|--------------------------------|----------------------|----------------|------------------------|--------------------------------|-------------------------------|
| Development | | | | | |
| 450 Kendall Street (Kendall G) | 63,000 | — | \$10,900 | \$44,100 | Q3 2015 |
| Landmark at Eastview III | 297,000 | 100.0 | % 15,900 | 152,700 | Q3 2015 |
| 3737 Market Street | 334,305 | 55.2 | % 50,600 | 99,400 | Q4 2014 |
| Total / weighted-average | 694,305 | 69.3 | % \$77,400 | \$296,200 | |
| Redevelopment | | | | | |
| 60 Hampshire Street | 41,257 | 86.5 | % \$4,800 | \$14,800 | Q4 2014 |
| 1701 / 1711 Research Blvd | 104,743 | 100.0 | % 20,100 | 34,200 | Q1 2014 |
| Total / weighted-average | 146,000 | 96.2 | % \$24,900 | \$49,000 | |
| Total | | | \$102,300 | | |

Includes amounts paid for acquiring the property, landlord improvements and tenant improvement allowances, but (1) for redevelopment properties excludes any amounts accrued, and payroll, interest or operating expenses capitalized, through December 31, 2013.

(2) Includes construction costs associated with speculative leasing.

(3)

Management's estimate of the time in which construction will be substantially completed. A project is considered substantially complete and held available for occupancy upon the completion of tenant improvements, but no later than one year from cessation of major construction activity.

The following summarizes our capital expenditures during the year ended December 31, 2013 and 2012 (dollars in thousands):

48

Table of Contents

| | Year Ended | | | Percent | |
|--|--------------|------------|-----------|---------|---|
| | December 31, | | Change | Change | |
| | 2013 | 2012 | | | |
| Development / Pre-development (1) | \$ 101,380 | \$ 5,397 | \$ 95,983 | 1,778.5 | % |
| Redevelopment | 4,860 | 22,963 | (18,103) | (78.8) | % |
| Tenant improvements - first generation | 34,208 | 63,825 | (29,617) | (46.4) | % |
| Recurring capital expenditures and second generation tenant improvements (2) | 40,279 | 14,822 | 25,457 | 171.8 | % |
| Other capital | 36,816 | 31,863 | 4,953 | 15.5 | % |
| Total capital expenditures | \$ 217,543 | \$ 138,870 | \$ 78,673 | 56.7 | % |

- (1) Includes projects that received tax credit funding that offset actual capital expenditures incurred during the year. Recurring capital expenditures exclude (a) items associated with the expansion of a building or its improvements, (b) renovations to a building which change the underlying classification of the building, incurred to prepare or (2) condition the premises for its intended purpose (for example, from office to laboratory) or (c) capital improvements that represent an addition to the property rather than the replacement of property, plant or equipment. Includes revenue enhancing and non-revenue enhancing recurring capital expenditures.

Total capital expenditures increased \$78.7 million to \$217.5 million for the year ended December 31, 2013 from \$138.9 million for the year ended December 31, 2012. The change was primarily the result of projects under development in the Wexford portfolio, which was acquired in May 2013, and an increase in maintenance capital expenditures and second generation tenant improvements related to increased leasing activity, partially offset by certain projects which were in redevelopment during 2012 being placed into service in 2013. See the section entitled "Liquidity and Capital Resources of BioMed Realty, L.P." below for further information on obligations for capital expenditures expected to be incurred in the future.

Acquisition Activity

During the year ended December 31, 2013, we acquired approximately 2.9 million rentable square feet of laboratory and office space, which was 83.5% leased on a weighted-average basis at acquisition, and approximately 580,000 square feet of development potential for approximately \$842.6 million, excluding transaction costs:

| Property | Market | Closing Date | Rentable Square Feet (1) | Investment (In thousands) | Percent Leased at Acquisition | |
|-------------------------------------|---------------|-------------------|--------------------------------|-------------------------------------|-------------------------------------|---|
| Woodside Technology Park | San Francisco | February 28, 2013 | 255,650 | \$ 87,000 | 100.0 | % |
| The Campus at Lincoln Centre (2) | San Francisco | March 20, 2013 | — | 37,000 | n/a | |
| Wexford (3) | Various | May 31, 2013 | 2,555,174 | 669,100 | 81.2 | % |
| 320 Charles Street | Boston | June 18, 2013 | 99,513 | 49,518 | 100.0 | % |
| Total | | | 2,910,337 | \$ 842,618 | 83.5 | % |

(1) Rentable square feet at time of acquisition.

(2) Includes approximately 280,000 square feet of development potential.

(3) Includes approximately 935,000 square feet in development and approximately 300,000 square feet of development potential.

We also acquired properties with approximately 274,000 and 300,000 square feet of pre-development and development potential, respectively, for approximately \$13.4 million.

Comparison of the Year Ended December 31, 2013 to the Year Ended December 31, 2012

The following table sets forth historical financial information of the continuing operations for same properties (all properties except properties held for sale, development/redevelopment properties, new properties and corporate entities), development/redevelopment properties (properties that were entirely or primarily under redevelopment or development during either of the year ended December 31, 2013 or 2012), new properties (properties that were not owned for each of the year ended December 31, 2013 and 2012 and were not under development/redevelopment) and corporate entities (legal entities performing general and administrative and other corporate level functions) (dollars in thousands, except on a per square foot basis):

Table of Contents

| | Same Properties | | Development/Redevelopment Properties | | | | New Properties | | Corporate | | Total | |
|---|-------------------------|------------|---|-----------|-----------|----------|----------------|-----------|------------|------------|-------|------|
| | December 31, | | 2013 | | 2012 | | 2013 | | 2012 | | 2013 | |
| | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 | 2013 | 2012 |
| Rentable square feet | 11,237,520 | 11,237,520 | 2,795,513 | 1,504,624 | 2,949,858 | 965,806 | N/A | N/A | 16,982,891 | 13,707,000 | | |
| Percent of total portfolio | 66.1 | % 82.0 | % 16.5 | % 11.0 | % 17.4 | % 7.0 | % N/A | N/A | 100.0 | % 100.0 | | |
| Percent leased | 88.7 | % 88.7 | % 46.7 | % 28.4 | % 94.1 | % 95.6 | % N/A | N/A | 82.7 | % 81.8 | | |
| Current annualized base rent per square foot - GAAP basis (1) | \$38.43 | \$38.25 | \$29.53 | \$43.54 | \$35.64 | \$39.17 | N/A | N/A | \$37.05 | \$38.11 | | |
| | Year Ended December 31, | | 2013 | | 2012 | | 2013 | | 2012 | | 2013 | |
| Rental revenue | \$370,704 | \$359,939 | \$5,582 | \$10,380 | \$69,738 | \$22,299 | \$(44) | \$10 | \$445,980 | \$392,600 | | |
| Tenant recoveries | 123,542 | 114,948 | 2,385 | 3,255 | 15,520 | 2,464 | 187 | 126 | 141,634 | 120,790 | | |
| Other revenue (2) | 42,911 | 3,643 | (645) | — | 1,147 | 61 | 6,287 | 1,042 | 49,700 | 4,746 | | |
| Total revenues | 537,157 | 478,530 | 7,322 | 13,635 | 86,405 | 24,824 | 6,430 | 1,178 | 637,314 | 518,136 | | |
| Rental operations | 143,426 | 135,107 | 5,029 | 5,247 | 24,552 | 5,129 | 11,066 | 6,736 | 184,073 | 152,210 | | |
| Net operating income/(loss) | 393,731 | 343,423 | 2,293 | 8,388 | 61,853 | 19,695 | (4,636) | (5,558) | 453,241 | 365,940 | | |
| Adjustments to cash basis (3) | (38,199) | (11,188) | 492 | 3,594 | (8,585) | (2,321) | (6,287) | (1,042) | (52,579) | (10,950) | | |
| Net operating income/(loss) - cash basis | \$355,532 | \$332,235 | \$2,785 | \$11,982 | \$53,268 | \$17,374 | \$(10,923) | \$(6,600) | \$400,662 | \$354,990 | | |

(1) Current annualized base rent per square foot - GAAP basis is the monthly contractual rent per square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per square foot due at each rent commencement date, multiplied by 12 months (as adjusted for straight line rent, fair-value lease revenue and lease incentive revenue).

(2) During the years ended December 31, 2013 and 2012, we recorded lease termination revenue of approximately \$42.8 million and \$3.5 million, respectively. Lease termination revenue for the year ended December 31, 2012 primarily related to the termination of a lease with Merck at our 320 Bent Street property, which expired in August 2013 and for which Merck paid us \$8.7 million in August 2012. Lease termination revenue for the year ended December 31, 2013 primarily related to the termination of a lease with Elan at our Science Center at Oyster Point property, for which Elan paid us \$46.5 million in 2013, and our Merck lease termination. During the year ended December 31, 2013, we also recorded \$5.6 million of interest income related to our Construction Loan.

(3) Adjustments to cash basis exclude adjustments to expenses accrued in rental operations, but include straight line rents, fair-value lease revenue, lease incentive revenue, bad debt expense and other revenue (including lease

termination revenue).

The following table provides a reconciliation of net operating income - cash basis to net income for the years ended December 31, 2013 and 2012 (dollars in thousands):

50

Table of Contents

| | Year Ended | | | Percent | |
|---|--------------|-----------|----------|---------|----|
| | December 31, | | | Change | |
| | 2013 | 2012 | Change | Change | |
| Net operating income - cash basis | \$400,662 | \$354,991 | \$45,671 | 12.9 | % |
| Adjustments to cash basis | 52,579 | 10,957 | 41,622 | 379.9 | % |
| Net operating income | 453,241 | 365,948 | 87,293 | 23.9 | % |
| Unallocated expense: | | | | | |
| Depreciation and amortization expense | 245,000 | 196,844 | 48,156 | 24.5 | % |
| General and administrative expense | 44,175 | 38,025 | 6,150 | 16.2 | % |
| Acquisition-related expenses | 5,282 | 13,077 | (7,795) | (59.6) |)% |
| Income from operations | 158,784 | 118,002 | 40,782 | 34.6 | % |
| Equity in net loss of unconsolidated partnerships | (905) | (1,389) | 484 | (34.8) |)% |
| Interest expense, net | (107,727) | (99,608) | (8,119) | 8.2 | % |
| Other expense | (2,943) | (872) | (2,071) | 237.5 | % |
| Income from continuing operations | 47,209 | 16,133 | 31,076 | 192.6 | % |
| Loss from discontinued operations | — | (4,370) | 4,370 | (100.0) |)% |
| Net income | \$47,209 | \$11,763 | \$35,446 | 301.3 | % |

Net Operating Income. Net operating income increased \$87.3 million to \$453.2 million for the year ended December 31, 2013 compared to \$365.9 million for the year ended December 31, 2012. This increase was primarily due to the following:

The acquisition of properties totaling approximately 1.0 million square feet in the year ended December 31, 2012 and properties totaling approximately 2.9 million square feet in the year ended December 31, 2013 contributed an additional \$42.2 million in net operating income for the year ended December 31, 2013 compared to the year ended December 31, 2012.

The placement of three properties that were operating in 2012 into redevelopment in 2013, partially offset by the placement of two properties that were under development in 2012 into service, reduced net operating income by \$6.1 million for the year ended December 31, 2013 compared to the year ended December 31, 2012.

Same property net operating income increased \$50.3 million to \$393.7 million for the year ended December 31, 2013 compared to \$343.4 million for the year ended December 31, 2012. This increase was primarily due to lease termination revenue and interest income on our Construction Loan. On a GAAP basis, the current annualized base rent per square foot increased from \$38.25 at December 31, 2012 to \$38.43 at December 31, 2013 due to lease up of previously vacant space at a higher average rent than our total overall portfolio on a per square foot basis.

Depreciation and Amortization Expense. Depreciation and amortization expense increased \$48.2 million to \$245.0 million for the year ended December 31, 2013 compared to \$196.8 million for the year ended December 31, 2012. The increase was primarily due to the acquisition of properties totaling approximately 1.0 million square feet with an acquisition date fair-value of \$436.4 million in 2012 and properties totaling approximately 2.9 million square feet with an acquisition date fair-value of \$842.6 million in the year ended December 31, 2013.

General and Administrative Expenses. General and administrative expenses increased \$6.2 million to \$44.2 million for the year ended December 31, 2013 compared to \$38.0 million for the year ended December 31, 2012. The increase was primarily due to higher staffing levels reflecting our merger with Wexford and compensation associated with our above-plan leasing and financial performance as compared to the prior year.

Acquisition-Related Expenses. Acquisition-related expenses decreased to \$5.3 million for the year ended December 31, 2013 compared to \$13.1 million for the year ended December 31, 2012. Acquisition-related expenses for the year ended December 31, 2013 primarily related to our merger with Wexford. Acquisition-related expenses for

the year ended December 31, 2012 primarily related to a United Kingdom transfer tax assessed in connection with our purchase of Granta Park.

Interest Expense, Net. Interest cost incurred for the year ended December 31, 2013 totaled \$121.9 million compared to \$108.3 million for the year ended December 31, 2012. Total interest cost incurred increased primarily as a result of higher average debt balances outstanding during 2013 due to the assumption of mortgages in our merger with Wexford and issuances of our Notes due

Table of Contents

2022 and Term Loan due 2018. Interest expense, net increased \$8.1 million to \$107.7 million for the year ended December 31, 2013 compared to \$99.6 million for the year ended December 31, 2012, primarily as a result of the increase in interest cost incurred, partially offset by a \$5.6 million increase in capitalized interest related to increased development in 2013.

Interest expense, net consisted of the following (in thousands):

| | Year Ended December 31, | |
|--|----------------------------|----------|
| | 2013 | 2012 |
| Mortgage notes payable | \$44,346 | \$40,336 |
| Amortization of debt premium on mortgage notes payable | (1,520) | (698) |
| Amortization of deferred interest costs | 6,832 | 6,933 |
| Derivative instruments | 2,619 | 1,578 |
| Unsecured senior term loans | 7,930 | 6,015 |
| Exchangeable senior notes | 6,750 | 6,750 |
| Unsecured senior notes | 41,338 | 36,114 |
| Amortization of debt discount on notes | 905 | 781 |
| Unsecured line of credit | 3,764 | 2,806 |
| Unsecured line of credit fees | 2,497 | 2,768 |
| Amortization of deferred loan fees | 6,053 | 4,869 |
| Amortization - put / call / preferred return | 418 | — |
| Interest cost incurred | 121,932 | 108,252 |
| Capitalized interest | (14,205) | (8,644) |
| Total interest expense, net | \$107,727 | \$99,608 |

Other Expense. Other expense increased to \$2.9 million for the year ended December 31, 2013 compared to \$872,000 for the year ended December 31, 2012 primarily due to increase in other-than-temporary impairment of marketable securities and a full year of foreign income tax expense relating to our Granta Park property, which was acquired in June 2012. For the year ended December 31, 2013, other expense was partially offset by \$1.2 million in dividend income and gain on sale of marketable securities.

Comparison of the Year Ended December 31, 2012 to the Year Ended December 31, 2011

The following table sets forth historical financial information of the continuing operations for same properties (all properties except properties held for sale, development/redevelopment properties, new properties and corporate entities), development/redevelopment properties (properties that were entirely or primarily under redevelopment or development during either of the year ended December 31, 2012 or 2011), new properties (properties that were not owned for each of the year ended December 31, 2012 and 2011 and were not under development/redevelopment) and corporate entities (legal entities performing general and administrative and other corporate level functions) (dollars in thousands, except on a per square foot basis):

Table of Contents

| | Same Properties | | Development/Redevelopment Properties | | | | New Properties | | Corporate | | Total | |
|---|-------------------------|------------|---|---------|-----------|---------|----------------|-----------|------------|------------|-------|------|
| | December 31, | | 2012 | | 2011 | | 2012 | | 2011 | | 2011 | |
| | 2012 | 2011 | 2012 | 2011 | 2012 | 2011 | 2012 | 2011 | 2012 | 2011 | 2012 | 2011 |
| Rentable square feet | 10,462,400 | 10,462,400 | 533,367 | 533,367 | 1,723,798 | 718,978 | N/A | N/A | 12,719,565 | 11,714,770 | | |
| Percent of total portfolio | 82.2 | % 89.3 | % 4.2 | % 4.6 | % 13.6 | % 6.1 | % N/A | N/A | 100.0 | % 100.0 | | |
| Percent leased | 88.4 | % 84.6 | % 85.7 | % 86.9 | % 95.1 | % 78.2 | % N/A | N/A | 88.2 | % 84.8 | | |
| Current annualized base rent per square foot - GAAP basis (1) | \$37.89 | \$38.20 | \$34.57 | \$33.88 | \$42.77 | \$50.05 | N/A | N/A | \$38.46 | \$43.57 | | |
| | Year Ended December 31, | | 2012 | | 2011 | | 2012 | | 2011 | | 2011 | |
| Rental revenue | \$329,059 | \$321,763 | \$11,060 | \$5,868 | \$52,499 | \$1,816 | \$10 | \$7 | \$392,628 | \$329,454 | | |
| Tenant recoveries | 103,011 | 99,405 | 2,413 | 731 | 15,243 | 656 | 126 | 1,173 | 120,793 | 101,965 | | |
| Other revenue (2) | 480 | 6,696 | — | — | 3,222 | — | 1,044 | 85 | 4,746 | 6,781 | | |
| Total revenues | 432,550 | 427,864 | 13,473 | 6,599 | 70,964 | 2,472 | 1,180 | 1,265 | 518,167 | 438,200 | | |
| Rental operations | 115,727 | 119,246 | 4,442 | 2,748 | 25,315 | 1,016 | 6,735 | 5,136 | 152,219 | 128,146 | | |
| Net operating income/(loss) | 316,823 | 308,618 | 9,031 | 3,851 | 45,649 | 1,456 | (5,555) | (3,871) | 365,948 | 310,054 | | |
| Adjustments to cash basis (3) | (9,033) | (15,935) | (1,381) | (2,710) | 499 | 308 | (1,042) | (85) | (10,957) | (18,422) | | |
| Net operating income/(loss) - cash basis | \$307,790 | \$292,683 | \$7,650 | \$1,141 | \$46,148 | \$1,764 | \$(6,597) | \$(3,956) | \$354,991 | \$291,632 | | |

(1) Current annualized base rent per square foot - GAAP basis is the monthly contractual rent per square foot as of the period end, or if rent has not yet commenced, the first monthly rent payment per square foot due at each rent commencement date, multiplied by 12 months (as adjusted for straight line rent, fair-value lease revenue and lease incentive revenue).

(2) During the years ended December 31, 2012 and 2011, we recorded lease termination revenue of \$3.5 million and \$6.2 million, respectively. Lease termination revenue for the year ended 2012 primarily related to the termination of a lease with Merck at our 320 Bent Street property, which expired in August 2013. Lease termination revenue for the year ended December 31, 2011 related to an early lease termination at one of our properties.

(3) Adjustments to cash basis exclude adjustments to expenses accrued in rental operations, but include straight line rents, fair-value lease revenue, lease incentive revenue, bad debt expense and other revenue (including lease termination revenue).

The following table provides a reconciliation of net operating income - cash basis to net income for the years ended December 31, 2012 and 2011 (dollars in thousands):

53

Table of Contents

| | Year Ended | | | Percent | |
|---|--------------|-----------|------------|-----------|----|
| | December 31, | | Change | Change | |
| | 2012 | 2011 | | | |
| Net operating income - cash basis | \$354,991 | \$291,632 | \$63,359 | 21.7 | % |
| Adjustments to cash basis | 10,957 | 18,422 | (7,465) | (40.5) |)% |
| Net operating income | 365,948 | 310,054 | 55,894 | 18.0 | % |
| Unallocated expense: | | | | | |
| Depreciation and amortization expense | 196,844 | 142,319 | 54,525 | 38.3 | % |
| General and administrative expense | 38,025 | 30,966 | 7,059 | 22.8 | % |
| Acquisition-related expenses | 13,077 | 1,099 | 11,978 | 1,089.9 | % |
| Income from operations | 118,002 | 135,670 | (17,668) | (13.0) |)% |
| Equity in net loss of unconsolidated partnerships | (1,389) | (2,489) | 1,100 | (44.2) |)% |
| Interest expense, net | (99,608) | (89,181) | (10,427) | 11.7 | % |
| Other expense | (872) | (1,760) | 888 | (50.5) |)% |
| Income from continuing operations | 16,133 | 42,240 | (26,107) | (61.8) |)% |
| (Loss) / income from discontinued operations | (4,370) | 474 | (4,844) | (1,021.9) |)% |
| Net income | \$11,763 | \$42,714 | \$(30,951) | (72.5) |)% |

Net Operating Income. Net operating income increased \$55.9 million to \$365.9 million for the year ended December 31, 2012 compared to \$310.1 million for the year ended December 31, 2011. This increase was primarily due to the following:

The acquisition of properties totaling 718,978 square feet in 2011 and properties totaling approximately 1.0 million square feet in the year ended December 31, 2012 contributed an additional \$44.2 million in net operating income for the year ended December 31, 2012 compared to the year ended December 31, 2011.

The placement into service in 2012 of a property that was under development in 2011 and a property that was placed into service in 2011 that was operating throughout 2012, partially offset by properties that were operating in 2011 and began redevelopment in 2012, resulted in an increase of \$5.2 million in net operating income for the year ended December 31, 2012 compared to the year ended December 31, 2011.

Same property net operating income increased \$8.2 million to \$316.8 million for the year ended December 31, 2012 compared to \$308.6 million for the year ended December 31, 2011. This increase was primarily due to increased leasing activity in our same property portfolio during 2012, which increased the leased percentage from 84.6% at December 31, 2011 to 88.4% at December 31, 2012, and resulted in the following:

An increase in the percentage of recoverable expenses in our same property portfolio to 89.0% for the year ended December 31, 2012 compared to 83.4% for the year ended December 31, 2011, which contributed an additional \$7.1 million in net operating income for the year ended December 31, 2012.

An increase in rental revenue of \$7.3 million directly attributable to the commencement of leases in our same property portfolio. On a GAAP basis, the current annualized base rent per square foot decreased to \$37.89 at December 31, 2012 from \$38.20 at December 31, 2011 due to lease up of previously vacant space at a lower average rent than our total overall portfolio on a per square foot basis.

These increases were partially offset by a decrease of \$6.2 million in other revenue which resulted from higher termination payments received for terminated leases for the year ended December 31, 2011.

Depreciation and Amortization Expense. Depreciation and amortization expense increased \$54.5 million to \$196.8 million for the year ended December 31, 2012 compared to \$142.3 million for the year ended December 31, 2011. The increase was primarily due to the acquisition of properties totaling approximately 719,000 square feet with an acquisition date fair-value of \$431.5 million in 2011 and properties totaling approximately 1.0 million square feet with an acquisition date fair-value of \$436.4 million in the year ended December 31, 2012.

General and Administrative Expenses. General and administrative expenses increased \$7.1 million to \$38.0 million for the year ended December 31, 2012 compared to \$31.0 million for the year ended December 31, 2011. The increase was primarily due

Table of Contents

to higher staffing levels reflecting our continuing growth and compensation associated with our above-plan leasing and financial performance as compared to the prior year.

Acquisition-Related Expenses. Acquisition-related expenses increased to \$13.1 million for the year ended December 31, 2012 compared to \$1.1 million for the year ended December 31, 2011. The increase was primarily due to a United Kingdom transfer tax assessed in connection with our purchase of Granta Park in 2012.

Interest Expense, Net. Interest cost incurred for the year ended December 31, 2012 totaled \$108.3 million compared to \$96.7 million for the year ended December 31, 2011. Total interest cost incurred increased primarily as a result of higher average debt balances outstanding during 2012 and increases in the average interest rate on our outstanding borrowings due to the issuance of new indebtedness, partially offset by the repayment of certain higher coupon mortgage notes payable. Interest expense, net increased \$10.4 million to \$99.6 million for the year ended December 31, 2012 compared to \$89.2 million for the year ended December 31, 2011 primarily as a result of the increase in interest cost incurred.

Interest expense, net consisted of the following (in thousands):

| | Year Ended December 31, | |
|--|----------------------------|----------|
| | 2012 | 2011 |
| Mortgage notes payable | \$40,336 | \$43,803 |
| Amortization of debt premium on mortgage notes payable | (698) | (1,678) |
| Amortization of deferred interest costs | 6,933 | 7,027 |
| Derivative instruments | 1,578 | 3,385 |
| Unsecured senior term loans | 6,015 | — |
| Exchangeable senior notes | 6,750 | 7,429 |
| Unsecured senior notes | 36,114 | 26,905 |
| Amortization of debt discount on notes | 781 | 829 |
| Unsecured line of credit | 2,806 | 3,075 |
| Unsecured line of credit fees | 2,768 | 1,619 |
| Amortization of deferred loan fees | 4,869 | 4,355 |
| Interest cost incurred | 108,252 | 96,749 |
| Capitalized interest | (8,644) | (7,568) |
| Total interest expense, net | \$99,608 | \$89,181 |

Other Expense. Other expense decreased to \$872,000 for the year ended December 31, 2012 compared to \$1.8 million for the year ended December 31, 2011. For the year ended December 31, 2012, other expense was primarily related to other-than-temporary impairment of marketable securities and foreign income tax expense relating to our Granta Park investment. For the year ended December 31, 2011, other expense was primarily related to other-than-temporary impairment of marketable securities and loss on early extinguishment of debt, partially offset by gain on revaluation of acquired unconsolidated partnerships.

Loss from Discontinued Operations. Loss from discontinued operations was approximately \$4.4 million for the year ended December 31, 2012 due to an impairment loss that was recorded as a result of the completion of the exchange of our Forbes Boulevard property.

Cash Flows

The following summary discussion of our cash flows is based on the consolidated statements of cash flows in “Item 8. Financial Statements and Supplementary Data” and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below (in thousands):

| | 2013 | 2012 | 2011 |
|---|-----------|-----------|-----------|
| Net cash provided by operating activities | \$279,789 | \$238,235 | \$175,031 |
| Net cash used in investing activities | (833,219) | (537,982) | (604,331) |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | |
|---|---------|---------|---------|
| Net cash provided by financing activities | 568,576 | 303,285 | 424,244 |
| Ending cash and cash equivalents balance | 34,706 | 19,976 | 16,411 |

55

Table of Contents

Comparison of the Year Ended December 31, 2013 to the Year Ended December 31, 2012

Net cash provided by operating activities increased \$41.6 million to \$279.8 million for the year ended December 31, 2013 compared to \$238.2 million for the year ended December 31, 2012. The increase was primarily due to cash flow generated by acquisitions, cash rent starts on new leases and lease termination payments.

Net cash used in investing activities increased \$295.2 million to \$833.2 million for the year ended December 31, 2013 compared to \$538.0 million for the year ended December 31, 2012. The increase primarily reflects increased acquisition-related activity, capital expenditures and funding of our Construction Loan during the year ended December 31, 2013 compared to the year ended December 31, 2012.

Net cash provided by financing activities increased \$265.3 million to \$568.6 million for the year ended December 31, 2013 compared to \$303.3 million for the year ended December 31, 2012. The increase primarily reflects increased financing requirements due to increased acquisition-related activity and capital expenditures during the year ended December 31, 2013 compared to the year ended December 31, 2012. The proceeds from our common stock offerings in February 2013 and April 2013 were primarily used to redeem our Series A preferred stock and to acquire properties, including the Wexford portfolio.

Comparison of the Year Ended December 31, 2012 to the Year Ended December 31, 2011

Net cash provided by operating activities increased \$63.2 million to \$238.2 million for the year ended December 31, 2012 compared to \$175.0 million for the year ended December 31, 2011. The increase was primarily due to cash flow generated by acquisitions and cash rent starts on new leases.

Net cash used in investing activities decreased \$66.3 million to \$538.0 million for the year ended December 31, 2012 compared to \$604.3 million for the year ended December 31, 2011. The decrease reflects a cash contribution to one of our joint ventures with PREI in 2011 to repay a portion of the joint venture's outstanding debt in connection with our Rogers Street acquisition, and decreased acquisition and construction activity during the year ended December 31, 2012 compared to the year ended December 31, 2011, partially offset by the funding of our Construction Loan.

Net cash provided by financing activities decreased \$120.9 million to \$303.3 million for the year ended December 31, 2012 compared to \$424.2 million for the year ended December 31, 2011. The decrease primarily reflects decreased financing requirements due to decreased acquisition and construction activity during the year ended December 31, 2012 compared to the year ended December 31, 2011. The proceeds from the issuances of our Unsecured Senior Term Loan in March 2012 and Notes due 2022 in June 2012 were primarily used to repay balances due under our unsecured line of credit and mortgage notes payable.

Funds from Operations

We present funds from operations, or FFO, and FFO excluding acquisition-related expenses, or CFFO, available to common shares and OP units because we consider them to be important supplemental measures of our operating performance and believe they are frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO and CFFO when reporting their results. FFO and CFFO are intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO and CFFO exclude depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, and, in the case of CFFO, acquisition-related expenses, they provide performance measures that, when compared year over year, reflect the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of

Governors of the National Association of Real Estate Investment Trusts, or NAREIT. As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of depreciable property, impairment charges on depreciable real estate, real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computations may differ from the methodologies for calculating FFO and CFFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO and CFFO do not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO and CFFO should not be considered alternatives to net income / (loss) (computed in accordance with GAAP) as indicators of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as indicators of our liquidity, nor are they indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.

Table of Contents

Our FFO and CFFO available to common shares and OP units and a reconciliation to net income for the years ended December 31, 2013, 2012 and 2011 (in thousands, except per share and share data) were as follows:

| | Year Ended | | |
|---|--------------|-------------|-------------|
| | December 31, | | |
| | 2013 | 2012 | 2011 |
| Net income / (loss) available to the common stockholders | \$37,720 | \$ (2,778 |) \$25,991 |
| Adjustments: | | | |
| (Gain) / loss on sale of assets | (229 |) 4,552 | — |
| Gain on revaluation of acquired unconsolidated partnership | — | — | (4,679 |
| Noncontrolling interests in operating partnership (1) | 819 | (54 |) 569 |
| Depreciation and amortization - unconsolidated partnerships | 1,497 | 1,291 | 3,636 |
| Depreciation and amortization - consolidated entities | 245,000 | 196,844 | 142,319 |
| Depreciation and amortization - discontinued operations | — | 92 | 362 |
| Depreciation and amortization - allocable to noncontrolling interest of consolidated joint ventures | (1,128 |) (112 |) (104 |
| FFO available to common shares and units - basic | 283,679 | 199,835 | 168,094 |
| Interest expense on Exchangeable Senior Notes (2) | 6,750 | 6,750 | 6,750 |
| FFO available to common shares and units - diluted | 290,429 | 206,585 | 174,844 |
| Acquisition-related expenses | 5,282 | 13,077 | 1,099 |
| CFFO available to common shares and units - diluted | \$295,711 | \$219,662 | \$175,943 |
| FFO per share - diluted | \$1.47 | \$1.23 | \$1.19 |
| CFFO per share - diluted | \$1.49 | \$1.31 | \$1.20 |
| Weighted-average common shares and units outstanding - diluted (2) | 198,193,909 | 167,437,187 | 147,061,166 |
| (3) | | | |

Net income allocable to noncontrolling interests in the operating partnership is included in net income available to (1) unitholders of the operating partnership as reflected in the consolidated financial statements of our operating partnership, included elsewhere herein.

Reflects interest expense adjustment of the Exchangeable Senior Notes based on the “if converted” method. The (2) years ended December 31, 2013, 2012 and 2011 include 10,405,224, 10,259,496 and 10,017,858 shares of common stock, respectively, potentially issuable pursuant to the exchange feature of the Exchangeable Senior Notes based on the “if converted” method.

The years ended December 31, 2013, 2012 and 2011 include 1,391,663, 1,477,304 and 1,433,465 shares of (3) unvested restricted stock, respectively, which are considered anti-dilutive for purposes of calculating diluted earnings per share.

Liquidity and Capital Resources of BioMed Realty Trust, Inc.

In this “Liquidity and Capital Resources of BioMed Realty Trust, Inc.” section, the term the “Company” refers only to BioMed Realty Trust, Inc. on an unconsolidated basis, and excludes the operating partnership and all other subsidiaries. For further discussion of the liquidity and capital resources of the Company on a consolidated basis, see the section entitled “Liquidity and Capital Resources of BioMed Realty, L.P.” below.

The Company’s business is operated primarily through the operating partnership. The Company issues public equity from time to time, but does not otherwise generate any capital itself or conduct any business itself, other than incurring certain expenses in operating as a public company which are fully reimbursed by the operating partnership. The Company itself does not hold any indebtedness, and its only material asset is its ownership of partnership interests of the operating partnership. The Company’s principal funding requirement is the payment of dividends on its common stock. The Company’s principal source of funding for its dividend payments is distributions it receives from the

operating partnership.

As of December 31, 2013, the Company owned an approximate 97.3% partnership interest and other limited partners, including some of our directors, executive officers and their affiliates, owned the remaining 2.7% partnership interest (including LTIP units) in the operating partnership. As the sole general partner of the operating partnership, BioMed Realty Trust, Inc. has the full, exclusive and complete responsibility for the operating partnership's day-to-day management and control.

57

Table of Contents

The liquidity of the Company is dependent on the operating partnership's ability to make sufficient distributions to the Company. The primary cash requirement of the Company is its payment of dividends to its stockholders. The Company also guarantees some of the operating partnership's debt, as discussed further in Note 5 of the Notes to Consolidated Financial Statements included elsewhere herein. If the operating partnership fails to fulfill certain of its debt requirements, which trigger the Company's guarantee obligations, then the Company will be required to fulfill its cash payment commitments under such guarantees. However, the Company's only significant asset is its investment in the operating partnership.

We believe the operating partnership's sources of working capital, specifically its cash flow from operations, and borrowings available under its unsecured line of credit, are adequate for it to make its distribution payments to the Company and, in turn, for the Company to make its dividend payments to its stockholders. However, we cannot assure you that the operating partnership's sources of capital will continue to be available at all or in amounts sufficient to meet its needs, including its ability to make distribution payments to the Company. The unavailability of capital could adversely affect the operating partnership's ability to pay its distributions to the Company, which would in turn, adversely affect the Company's ability to pay cash dividends to its stockholders.

Our short-term liquidity requirements consist primarily of funds to pay for future dividends expected to be paid to the Company's stockholders, operating expenses and other expenditures directly associated with our properties, interest expense and scheduled principal payments on outstanding indebtedness, general and administrative expenses, funding the Construction Loan, construction projects, capital expenditures, tenant improvements and leasing commissions.

The Company may from time to time seek to repurchase or redeem the operating partnership's outstanding debt, the Company's shares of common stock or other securities in open market purchases, privately negotiated transactions or otherwise. Such repurchases or redemptions, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

For the Company to maintain its qualification as a REIT, it must pay dividends to its stockholders aggregating annually at least 90% of its REIT taxable income, excluding net capital gains. While historically the Company has satisfied this distribution requirement by making cash distributions to its stockholders, it may choose to satisfy this requirement by making distributions of cash or other property, including, in limited circumstances, the Company's own stock. As a result of this distribution requirement, the operating partnership cannot rely on retained earnings to fund its ongoing operations to the same extent that other companies whose parent companies are not REITs can. The Company may need to continue to raise capital in the equity markets to fund the operating partnership's working capital needs, acquisitions and developments.

The Company is a well-known seasoned issuer with an effective shelf registration statement that allows the Company to register an unspecified amount of various classes of equity securities and the operating partnership to register an unspecified amount of various classes of debt securities. As circumstances warrant, the Company may issue equity from time to time on an opportunistic basis, dependent upon market conditions and available pricing. When the Company receives proceeds from preferred or common equity issuances, it is required by the operating partnership's partnership agreement to contribute the proceeds from its equity issuances to the operating partnership in exchange for preferred or common partnership units of the operating partnership. The operating partnership may use the proceeds to repay debt, to develop new or existing properties, to acquire properties or for general corporate purposes.

Liquidity and Capital Resources of BioMed Realty, L.P.

In this "Liquidity and Capital Resources of BioMed Realty, L.P." section, the terms "we," "our" and "us" refer to the operating partnership together with its consolidated subsidiaries or the operating partnership and BioMed Realty Trust, Inc. together with their consolidated subsidiaries, as the context requires. BioMed Realty Trust, Inc., or our Parent Company, is our sole general partner and consolidates our results of operations for financial reporting purposes. Because we operate on a consolidated basis with our Parent Company, the section entitled "Liquidity and Capital Resources of BioMed Realty Trust, Inc." should be read in conjunction with this section to understand our liquidity and capital resources on a consolidated basis.

Our short-term liquidity requirements consist primarily of funds to pay for future dividends expected to be paid to our Parent Company's stockholders, operating expenses and other expenditures directly associated with our properties,

interest expense and scheduled principal payments on outstanding indebtedness, general and administrative expenses, construction projects, capital expenditures, tenant improvements and leasing commissions.

The remaining principal payments due for our consolidated and our proportionate share of unconsolidated indebtedness (excluding debt premiums and discounts) as of December 31, 2013 were as follows (in thousands):

58

Table of Contents

| | 2014 | 2015 | 2016 | 2017 | 2018 | Thereafter | Total |
|--|-----------|----------|-----------|-----------|-----------|------------|-------------|
| Consolidated indebtedness: | | | | | | | |
| Secured mortgages | \$341,416 | \$30,006 | \$166,516 | \$30,294 | \$45,663 | \$84,153 | \$698,048 |
| Unsecured line of credit | — | — | — | — | 128,000 | — | 128,000 |
| Term Loan due 2017 - U.S. dollar | — | — | — | 243,596 | — | — | 243,596 |
| Term Loan due 2017 - GBP (1) | — | — | — | 165,190 | — | — | 165,190 |
| Term Loan due 2018 | — | — | — | — | 350,000 | — | 350,000 |
| Exchangeable Senior Notes | — | — | — | — | — | 180,000 | 180,000 |
| Notes due 2016 | — | — | 400,000 | — | — | — | 400,000 |
| Notes due 2020 | — | — | — | — | — | 250,000 | 250,000 |
| Notes due 2022 | — | — | — | — | — | 250,000 | 250,000 |
| Total consolidated indebtedness | 341,416 | 30,006 | 566,516 | 439,080 | 523,663 | 764,153 | 2,664,834 |
| Share of unconsolidated indebtedness: | | | | | | | |
| Secured mortgage | 1,356 | — | — | — | — | — | 1,356 |
| Secured construction loan | 27,795 | — | — | — | — | — | 27,795 |
| Total share of unconsolidated indebtedness | 29,151 | — | — | — | — | — | 29,151 |
| Total indebtedness | \$370,567 | \$30,006 | \$566,516 | \$439,080 | \$523,663 | \$764,153 | \$2,693,985 |

(1) The principal balance represents the U.S. dollar amount based on the exchange rate of \$1.65 to £1.00 at December 31, 2013.

Certain of our mortgage loans include financial covenants which require us to maintain minimum levels of debt service coverage and a minimum amount of net worth. Management believes that we were in compliance with these covenants as of December 31, 2013.

On February 19, 2013, our Parent Company issued 14,605,000 shares of common stock, including the exercise in full of the underwriters' option to purchase an additional 1,905,000 shares, resulting in net proceeds of approximately \$287.0 million, after deducting the underwriters' discounts and commissions and offering expenses. The net proceeds were contributed to us in exchange for 14,605,000 operating partnership units, and we utilized the net proceeds to fund the acquisition of the Woodside Technology Park property, to fund a portion of the redemption of our Parent Company's Series A preferred stock, to repay a portion of the outstanding indebtedness on our unsecured line of credit and for other general corporate and working capital purposes.

On March 15, 2013, our Parent Company redeemed all 7,920,000 outstanding shares of its Series A preferred stock for approximately \$198.0 million, or \$25.00 per share, net of accrued dividends of approximately \$2.4 million, or \$0.30217 per share. We concurrently redeemed all 7,920,000 Series A preferred operating partnership units held by the Parent Company.

On April 2, 2013, our Parent Company issued 17,250,000 shares of common stock, including the exercise in full of the underwriters' option to purchase an additional 2,250,000 shares, resulting in net proceeds of approximately \$354.1 million, after deducting the underwriters' discounts and commissions and offering expenses. The net proceeds were contributed to us in exchange for 17,250,000 operating partnership units, and we utilized the net proceeds to fund a portion of the purchase price in connection with our merger with Wexford, to repay a portion of the outstanding indebtedness under our unsecured line of credit and for other general corporate and working capital purposes.

On May 31, 2013, we completed our merger with Wexford. The aggregate consideration for Wexford at the close of the transaction was approximately \$669.1 million. We assumed approximately \$255 million in debt at fair-value. The sellers received 5,568,227 shares of our Parent Company's common stock and 336,960 operating partnership units, with the balance of the merger consideration paid in cash.

Table of Contents

On June 18, 2013, we acquired the 320 Charles Street property in Cambridge, Massachusetts for \$49.5 million, with approximately \$8.0 million paid in cash and the remaining consideration paid through the issuance of 2,034,211 operating partnership units.

On September 24, 2013, we entered into the Amended and Restated Credit Facility, amending and restating our unsecured credit agreement dated July 14, 2011, as amended. The Amended and Restated Credit Facility provides for aggregate borrowings of up to \$1.25 billion, consisting of the \$900.0 million unsecured line of credit and the \$350.0 million Term Loan due 2018.

The credit facilities governing the Amended and Restated Credit Facility and the Term Loan due 2017 include certain restrictions and covenants relating to, among other things, overall leverage and unsecured leverage ratios, fixed charge coverage, unsecured debt service coverage, maximum amount of secured indebtedness and certain investment limitations. Management believes that we were in compliance with these covenants as of December 31, 2013.

The terms of the indentures governing the Notes due 2016, the Notes due 2020 and the Notes due 2022 require compliance with various financial covenants, including limits on the amount of total leverage and secured debt maintained by us and which require us to maintain minimum levels of debt service coverage. Management believes that we were in compliance with these covenants as of December 31, 2013.

Our long-term liquidity requirements consist primarily of funds to pay for scheduled debt maturities, construction obligations, renovations, expansions, capital commitments and other non-recurring capital expenditures that need to be made periodically, and the costs associated with acquisitions of properties that we pursue. At December 31, 2013, we had acquired a participating interest in a Construction Loan and entered into construction contracts and lease agreements, with a remaining commitment totaling approximately \$415.8 million related to funding the Construction Loan, tenant improvements, leasing commissions and construction-related capital expenditures.

We expect to satisfy our short-term liquidity requirements through our existing working capital and cash provided by our operations, the issuance of long-term secured and unsecured indebtedness, the issuance of additional equity or debt securities and the use of net proceeds from the disposition of non-strategic assets. Our rental revenues, provided by our leases, generally provide cash inflows to meet our debt service obligations, pay general and administrative expenses, and fund regular distributions. We expect to satisfy our long-term liquidity requirements through our existing working capital, cash provided by operations, long-term secured and unsecured indebtedness and the issuance of additional equity or debt securities. We also expect to use funds available under our unsecured line of credit to finance acquisition and development activities and capital expenditures on an interim basis. We also expect to utilize tax credits, grants and other subsidies from time to time to fund development activities. In addition, we have an investment grade credit rating, which we believe will provide us with continued access to the unsecured debt markets, providing us with an additional source of long term financing.

BioMed Realty Trust, Inc.'s total capitalization at December 31, 2013 was approximately \$6.2 billion and was comprised of the following (dollars in thousands):

| | Shares/Units at December 31, 2013 | Aggregate Principal Amount or Dollar Value Equivalent | Percent of Total Capitalization | |
|------------------------------------|---|---|------------------------------------|---|
| Debt: | | | | |
| Mortgage notes payable (1) | | \$698,048 | 11.2 | % |
| Exchangeable senior notes | | 180,000 | 2.9 | % |
| Unsecured senior notes (1) | | 900,000 | 14.3 | % |
| Unsecured senior term loans (1)(2) | | 758,786 | 12.2 | % |
| Unsecured line of credit | | 128,000 | 2.0 | % |
| Total debt | | 2,664,834 | 42.6 | % |
| Equity: | | | | |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | |
|--|-------------|-------------|-------|---|
| Common shares, operating partnership and LTIP units outstanding (3) | 197,530,976 | 3,579,261 | 57.4 | % |
| Total equity | | 3,579,261 | 57.4 | % |
| Total capitalization | | \$6,244,095 | 100.0 | % |

(1) Amounts exclude unamortized debt premiums and unamortized debt discounts.

60

Table of Contents

In August 2012, the Operating Partnership converted approximately \$156.4 million of outstanding borrowings of the Term Loan due 2017 into British pounds sterling (“GBP”) equal to £100.0 million, which was designated as a net (2) investment hedge to mitigate the risk of fluctuations in foreign currency exchange rates. \$165.2 million of the principal balance represents the U.S. dollar amount based on the exchange rate of \$1.65 to £1.00 at December 31, 2013.

Aggregate amount based on the market closing price of the common stock of our Parent Company of \$18.12 per share on the last trading day of the quarter. Limited partners who have been issued OP units have the right to require the operating partnership to redeem part or all of their OP units, which right with respect to LTIP units is (3) subject to vesting and the satisfaction of other conditions. We may elect to redeem those OP units in exchange for shares of our Parent Company’s common stock on a one-for-one basis, subject to adjustment. At December 31, 2013, 192,115,002 of the outstanding OP units had been issued to our Parent Company upon receipt of the net proceeds from the issuance of an equal number of shares of our Parent Company’s common stock.

Our organizational documents do not limit the amount of indebtedness that we may incur, and we may modify our financing strategy from time to time in light of current economic or market conditions including, but not limited to, the relative costs of debt and equity capital, market conditions for debt and equity securities and fluctuations in the market price of our Parent Company’s common stock. In addition, the terms of the indentures governing our Notes due 2016, Notes due 2020 and Notes due 2022, the Unsecured Senior Term Loan credit facility and Amended and Restated Credit Facility require compliance with various financial covenants and ratios, which are discussed in detail above and in Note 5 of the Notes to Consolidated Financial Statements contained elsewhere herein.

We may from time to time seek to repurchase or redeem our outstanding debt or OP units (subject to the repurchase or redemption of an equivalent number of shares of common stock by our Parent Company) or other securities, and our Parent Company may seek to repurchase or redeem its outstanding shares of common stock or other securities, in each case in open market purchases, privately negotiated transactions or otherwise. Such repurchases or redemptions, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. Our Amended and Restated Credit Facility provides for borrowing capacity on our unsecured line of credit of \$900.0 million and a \$350.0 million Term Loan due 2018, with a maturity date of March 24, 2018. Subject to the administrative agent’s reasonable discretion, we may increase the borrowing capacity of the Amended and Restated Credit Facility to \$1.8 billion upon satisfying certain conditions. In addition, we may, in our sole discretion, extend the maturity date of the unsecured line of credit to September 24, 2018 after satisfying certain conditions and paying an extension fee. At maturity, we may refinance the Amended and Restated Credit Facility, depending on market conditions and the availability of credit, or we may execute the extension option.

Borrowings under the Amended and Restated Credit Facility bear interest at floating rates equal to, at the Operating Partnership's option, either (1) reserve-adjusted LIBOR plus a spread which ranges from 92.5 to 170 basis points (with respect to the unsecured line of credit) and a spread which ranges from 95 to 195 basis points (with respect to the Term Loan due 2018), in each case depending on the Parent Company's credit ratings, or (2) the highest of (a) the prime rate then in effect plus a spread which ranges from 0 to 70 basis points, (b) the federal funds rate then in effect plus a spread which ranges from 50 to 120 basis points or (c) one-month LIBOR plus a spread which ranges from 92.5 to 170 basis points (with respect to the unsecured line of credit) and a spread which ranges from 95 to 195 basis points (with respect to the Term Loan due 2018), in each case depending on the Parent Company’s credit ratings. In addition, a facility fee is payable on the total \$900.0 million capacity of the unsecured line of credit, which ranges from 12.5 to 30 basis points per annum, depending on the Parent Company’s credit ratings.

At December 31, 2013, we had \$128.0 million in outstanding borrowings on the unsecured line of credit portion of our Amended and Restated Credit Facility, with a weighted-average interest rate of 1.46%. At December 31, 2013, we had additional borrowing capacity under the unsecured line of credit of up to approximately \$772.0 million.

A summary of our outstanding consolidated mortgage notes payable as of December 31, 2013 and December 31, 2012 is as follows (in thousands):

Table of Contents

| | Stated Interest Rate | Effective Interest Rate | Principal Balance December 31, 2013 | December 31, 2012 | Maturity Date |
|---|----------------------------|-------------------------------|---|----------------------|-------------------|
| Mortgage Notes Payable | | | | | |
| 9900 Belward Campus Drive | 5.64 | % 3.99 | % \$10,631 | \$10,767 | July 1, 2017 |
| 9901 Belward Campus Drive | 5.64 | % 3.99 | % 13,091 | 13,260 | July 1, 2017 |
| Center for Life Science Boston | 7.75 | % 7.75 | % 334,447 | 338,447 | June 30, 2014 |
| 4320 Forest Park Avenue (1) | 4.00 | % 2.70 | % 21,000 | — | June 30, 2015 |
| Hershey Center for Applied Research (1) | 6.15 | % 4.71 | % 13,449 | — | May 5, 2027 |
| 500 Kendall Street (Kendall D) | 6.38 | % 5.45 | % 57,927 | 60,164 | December 1, 2018 |
| Shady Grove Road | 5.97 | % 5.97 | % 143,067 | 144,889 | September 1, 2016 |
| University of Maryland BioPark I (1) | 5.93 | % 4.69 | % 16,752 | — | May 15, 2025 |
| University of Maryland BioPark II (1) | 5.20 | % 4.33 | % 62,946 | — | September 5, 2021 |
| University of Maryland BioPark Garage (1) | 5.20 | % 4.33 | % 4,738 | — | September 1, 2021 |
| University of Miami Life Science & Technology Park (1) | 4.00 | % 2.89 | % 20,000 | — | February 1, 2016 |
| | | | \$698,048 | \$567,527 | |
| Unamortized premiums | | | 11,276 | 4,125 | |
| Mortgage notes payable, net | | | \$709,324 | \$571,652 | |

(1) Mortgage notes which were assumed on May 31, 2013 in connection with the Company's merger with Wexford. Premiums were recorded upon assumption of the mortgage notes payable at the time of the related acquisition to account for above-market interest rates. Amortization of these premiums is recorded as a reduction to interest expense over the remaining term of the respective note using a method that approximates the effective-interest method. As of December 31, 2013, principal payments due for our indebtedness (excluding debt premiums and discounts, and our proportionate share of the indebtedness of our unconsolidated partnerships) were as follows (in thousands):

| | |
|----------------|-------------|
| 2014 | \$341,416 |
| 2015 | 30,006 |
| 2016 | 566,516 |
| 2017 | 439,080 |
| 2018 | 523,663 |
| Thereafter (1) | 764,153 |
| | \$2,664,834 |

(1) Includes \$180.0 million in principal payments of the Exchangeable Senior Notes based on a contractual maturity date of January 15, 2030.

The following table provides information with respect to our contractual obligations at December 31, 2013, including maturities and scheduled principal repayments, but excluding related unamortized debt premiums. We were not subject to any material capital lease obligations or unconditional purchase obligations as of December 31, 2013.

Table of Contents

| Obligation | 2014 | 2015-2016 | 2017-2018 | Thereafter | Total |
|---|----------------|-----------|-------------|-------------|-------------|
| | (In thousands) | | | | |
| Mortgage notes payable (1) | \$341,416 | \$196,522 | \$75,957 | \$84,153 | \$698,048 |
| Exchangeable Senior Notes | — | — | — | 180,000 | 180,000 |
| Notes due 2016 (2) | — | 400,000 | — | — | 400,000 |
| Notes due 2020 (2) | — | — | — | 250,000 | 250,000 |
| Notes due 2022 (2) | — | — | — | 250,000 | 250,000 |
| Term Loan due 2017 - US dollar | — | — | 243,596 | — | 243,596 |
| Term Loan - GBP | — | — | 165,190 | — | 165,190 |
| Term Loan due 2018 | — | — | 350,000 | — | 350,000 |
| Unsecured line of credit | — | — | 128,000 | — | 128,000 |
| Share of debt of unconsolidated partnerships (1) | 29,151 | — | — | — | 29,151 |
| Interest payments on debt obligations (3) | 99,939 | 152,188 | 92,727 | 147,482 | 492,336 |
| Ground lease obligations | 4,505 | 9,619 | 10,281 | 488,757 | 513,162 |
| Construction loan receivable | 86,916 | — | — | — | 86,916 |
| Construction projects | 152,141 | 25,757 | — | — | 177,898 |
| Tenant obligations, lease commissions and other commitments | 111,397 | 38,418 | 1,176 | — | 150,991 |
| Total | \$825,465 | \$822,504 | \$1,066,927 | \$1,400,392 | \$4,115,288 |

(1) Balance excludes unamortized debt premium.

(2) Balance excludes unamortized debt discount.

(3) Interest payments reflect cash payments that are based on the interest rates in effect and debt balances outstanding on December 31, 2013.

Off-Balance Sheet Arrangements

As of December 31, 2013, we had investments in the following unconsolidated partnerships: (1) BioPark Fremont, LLC, which owns a land parcel located in Baltimore; (2) McKellar Court limited partnership, which owns a single tenant occupied property located in San Diego; and (3) two limited liability companies with PREI, which own a portfolio of properties located in Cambridge, Massachusetts (see Note 8 of the Notes to Consolidated Financial Statements included elsewhere herein for more information).

BioPark Fremont, LLC is a VIE; however, we are not the primary beneficiary. We will receive 50% of the operating cash flows and 50% of the gains upon sale of the property. We account for our membership interest using the equity method. The assets of BioPark Fremont, LLC were \$2.7 million and the liabilities were \$2.8 million at December 31, 2013.

The McKellar Court partnership is a VIE; however, we are not the primary beneficiary. The limited partner at McKellar Court is the only tenant in the property and will bear a disproportionate amount of any losses. We, as the general partner, will receive 22% of the operating cash flows and 75% of the gains upon sale of the property. We account for our general partner interest using the equity method. The assets of the McKellar Court partnership were \$13.8 million and \$14.1 million at December 31, 2013 and December 31, 2012, respectively. The liabilities were \$10.7 million and \$10.5 million at December 31, 2013 and December 31, 2012, respectively. Our equity in net income of the McKellar Court partnership was \$913,000 and \$915,000 for the years ended December 31, 2013 and 2012, respectively. In December 2009, we provided funding in the form of a promissory note to the McKellar Court partnership in the amount of \$10.3 million, which matures at the earlier of (1) January 1, 2020, or (2) the day that the limited partner exercises an option to purchase our ownership interest. Interest-only payments on the promissory note are due monthly at a fixed rate of 8.15% (the rate may adjust higher after January 1, 2015), with the principal balance outstanding due at maturity.

PREI II LLC is a VIE; however, we are not the primary beneficiary. PREI will bear the majority of any losses incurred. PREI I LLC does not qualify as a VIE. In addition, consolidation is not required as we do not control the limited liability companies. In connection with the formation of the PREI joint ventures in April 2007, we contributed 20% of the initial capital. However, the amount of cash flow distributions that we receive may be more or less based on the nature of the circumstances underlying the cash distributions due to provisions in the operating agreements governing the distribution of funds to each member and the occurrence of extraordinary cash flow events. We account for our member interests using the equity method for both limited liability companies. The assets of the PREI joint ventures were \$255.5 million and \$249.9 million at December 31, 2013 and

Table of Contents

December 31, 2012, respectively, and the liabilities were \$150.7 million and \$144.7 million at December 31, 2013 and December 31, 2012, respectively. Our equity in net loss of the PREI joint ventures was \$1.8 million and \$2.3 million for the years ended December 31, 2013 and 2012, respectively.

We are the primary beneficiary in five other VIEs, consisting of single-tenant properties in which the tenant has a fixed-price purchase option, and VIEs at nine properties with tax credit structures, which are consolidated and reflected in our consolidated financial statements.

Our proportionate share of outstanding debt related to our unconsolidated partnerships is summarized below (dollars in thousands):

| Name | Ownership Percentage | Interest Rate(2) | Principal Amount(1) | | Maturity Date |
|-----------------|----------------------|------------------|---------------------|-------------------|-----------------|
| | | | December 31, 2013 | December 31, 2012 | |
| BioPark Fremont | 50 | % 3.7 | % 1,356 | \$ — | May 1, 2014 |
| PREI I LLC (3) | 20 | % 3.2 | % 27,795 | 27,795 | August 13, 2014 |
| Total | | | \$29,151 | \$ 27,795 | |

(1) Amount represents our proportionate share of the total outstanding indebtedness for each of the unconsolidated partnerships.

(2) Effective or weighted-average interest rate of the outstanding indebtedness as of December 31, 2013.

Amount represents our proportionate share of a secured loan, which bears interest at a LIBOR-indexed variable rate with a borrowing capacity of up to \$139.0 million. The secured loan was executed by a wholly-owned

(3) subsidiary of PREI I LLC in connection with the construction of the 650 East Kendall Street property. In accordance with the loan agreement, Prudential Insurance Corporation of America has guaranteed repayment of the secured loan.

Inflation

Some of our leases contain provisions designed to mitigate the adverse impact of inflation. These provisions generally increase rental rates during the terms of the leases either at fixed rates or indexed escalations (based on the Consumer Price Index or other measures). We may be adversely impacted by inflation on the leases that do not contain indexed escalation provisions. In addition, most of our leases require the tenant to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes and insurance. This may reduce our exposure to increases in costs and operating expenses resulting from inflation, assuming our properties remain leased and tenants fulfill their obligations to reimburse us for such expenses.

Our unsecured line of credit, a portion of our Term Loan due 2017, a portion of our Term Loan due 2018, the outstanding balance of a mortgage secured by a property in Pennsylvania and our proportionate share of the outstanding balance of the PREI joint ventures' secured construction loan bear interest at variable rates, which will be influenced by changes in short-term interest rates, and will be sensitive to inflation.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our future income, cash flows and fair-values relevant to financial instruments depend upon prevailing market interest rates. Market risk is the exposure to loss resulting from changes in interest rates, foreign currency exchange rates, commodity prices and equity prices. Many factors, including governmental monetary and tax policies, domestic and international economic and political considerations and other factors that are beyond our control contribute to interest rate risk, equity price risk and foreign currency exchange rate risk.

Interest Rate Risk

As of December 31, 2013, our consolidated debt consisted of the following (dollars in thousands):

| Principal Balance (1) | Percent of Total Debt | Effective Interest |
|--------------------------|--------------------------|------------------------------|
| | | Rate at December 31, 2013 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | |
|--|-------------|-------|--------|---|
| Fixed interest rate (2) | \$1,778,048 | 66.7 | % 5.25 | % |
| Variable interest rate - hedged (3) | 565,190 | 21.2 | % 2.47 | % |
| Variable interest rate - unhedged (4) | 321,596 | 12.1 | % 1.61 | % |
| Total/weighted-average effective interest rate | \$2,664,834 | 100.0 | % 4.22 | % |

64

Table of Contents

(1) Principal balance includes only consolidated indebtedness.

Includes eleven mortgage notes payable secured by certain of our properties (including unamortized premiums), (2) our Exchangeable Senior Notes, our Notes due 2016 (including unamortized debt discount), our Notes due 2020 (including unamortized debt discount) and our Notes due 2022 (including unamortized debt discount).

Includes the hedged portions of our Term Loan due 2017 and Term Loan due 2018, which bear interest at LIBOR-indexed variable interest rates, plus a credit spread. On August 2, 2012, we converted approximately \$156.4 million of outstanding borrowings of the Term Loan due 2017 into GBP equal to £100.0 million. The principal balance represents the U.S. dollar amount based on the exchange rate of \$1.65 to £1.00 at December 31, 2013. The stated effective rate for the variable interest hedged debt includes the impact of our interest rate swap agreements. We have entered into four U.S. dollar interest rate swaps, which are intended to have the effect of initially fixing the interest rate on \$200.0 million of the outstanding amount under our Term Loan due 2017 at a (3) weighted-average interest rate of approximately 2.81% for a five-year term (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings. We have entered into two GBP interest rate swaps, which are intended to have the effect of initially fixing the interest rate on £100.0 million of the outstanding amount under our Term Loan due 2017 at approximately 2.39% for the remaining term of the Term Loan due 2017 (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings. On September 25, 2013, we entered into three U.S. dollar interest rate swaps, which are intended to have the effect of initially fixing the interest rate on \$200.0 million of the outstanding amount under our Term Loan due 2018 at a weighted-average interest rate of approximately 2.20% for a three-year term (including applicable credit spreads for the underlying debt), subject to adjustment based on our credit ratings.

(4) Includes one variable rate mortgage, the unhedged portions of our Term Loan due 2017 and Term Loan due 2018 and our unsecured line of credit, which bear interest at LIBOR-indexed variable interest rates, plus a credit spread. To determine the fair-value of our outstanding consolidated indebtedness, we utilize quoted market prices to estimate the fair-value, when available. If quoted market prices are not available, we calculate the fair-value of our mortgage notes payable and other fixed-rate debt based on an estimate of current lending rates, assuming the debt is outstanding through maturity and considering the notes' collateral. In determining the current market rate for fixed-rate debt, a market credit spread is added to the quoted yields on federal government treasury securities with similar terms to debt. In determining the current market rate for variable-rate debt, a market credit spread is added to the current effective interest rate. At December 31, 2013, the fair-value of all fixed-rate debt was estimated to be \$1.9 billion compared to the net carrying value of \$1.8 billion (including debt premiums and discounts). At December 31, 2013, the fair-value of all variable-rate debt was estimated to be \$888.7 million compared to the net carrying value of \$886.8 million. We do not believe that the interest rate risk represented by our fixed-rate debt or the risk of changes in the credit spread related to our variable-rate debt was material as of December 31, 2013 in relation to total assets of \$6.0 billion and equity market capitalization of \$3.6 billion of BioMed Realty Trust, Inc.'s common stock, and BioMed Realty, L.P.'s OP units.

Based on the unhedged outstanding balances of our unsecured line of credit, our Term Loan due 2017, our Term Loan due 2018 and our proportionate share of the outstanding balance of the PREI joint ventures' secured construction loan at December 31, 2013, a 1% change in interest rates would change our interest costs by approximately \$3.5 million per year. This amount was determined by considering the impact of hypothetical interest rates on our financial instruments. This analysis does not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of the magnitude discussed above, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, this analysis assumes no changes in our financial structure.

In order to modify and manage the interest rate characteristics of our outstanding debt and to limit the effects of interest rate risks on our operations, we may utilize a variety of financial instruments, including interest rate swaps, caps and treasury locks in order to mitigate our interest rate risk on a related financial instrument. The use of these types of instruments to hedge our exposure to changes in interest rates carries additional risks, including counterparty credit risk, the enforceability of hedging contracts and the risk that unanticipated and significant changes in interest rates will cause a significant loss of basis in the contract. To limit counterparty credit risk we will seek to enter into

such agreements with major financial institutions with high credit ratings. There can be no assurance that we will be able to adequately protect against the foregoing risks and will ultimately realize an economic benefit that exceeds the related amounts incurred in connection with engaging in such hedging activities. We do not enter into such contracts for speculative or trading purposes.

Equity Price Risk

We have exposure to equity price market risk because of our equity investments in certain publicly-traded companies and privately-held entities. We classify investments in publicly traded companies as “available for sale” and, consequently, record them on our condensed consolidated balance sheets at fair-value, with unrealized gains or losses reported as a component of accumulated other comprehensive income or loss. Investments in privately-held entities are generally accounted for under the cost method because we do not influence any of the operating or financial policies of the entities in which we invest. For all investments,

Table of Contents

we recognize other-than-temporary declines in value against earnings in the same period during which the decline in value was deemed to have occurred. There is no assurance that future declines in value will not have a material adverse impact on our future results of operations. A 10% decrease in the fair-value of our equity investments as of December 31, 2013, would equal approximately \$3.8 million.

Foreign Currency Exchange Rate Risk

We have exposure to foreign currency exchange rate risk related to our subsidiary operating in the United Kingdom. The functional currency of our foreign subsidiary is GBP. Gains or losses resulting from the translation of our foreign subsidiary's balance sheet and statement of income are included in other comprehensive income. Gains or losses will be reflected in our statements of income when there is a sale of our investment in these operations or upon a complete or substantially complete liquidation of the investment. For the quarter ended December 31, 2013 and 2012, total revenues from our foreign subsidiary were \$4.7 million and \$5.0 million, respectively, which represented 3.0% and 3.6% of our total revenues for the respective periods. For the year ended December 31, 2013 and 2012, total revenues from our foreign subsidiary were \$18.2 million and \$10.3 million, respectively, which represented 2.9% and 2.0% of our total revenues for the respective periods. Our net investment in properties outside the United States was \$190.2 million and \$188.8 million as of December 31, 2013 and December 31, 2012, respectively. On August 2, 2012, we converted a portion of the outstanding borrowings of our Term Loan due 2017 into GBP, which we designated as a net investment hedge to mitigate our risk to fluctuations in foreign currency exchange rates. As a result, our unhedged net investment in properties outside the United States was \$25.0 million as of December 31, 2013.

Table of Contents

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

| | Page |
|---|------------|
| <u>Reports of Independent Registered Public Accounting Firm</u> | <u>68</u> |
| Consolidated Financial Statements of BioMed Realty Trust, Inc.: | |
| <u>Consolidated Balance Sheets as of December 31, 2013 and 2012</u> | <u>72</u> |
| <u>Consolidated Statements of Operations for the years ended December 31, 2013, 2012 and 2011</u> | <u>73</u> |
| <u>Consolidated Statements of Comprehensive Income for the years ended December 31, 2013, 2012 and 2011</u> | <u>74</u> |
| <u>Consolidated Statements of Equity for the years ended December 31, 2013, 2012 and 2011</u> | <u>75</u> |
| <u>Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012 and 2011</u> | <u>77</u> |
| Consolidated Financial Statements of BioMed Realty, L.P.: | |
| <u>Consolidated Balance Sheets as of December 31, 2013 and 2012</u> | <u>79</u> |
| <u>Consolidated Statements of Operations for the years ended December 31, 2013, 2012 and 2011</u> | <u>80</u> |
| <u>Consolidated Statements of Comprehensive Income for the years ended December 31, 2013, 2012 and 2011</u> | <u>81</u> |
| <u>Consolidated Statements of Capital for the years ended December 31, 2013, 2012 and 2011</u> | <u>82</u> |
| <u>Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012 and 2011</u> | <u>84</u> |
| <u>Notes to Consolidated Financial Statements of BioMed Realty Trust, Inc. and BioMed Realty, L.P.</u> | <u>86</u> |
| <u>Financial Statement — Schedule III</u> | <u>121</u> |

Table of Contents

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders

BioMed Realty Trust, Inc.:

We have audited the accompanying consolidated balance sheets of BioMed Realty Trust, Inc. and subsidiaries (the Company) as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income, equity, and cash flows for each of the years in the three year period ended December 31, 2013. In connection with our audits of the consolidated financial statements, we also have audited the accompanying financial statement schedule III. These consolidated financial statements and financial statement schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of BioMed Realty Trust, Inc. and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the years in the three year period ended December 31, 2013, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), BioMed Realty Trust, Inc.'s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 7, 2014 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.

/s/ KPMG LLP

San Diego, California

February 7, 2014

Table of Contents

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders

BioMed Realty Trust, Inc.:

We have audited BioMed Realty Trust, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control - Integrated Framework (1992), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, BioMed Realty Trust, Inc. and subsidiaries maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control - Integrated Framework (1992), issued by the Committee of Sponsoring Organizations of the Treadway Commission.

BioMed Realty Trust, Inc. acquired Wexford Science and Technology, LLC during 2013. Management excluded Wexford Science and Technology, LLC's internal control over financial reporting as of December 31, 2013, which constituted 14% and 5% of total assets and total revenue, respectively, of BioMed Realty Trust, Inc.'s consolidated financial statement amounts as of and for the year ended December 31, 2013, from the scope of its assessment of the effectiveness of BioMed Realty Trust, Inc.'s internal control over financial reporting as of December 31, 2013. Our audit of internal control over financial reporting of BioMed Realty Trust, Inc. also excluded an evaluation of the internal control over financial reporting of Wexford Science & Technology, LLC.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of BioMed Realty Trust, Inc. and subsidiaries as of December 31, 2013 and

Table of Contents

2012, and the related consolidated statements of operations, comprehensive income, equity, and cash flows for each of the years in the three year period ended December 31, 2013, and our report dated February 7, 2014 expressed an unqualified opinion on those consolidated financial statements.

/s/ KPMG LLP

San Diego, California
February 7, 2014

Table of Contents

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of the General Partner
BioMed Realty, L.P.:

We have audited the accompanying consolidated balance sheets of BioMed Realty, L.P. and subsidiaries (the Operating Partnership) as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income, capital, and cash flows for each of the years in the three year period ended December 31, 2013. In connection with our audits of the consolidated financial statements, we also have audited the accompanying financial statement schedule III. These consolidated financial statements and financial statement schedule are the responsibility of the Operating Partnership's management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of BioMed Realty, L.P. and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the years in the three year period ended December 31, 2013, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ KPMG LLP

San Diego, California
February 7, 2014

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

| | December 31, 2013 | 2012 |
|--|----------------------|--------------|
| ASSETS | | |
| Investments in real estate, net | \$5,217,902 | \$4,319,716 |
| Investments in unconsolidated partnerships | 32,137 | 32,367 |
| Cash and cash equivalents | 34,706 | 19,976 |
| Accounts receivable, net | 8,421 | 4,507 |
| Accrued straight-line rents, net | 173,779 | 152,096 |
| Deferred leasing costs, net | 198,067 | 172,363 |
| Other assets | 307,589 | 133,454 |
| Total assets | \$5,972,601 | \$4,834,479 |
| LIABILITIES AND EQUITY | | |
| Mortgage notes payable, net | \$709,324 | \$571,652 |
| Exchangeable senior notes | 180,000 | 180,000 |
| Unsecured senior notes, net | 895,083 | 894,177 |
| Unsecured senior term loans | 758,786 | 405,456 |
| Unsecured line of credit | 128,000 | 118,000 |
| Accounts payable, accrued expenses and other liabilities | 314,383 | 180,653 |
| Total liabilities | 2,985,576 | 2,349,938 |
| Equity: | | |
| Stockholders' equity: | | |
| Preferred stock, \$.01 par value, 15,000,000 shares authorized: 7.375% Series A cumulative redeemable preferred stock, no shares issued and outstanding at December 31, 2013; and 7,920,000 shares issued and outstanding at December 31, 2012, \$198,000 liquidation preference (\$25.00 per share) | — | 191,469 |
| Common stock, \$.01 par value, 250,000,000 shares authorized, 192,115,002 shares issued and outstanding at December 31, 2013; and 200,000,000 shares authorized, 154,327,818 shares issued and outstanding at December 31, 2012 | 1,921 | 1,543 |
| Additional paid-in capital | 3,554,558 | 2,781,849 |
| Accumulated other comprehensive loss, net | (32,923 |) (54,725) |
| Dividends in excess of earnings | (583,569 |) (443,280) |
| Total stockholders' equity | 2,939,987 | 2,476,856 |
| Noncontrolling interests | 47,038 | 7,685 |
| Total equity | 2,987,025 | 2,484,541 |
| Total liabilities and equity | \$5,972,601 | \$4,834,479 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share data)

| | For the Year Ended December 31, | | |
|---|------------------------------------|-------------|-------------|
| | 2013 | 2012 | 2011 |
| Revenues: | | | |
| Rental | \$445,980 | \$392,628 | \$329,454 |
| Tenant recoveries | 141,634 | 120,793 | 101,965 |
| Other revenue | 49,700 | 4,746 | 6,781 |
| Total revenues | 637,314 | 518,167 | 438,200 |
| Expenses: | | | |
| Rental operations | 184,073 | 152,219 | 128,146 |
| Depreciation and amortization | 245,000 | 196,844 | 142,319 |
| General and administrative | 44,175 | 38,025 | 30,966 |
| Acquisition-related expenses | 5,282 | 13,077 | 1,099 |
| Total expenses | 478,530 | 400,165 | 302,530 |
| Income from operations | 158,784 | 118,002 | 135,670 |
| Equity in net loss of unconsolidated partnerships | (905) | (1,389) | (2,489) |
| Interest expense, net | (107,727) | (99,608) | (89,181) |
| Other expense | (2,943) | (872) | (1,760) |
| Income from continuing operations | 47,209 | 16,133 | 42,240 |
| (Loss) / income from discontinued operations | — | (4,370) | 474 |
| Net income | 47,209 | 11,763 | 42,714 |
| Net (income) / loss attributable to noncontrolling interests | (565) | 62 | (525) |
| Net income attributable to the Company | 46,644 | 11,825 | 42,189 |
| Preferred stock dividends | (2,393) | (14,603) | (16,033) |
| Cost on redemption of preferred stock | (6,531) | — | (165) |
| Net income / (loss) available to common stockholders | \$37,720 | \$(2,778) | \$25,991 |
| Income from continuing operations per share available to common stockholders: | | | |
| Basic and diluted earnings per share | \$0.20 | \$— | \$0.19 |
| Loss from discontinued operations per share available to common stockholders: | | | |
| Basic and diluted earnings per share | \$— | \$(0.03) | \$— |
| Net income / (loss) per share available to common stockholders: | | | |
| Basic and diluted earnings per share | \$0.20 | \$(0.03) | \$0.19 |
| Weighted-average common shares outstanding: | | | |
| Basic | 182,043,391 | 152,752,086 | 132,625,915 |
| Diluted | 186,397,022 | 155,700,387 | 135,609,843 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

| | Year Ended | | |
|---|--------------|----------|------------|
| | December 31, | | |
| | 2013 | 2012 | 2011 |
| Net income | \$47,209 | \$11,763 | \$42,714 |
| Other comprehensive income: | | | |
| Foreign currency translation adjustments | 395 | 3,611 | — |
| Unrealized gain / (loss) from derivative instruments, net | 6,116 | (5,144 |) 3,857 |
| Amortization of deferred interest costs | 6,832 | 6,933 | 7,027 |
| Reclassification of unrealized loss on equity securities | — | 545 | 5,132 |
| Reclassification on sale of equity securities | — | (38 |) 70 |
| Unrealized gain / (loss) on equity securities | 10,907 | (390 |) (5,131) |
| Total other comprehensive income | 24,250 | 5,517 | 10,955 |
| Comprehensive income | 71,459 | 17,280 | 53,669 |
| Comprehensive income attributable to noncontrolling interests | (3,013 |) (42 |) (760) |
| Comprehensive income attributable to the Company | \$68,446 | \$17,238 | \$52,909 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENT OF EQUITY

(In thousands, except share data)

| | Series A Preferred Stock | Common Stock Shares | Common Stock Amount | Additional Paid-In Capital | Accumulated Other Comprehensive (Loss)/Income net | Dividends in Excess of Earnings | Total Stockholders' Equity | Noncontrolling Interests | Total Equity |
|---|--------------------------------|------------------------|------------------------|----------------------------------|---|---|----------------------------------|-----------------------------|-----------------|
| Balance at December 31, 2010 | \$222,413 | 131,046,509 | \$1,310 | \$2,371,488 | \$(70,857) | \$(221,176) | \$2,303,178 | \$9,718 | \$2,312,896 |
| Net proceeds from sale of common stock | — | 22,562,922 | 225 | 399,346 | — | — | 399,571 | — | 399,571 |
| Net issuances of unvested restricted common stock | — | 470,780 | 5 | (2,425) | — | — | (2,420) | — | (2,420) |
| Conversion of OP units to common stock | — | 21,271 | 1 | (50) | — | — | (49) | 49 | — |
| Redemption of preferred stock | (30,944) | — | — | — | — | (165) | (31,109) | — | (31,109) |
| Vesting of share-based awards | — | — | — | 7,582 | — | — | 7,582 | — | 7,582 |
| Reallocation of equity to noncontrolling interests | — | — | — | (1,947) | — | — | (1,947) | 1,947 | — |
| Common stock dividends | — | — | — | — | — | (109,574) | (109,574) | — | (109,574) |
| OP unit distributions | — | — | — | — | — | — | — | (2,386) | (2,386) |
| Net income | — | — | — | — | — | 42,189 | 42,189 | 525 | 42,714 |
| Preferred stock dividends | — | — | — | — | — | (16,033) | (16,033) | — | (16,033) |
| Reclassification on unrealized loss on equity securities | — | — | — | — | 5,021 | — | 5,021 | 111 | 5,132 |
| Reclassification on sale of equity securities | — | — | — | — | 69 | — | 69 | 1 | 70 |
| | — | — | — | — | (5,021) | — | (5,021) | (110) | (5,131) |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | | | | | | |
|---|-----------|-------------|---------|-------------|------------|-------------|-------------|----------|-------------|
| Unrealized loss on equity securities | | | | | | | | | |
| Amortization of deferred interest costs | — | — | — | — | 6,877 | — | 6,877 | 150 | 7,027 |
| Unrealized gain on derivative instruments, net | — | — | — | — | 3,773 | — | 3,773 | 84 | 3,857 |
| Balance at December 31, 2011 | \$191,469 | 154,101,482 | \$1,541 | \$2,773,994 | \$(60,138) | \$(304,759) | \$2,602,107 | \$10,089 | \$2,612,196 |
| Net issuances of unvested restricted common stock | — | 179,115 | 1 | (3,529) |) — | — | (3,528) |) — | (3,528) |
| Conversion of OP units to common stock | — | 47,221 | 1 | — | — | — | 1 | (1) |) — |
| Vesting of share-based awards | — | — | — | 11,530 | — | — | 11,530 | — | 11,530 |
| Reallocation of equity to noncontrolling interests | — | — | — | (146) |) — | — | (146) |) 146 | — |
| Common stock dividends | — | — | — | — | — | (135,743) | (135,743) |) — | (135,743) |
| OP unit distributions | — | — | — | — | — | — | — | (2,591) |) (2,591) |
| Net income / (loss) | — | — | — | — | — | 11,825 | 11,825 | (62) |) 11,763 |

75

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

Table of Contents

| | Series A Preferred Stock | Common Stock Shares | Amount | Additional Paid-In Capital | Accumulated Other Comprehensive (Loss)/Income net | Dividends in Excess of Earnings | Total Stockholders' Equity | Noncontrolling Interests | Total Equity |
|--|--------------------------------|------------------------|---------|----------------------------------|---|---|----------------------------------|-----------------------------|-----------------|
| Preferred stock dividends | — | — | — | — | — | (14,603) | (14,603) | — | (14,603) |
| Foreign currency translation adjustment | — | — | — | — | 3,543 | — | 3,543 | 68 | 3,611 |
| Reclassification on unrealized loss on equity securities | — | — | — | — | 535 | — | 535 | 10 | 545 |
| Reclassification on sale of equity securities | — | — | — | — | (38) | — | (38) | — | (38) |
| Unrealized loss on equity securities | — | — | — | — | (382) | — | (382) | (8) | (390) |
| Amortization of deferred interest costs | — | — | — | — | 6,803 | — | 6,803 | 130 | 6,933 |
| Unrealized loss on derivative instruments, net | — | — | — | — | (5,048) | — | (5,048) | (96) | (5,144) |
| Balance at December 31, 2012 | \$191,469 | 154,327,818 | \$1,543 | \$2,781,849 | \$(54,725) | \$(443,280) | \$2,476,856 | \$7,685 | \$2,484,541 |
| Net proceeds from sale of common stock | — | 31,855,000 | 319 | 640,778 | — | — | 641,097 | — | 641,097 |
| Net issuances of unvested restricted common stock | — | 343,561 | 3 | (5,053) | — | — | (5,050) | — | (5,050) |
| Conversion of OP units to common stock | — | 20,396 | — | (87) | — | — | (87) | 87 | — |
| Redemption of Series A preferred stock | (191,469) | — | — | — | — | (6,531) | (198,000) | — | (198,000) |
| Vesting of share-based awards | — | — | — | 12,852 | — | — | 12,852 | — | 12,852 |
| | — | 5,568,227 | 56 | 116,487 | — | — | 116,543 | — | 116,543 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | | | | | | |
|--|-----|-------------|---------|-------------|------------|-------------|-------------|----------|-------------|
| Issuance of common stock in connection with Wexford merger | | | | | | | | | |
| Issuance of OP units | — | — | — | — | — | — | — | 48,571 | 48,571 |
| Reallocation of noncontrolling interests to equity | — | — | — | 7,732 | — | — | 7,732 | (7,732) | — |
| Common stock dividends | — | — | — | — | — | (178,009) | (178,009) | — | (178,009) |
| OP unit distributions | — | — | — | — | — | — | — | (4,586) | (4,586) |
| Net income | — | — | — | — | — | 46,644 | 46,644 | 565 | 47,209 |
| Preferred stock dividends | — | — | — | — | — | (2,393) | (2,393) | — | (2,393) |
| Foreign currency translation adjustments | — | — | — | — | 362 | — | 362 | 33 | 395 |
| Unrealized gain on equity securities | — | — | — | — | 8,824 | — | 8,824 | 2,083 | 10,907 |
| Amortization of deferred interest costs | — | — | — | — | 6,665 | — | 6,665 | 167 | 6,832 |
| Unrealized gain on derivative instruments, net | — | — | — | — | 5,951 | — | 5,951 | 165 | 6,116 |
| Balance at December 31, 2013 | \$— | 192,115,002 | \$1,921 | \$3,554,558 | \$(32,923) | \$(583,569) | \$2,939,987 | \$47,038 | \$2,987,025 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

| | Year Ended | | |
|---|--------------|------------|------------|
| | December 31, | | |
| | 2013 | 2012 | 2011 |
| Operating activities: | | | |
| Net income | \$47,209 | \$11,763 | \$42,714 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | |
| Depreciation and amortization | 245,000 | 196,927 | 142,681 |
| Allowance for doubtful accounts | 931 | 1,656 | 2,277 |
| Non-cash revenue adjustments | 9,870 | 11,261 | 10,400 |
| Other non-cash adjustments | 9,095 | 19,027 | 9,130 |
| Compensation expense related to restricted common stock and LTIP units | 12,852 | 11,530 | 7,582 |
| Distributions representing a return on capital from unconsolidated partnerships | 237 | 1,202 | 2,428 |
| Changes in operating assets and liabilities: | | | |
| Accounts receivable | (2,958) | 282 | (1,308) |
| Accrued straight-line rents | (22,027) | (23,044) | (24,925) |
| Deferred leasing costs | (13,597) | (13,993) | (12,583) |
| Other assets | (2,798) | 2,748 | 2,640 |
| Accounts payable, accrued expenses and other liabilities | (4,025) | 18,876 | (6,005) |
| Net cash provided by operating activities | 279,789 | 238,235 | 175,031 |
| Investing activities: | | | |
| Purchases of investments in real estate and related intangible assets | (480,049) | (366,492) | (393,481) |
| Capital expenditures | (252,128) | (138,870) | (143,354) |
| Contributions from historic tax credit transactions, net | 23,334 | — | — |
| Contributions from new market tax credit transactions, net | 11,251 | — | — |
| Draws on construction loan receivable | (124,048) | (21,697) | — |
| Contributions to unconsolidated partnerships, net | (1,730) | (2,410) | (54,436) |
| Purchases of debt and equity securities | (16,081) | (8,645) | (5,245) |
| Proceeds from the sale of debt and equity securities | 6,232 | 132 | 125 |
| Deposits to escrow for acquisitions | — | — | (7,940) |
| Net cash used in investing activities | (833,219) | (537,982) | (604,331) |
| Financing activities: | | | |
| Proceeds from common stock offering | 668,553 | — | 404,328 |
| Payment of offering costs | (27,456) | — | (4,757) |
| Redemption of Series A preferred stock | (198,000) | — | (31,109) |
| Payment of deferred loan costs | (6,947) | (5,937) | (9,733) |
| Unsecured line of credit proceeds | 805,000 | 596,000 | 771,575 |
| Unsecured line of credit payments | (795,000) | (746,000) | (896,025) |
| Mortgage notes proceeds | 4,182 | — | — |
| Principal payments on mortgage notes payable | (115,542) | (41,196) | (67,741) |
| Proceeds from unsecured senior term loans | 350,000 | 556,404 | — |
| Unsecured senior term loan payments | — | (156,404) | — |
| Repurchases of unsecured senior notes | — | — | (19,800) |

| | | | |
|--------------------------------------|---|---------|---------|
| Proceeds from unsecured senior notes | — | 247,815 | 397,460 |
|--------------------------------------|---|---------|---------|

77

Table of Contents

| | Year Ended December 31, | | |
|---|----------------------------|------------|------------|
| | 2013 | 2012 | 2011 |
| Release of restriction of cash for repayment of debt | 60,000 | — | — |
| Distributions to operating partnership unit and LTIP unit holders | (3,921) | (2,498) | (2,299) |
| Dividends paid to common stockholders | (166,248) | (130,298) | (101,032) |
| Dividends paid to preferred stockholders | (6,045) | (14,601) | (16,623) |
| Net cash provided by financing activities | 568,576 | 303,285 | 424,244 |
| Effect of exchange rate changes on cash and cash equivalents | (416) | 27 | — |
| Net increase in cash and cash equivalents | 14,730 | 3,565 | (5,056) |
| Cash and cash equivalents at beginning of period | 19,976 | 16,411 | 21,467 |
| Cash and cash equivalents at end of period | \$34,706 | \$19,976 | \$16,411 |
| Supplemental disclosure of cash flow information: | | | |
| Cash paid during the period for interest (net of amounts capitalized of \$14,205, \$8,644 and \$7,568 for the years ended December 31, 2013, 2012 and 2011, respectively) | \$94,938 | \$81,868 | \$76,005 |
| Supplemental disclosure of non-cash investing and financing activities: | | | |
| Accrual for preferred stock dividends declared | \$— | \$3,651 | \$3,651 |
| Accrual for common stock dividends declared | 48,029 | 36,268 | 30,821 |
| Accrual for distributions declared for operating partnership unit and LTIP unit holders | 1,354 | 689 | 596 |
| Accrued additions to real estate and related intangible assets | 56,712 | 33,153 | 24,317 |
| Mortgage notes assumed (includes premiums of \$8,671 and \$1,802 for the years ended December 31, 2013 and 2012, respectively) | 250,466 | 25,947 | — |
| Equity issued in connection with Wexford merger and 320 Charles Street acquisition | 165,114 | — | — |
| Deposits applied for acquisitions | — | 18,649 | 1,800 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED BALANCE SHEETS

(In thousands, except unit data)

| | December 31, 2013 | 2012 |
|--|----------------------|-------------|
| ASSETS | | |
| Investments in real estate, net | \$5,217,902 | \$4,319,716 |
| Investments in unconsolidated partnerships | 32,137 | 32,367 |
| Cash and cash equivalents | 34,706 | 19,976 |
| Accounts receivable, net | 8,421 | 4,507 |
| Accrued straight-line rents, net | 173,779 | 152,096 |
| Deferred leasing costs, net | 198,067 | 172,363 |
| Other assets | 307,589 | 133,454 |
| Total assets | \$5,972,601 | \$4,834,479 |
| LIABILITIES AND CAPITAL | | |
| Mortgage notes payable, net | \$709,324 | \$571,652 |
| Exchangeable senior notes | 180,000 | 180,000 |
| Unsecured senior notes, net | 895,083 | 894,177 |
| Unsecured senior term loans | 758,786 | 405,456 |
| Unsecured line of credit | 128,000 | 118,000 |
| Accounts payable, accrued expenses and other liabilities | 314,383 | 180,653 |
| Total liabilities | 2,985,576 | 2,349,938 |
| Capital: | | |
| Partners' capital: | | |
| Preferred units, 7.375% Series A cumulative redeemable preferred units, no units issued and outstanding at December 31, 2013; and 7,920,000 units issued and outstanding at December 31, 2012, \$198,000 liquidation preference (\$25.00 per unit) | — | 191,469 |
| Limited partners' capital, 5,415,974 and 2,932,758 units issued and outstanding at December 31, 2013 and December 31, 2012, respectively | 45,708 | 7,937 |
| General partner's capital, 192,115,002 and 154,327,818 units issued and outstanding at December 31, 2013 and December 31, 2012, respectively | 2,970,650 | 2,338,464 |
| Accumulated other comprehensive loss | (30,663 |) (53,077 |
| Total partners' capital | 2,985,695 | 2,484,793 |
| Noncontrolling interests / (deficit) | 1,330 | (252 |
| Total capital | 2,987,025 | 2,484,541 |
| Total liabilities and capital | \$5,972,601 | \$4,834,479 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except unit data)

| | For the Year Ended December 31, | | |
|--|------------------------------------|-------------|-------------|
| | 2013 | 2012 | 2011 |
| Revenues: | | | |
| Rental | \$445,980 | \$392,628 | \$329,454 |
| Tenant recoveries | 141,634 | 120,793 | 101,965 |
| Other revenue | 49,700 | 4,746 | 6,781 |
| Total revenues | 637,314 | 518,167 | 438,200 |
| Expenses: | | | |
| Rental operations | 184,073 | 152,219 | 128,146 |
| Depreciation and amortization | 245,000 | 196,844 | 142,319 |
| General and administrative | 44,175 | 38,025 | 30,966 |
| Acquisition-related expenses | 5,282 | 13,077 | 1,099 |
| Total expenses | 478,530 | 400,165 | 302,530 |
| Income from operations | 158,784 | 118,002 | 135,670 |
| Equity in net loss of unconsolidated partnerships | (905) | (1,389) | (2,489) |
| Interest expense, net | (107,727) | (99,608) | (89,181) |
| Other expense | (2,943) | (872) | (1,760) |
| Income from continuing operations | 47,209 | 16,133 | 42,240 |
| (Loss) / income from discontinued operations | — | (4,370) | 474 |
| Net income | 47,209 | 11,763 | 42,714 |
| Net loss attributable to noncontrolling interests | 254 | 8 | 44 |
| Net income attributable to the Operating Partnership | 47,463 | 11,771 | 42,758 |
| Preferred unit distributions | (2,393) | (14,603) | (16,033) |
| Cost on redemption of preferred units | (6,531) | — | (165) |
| Net income / (loss) available to unitholders | \$38,539 | \$(2,832) | \$26,560 |
| Income from continuing operations per unit available to unitholders: | | | |
| Basic and diluted earnings per unit | \$0.20 | \$— | \$0.19 |
| Loss from discontinued operations per unit available to unitholders: | | | |
| Basic and diluted earnings per unit | \$— | \$(0.03) | \$— |
| Net income / (loss) per unit available to unitholders: | | | |
| Basic and diluted earnings per unit | \$0.20 | \$(0.03) | \$0.19 |
| Weighted-average units outstanding: | | | |
| Basic | 186,333,292 | 155,670,931 | 135,549,934 |
| Diluted | 186,396,309 | 155,670,931 | 135,549,934 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

| | Year Ended | | |
|--|--------------|----------|-----------|
| | December 31, | | |
| | 2013 | 2012 | 2011 |
| Net income | \$47,209 | \$11,763 | \$42,714 |
| Other comprehensive income: | | | |
| Foreign currency translation adjustments | 395 | 3,611 | — |
| Unrealized gain / (loss) from derivative instruments, net | 6,116 | (5,144) |) 3,857 |
| Amortization of deferred interest costs | 6,832 | 6,933 | 7,027 |
| Reclassification of unrealized loss on equity securities | — | 545 | 5,132 |
| Reclassification on sale of equity securities | — | (38) |) 70 |
| Unrealized gain / (loss) on equity securities | 10,907 | (390) |) (5,131) |
| Total other comprehensive income | 24,250 | 5,517 | 10,955 |
| Comprehensive income | 71,459 | 17,280 | 53,669 |
| Comprehensive (income) / loss attributable to noncontrolling interests | (1,582) |) 8 | 44 |
| Comprehensive income attributable to the Operating Partnership | \$69,877 | \$17,288 | \$53,713 |

See accompanying notes to consolidated financial statements.

81

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENT OF CAPITAL

(In thousands, except unit data)

| | Preferred Series A | Limited Partners' Capital | General Partner's Capital | Accumulated Other Comprehensive (Loss)/Income | Total Partners' Capital | Noncontrolling Interests (Deficit) | Total Capital | | | |
|--|--------------------|---------------------------|---------------------------|---|-------------------------|------------------------------------|---------------|-----------|-----------|-----------|
| | Units | Amount | Units | Amount | Units | Amount | Amount | | | |
| Balance at December 31, 2010 | 9,200,000 | 222,413 | 1,001,250 | 9,918 | 131,046,509 | 2,150,314 | \$(69,549) | 2,313,000 | 2,312,896 | |
| Proceeds from issuance of OP units | — | — | — | — | 22,562,922 | 399,571 | — | 399,571 | 399,571 | |
| Net issuances of unvested restricted OP units | — | — | — | — | 470,780 | (2,420) | — | (2,420) | (2,420) | |
| Conversion of OP units | — | — | (21,271) | 49 | 21,271 | (49) | — | — | — | |
| Redemption of preferred units | (1,280,000) | (31,109) | — | — | — | — | — | (31,109) | (31,109) | |
| Vesting of share-based awards | — | — | — | — | — | 7,582 | — | 7,582 | 7,582 | |
| Reallocation of equity to limited partners | — | — | — | 2,182 | — | (2,182) | — | — | — | |
| Distributions | — | (16,033) | — | (2,386) | — | (109,574) | — | (127,993) | (127,993) | |
| Net income | — | 16,198 | — | 569 | — | 25,991 | — | 42,758 | (44) | 42,714 |
| Reclassification on unrealized loss on equity securities | — | — | — | — | — | — | 5,132 | 5,132 | — | 5,132 |
| Reclassification on sale of equity securities | — | — | — | — | — | — | 70 | 70 | — | 70 |
| Unrealized loss on equity securities | — | — | — | — | — | — | (5,131) | (5,131) | — | (5,131) |
| Amortization of deferred interest costs | — | — | — | — | — | — | 7,027 | 7,027 | — | 7,027 |
| Unrealized gain on derivative instruments, net | — | — | — | — | — | — | 3,857 | 3,857 | — | 3,857 |
| Balance at December 31, | 7,920,000 | 191,462 | 2,979,979 | 10,332 | 154,101,482 | 2,469,213 | \$(58,594) | 2,612,444 | (244) | 2,612,196 |

| | | | | | | | | | | |
|--|---|----------|----------|---------|---------|-----------|-------|-----------|-----|-----------|
| 2011 | | | | | | | | | | |
| Net issuances of unvested restricted OP units | — | — | — | — | 179,115 | (3,528) | — | (3,528) | — | (3,528) |
| Conversion of OP units | — | — | (47,221) | (1) | 47,221 | 1 | — | — | — | — |
| Vesting of share-based awards | — | — | — | — | — | 11,530 | — | 11,530 | — | 11,530 |
| Reallocation of equity to limited partners | — | — | — | 251 | — | (251) | — | — | — | — |
| Distributions | — | (14,603) | — | (2,591) | — | (135,743) | — | (152,937) | — | (152,937) |
| Net income / (loss) | — | 14,603 | — | (54) | — | (2,778) | — | 11,771 | (8) | 11,763 |
| Foreign currency translation adjustment | — | — | — | — | — | — | 3,611 | 3,611 | — | 3,611 |

82

Table of Contents

| | Preferred Series A | | Limited Partners' Capital | | General Partner's Capital | | Accumulated Other Comprehensive (Loss)/Income | Total Partners' Capital | Noncontrolling Interests Total / (Deficit) | Total Capital |
|--|--------------------|------------|---------------------------|----------|---------------------------|--------------|---|-------------------------|--|---------------|
| | Units | Amount | Units | Amount | Units | Amount | | | | |
| Reclassification on unrealized loss on equity securities | — | — | — | — | — | — | 545 | 545 | — | 545 |
| Reclassification on sale of equity securities | — | — | — | — | — | — | (38) | (38) | — | (38) |
| Unrealized loss on equity securities | — | — | — | — | — | — | (390) | (390) | — | (390) |
| Amortization of deferred interest costs | — | — | — | — | — | — | 6,933 | 6,933 | — | 6,933 |
| Unrealized loss on derivative instruments, net | — | — | — | — | — | — | (5,144) | (5,144) | — | (5,144) |
| Balance at December 31, 2012 | 7,920,000 | \$ 191,469 | 2,932,758 | \$ 7,937 | 154,327,818 | \$ 2,338,464 | \$(53,077) | \$ 2,484,793 | \$(252) | \$ 2,484,541 |
| Proceeds from issuance of OP units | — | — | 2,034,211 | 41,518 | 31,855,000 | 641,097 | — | 682,615 | — | 682,615 |
| Net issuances of unvested restricted OP units | — | — | 132,441 | — | 343,561 | (5,050) | — | (5,050) | — | (5,050) |
| Conversion of OP units | — | — | (20,396) | 87 | 20,396 | (87) | — | — | — | — |
| Redemption of Series A preferred units | (7,920,000) | (198,000) | — | — | — | — | — | (198,000) | — | (198,000) |
| Vesting of share-based awards | — | — | — | — | — | 12,852 | — | 12,852 | — | 12,852 |
| Issuance of OP units in connection with Wexford merger | — | — | 336,960 | 7,053 | 5,568,227 | 116,543 | — | 123,596 | — | 123,596 |
| Reallocation of capital to limited partners | — | — | — | (7,120) | — | 7,120 | — | — | — | — |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | | | | | | | |
|---|---|----------|-----------|----------|-------------|-------------|------------|-------------|---------|-------------|
| Distributions | — | (2,393) | — | (4,586) | — | (178,009) | — | (184,988) | — | (18,000) |
| Net income | — | 8,924 | — | 819 | — | 37,720 | — | 47,463 | (254) | 47,209 |
| Foreign currency translation adjustments | — | — | — | — | — | — | 395 | 395 | — | 395 |
| Reclassification on sale of equity securities | — | — | — | — | — | — | — | — | — | — |
| Unrealized gain on equity securities | — | — | — | — | — | — | 9,071 | 9,071 | 1,836 | 10,907 |
| Amortization of deferred interest costs | — | — | — | — | — | — | 6,832 | 6,832 | — | 6,832 |
| Unrealized gain on derivative instruments, net | — | — | — | — | — | — | 6,116 | 6,116 | — | 6,116 |
| Balance at December 31, 2013 | — | \$— | 5,415,974 | \$45,708 | 192,115,002 | \$2,970,650 | \$(30,663) | \$2,985,695 | \$1,330 | \$2,987,025 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY, L.P.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

| | Year Ended December 31, | | | |
|---|----------------------------|------------|------------|---|
| | 2013 | 2012 | 2011 | |
| Operating activities: | | | | |
| Net income | \$47,209 | \$11,763 | \$42,714 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | | |
| Depreciation and amortization | 245,000 | 196,927 | 142,681 | |
| Allowance for doubtful accounts | 931 | 1,656 | 2,277 | |
| Non-cash revenue adjustments | 9,870 | 11,261 | 10,400 | |
| Other non-cash adjustments | 9,095 | 19,027 | 9,130 | |
| Compensation expense related to share-based payments | 12,852 | 11,530 | 7,582 | |
| Distributions representing a return on capital from unconsolidated partnerships | 237 | 1,202 | 2,428 | |
| Changes in operating assets and liabilities: | | | | |
| Accounts receivable | (2,958 |) 282 | (1,308 |) |
| Accrued straight-line rents | (22,027 |) (23,044 |) (24,925 |) |
| Deferred leasing costs | (13,597 |) (13,993 |) (12,583 |) |
| Other assets | (2,798 |) 2,748 | 2,640 | |
| Accounts payable, accrued expenses and other liabilities | (4,025 |) 18,876 | (6,005 |) |
| Net cash provided by operating activities | 279,789 | 238,235 | 175,031 | |
| Investing activities: | | | | |
| Purchases of investments in real estate and related intangible assets | (480,049 |) (366,492 |) (393,481 |) |
| Capital expenditures | (252,128 |) (138,870 |) (143,354 |) |
| Contributions from historic tax credit transactions, net | 23,334 | — | — | |
| Contributions from new market tax credit transactions, net | 11,251 | — | — | |
| Draws on construction loan receivable | (124,048 |) (21,697 |) — | |
| Contributions to unconsolidated partnerships, net | (1,730 |) (2,410 |) (54,436 |) |
| Purchases of debt and equity securities | (16,081 |) (8,645 |) (5,245 |) |
| Proceeds from the sale of debt and equity securities | 6,232 | 132 | 125 | |
| Deposits to escrow for acquisitions | — | — | (7,940 |) |
| Net cash used in investing activities | (833,219 |) (537,982 |) (604,331 |) |
| Financing activities: | | | | |
| Proceeds from issuance of OP units | 641,097 | — | 399,571 | |
| Redemption of Series A preferred units | (198,000 |) — | (31,109 |) |
| Payment of deferred loan costs | (6,947 |) (5,937 |) (9,733 |) |
| Unsecured line of credit proceeds | 805,000 | 596,000 | 771,575 | |
| Unsecured line of credit payments | (795,000 |) (746,000 |) (896,025 |) |
| Mortgage notes proceeds | 4,182 | — | — | |
| Principal payments on mortgage notes payable | (115,542 |) (41,196 |) (67,741 |) |
| Proceeds from unsecured senior term loans | 350,000 | 556,404 | — | |
| Unsecured senior term loan payments | — | (156,404 |) — | |

Table of Contents

| | Year Ended December 31, | | |
|---|----------------------------|------------|------------|
| | 2013 | 2012 | 2011 |
| Repurchases of unsecured senior notes | — | — | (19,800) |
| Proceeds from unsecured senior notes | — | 247,815 | 397,460 |
| Release of restriction of cash for repayment of debt | 60,000 | — | — |
| Distributions paid to unitholders | (170,169) | (132,796) | (103,331) |
| Distributions paid to preferred unitholders | (6,045) | (14,601) | (16,623) |
| Net cash provided by financing activities | 568,576 | 303,285 | 424,244 |
| Effect of exchange rate changes on cash and cash equivalents | (416) | 27 | — |
| Net increase in cash and cash equivalents | 14,730 | 3,565 | (5,056) |
| Cash and cash equivalents at beginning of period | 19,976 | 16,411 | 21,467 |
| Cash and cash equivalents at end of period | \$34,706 | \$19,976 | \$16,411 |
| Supplemental disclosure of cash flow information: | | | |
| Cash paid during the period for interest (net of amounts capitalized of \$14,205, \$8,644 and \$7,568 for the years ended December 31, 2013, 2012 and 2011, respectively) | \$94,938 | \$81,868 | \$76,005 |
| Supplemental disclosure of non-cash investing and financing activities: | | | |
| Accrual for unit distributions declared | \$49,383 | \$36,957 | \$31,417 |
| Accrual for preferred unit distributions declared | — | 3,651 | 3,651 |
| Accrued additions to real estate and related intangible assets | 56,712 | 33,153 | 24,317 |
| Mortgage notes assumed (includes premiums of \$8,671 and \$1,802 for the years ended December 31, 2013 and 2012, respectively) | 250,466 | 25,947 | — |
| Equity issued in connection with Wexford merger and 320 Charles Street acquisition | 165,114 | — | — |
| Deposits applied for acquisitions | — | 18,649 | 1,800 |

See accompanying notes to consolidated financial statements.

Table of Contents

BIOMED REALTY TRUST, INC.

BIOMED REALTY, L.P.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization of the Parent Company and Description of Business

BioMed Realty Trust, Inc., a Maryland corporation (the “Parent Company”), operates as a fully integrated, self-administered and self-managed real estate investment trust (“REIT”) focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry principally through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership (the “Operating Partnership” and together with the Parent Company referred to as the “Company”). The Company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company’s properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania, North Carolina, Seattle and Cambridge (United Kingdom) and, through Wexford Science and Technology, LLC and related entities (collectively, “Wexford”), with universities and their related medical systems.

The Parent Company is the sole general partner of the Operating Partnership and, as of December 31, 2013, owned a 97.3% interest in the Operating Partnership. The remaining 2.7% interest in the Operating Partnership is held by limited partners. Each partner’s percentage interest in the Operating Partnership is determined based on the number of operating partnership units and long-term incentive plan units (“LTIP units” and together with the operating partnership units, the “OP units”) owned as compared to total OP units (and potentially issuable OP units, as applicable) outstanding as of each period end and is used as the basis for the allocation of net income or loss to each partner.

Information with respect to the square footage and the percent of rentable square feet leased to tenants is unaudited.

2. Basis of Presentation and Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, partnerships and limited liability companies it controls, and variable interest entities (“VIEs”) for which the Company has determined itself to be the primary beneficiary. All material intercompany transactions and balances have been eliminated. The Company consolidates entities the Company controls and records a noncontrolling interest for the portions not owned by the Company. Control is determined, where applicable, by the sufficiency of equity invested and the rights of the equity holders, and by the ownership of a majority of the voting interests, with consideration given to the existence of approval or veto rights granted to the minority stockholder. If the minority stockholder holds substantive participating rights, it overcomes the presumption of control by the majority voting interest holder. In contrast, if the minority stockholder simply holds protective rights (such as consent rights over certain actions), it does not overcome the presumption of control by the majority voting interest holder.

Assets and liabilities of subsidiaries outside the United States with non-U.S. dollar functional currencies are translated into U.S. dollars using exchange rates as of the balance sheet dates. Income and expenses are translated using the average exchange rates for the reporting period. Foreign currency translation adjustments are recorded as a component of other comprehensive income. For the years ended December 31, 2013 and 2012, total revenues from properties outside the United States were \$18.2 million and \$10.3 million, respectively, which represented 2.9% and 2.0% of the Company’s total revenues during the respective periods. The Company’s net investments in properties outside the United States were \$190.2 million and \$188.8 million at December 31, 2013 and December 31, 2012, respectively.

Investments in Partnerships and Limited Liability Companies

The Company evaluates its investments in limited liability companies and partnerships to determine whether such entities may be a VIE, and, if a VIE, whether the Company is the primary beneficiary. Generally, an entity is determined to be a VIE when either (1) the equity investors (if any) lack one or more of the essential characteristics of a controlling financial interest, (2) the equity investment at risk is insufficient to finance that entity's activities without additional subordinated financial support or (3) the equity investors have voting rights that are not proportionate to their economic interests and the activities of the entity involve or are conducted on behalf of an investor with a disproportionately small voting interest. The primary beneficiary is the entity that has both (1) the power to direct matters that most significantly impact the VIE's economic performance and (2) the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company considers a variety of factors in identifying the entity that holds the power to direct matters that most significantly impact the VIE's economic

Table of Contents

performance including, but not limited to, the ability to direct financing, leasing, construction and other operating decisions and activities. In addition, the Company considers the rights of other investors to participate in policy making decisions, to replace or remove the manager and to liquidate or sell the entity. The obligation to absorb losses and the right to receive benefits when a reporting entity is affiliated with a VIE must be based on ownership, contractual, and/or other pecuniary interests in that VIE. The Company has determined that it is the primary beneficiary in five VIEs (excluding certain VIEs through its ownership of Wexford), consisting of single-tenant properties in which the tenant has a fixed-price purchase option, which are consolidated and reflected in the accompanying consolidated financial statements. Selected financial data of the VIEs at December 31, 2013 and December 31, 2012 consist of the following (in thousands):

| | December 31, 2013 | December 31, 2012 |
|--------------------------------|----------------------|----------------------|
| Investment in real estate, net | \$336,832 | \$334,331 |
| Total assets | 375,443 | 369,460 |
| Total debt | 143,067 | 144,889 |
| Total liabilities | 154,953 | 149,336 |

If the foregoing conditions do not apply, the Company considers whether a general partner or managing member controls a limited partnership or limited liability company. The general partner in a limited partnership or managing member in a limited liability company is presumed to control that limited partnership or limited liability company. The presumption may be overcome if the limited partners or members have either (1) the substantive ability to dissolve the limited partnership or limited liability company or otherwise remove the general partner or managing member without cause or (2) substantive participating rights, which provide the limited partners or members with the ability to effectively participate in significant decisions that would be expected to be made in the ordinary course of the limited partnership's or limited liability company's business and thereby preclude the general partner or managing member from exercising unilateral control over the partnership or company. If these criteria are met and the Company is the general partner or the managing member, as applicable, the consolidation of the partnership or limited liability company is required.

Except for investments that are consolidated, the Company accounts for investments in entities over which it exercises significant influence, but does not control, under the equity method of accounting. These investments are recorded initially at cost and subsequently adjusted for equity in earnings and cash contributions and distributions. Under the equity method of accounting, the Company's net equity in the investment is reflected in the consolidated balance sheets and its share of net income or loss is included in the Company's consolidated statements of income.

On a periodic basis, management assesses whether there are any indicators that the carrying value of the Company's investments in unconsolidated partnerships or limited liability companies may be impaired on a more than temporary basis. An investment is impaired only if management's estimate of the fair-value of the investment is less than the carrying value of the investment on a more than temporary basis. To the extent impairment has occurred, the loss is measured as the excess of the carrying value of the investment over the fair-value of the investment. Management does not believe that the carrying value of any of the Company's unconsolidated investments in partnerships or limited liability companies was impaired as of December 31, 2013.

The Company is also a party to certain VIEs through its ownership of Wexford, which are described in further detail in Note 11.

Investments in Real Estate, Net

Investments in real estate are carried at depreciated cost. Depreciation and amortization are recorded on a straight-line basis over the estimated useful lives of the assets as follows:

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | |
|---|--|
| Buildings and improvements | Remaining useful life, not to exceed 40 years |
| Tenant improvements | Shorter of the useful lives or the terms of the related leases |
| Furniture, fixtures, and equipment (other assets) | Three to five years |
| Acquired in-place leases | Non-cancelable term of the related lease |
| Acquired management agreements | Non-cancelable term of the related agreement |

Investments in real estate, net consisted of the following (in thousands):

87

Table of Contents

| | December 31, 2013 | December 31, 2012 |
|----------------------------|----------------------|----------------------|
| Land | \$713,955 | \$702,993 |
| Land under development | 119,325 | 48,744 |
| Buildings and improvements | 4,854,175 | 4,028,089 |
| Construction in progress | 316,025 | 143,340 |
| | 6,003,480 | 4,923,166 |
| Accumulated depreciation | (785,578) | (603,450) |
| | \$5,217,902 | \$4,319,716 |

Purchase accounting is applied to the assets and liabilities of real estate properties in which the Company acquires a controlling interest or a partial interest. The fair-value of tangible assets of an acquired property (which includes land, buildings, and improvements) is determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land, buildings and improvements based on management’s determination of the fair-value of these assets. Factors considered by the Company in performing these analyses include an estimate of the carrying costs during the expected lease-up periods, current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rental revenue during the expected lease-up periods based on current market demand. Upon the acquisition of a controlling interest of an investment in an unconsolidated partnership, such partnership is consolidated and a gain is recognized equal to the amount in which the fair-value of the noncontrolling interest in such partnership exceeded its carrying value at the time of obtaining control.

The aggregate value of other acquired intangible assets consisting of acquired in-place leases and acquired management agreements (see deferred leasing costs below) are recorded based on a variety of considerations including, but not necessarily limited to: (1) the value associated with avoiding the cost of originating the acquired in-place leases (i.e. the market cost to execute a lease, including leasing commissions and legal fees, if any); (2) the value associated with lost revenue related to tenant reimbursable operating costs estimated to be incurred during the assumed lease-up period (i.e. real estate taxes and insurance); and (3) the value associated with lost rental revenue from existing leases during the assumed lease-up period (see discussion of the recognition of acquired above-market and below-market leases in Revenue Recognition section below). The fair-value assigned to the acquired management agreements are recorded at the present value (using a discount rate which reflects the risks associated with the management agreements acquired) of the acquired management agreements with certain tenants of the acquired properties. The Company has also considered the existence of a tenant relationship intangible asset, but has not historically allocated any value to tenant relationships apart from acquired in-place leases. The values of in-place leases and management agreements are amortized to expense over the remaining non-cancelable period of the respective leases or agreements. If a lease were to be terminated or if termination is determined to be likely (e.g., in the case of a tenant bankruptcy) prior to its contractual expiration, amortization of all unamortized amounts related to that lease would be accelerated and such amounts written off.

Costs incurred in connection with the development or construction of properties and improvements are capitalized. Capitalized costs include pre-construction costs essential to the development of the property, development costs, construction costs, interest costs, real estate taxes, salaries and related costs and other direct costs incurred during the period of development. The Company capitalizes costs on land and buildings under development until construction is substantially complete and the property is held available for occupancy. Determination of when a development project is substantially complete and when capitalization must cease involves a degree of judgment. The Company considers a construction project as substantially complete and held available for occupancy upon the completion of landlord-owned tenant improvements or when the lessee takes possession of the unimproved space for construction of its own improvements, but no later than one year from cessation of major construction activity. The Company ceases capitalization on the portion substantially completed and occupied or held available for occupancy, and capitalizes

only those costs associated with any remaining portion under construction. Interest costs capitalized for the years ended December 31, 2013, 2012 and 2011 were \$14.2 million, \$8.6 million and \$7.6 million, respectively. Payroll costs capitalized for the years ended December 31, 2013, 2012 and 2011 were \$3.6 million, \$2.0 million and \$1.3 million, respectively. Costs associated with acquisitions of businesses are charged to expense.

Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repairs and maintenance costs include all costs that do not extend the useful life of an asset or increase its operating efficiency. Significant replacement and betterments represent costs that extend an asset's useful life or increase its operating efficiency.

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed

Table of Contents

The Company reviews long-lived assets and certain identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The review of recoverability is based on an estimate of the future undiscounted cash flows (excluding interest charges) expected to result from the long-lived asset's use and eventual disposition. These cash flows consider factors such as expected future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. If impairment exists due to the inability to recover the carrying value of a long-lived asset, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair-value of the property. The Company is required to make subjective assessments as to whether there are impairments in the values of its investments in long-lived assets. These assessments have a direct impact on the Company's net income because recording an impairment loss results in an immediate negative adjustment to net income. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. Although the Company's strategy is to hold its properties over the long-term, if the Company's strategy changes or market conditions otherwise dictate an earlier sale date, an impairment loss may be recognized to reduce the property to the lower of the carrying amount or fair-value, and such loss could be material.

In April 2012, the Company completed the exchange of a property for another real estate operating property. As a result, the property disposed of was reclassified as a discontinued operation. This property was written down to its estimated fair-value of \$28.0 million, less costs to sell, which resulted in an impairment loss of \$4.6 million that is included in loss from discontinued operations for the year ended December 31, 2012. The parties to the exchange determined and agreed upon the fair-value of the property received in the transaction, which the Company considers to be a Level 2 input in the fair-value hierarchy. See Note 12 for discussion of discontinued operations.

Cash and Cash Equivalents

Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less. The Company maintains its cash at insured financial institutions. The combined account balances at each institution periodically exceed FDIC insurance coverage, and, as a result, there is a concentration of credit risk related to amounts in excess of FDIC limits. The Company believes that the risk is not significant.

Deferred Leasing Costs, Net

Leasing commissions and other direct costs associated with obtaining new or renewal leases are recorded at cost and amortized on a straight-line basis over the terms of the respective leases, with remaining terms ranging from less than one year to approximately 20 years as of December 31, 2013. Deferred leasing costs also include the net carrying value of acquired in-place leases and acquired management agreements.

Deferred leasing costs, net at December 31, 2013 consisted of the following (in thousands):

| | Balance at December 31, 2013 | Accumulated Amortization | Net |
|---|------------------------------------|-----------------------------|-------------|
| Acquired in-place leases | \$365,753 | \$(233,935) |) \$131,818 |
| Acquired management agreements | 25,801 | (20,053) |) 5,748 |
| Deferred leasing and other direct costs | 91,142 | (30,641) |) 60,501 |
| | \$482,696 | \$(284,629) |) \$198,067 |

Deferred leasing costs, net at December 31, 2012 consisted of the following (in thousands):

| | Balance at | Accumulated Amortization | Net |
|--|------------|-----------------------------|-----|
|--|------------|-----------------------------|-----|

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | December 31, 2012 | | |
|---|----------------------|------------|-------------|
| Acquired in-place leases | \$303,521 | \$(185,463 |) \$118,058 |
| Acquired management agreements | 24,963 | (15,242 |) 9,721 |
| Deferred leasing and other direct costs | 68,175 | (23,591 |) 44,584 |
| | \$396,659 | \$(224,296 |) \$172,363 |

The estimated amortization expense for deferred leasing costs at December 31, 2013 was as follows (in thousands):

89

Table of Contents

| | |
|------------|-----------|
| 2014 | \$40,251 |
| 2015 | 31,707 |
| 2016 | 25,031 |
| 2017 | 22,959 |
| 2018 | 18,581 |
| Thereafter | 59,538 |
| Total | \$198,067 |

Revenue Recognition, Operating Expenses and Lease Terminations

The Company commences revenue recognition on its leases based on a number of factors. In most cases, revenue recognition under a lease begins when the lessee takes possession of or controls the physical use of the leased asset. Generally, this occurs on the lease commencement date. In determining what constitutes the leased asset, the Company evaluates whether the Company or the lessee is the owner, for accounting purposes, of the tenant improvements. If the Company is the owner, for accounting purposes, of the tenant improvements, then the leased asset is the finished space and revenue recognition begins when the lessee takes possession of the finished space, typically when the improvements are substantially complete. If the Company concludes that it is not the owner, for accounting purposes, of the tenant improvements (the lessee is the owner), then the leased asset is the unimproved space and any tenant improvement allowances funded under the lease are treated as lease incentives, which reduce revenue recognized on a straight-line basis over the remaining non-cancelable term of the respective lease. In these circumstances, the Company begins revenue recognition when the lessee takes possession of the unimproved space for the lessee to construct improvements. The determination of who is the owner, for accounting purposes, of the tenant improvements determines the nature of the leased asset and when revenue recognition under a lease begins. The Company considers a number of different factors to evaluate whether it or the lessee is the owner of the tenant improvements for accounting purposes. These factors include:

- whether the lease stipulates how and on what a tenant improvement allowance may be spent;
- whether the tenant or landlord retain legal title to the improvements;
- the uniqueness of the improvements;
- the expected economic life of the tenant improvements relative to the length of the lease;
- the responsible party for construction cost overruns; and
- who constructs or directs the construction of the improvements.

The determination of who owns the tenant improvements, for accounting purposes, is subject to significant judgment. In making that determination, the Company considers all of the above factors. However, no one factor is determinative in reaching a conclusion.

All leases are classified as operating leases and minimum rents are recognized on a straight-line basis over the term of the related lease. The excess of rents recognized over amounts contractually due pursuant to the underlying leases are included in accrued straight-line rents on the accompanying consolidated balance sheets and contractually due but unpaid rents are included in accounts receivable. Existing leases at acquired properties are reviewed at the time of acquisition to determine if contractual rents are above or below current market rents for the acquired property. An identifiable lease intangible asset or liability is recorded based on the present value (using a discount rate that reflects the risks associated with the acquired leases) of the difference between (1) the contractual amounts to be paid pursuant to the in-place leases and (2) the Company's estimate of the fair market lease rates for the corresponding in-place leases at acquisition, measured over a period equal to the remaining non-cancelable term of the leases and any fixed rate renewal periods (based on the Company's assessment of the likelihood that the renewal periods will be exercised). The capitalized above-market lease values are amortized as a reduction of rental revenue on a straight-line basis over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values are amortized as an increase to rental revenue on a straight-line basis over the remaining non-cancelable terms of the respective leases and any fixed-rate renewal periods, if applicable. If a tenant vacates its space prior to the contractual

termination of the lease and no rental payments are being made on the lease, any unamortized balance of the related intangible will be written off.

The impact of the straight-line rent revenue, acquired above and below market lease revenue, and lease incentive revenue consisted of the following (in thousands):

90

Table of Contents

| | Years Ended December 31, | | |
|-------------------------------------|--------------------------|----------|----------|
| | 2013 | 2012 | 2011 |
| Straight-line rent revenue | \$23,136 | \$23,288 | \$25,243 |
| Acquired above-market lease revenue | (11,913) | (9,977) | (9,607) |
| Acquired below-market lease revenue | 4,325 | 1,684 | 1,453 |
| Lease incentive revenue | (2,295) | (2,969) | (2,246) |
| Net increase in revenue | \$13,253 | \$12,026 | \$14,843 |

Total estimated minimum rents under non-cancelable operating tenant leases in effect at December 31, 2013 were as follows (in thousands):

| | |
|------------|-------------|
| 2014 | \$455,359 |
| 2015 | 450,564 |
| 2016 | 424,331 |
| 2017 | 400,787 |
| 2018 | 342,864 |
| Thereafter | 2,037,341 |
| Total | \$4,111,246 |

The estimated amortization for acquired above- and below-market lease revenue and lease incentive revenue at December 31, 2013 was as follows (in thousands):

| | 2014 | 2015 | 2016 | 2017 | 2018 | Thereafter | Total |
|------------------------------|------------|------------|------------|------------|------------|------------|-------------|
| Amortization of: | | | | | | | |
| Acquired above-market leases | \$(4,457) | \$(1,942) | \$(1,317) | \$(1,196) | \$(1,112) | \$(5,804) | \$(15,828) |
| Acquired below-market leases | 5,262 | 3,721 | 3,487 | 3,435 | 3,427 | 18,789 | 38,121 |
| Lease incentive | (2,232) | (2,225) | (2,152) | (1,728) | (1,329) | (9,973) | (19,639) |

Rental operations expenses, consisting of real estate taxes, insurance and common area maintenance costs, are subject to recovery from tenants under the terms of lease agreements. Amounts recovered are dependent on several factors, including occupancy and lease terms. Revenues are recognized in the period the expenses are incurred. The reimbursements are recorded in revenues as tenant recoveries, and the expenses are recorded in rental operations expenses, as the Company is generally the primary obligor with respect to purchasing goods and services from third-party suppliers, has discretion in selecting the supplier and bears the credit risk.

On an ongoing basis, the Company evaluates the recoverability of tenant balances, including rents receivable, straight-line rents receivable, tenant improvements, deferred leasing costs and any acquisition intangibles. Factors considered by the Company as part of this evaluation include, among other things, the financial strength of the tenant and any guarantors, a review of publicly filed documents and analyst research reports, a review of the tenant's cash balance and estimated cash "burn" rate if the tenant's cash flow from operations is negative, and the tenant's payment history. When it is determined that the recoverability of tenant balances is not probable, an allowance for expected losses related to tenant receivables, including straight-line rents receivable is recorded as a charge to earnings. Upon the termination of a lease, the amortization of tenant improvements, deferred leasing costs and acquisition intangible assets and liabilities is accelerated to the expected termination date as a charge to their respective line items and tenant receivables are written off as a reduction of the allowance in the period in which the balance is deemed to be no longer collectible. For financial reporting purposes, a lease is treated as terminated upon a tenant filing for bankruptcy, when a space is abandoned and a tenant ceases rent payments, or when other circumstances indicate that termination of a tenant's lease is probable (e.g., eviction). Lease termination fees are recognized in other income when the related leases are canceled, the amounts to be received are fixed and determinable and collectability is assured, and when the

Company has no continuing obligation to provide services to such former tenants.

Allowance for Doubtful Accounts

91

Table of Contents

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent and tenant recovery payments or defaults. The Company maintains an allowance for accrued straight-line rents. The determination of this allowance is based on the tenants' payment history and current credit status. Bad debt expense included in rental operations expenses was approximately \$931,000, \$1.7 million and \$2.3 million for the years ended December 31, 2013, 2012 and 2011, respectively. The Company's allowance for doubtful accounts included in accounts receivable, net and accrued straight line rent, net was approximately \$2.3 million, \$4.2 million and \$2.9 million as of December 31, 2013, 2012 and 2011, respectively.

Investments

The Company, through its Operating Partnership, holds equity investments in certain publicly-traded companies and privately-held companies primarily involved in the life science industry. The Company may accept equity investments from tenants in lieu of cash rents, as prepaid rent pursuant to the execution of a lease, or as additional consideration for a lease termination. The Company does not acquire investments for trading purposes and, as a result, all of the Company's investments in publicly-traded companies are considered "available-for-sale" and are recorded at fair-value. Changes in the fair-value of investments classified as available-for-sale are recorded in comprehensive income. The fair-value of the Company's equity investments in publicly-traded companies is determined based upon the closing trading price of the equity security as of the balance sheet date, with unrealized gains and losses shown as a separate component of equity. Investments in privately-held companies are generally accounted for under the cost method, because the Company does not influence any operating or financial policies of the companies in which it invests. The classification of investments is determined at the time each investment is made, and such determination is reevaluated at each balance sheet date. The cost of investments sold is determined by the specific identification method, with net realized gains and losses included in other income. For all investments, if a decline in the fair-value of an investment below its carrying value is determined to be other-than-temporary, such investment is written down to its estimated fair-value with a non-cash charge to earnings. The factors that the Company considers in making these assessments include, but are not limited to, market prices, market conditions, available financing, prospects for favorable or unfavorable clinical trial results, new product initiatives and new collaborative agreements.

Investments in equity securities, which are included in other assets on the accompanying consolidated balance sheets, consisted of the following (in thousands):

| | December 31, 2013 | December 31, 2012 |
|--|----------------------|----------------------|
| Available-for-sale securities, historical cost | \$8,543 | \$275 |
| Unrealized gain, net | 11,023 | 115 |
| Available-for-sale securities, fair-value (1) | 19,566 | 390 |
| Privately-held securities, cost basis | 18,485 | 12,280 |
| Total equity securities | \$38,051 | \$12,670 |

(1) Determination of fair-value is classified as Level 1 in the fair-value hierarchy based on the use of quoted prices in active markets.

The Company holds investments in available-for-sale securities of certain publicly-traded companies. Certain of these investments have fair-values less than the Company's cost basis, net of previous other-than-temporary impairment in these securities due to decreases in their respective stock prices during the year ended December 31, 2013. However, management has the intent and ability to retain the investments for a period of time sufficient to allow for an anticipated recovery in their market value. Management will continue to periodically evaluate whether any investment, the fair-value of which is less than the Company's cost basis, should be considered other-than-temporarily impaired. If other-than-temporary impairment is considered to exist, the related unrealized loss will be reclassified from accumulated other comprehensive loss and recorded as a reduction of net income.

The Company also holds investments in securities of certain privately-held companies and funds, which are recorded at cost basis due to the Company's lack of control or significant influence over such companies and funds.

During the year ended December 31, 2013, the Company recorded a \$2.8 million impairment charge, which is included in other expense in the consolidated statements of operations. The impairment charge related to the Company's investment in a privately-held company, comprising a \$2.0 million cost basis equity investment and \$825,000 related to notes receivable that were included in other assets on the consolidated balance sheets. Other than this investment there were no identified events or changes in circumstances that may have a significant adverse effect on the carrying value of the Company's cost basis investments

Table of Contents

and therefore, no evaluation of impairment was performed during the year ended December 31, 2013 on the Company's remaining cost basis investments.

Share-Based Payments

All share-based payments to employees are recognized in the consolidated statement of operations based on their fair-value. Through December 31, 2013, the Company had awarded restricted stock of the Parent Company and LTIP unit grants of the Operating Partnership under its incentive award plan, both of which are valued based on the closing market price of the underlying common stock on the date of grant, and had not granted any stock options. During the years ended December 31, 2013 and 2012, the Parent Company awarded performance units (the "Performance Units") to certain of its executive officers. Each Performance Unit represents a contingent right to receive one share of the Parent Company's common stock if vesting conditions are satisfied. The grant date fair-value of the Performance Units was estimated using a Monte Carlo simulation which considered the likelihood of achieving the vesting conditions (see Note 13 for further information on the fair-value of the Performance Units). The fair-value of all share-based payments is amortized to general and administrative expense and rental operations expense over the relevant service period, adjusted for anticipated forfeitures.

Assets and Liabilities Measured at Fair-Value

The Company measures financial instruments and other items at fair-value where required under GAAP, but has elected not to measure any additional financial instruments and other items at fair-value as permitted under fair-value option accounting guidance.

Fair-value measurement is determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair-value measurements, there is a fair-value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair-value measurement is based on inputs from different levels of the fair-value hierarchy, the level in the fair-value hierarchy within which the entire fair-value measurement falls is based on the lowest level input that is significant to the fair-value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair-value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

The Company has used interest rate swaps to manage its interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair-values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash receipts (or payments) and the discounted expected variable cash payments (or receipts). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate

curves. The Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty's nonperformance risk in the fair-value measurements. In adjusting the fair-value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts, and guarantees.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair-value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by itself and its counterparties. However, as of December 31, 2013, the Company has determined that the impact of the credit valuation adjustments on the overall valuation of its derivative positions is not significant. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair-value hierarchy (see Note 9).

Table of Contents

The valuation of the Company's investments in publicly-traded companies utilizes observable market-based inputs, based on the closing trading price of securities as of the balance sheet date, therefore, the Company has determined that valuations of available-for-sale securities are classified in Level 1 of the fair-value hierarchy.

No other assets or liabilities are measured at fair-value on a recurring basis, or have been measured at fair-value on a non-recurring basis subsequent to initial recognition, in the accompanying consolidated balance sheets as of December 31, 2013 and 2012.

Derivative Instruments

The Company records all derivatives on the consolidated balance sheets at fair-value. In determining the fair-value of its derivatives, the Company considers the credit risk of its counterparties and the Company. These counterparties are generally larger financial institutions engaged in providing a variety of financial services. These institutions generally face similar risks regarding adverse changes in market and economic conditions, including, but not limited to, fluctuations in interest rates, exchange rates, equity and commodity prices and credit spreads. The ongoing disruptions in the financial markets have heightened the risks to these institutions. While management believes that its counterparties will meet their obligations under the derivative contracts, it is possible that defaults may occur.

The accounting for changes in the fair-value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair-value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair-value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair-value of the hedged asset or liability that are attributable to the hedged risk in a fair-value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.

For derivatives designated as cash flow hedges, the effective portion of changes in the fair-value of the derivative is initially reported in other comprehensive income (outside of earnings) and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings. If charges relating to the hedged transaction are being deferred pursuant to redevelopment or development activities, the effective portion of changes in the fair-value of the derivative are also deferred in accumulated other comprehensive income on the consolidated balance sheet, and are amortized to the income statement once the deferred charges from the hedged transaction begin again to affect earnings. The ineffective portion of changes in the fair-value of the derivative is recognized directly in earnings. The Company assesses the effectiveness of each hedging relationship by comparing the changes in cash flows of the derivative hedging instrument with the changes in cash flows of the designated hedged item or transaction. For derivatives that are not classified as hedges, changes in the fair-value of the derivative are recognized directly in earnings in the period in which the change occurs.

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise

from business activities that result in the receipt or payment of future known or expected cash amounts, the value of which are determined by interest rates. The Company's derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company's known or expected cash receipts and its known or expected cash payments principally related to the Company's investments and borrowings.

The Company's primary objective in using derivatives is to add stability to interest expense and to manage its exposure to interest rate movements or other identified risks. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying principal amount. During the years ended December 31, 2013, 2012 and 2011, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt and future variability in the interest-related cash flows from forecasted issuances of debt (see Note 9). The Company formally documents the hedging relationships for all derivative instruments, has historically accounted for its interest rate swap agreements as cash flow hedges, and does not use derivatives for trading or speculative purposes.

Table of Contents

Equity Offering Costs

Underwriting commissions and offering costs are reflected as a reduction of proceeds.

Income Taxes of the Parent Company

The Parent Company has elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986, as amended. The Parent Company believes it has qualified and continues to qualify as a REIT. A REIT is generally not subject to federal income tax on that portion of its taxable income that is distributed to its stockholders. Accordingly, no provision has been made for federal income taxes in the accompanying consolidated financial statements. REITs are subject to a number of organizational and operational requirements. If the Parent Company fails to qualify as a REIT in any taxable year, the Parent Company will be subject to federal income tax (including any applicable alternative minimum tax) and, in most of the states, state income tax on its taxable income at regular corporate tax rates. The Parent Company is subject to certain state and local taxes.

Income Taxes of the Operating Partnership

As a partnership, the allocated share of income of the Operating Partnership is included in the income tax returns of the general and limited partners. Accordingly, no accounting for income taxes is required in the accompanying consolidated financial statements. The Operating Partnership may be subject to certain state or local taxes on its income and property.

The Operating Partnership has formed certain taxable REIT subsidiaries (each a "TRS") on behalf of the Parent Company. In general, each TRS may perform non-customary services for tenants, hold assets that the Parent Company cannot hold directly and, except for the operation or management of health care facilities or lodging facilities or the providing of any person, under a franchise, license or otherwise, rights to any brand name under which any lodging facility or health care facility is operated, may engage in any real estate or non-real estate related business. Each TRS is subject to corporate federal and state income taxes on its taxable income at regular corporate tax rates. There is no tax provision for any TRS for the periods presented in the accompanying consolidated statements of income due to net operating losses incurred. No tax benefits have been recorded since it is not considered more likely than not that the deferred tax asset related to the net operating loss carryforwards will be utilized.

Dividends and Distributions

Earnings and profits, which determine the taxability of dividends and distributions to stockholders, will differ from income reported for financial reporting purposes due to the difference for federal income tax purposes in the treatment of revenue recognition, compensation expense, and in the estimated useful lives of real estate assets used to compute depreciation.

The income tax treatment for dividends was as follows:

| | For the Years Ended December 31, | | | | | | |
|-------------------|----------------------------------|--------|-----------|--------|-----------|--------|---|
| | 2013 | | 2012 | | 2011 | | |
| | Per Share | % | Per Share | % | Per Share | % | |
| Common stock: | | | | | | | |
| Ordinary income | \$0.94 | 100.00 | % \$0.63 | 74.12 | % \$0.44 | 57.14 | % |
| Capital gain | — | — | — | — | — | — | |
| Return of capital | — | — | 0.22 | 25.88 | % 0.33 | 42.86 | % |
| Total | \$0.94 | 100.00 | % \$0.85 | 100.00 | % \$0.77 | 100.00 | % |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | | | | | |
|-------------------|--------|--------|----------|--------|----------|--------|---|--|
| Preferred stock: | | | | | | | | |
| Ordinary income | \$0.76 | 100.00 | % \$1.84 | 100.00 | % \$1.84 | 100.00 | % | |
| Capital gain | — | — | — | — | — | — | | |
| Return of capital | — | — | — | — | — | — | | |
| Total | \$0.76 | 100.00 | % \$1.84 | 100.00 | % \$1.84 | 100.00 | % | |

Construction Loan Receivable

Table of Contents

The Company has a \$255.0 million interest in a \$355.0 million construction loan secured by first priority mortgages on a 1.1 million square foot laboratory, office and retail development project located in Boston, Massachusetts, which is 95% leased to Vertex Pharmaceuticals Incorporated to serve as its new corporate headquarters.

The construction loan matures on September 30, 2014, with two one -year extension options exercisable at the borrower's election after paying the lenders an extension fee on the then-outstanding principal amount. The construction loan bears interest on the outstanding principal amount at a floating rate equal to the greater of (1) reserve adjusted LIBOR plus 550 basis points and (2) 6.5%. In addition, the borrower is required to pay a fee to the lenders based on a specified percentage of the average daily unfunded amount of the construction loan. The borrower may prepay the construction loan in part under certain circumstances, and may prepay the construction loan in full with prior notice and a prepayment fee to the lenders. As of December 31, 2013 and December 31, 2012, the Company had invested approximately \$151.8 million and \$21.7 million in the construction loan, respectively, which are included in other assets on the Company's consolidated balance sheet. The Company expects to have fully funded its obligation in the third quarter of 2014.

Lease Termination

During the years ended December 31, 2013, 2012 and 2011, the Company recorded lease termination revenue, net of write-offs of lease intangibles, included in other revenue on the consolidated statement of operations of approximately \$42.8 million, \$3.5 million and \$6.2 million, respectively. Lease termination revenue for the year ended December 31, 2013 related to the termination of a lease with Elan Corporation ("Elan") at the Company's Science Center at Oyster Point property for which Elan paid the Company \$46.5 million, and the termination of a lease effective August 2013 with Merck at the Company's 320 Bent Street property for which Merck paid the Company \$8.7 million in August 2012. Lease termination revenue for the year ended December 31, 2012 primarily related to the termination of the lease with Merck. Lease termination revenue for the year ended December 31, 2011 related to an early lease termination at one of our properties.

Management's Estimates

Management has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reporting of revenue and expenses during the reporting period to prepare these consolidated financial statements in conformity with GAAP. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates under different assumptions or conditions.

3. Equity of the Parent Company

During the year ended December 31, 2013, the Parent Company issued restricted stock awards to the Company's employees and directors totaling 625,840 and 31,266 shares of common stock, respectively (253,671 shares of common stock were surrendered to the Company and subsequently retired in lieu of cash payments for taxes due on the vesting of restricted stock and 39,805 shares were forfeited during the same period), which are included in the total of common stock outstanding as of the period end.

Of the restricted stock awards issued to the Company's employees, 20,069 shares were issued as part of the consideration paid in the Company's merger with Wexford (as discussed below), and 41,568 shares are subject to performance-based vesting conditions. In addition, in connection with the merger with Wexford, the Operating Partnership issued 132,441 operating partnership units which are also subject to performance-based vesting

conditions. The aggregate grant date fair-value of these performance-based awards of approximately \$3.6 million will be recognized as compensation expense on a straight-line basis over each respective vesting period. The total compensation expense remaining for these awards to be expensed in future periods as of December 31, 2013 was approximately \$3.2 million over a weighted-average term of approximately 3.40 years. Dividends and distributions are payable on these awards from the date of issuance.

The Parent Company awarded units to certain of its executive officers (the "Performance Units"), which represent a contingent right to receive one share of the Parent Company's common stock if vesting conditions are satisfied. Outstanding Performance Units vest ratably over two or three year periods (each, a "Performance Period") based upon the Parent Company's total stockholder return relative to its peer group (the "Market Conditions"). The grant date fair-value of the Performance Units was estimated using a Monte Carlo simulation which considered the likelihood of achieving the Market Conditions. The expected value of the Performance Units on the grant date was determined by simulating the total stockholder return for the Parent Company and the peer group, considering the stock price variance for each of the peer group companies compared to each other and the Parent Company. In January 2013, 136,296 Performance Units, which were originally granted to certain executive officers in January

Table of Contents

2012 and represent the maximum number of Performance Units that could have vested, were forfeited as a result of the Parent Company's total stockholder return relative to its peer group in 2012 being below the threshold for any payout. In January 2014, of the 136,296 Performance Units which were originally granted to certain executive officers in January 2012 and represent the maximum number of Performance Units that could have vested, 20,224 Performance Units vested (resulting in the issuance of 20,224 shares of the Parent Company's common stock) and the remaining 116,072 Performance Units were forfeited, based on the Parent Company's total stockholder return relative to its peer group for the two years ending December 31, 2013. During the year ended December 31, 2013, the Parent Company awarded 406,288 performance units which represent the maximum number of Performance Units that may vest. The grant date fair-value of these awards of approximately \$3.6 million will be recognized as compensation expense on a straight-line basis over each respective Performance Period. The total compensation remaining on the Performance Units granted during the year ended December 31, 2013 to be expensed in future periods over a weighted-average term of approximately 1.56 years was \$2.1 million as of December 31, 2013. No dividends will be paid or accrued on the Performance Units, and shares of the Parent Company's common stock will not be issued until vesting of the Performance Units occurs.

In February 2013, the Parent Company issued 14,605,000 shares of common stock and contributed net proceeds of approximately \$287.0 million, after deducting the underwriters' discounts and commissions and offering expenses, to the Operating Partnership in exchange for the issuance of 14,605,000 operating partnership units. The net proceeds to the Operating Partnership were utilized to fund the acquisition of the Woodside Technology Park property in Redwood City, California, to fund a portion of the redemption of all 7,920,000 outstanding shares of the Parent Company's 7.375% Series A Cumulative Redeemable Preferred Stock ("Series A preferred stock"), to repay a portion of the outstanding indebtedness under its unsecured line of credit and for other general corporate and working capital purposes.

In April 2013, the Parent Company issued 17,250,000 shares of common stock and contributed net proceeds of approximately \$354.1 million, after deducting the underwriters' discounts and commissions and offering expenses, to the Operating Partnership in exchange for the issuance of 17,250,000 operating partnership units. The net proceeds to the Operating Partnership were utilized to repay a portion of the outstanding indebtedness under its unsecured line of credit, to fund a portion of the purchase price of the merger with Wexford and for other general corporate and working capital purposes.

In May 2013, as part of the consideration paid for the merger with Wexford, the sellers received 5,568,227 shares of the Parent Company's common stock and 336,960 operating partnership units, of which 20,069 shares of common stock and all of the operating partnership units are subject to certain restrictions.

In June 2013, as part of the consideration paid for the Company's acquisition of the 320 Charles Street property in Cambridge, Massachusetts, the seller received 2,034,211 operating partnership units.

Common Stock, Operating Partnership Units and LTIP Units

As of December 31, 2013, the Company had outstanding 192,115,002 shares of the Parent Company's common stock and 5,083,400 and 332,574 operating partnership and LTIP units, respectively (excluding operating partnership units held by the Parent Company). A share of the Parent Company's common stock and the operating partnership and LTIP units have essentially the same economic characteristics as they share equally in the total net income or loss and distributions of the Operating Partnership.

7.375% Series A Cumulative Redeemable Preferred Stock

On March 15, 2013, the Parent Company redeemed all 7,920,000 outstanding shares of its Series A preferred stock for approximately \$198.0 million, or \$25.00 per share, net of accrued dividends of approximately \$2.4 million, or \$0.30217 per share. The redemption of the Series A preferred stock resulted in the recognition of costs on redemption of preferred stock of approximately \$6.5 million for the year ended December 31, 2013 as a result of the difference between the carrying value and the price paid to redeem the Series A preferred stock.

Dividends and Distributions

The following table lists the dividends and distributions declared by the Parent Company and the Operating Partnership during the year ended December 31, 2013:

Table of Contents

| Declaration Date | Securities Class | Amount Per Share/Unit | Period Covered | Dividend and Distribution Payable Date | Dividend and Distribution Amount (In thousands) |
|--------------------|---------------------------|-----------------------|--------------------------------------|--|---|
| March 15, 2013 | Common stock and OP units | \$0.235 | January 1, 2013 to March 31, 2013 | April 15, 2013 | \$40,413 |
| June 14, 2013 | Common stock and OP units | \$0.235 | April 1, 2013 to June 30, 2013 | July 15, 2013 | \$46,381 |
| September 16, 2013 | Common stock and OP units | \$0.235 | July 1, 2013 to September 30, 2013 | October 15, 2013 | \$46,418 |
| December 12, 2013 | Common stock and OP units | \$0.250 | October 1, 2013 to December 31, 2013 | January 15, 2014 | \$49,383 |

Total 2013 dividends and distributions declared through December 31, 2013 (in thousands):

| | |
|------------------------------------|-----------|
| Common stock and OP units | \$182,595 |
| Series A preferred stock/units (1) | 2,393 |
| | \$184,988 |

On March 15, 2013, the Parent Company redeemed all 7,920,000 outstanding shares of its Series A preferred stock (1) for approximately \$198.0 million, or \$25.00 per share, net of accrued dividends of approximately \$2.4 million, or \$0.30217 per share.

Changes in Accumulated Other Comprehensive Loss by Component

| | Foreign currency translation adjustments | Unrealized gains on available-for-sale securities | Gain / (loss) on derivative instruments | Total |
|--|--|---|---|-------------|
| Balance at December 31, 2012 | \$3,543 | \$ 114 | \$(58,382) | \$(54,725) |
| Other comprehensive income before reclassifications | 395 | 9,071 | 3,497 | 12,963 |
| Amounts reclassified from accumulated other comprehensive income (1) | — | 1,836 | 9,451 | 11,287 |
| Net other comprehensive income | 395 | 10,907 | 12,948 | 24,250 |
| Net other comprehensive income allocable to noncontrolling interests | (33) | (2,083) | (332) | (2,448) |
| Balance as of December 31, 2013 | \$3,905 | \$ 8,938 | \$(45,766) | \$(32,923) |

(1) Amounts reclassified from loss on derivative instruments are included in interest expense, net in the consolidated statements of operations. See Note 9 for further information.

Noncontrolling Interests

Noncontrolling interests on the consolidated balance sheets of the Parent Company relate primarily to the OP units in the Operating Partnership that are not owned by the Parent Company. With respect to the noncontrolling interests in the Operating Partnership, noncontrolling interests with redemption provisions that permit the issuer to settle in either cash or common stock at the option of the issuer are further evaluated to determine whether temporary or permanent equity classification on the balance sheet is appropriate. Because the OP units comprising the noncontrolling interests

contain such a provision, the Company evaluated this guidance, including the requirement to settle in unregistered shares, and determined that the OP units meet the requirements to qualify for presentation as permanent equity.

The Company evaluates individual redeemable noncontrolling interests for the ability to continue to recognize the noncontrolling interest as permanent equity in the consolidated balance sheets. Any redeemable noncontrolling interest that fails to qualify as permanent equity will be reclassified as temporary equity and adjusted to the greater of (1) the carrying amount, or (2) its redemption value at the end of the period in which the determination is made.

Table of Contents

The redemption value of the OP units not owned by the Parent Company, had such units been redeemed at December 31, 2013, was approximately \$99.4 million based on the average closing price of the Parent Company's common stock of \$18.35 per share for the ten consecutive trading days immediately preceding December 31, 2013.

The following table shows the vested ownership interests in the Operating Partnership:

| | December 31, 2013 | | December 31, 2012 | | |
|--|--|---------------------|-----------------------------|---------------------|---|
| | Operating Partnership Units and LTIP Units | Percentage of Total | Operating Partnership Units | Percentage of Total | |
| BioMed Realty Trust | 190,676,428 | 97.3 | % 152,853,368 | 98.1 | % |
| Noncontrolling interest consisting of: | | | | | |
| Operating partnership and LTIP units held by employees and related parties | 2,656,388 | 1.4 | % 2,339,314 | 1.5 | % |
| Operating partnership and LTIP units held by third parties | 2,627,145 | 1.3 | % 565,051 | 0.4 | % |
| Total | 195,959,961 | 100.0 | % 155,757,733 | 100.0 | % |

4. Capital of the Operating Partnership

Operating Partnership Units and LTIP Units

As of December 31, 2013, the Operating Partnership had outstanding 197,198,402 operating partnership units and 332,574 LTIP units. The Parent Company owned 97.3% of the partnership interests in the Operating Partnership at December 31, 2013, is the Operating Partnership's general partner and is responsible for the management of the Operating Partnership's business. As the general partner of the Operating Partnership, the Parent Company effectively controls the ability to issue common stock of the Parent Company upon a limited partner's notice of redemption. In addition, the Parent Company has generally acquired OP units upon a limited partner's notice of redemption in exchange for shares of its common stock. The redemption provisions of OP units owned by limited partners that permit the Parent Company to settle in either cash or common stock at the option of the Parent Company are further evaluated in accordance with applicable accounting guidance to determine whether temporary or permanent equity classification on the balance sheet is appropriate. The Operating Partnership evaluated this guidance, including the requirement to settle in unregistered shares, and determined that these OP units meet the requirements to qualify for presentation as permanent equity.

LTIP units represent a profits interest in the Operating Partnership for services rendered or to be rendered by the LTIP unit holder in its capacity as a partner, or in anticipation of becoming a partner, in the Operating Partnership. Upon the occurrence of specified events, LTIP units may over time achieve full parity with common units of the Operating Partnership for all purposes. Upon achieving full parity, LTIP units may be redeemed for an equal number of the Parent Company's common stock or cash, at the Parent Company's election.

The redemption value of the OP units owned by the limited partners, not including the Parent Company, had such units been redeemed at December 31, 2013, was approximately \$99.4 million based on the average closing price of the Parent Company's common stock of \$18.35 per share for the ten consecutive trading days immediately preceding December 31, 2013.

Changes in Accumulated Other Comprehensive Loss by Component

Table of Contents

| | Foreign currency translation adjustments | Unrealized gains on available- for-sale securities | Gain / (loss) on derivative instruments | Total |
|--|---|--|---|-------------|
| Balance at December 31, 2012 | \$3,611 | \$115 | \$(56,803) | \$(53,077) |
| Other comprehensive income before reclassifications | 395 | 9,071 | 3,497 | 12,963 |
| Amounts reclassified from accumulated other comprehensive income (1) | — | 1,836 | 9,451 | 11,287 |
| Net other comprehensive income | 395 | 10,907 | 12,948 | 24,250 |
| Net other comprehensive income allocable to noncontrolling interest | \$— | \$(1,836) | \$— | \$(1,836) |
| Balance as of December 31, 2013 | \$4,006 | \$9,186 | \$(43,855) | \$(30,663) |

(1) Amounts reclassified from loss on derivative instruments are included in interest expense, net in the consolidated statements of operations. See Note 9 for further information.

5. Debt

Debt of the Parent Company

The Parent Company does not hold any indebtedness. All debt is held directly or indirectly by the Operating Partnership; however, the Parent Company has guaranteed the Operating Partnership's mortgage loan secured by the Company's Center for Life Science | Boston property, Exchangeable Senior Notes due 2030 (the "Exchangeable Senior Notes"), Unsecured Senior Notes due 2016 (the "Notes due 2016"), Unsecured Senior Notes due 2020 (the "Notes due 2020"), Unsecured Senior Notes due 2022 (the "Notes due 2022"), Unsecured Senior Term Loan due 2017 (the "Term Loan due 2017"), Unsecured Senior Term Loan due 2018 (the "Term Loan due 2018") and unsecured line of credit.

Debt of the Operating Partnership

The following is a summary of the Operating Partnership's outstanding consolidated debt as of December 31, 2013 and December 31, 2012 (dollars in thousands):

Table of Contents

| | Stated Interest Rate | Effective Interest Rate | Principal Balance | | Maturity Date |
|---|----------------------------|-------------------------------|----------------------|----------------------|-------------------|
| | | | December 31, 2013 | December 31, 2012 | |
| Mortgage Notes Payable | | | | | |
| 9900 Belward Campus Drive | 5.64 | % 3.99 | % \$10,631 | \$10,767 | July 1, 2017 |
| 9901 Belward Campus Drive | 5.64 | % 3.99 | % 13,091 | 13,260 | July 1, 2017 |
| Center for Life Science I Boston | 7.75 | % 7.75 | % 334,447 | 338,447 | June 30, 2014 |
| 4320 Forest Park Avenue (1) | 4.00 | % 2.70 | % 21,000 | — | June 30, 2015 |
| Hershey Center for Applied Research (1) | 6.15 | % 4.71 | % 13,449 | — | May 5, 2027 |
| 500 Kendall Street (Kendall D) | 6.38 | % 5.45 | % 57,927 | 60,164 | December 1, 2018 |
| Shady Grove Road | 5.97 | % 5.97 | % 143,067 | 144,889 | September 1, 2016 |
| University of Maryland BioPark I (1) | 5.93 | % 4.69 | % 16,752 | — | May 15, 2025 |
| University of Maryland BioPark II (1) | 5.20 | % 4.33 | % 62,946 | — | September 5, 2021 |
| University of Maryland BioPark Garage (1) | 5.20 | % 4.33 | % 4,738 | — | September 1, 2021 |
| University of Miami Life Science & Technology Park (1) | 4.00 | % 2.89 | % 20,000 | — | February 1, 2016 |
| | | | 698,048 | 567,527 | |
| Unamortized premiums | | | 11,276 | 4,125 | |
| Mortgage notes payable, net | | | 709,324 | 571,652 | |
| Exchangeable Senior Notes | 3.75 | % 3.75 | % 180,000 | 180,000 | January 15, 2030 |
| Notes due 2016 | 3.85 | % 3.99 | % 400,000 | 400,000 | April 15, 2016 |
| Notes due 2020 | 6.13 | % 6.27 | % 250,000 | 250,000 | April 15, 2020 |
| Notes due 2022 | 4.25 | % 4.36 | % 250,000 | 250,000 | July 15, 2022 |
| | | | 900,000 | 900,000 | |
| Unamortized discounts | | | (4,917 |) (5,823 |) |
| Unsecured senior notes, net | | | 895,083 | 894,177 | |
| Term Loan due 2017 - U.S. dollar (2) | 1.82 | % 2.63 | % 243,596 | 243,596 | March 30, 2017 |
| Term Loan due 2017 - GBP (2) | 2.14 | % 2.39 | % 165,190 | 161,860 | March 30, 2017 |
| Term Loan due 2018 (3) | 1.67 | % 1.97 | % 350,000 | — | March 24, 2018 |
| Unsecured senior term loans | | | 758,786 | 405,456 | |
| Unsecured line of credit (3) (4) | 1.46 | % 1.46 | % 128,000 | 118,000 | March 24, 2018 |
| Total consolidated debt | | | \$2,671,193 | \$2,169,285 | |

(1) Mortgage notes which were assumed on May 31, 2013 in connection with the Company's merger with Wexford.

In August 2012, the Operating Partnership converted approximately \$156.4 million of outstanding borrowings into British pounds sterling ("GBP") equal to £100.0 million, which was designated as a net investment hedge to mitigate the risk of fluctuations in foreign currency exchange rates. The principal balance represents the U.S. dollar amount based on the exchange rates of \$1.65 to £1.00 and \$1.62 to £1.00 at December 31, 2013 and December 31, 2012, respectively. The effective interest rate includes the impact of interest rate swap agreements (see Note 9 for further discussion of interest rate swap agreements).

In September 2013, the Operating Partnership amended and restated its unsecured credit agreement, providing for aggregate borrowing of up to \$1.25 billion, consisting of an unsecured line of credit of \$900.0 million and a term loan of \$350.0 million (the Term Loan due 2018). In connection with the amendment and restatement of the credit agreement, unamortized loan fees under the previous credit agreement of approximately \$462,500 were charged to interest expense.

(4) At December 31, 2013, the Operating Partnership had additional borrowing capacity under the unsecured line of credit of up to approximately \$772.0 million.

Mortgage Notes Payable, net

The net carrying value of properties (investments in real estate) secured by the Operating Partnership's mortgage notes payable was approximately \$1.2 billion and \$1.0 billion at December 31, 2013 and 2012, respectively.

101

Table of Contents

The Operating Partnership's \$334.4 million mortgage loan, which is secured by the Company's Center for Life Science | Boston property in Boston, Massachusetts, includes a financial covenant relating to a minimum amount of net worth. Management believes that the Operating Partnership was in compliance with this covenant as of December 31, 2013. Notwithstanding the financial covenant related to the Center for Life Science | Boston mortgage, no other financial covenants are required on the remaining mortgage notes payable.

Premiums were recorded upon assumption of the mortgage notes payable at the time of the related property acquisition to account for above-market interest rates. Amortization of these premiums is recorded as a reduction to interest expense over the remaining term of the respective note using a method that approximates the effective-interest method.

Exchangeable Senior Notes

On January 11, 2010, the Operating Partnership issued \$180.0 million aggregate principal amount of its Exchangeable Senior Notes. The Exchangeable Senior Notes are general senior unsecured obligations of the Operating Partnership and rank equally in right of payment with all other senior unsecured indebtedness of the Operating Partnership. Interest at a rate of 3.75% per annum is payable on January 15 and July 15 of each year, beginning on July 15, 2010, until the stated maturity date of January 15, 2030. The terms of the Exchangeable Senior Notes are governed by an indenture, dated January 11, 2010, among the Operating Partnership, as issuer, the Parent Company, as guarantor, and U.S. Bank National Association, as trustee. The Exchangeable Senior Notes contain an exchange settlement feature, which provides that the Exchangeable Senior Notes may, at any time prior to the close of business on the second scheduled trading day preceding the maturity date, be exchangeable for shares of the Parent Company's common stock at the then applicable exchange rate. As the exchange feature for the Exchangeable Senior Notes must be settled in the common stock of the Parent Company, accounting guidance applicable to convertible debt instruments that permit the issuer to settle all or a portion of the exchange feature in cash upon conversion does not apply. The initial exchange rate was 55.0782 shares per \$1,000 principal amount of Exchangeable Senior Notes, representing an exchange price of approximately \$18.16 per share of the Parent Company's common stock. If certain designated events occur on or prior to January 15, 2015 and a holder elects to exchange Exchangeable Senior Notes in connection with any such transaction, the Company will increase the exchange rate by a number of additional shares of the Parent Company's common stock based on the date the transaction becomes effective and the price paid per share of the Parent Company's common stock in the transaction, as set forth in the indenture governing the Exchangeable Senior Notes. The exchange rate for the Exchangeable Senior Notes may be adjusted under certain circumstances, including the payment of cash dividends in excess of \$0.14 per share of common stock. The increase in the quarterly cash dividend through 2013 resulted in an increase in the exchange rate of the Exchangeable Senior Notes to 57.8068 shares per \$1,000 principal amount of Exchangeable Senior Notes (a conversion value of \$17.30 per share), effective as of September 26, 2013, the Company's ex-dividend date for the third quarter 2013 dividend.

The Operating Partnership may redeem the Exchangeable Senior Notes, in whole or in part, at any time to preserve the Parent Company's status as a REIT or at any time on or after January 21, 2015 for cash at 100% of the principal amount plus accrued and unpaid interest. The holders of the Exchangeable Senior Notes have the right to require the Operating Partnership to repurchase the Exchangeable Senior Notes, in whole or in part, for cash on each of January 15, 2015, January 15, 2020 and January 15, 2025, or upon the occurrence of a designated event, in each case for a repurchase price equal to 100% of the principal amount of the Exchangeable Senior Notes plus accrued and unpaid interest. The terms of the indenture for the Exchangeable Senior Notes do not require compliance with any financial covenants.

Unsecured Senior Notes due 2016, net

On March 30, 2011, the Operating Partnership issued \$400.0 million aggregate principal amount of its Notes due 2016. The purchase price paid by the underwriters was 99.365% of the principal amount and the Notes due 2016 have been recorded on the consolidated balance sheet net of the discount. The Notes due 2016 are senior unsecured obligations of the Operating Partnership and rank equally in right of payment with all other senior unsecured indebtedness of the Operating Partnership. However, the Notes due 2016 are effectively subordinated to the Operating Partnership's existing and future mortgages and other secured indebtedness (to the extent of the value of the collateral securing such indebtedness) and to all existing and future preferred equity and liabilities, whether secured or unsecured, of the Operating Partnership's subsidiaries, including guarantees provided by the Operating Partnership's subsidiaries under the Operating Partnership's unsecured line of credit. Interest at a rate of 3.85% per year is payable on April 15 and October 15 of each year, beginning on October 15, 2011, until the stated maturity date of April 15, 2016. The terms of the Notes due 2016 are governed by a base indenture and supplemental indenture, each dated March 30, 2011, among the Operating Partnership, as issuer, the Parent Company, as guarantor, and U.S. Bank National Association, as trustee.

The Operating Partnership may redeem the Notes due 2016, in whole or in part, at any time for cash at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes due 2016 being redeemed; or (2) the sum of the present

Table of Contents

values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis at the adjusted treasury rate plus 30 basis points, plus in each case, accrued and unpaid interest.

The terms of the indenture for the Notes due 2016 require compliance with various financial covenants, including limits on the amount of total leverage and secured debt maintained by the Operating Partnership and which require the Operating Partnership to maintain minimum levels of debt service coverage. Management believes that it was in compliance with these covenants as of December 31, 2013.

Unsecured Senior Notes due 2020, net

On April 29, 2010, the Operating Partnership issued \$250.0 million aggregate principal amount of its Notes due 2020. The purchase price paid by the initial purchasers was 98.977% of the principal amount and the Notes due 2020 have been recorded on the consolidated balance sheet net of the discount. The Notes due 2020 are senior unsecured obligations of the Operating Partnership and rank equally in right of payment with all other senior unsecured indebtedness of the Operating Partnership. However, the Notes due 2020 are effectively subordinated to the Operating Partnership's existing and future mortgages and other secured indebtedness (to the extent of the value of the collateral securing such indebtedness) and to all existing and future preferred equity and liabilities, whether secured or unsecured, of the Operating Partnership's subsidiaries, including guarantees provided by the Operating Partnership's subsidiaries under the Company's unsecured line of credit. Interest at a rate of 6.125% per year is payable on April 15 and October 15 of each year, beginning on October 15, 2010, until the stated maturity date of April 15, 2020. The terms of the Notes due 2020 are governed by an indenture, dated April 29, 2010, among the Operating Partnership, as issuer, the Parent Company, as guarantor, and U.S. Bank National Association, as trustee.

The Operating Partnership may redeem the Notes due 2020, in whole or in part, at any time for cash at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes due 2020 being redeemed; or (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis at the adjusted treasury rate plus 40 basis points, plus in each case, accrued and unpaid interest.

The terms of the indenture for the Notes due 2020 require compliance with various financial covenants, including limits on the amount of total leverage and secured debt maintained by the Operating Partnership and which require the Operating Partnership to maintain minimum levels of debt service coverage. Management believes that it was in compliance with these covenants as of December 31, 2013.

On January 12, 2011, in accordance with the registration rights agreement entered into among the Company, the Operating Partnership and the initial purchasers of the Notes due 2020, the Operating Partnership completed its exchange offer to exchange all of the outstanding unregistered Notes due 2020 for an equal principal amount of a new issue of 6.125% Senior Notes due 2020 pursuant to an effective registration statement on Form S-4 filed with the Securities and Exchange Commission. A total of \$250.0 million aggregate principal amount of the original Notes due 2020, representing 100% of the outstanding principal amount of the original Notes due 2020, was tendered and received prior to the expiration of the exchange offer. The terms of the Notes due 2020 are substantially identical to the original Notes due 2020, except for transfer restrictions and registration rights relating to the original Notes due 2020.

Unsecured Senior Notes due 2022, net

On June 28, 2012, the Operating Partnership issued \$250.0 million aggregate principal amount of its Notes due 2022. The purchase price paid by the underwriters was 99.126% of the principal amount and the Notes due 2022 have been recorded on the consolidated balance sheet net of the discount. The Notes due 2022 are senior unsecured obligations

of the Operating Partnership and rank equally in right of payment with all other senior unsecured indebtedness of the Operating Partnership. However, the Notes due 2022 are effectively subordinated to the Operating Partnership's existing and future mortgages and other secured indebtedness (to the extent of the value of the collateral securing such indebtedness) and to all existing and future preferred equity and liabilities, whether secured or unsecured, of the Operating Partnership's subsidiaries, including guarantees provided by the Operating Partnership's subsidiaries under the Operating Partnership's unsecured line of credit. Interest at a rate of 4.25% per year is payable on January 15 and July 15 of each year, beginning on January 15, 2013, until the stated maturity date of July 15, 2022. The terms of the Notes due 2022 are governed by a base indenture and supplemental indenture, dated March 30, 2011 and June 28, 2012, respectively, among the Operating Partnership, as issuer, the Parent Company, as guarantor, and U.S. Bank National Association, as trustee.

The Operating Partnership may redeem the Notes due 2022, in whole or in part, at any time for cash at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes due 2022 being redeemed; or (2) the sum of the present

Table of Contents

values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis at the adjusted treasury rate plus 45 basis points, plus in each case, accrued and unpaid interest.

The terms of the indenture for the Notes due 2022 require compliance with various financial covenants, including limits on the amount of total leverage and secured debt maintained by the Operating Partnership and which require the Operating Partnership to maintain minimum levels of debt service coverage. Management believes that it was in compliance with these covenants as of December 31, 2013.

Unsecured Senior Term Loan due 2017
Term Loan due 2017 - U.S. dollar

On March 30, 2012, the Operating Partnership entered into the \$400.0 million Term Loan due 2017 with KeyBank National Association (“KeyBank”) as administrative agent and co-lead arranger, Wells Fargo Securities, LLC as co-lead arranger and Wells Fargo Bank National Association as co-syndication agent, U.S. Bank National Association as co-syndication agent and co-lead arranger and other lenders. The Term Loan due 2017 has a maturity date of March 30, 2017. Subject to the administrative agent’s reasonable discretion, the Operating Partnership may increase the amount of the borrowings to \$500.0 million under the Term Loan due 2017 upon satisfying certain conditions. Borrowings under the Term Loan due 2017 are guaranteed by the Parent Company.

Borrowings for the U.S. dollar-denominated debt under the Term Loan due 2017 bear interest at a floating rate equal to, at the Operating Partnership’s option, either (1) reserve adjusted U.S. dollar-LIBOR plus a spread which ranges from 115 to 205 basis points, depending on the Parent Company’s credit ratings, or (2) the highest of (a) the prime rate then in effect plus a spread which ranges from 15 to 120 basis points, (b) the federal funds rate then in effect plus a spread which ranges from 65 to 170 basis points or (c) one-month U.S. dollar-LIBOR plus a spread which ranges from 115 to 205 basis points, in each case, depending on the Parent Company’s credit ratings.

Concurrent with the closing of the Term Loan due 2017 in March 2012, the Operating Partnership entered into interest rate swap agreements, which are intended to have the effect of fixing interest payments associated with \$200.0 million of the outstanding balance under the Term Loan due 2017 at approximately 2.81% for a five-year term, subject to change depending on the Parent Company’s credit ratings.

Term Loan due 2017 - GBP

On August 2, 2012, the Operating Partnership amended the Term Loan due 2017 agreement to convert approximately \$156.4 million of outstanding borrowings of the Term Loan due 2017 into GBP equal to £100.0 million. Borrowings for the GBP-denominated debt under the Term Loan due 2017 bear interest at a floating rate equal to reserve adjusted GBP-LIBOR plus a spread which ranges from 115 to 205 basis points, depending on the Parent Company’s credit ratings.

The Operating Partnership designated the GBP-denominated debt under the Term Loan due 2017 as a net investment hedge. The Operating Partnership intended to hedge the foreign currency exchange risk attributable to changes in the GBP/U.S. dollar exchange rate on a portion of its net investment in its GBP functional currency subsidiary during the period of investment during which the hedging instrument is outstanding. Variability in the GBP/U.S. dollar exchange rate impacts the Operating Partnership as the financial statements of the GBP functional currency subsidiary are translated each period, with the effect of changes in the GBP/U.S. dollar exchange rate being recorded as foreign currency translation gain or loss in other comprehensive income.

Concurrent with the conversion to GBP denominated debt, the Operating Partnership entered into interest rate swap agreements, which are intended to have the effect of fixing interest payments associated with £100.0 million of the

outstanding balance under the Term Loan due 2017 at approximately 2.39% for a five-year term of the Term Loan due 2017, subject to change depending on the Parent Company's credit ratings.

The Term Loan due 2017 includes certain restrictions and covenants which require compliance with financial covenants relating to the minimum amounts of net worth, fixed charge coverage, unsecured debt service coverage, overall leverage and unsecured leverage ratios, the maximum amount of secured indebtedness and certain investment limitations. The Term Loan due 2017 specifies a number of events of default (some of which are subject to applicable cure periods), including, among others, the failure to make payments when due, noncompliance with covenants and defaults under other agreements or instruments of indebtedness. Upon the occurrence of an event of default, the lenders may terminate the Term Loan due 2017 and declare all amounts outstanding to be immediately due and payable.

Table of Contents

On September 24, 2013, the Operating Partnership entered into a second amendment to the Term Loan due 2017, which changed, among other things, (1) the definition of “Capitalization Rate” to mean 7.25% with respect to all projects other than the Company's Center for Life Science | Boston property, and 6.25% with respect to the Center for Life Science | Boston property and (2) certain definitions used to calculate the financial covenants.

Management believes that the Operating Partnership was in compliance with the covenants as of December 31, 2013.

Unsecured Line of Credit and Term Loan due 2018

On July 14, 2011, the Operating Partnership entered into an unsecured credit agreement with KeyBank, as administrative agent and co-lead arranger, Wells Fargo Securities, LLC as co-lead arranger, and certain other lenders. The unsecured credit agreement provided for available borrowings under a revolving line of credit of \$750.0 million with a maturity date of March 24, 2018.

On September 24, 2013, the Operating Partnership entered into an amended and restated unsecured credit agreement (the “Amended and Restated Credit Facility”), amending and restating its unsecured credit agreement dated July 14, 2011, as amended. The Amended and Restated Credit Facility provides for aggregate borrowings of up to \$1.25 billion, consisting of a \$900.0 million revolving line of credit and a \$350.0 million Term Loan due 2018, with a maturity date of March 24, 2018. Subject to the administrative agent's reasonable discretion, the Operating Partnership may increase the amount of the commitments under the Amended and Restated Credit Facility up to \$1.8 billion upon satisfying certain conditions. In addition, the Operating Partnership, at its sole discretion, may extend the maturity date to September 24, 2018 after satisfying certain conditions and paying an extension fee. Borrowings under the unsecured line of credit and the Term Loan due 2018 are guaranteed by the Parent Company. In connection with the Amended and Restated Credit Facility, unamortized loan fees under the previous credit agreement of approximately \$462,500 were charged to interest expense.

Borrowings under the Amended and Restated Credit Facility bear interest at floating rates equal to, at the Operating Partnership's option, either (1) reserve-adjusted LIBOR plus a spread which ranges from 92.5 to 170 basis points (with respect to the unsecured line of credit) and a spread which ranges from 95 to 195 basis points (with respect to the Term Loan due 2018), in each case depending on the Parent Company's credit ratings, or (2) the highest of (a) the prime rate then in effect plus a spread which ranges from 0 to 70 basis points, (b) the federal funds rate then in effect plus a spread which ranges from 50 to 120 basis points, or (c) one-month LIBOR plus a spread which ranges from 92.5 to 170 basis points (with respect to the unsecured line of credit) and a spread which ranges from 95 to 195 basis points (with respect to the Term Loan due 2018), in each case depending on the Parent Company's credit ratings. In addition, a facility fee is payable on the total \$900.0 million capacity of the unsecured line of credit, which ranges from 12.5 to 30 basis points per annum, depending on the Parent Company's credit ratings.

The Amended and Restated Credit Facility includes certain restrictions and covenants which require compliance with financial covenants relating to the minimum amounts of net worth, fixed charge coverage, unsecured debt service coverage, overall leverage and unsecured leverage ratios, the maximum amount of secured indebtedness and certain investment limitations. The unsecured credit agreement specifies a number of events of default (some of which are subject to applicable cure periods), including, among others, the failure to make payments when due, noncompliance with covenants and defaults under other agreements or instruments of indebtedness. Upon the occurrence of an event of default, the lenders may terminate the revolving line of credit and declare all amounts outstanding to be immediately due and payable. Management believes that the Operating Partnership was in compliance with these covenants as of December 31, 2013.

On September 25, 2013, the Operating Partnership entered into interest rate swap agreements, which are intended to have the effect of fixing interest payments associated with \$200.0 million of the Term Loan due 2018 outstanding at approximately 2.2% for a three-year term, subject to adjustment based on the Parent Company's credit ratings. See

Note 9 for further details.

Net Investment Hedge

The Operating Partnership designated the GBP denominated debt under the Term Loan due 2017 as a net investment hedge. The Operating Partnership entered into this net investment hedge to protect a designated amount of the Operating Partnership's net investment in a GBP functional currency subsidiary against the risk of adverse changes in the GBP/U.S. dollar exchange rate (foreign exchange risk). Variability in the GBP/U.S. dollar exchange rate impacts the Operating Partnership (a U.S. dollar functional currency entity) as the financial statements of the GBP functional currency subsidiary are translated each period, with the effect of changes in the GBP/U.S. dollar exchange rate being recorded in accumulated other comprehensive income. When the net investment is sold or substantially liquidated, the balance of the translation adjustment accumulated in other comprehensive income will be reclassified into earnings. The Operating Partnership is hedging the risk of changes in the U.S. dollar equivalent value of a portion of its net investment in its GBP subsidiary attributable to changes in the GBP/U.S. dollar exchange rate during the period of investment during which the hedging instrument is outstanding.

105

Table of Contents

Maturities of Long-Term Debt

As of December 31, 2013, principal payments due for the Operating Partnership's consolidated indebtedness (excluding debt premiums and discounts) were as follows (in thousands):

| | |
|----------------|-------------|
| 2014 | \$341,416 |
| 2015 | 30,006 |
| 2016 | 566,516 |
| 2017 | 439,080 |
| 2018 | 523,663 |
| Thereafter (1) | 764,153 |
| | \$2,664,834 |

(1) Includes \$180.0 million in principal payments of the Exchangeable Senior Notes based on a contractual maturity date of January 15, 2030.

6. Earnings Per Share of the Parent Company

Grants of restricted stock of the Parent Company and LTIP units of the Operating Partnership in share-based payment transactions are considered participating securities prior to vesting and, therefore, are considered in computing basic earnings per share under the two-class method. The two-class method is an earnings allocation method for calculating earnings per share when a company's capital structure includes either two or more classes of common stock or common stock and participating securities. Basic earnings per share under the two-class method is calculated based on dividends declared on common shares and other participating securities ("distributed earnings") and the rights of participating securities in any undistributed earnings, which represents net income remaining after deduction of dividends accruing during the period. The undistributed earnings are allocated to all outstanding common shares and participating securities based on the relative percentage of each security to the total number of outstanding participating securities. Basic earnings per share represents the summation of the distributed and undistributed earnings per share class divided by the total number of shares.

Through December 31, 2013 all of the Company's participating securities (including the OP units) received dividends/distributions at an equal dividend/distribution rate per share/unit. As a result, the portion of net income allocable to the weighted-average unvested restricted stock outstanding for the years ended December 31, 2013, 2012 and 2011 has been deducted from net income available to common stockholders to calculate basic earnings per share. The calculation of diluted earnings per share for the years ended December 31, 2013, 2012 and 2011 includes the outstanding OP units (both vested and unvested) in the weighted-average shares, and net income attributable to noncontrolling interests in the Operating Partnership has been added back to net income available to common stockholders. For the year ended December 31, 2013, the Performance Units were dilutive to the calculation of diluted earnings per share as calculated, assuming that December 31, 2013 was the end date of the Performance Units' Performance Period. For the year ended December 31, 2012, the Performance Units were anti-dilutive to the calculation of diluted earnings per share as calculated, assuming that December 31, 2012 was the end date of the Performance Units' Performance Period. For the years ended December 31, 2013, 2012 and 2011, the unvested restricted stock was anti-dilutive to the calculation of diluted earnings per share and was therefore excluded. As a result, diluted earnings per share was calculated based upon net income available to common stockholders less net income allocable to unvested restricted stock and distributions in excess of earnings attributable to unvested restricted stock. In addition, 10,405,224, 10,259,496 and 10,017,858 shares issuable upon settlement of the exchange feature of the Exchangeable Senior Notes were anti-dilutive and were not included in the calculation of diluted earnings per share based on the "if converted" method for the years ended December 31, 2013, 2012 and 2011, respectively. No other

shares were considered anti-dilutive for the years ended December 31, 2013, 2012 and 2011.

Computations of basic and diluted earnings per share (in thousands, except share data) were as follows:

106

Table of Contents

| | Years Ended December 31, | | |
|--|--------------------------|-------------|-------------|
| | 2013 | 2012 | 2011 |
| Basic earnings per share: | | | |
| Income from continuing operations | \$47,209 | \$16,133 | \$42,240 |
| Income from continuing operations attributable to noncontrolling interests | (565 |) (20 |) (515 |
| Preferred stock dividends | (2,393 |) (14,603 |) (16,033 |
| Cost on redemption of preferred stock | (6,531 |) — | (165 |
| Net income allocable and distributions in excess of earnings to participating securities (continuing operations) | (1,350 |) (1,300 |) (1,172 |
| Income from continuing operations available to common stockholders - basic | 36,370 | 210 | 24,355 |
| (Loss) / income from discontinued operations | — | (4,370 |) 474 |
| Loss / (income) from discontinued operations attributable to noncontrolling interests | — | 82 | (10 |
| (Loss) / income from discontinued operations available to common stockholders - basic | — | (4,288 |) 464 |
| Net income / (loss) available to common stockholders - basic | \$36,370 | \$(4,078 |) \$24,819 |
| Diluted earnings per share: | | | |
| Income from continuing operations available to common stockholders - basic | 36,370 | 210 | 24,355 |
| Income from continuing operations attributable to noncontrolling interests in Operating Partnership | 819 | 29 | 559 |
| Income from continuing operations available to common stockholders - diluted | 37,189 | 239 | 24,914 |
| (Loss) / income from discontinued operations available to common stockholders - basic and diluted | — | (4,288 |) 464 |
| (Loss) / income from discontinued operations attributable to noncontrolling interests in the Operating Partnership | — | (82 |) 10 |
| (Loss) / income from discontinued operations available to common stockholders - basic and diluted | — | (4,370 |) 474 |
| Net income / (loss) available to common stockholders - diluted | \$37,189 | \$(4,131 |) \$25,388 |
| Weighted-average common shares outstanding: | | | |
| Basic | 182,043,391 | 152,752,086 | 132,625,915 |
| Incremental shares from assumed conversion: | | | |
| Performance units | 63,017 | — | — |
| Operating partnership and LTIP units | 4,290,614 | 2,948,301 | 2,983,928 |
| Diluted | 186,397,022 | 155,700,387 | 135,609,843 |
| Basic and diluted earnings per share: | | | |
| Income from continuing operations per share available to common stockholders - basic and diluted | \$0.20 | \$— | \$0.19 |
| | \$— | \$(0.03 |) \$— |

Loss from discontinued operations per share available to common
stockholders - basic and diluted

| | | | |
|---|--------|---------|----------|
| Net income / (loss) per share available to common stockholders - basic and diluted | \$0.20 | \$(0.03 |) \$0.19 |
|---|--------|---------|----------|

7. Earnings Per Unit of the Operating Partnership

107

Table of Contents

Restricted units granted in equity-based payment transactions are considered participating securities prior to vesting and, therefore, are considered in computing basic earnings per unit under the two-class method. The two-class method is an earnings allocation method for calculating earnings per unit when a company's capital structure includes either two or more classes of common equity or common equity and participating securities. Basic earnings per unit under the two-class method is calculated based on distributions declared on the OP units and other participating securities ("distributed earnings") and the rights of participating securities in any undistributed earnings, which represents net income remaining after deduction of distributions accruing during the period. The undistributed earnings are allocated to all outstanding OP units and participating securities based on the relative percentage of each security to the total number of outstanding participating securities. Basic earnings per unit represents the summation of the distributed and undistributed earnings per unit class divided by the total number of OP units.

Through December 31, 2013, all of the Operating Partnership's participating securities received distributions at an equal distribution rate per unit. As a result, the portion of net income allocable to the weighted-average unvested OP units outstanding for the years ended December 31, 2013, 2012 and 2011, has been deducted from net income available to unitholders to calculate basic earnings per unit. For the years ended December 31, 2013, 2012 and 2011, the unvested OP units were anti-dilutive to the calculation of earnings per unit and were therefore excluded from the calculation of diluted earnings per unit, and diluted earnings per unit is calculated based upon net income attributable to unitholders. For the year ended December 31, 2013, the Performance Units were dilutive to the calculation of diluted earnings per unit as calculated, assuming that December 31, 2013 was the end date of the Performance Units' Performance Period. For the year ended December 31, 2012, the Performance Units were anti-dilutive to the calculation of diluted earnings per share as calculated, assuming that December 31, 2012 was the end date of the Performance Units' Performance Period. In addition, 10,405,224, 10,259,496 and 10,017,858 units issuable upon settlement of the exchange feature of the Exchangeable Senior Notes were anti-dilutive and were not included in the calculation of diluted earnings per unit based on the "if converted" method for the years ended December 31, 2013, 2012 and 2011, respectively. No other units were considered anti-dilutive for the years ended December 31, 2013, 2012 or 2011.

Computations of basic and diluted earnings per unit (in thousands, except unit data) were as follows:

Table of Contents

| | Years Ended December 31, | | |
|--|--------------------------|-------------|-------------|
| | 2013 | 2012 | 2011 |
| Basic and diluted earnings per unit: | | | |
| Income from continuing operations | \$47,209 | \$16,133 | \$42,240 |
| Loss from continuing operations attributable to noncontrolling interests | 254 | 8 | 44 |
| Preferred unit distributions | (2,393) | (14,603) | (16,033) |
| Cost on redemption of preferred units | (6,531) | — | (165) |
| Net income allocable and distributions in excess of earnings to participating securities (continuing operations) | (1,354) | (1,326) | (1,220) |
| Income from continuing operations available to unitholders - basic and diluted | 37,185 | 212 | 24,866 |
| (Loss) / income from discontinued operations - basic and diluted | — | (4,370) | 474 |
| Net income / (loss) available to unitholders - basic and diluted | \$37,185 | \$(4,158) | \$25,340 |
| Weighted-average units outstanding: | | | |
| Basic | 186,333,292 | 155,670,931 | 135,549,934 |
| Incremental units from assumed conversion: | | | |
| Performance units | 63,017 | — | — |
| Diluted | 186,396,309 | 155,670,931 | 135,549,934 |
| Basic and diluted earnings per unit: | | | |
| Income from continuing operations per unit available to unitholders - basic and diluted | \$0.20 | \$— | \$0.19 |
| Loss from discontinued operations per share available to unitholders - basic and diluted | \$— | \$(0.03) | \$— |
| Net income / (loss) per unit available to unitholders, basic and diluted | \$0.20 | \$(0.03) | \$0.19 |

8. Investment in Unconsolidated Partnerships

The accompanying consolidated financial statements include investments in two limited liability companies with Prudential Real Estate Investors (“PREI”), 10165 McKellar Court, L.P. (“McKellar Court”), a limited partnership with Quidel Corporation, the tenant which occupies the McKellar Court property and BioPark Fremont, LLC (“BioPark Fremont”), a limited liability company with RPC Poppleton, LLC. General information on the PREI limited liability companies, the McKellar Court partnership and BioPark Fremont (each referred to in this footnote individually as a “partnership” and collectively as the “partnerships”) as of December 31, 2013 was as follows:

| Name | Partner | Company's Ownership Interest | Company's Economic Interest | Date Acquired |
|---------------------|--------------------|------------------------------|-----------------------------|--------------------|
| PREI I LLC (1) | PREI | 20% | 20% | April 4, 2007 |
| PREI II LLC | PREI | 20% | 20% | April 4, 2007 |
| McKellar Court (2) | Quidel Corporation | 22% | 22% | September 30, 2004 |
| BioPark Fremont (3) | RPC Poppleton, LLC | 50% | 50% | May 31, 2013 |

- (1) PREI I LLC owns two properties in Cambridge, Massachusetts. At December 31, 2013, there were \$139.0 million in outstanding borrowings on a secured loan facility held by a wholly-owned subsidiary of PREI I LLC, with a contractual interest rate of 3.17% (including the applicable credit spread) and a maturity date of August 13, 2014.

- (2) The Company's investment in the McKellar Court partnership (maximum exposure to losses) was approximately \$12.0 million at December 31, 2013. The Company's economic interest in the McKellar Court partnership entitles it to 75% of the extraordinary cash flows after repayment of the partners' capital contributions and 22% of the operating cash flows.

109

Table of Contents

(3) The Company's partnership interest was acquired in connection with the Company's merger with Wexford.

The condensed combined balance sheets for all of the Company's unconsolidated partnerships were as follows (in thousands):

| | December 31, 2013 | December 31, 2012 |
|---|----------------------|----------------------|
| Assets: | | |
| Investments in real estate, net | \$262,753 | \$257,666 |
| Cash and cash equivalents (including restricted cash) | 3,855 | 1,968 |
| Other assets | 5,301 | 4,370 |
| Total assets | \$271,909 | \$264,004 |
| Liabilities and members' equity: | | |
| Mortgage notes payable and secured loan | \$151,968 | \$149,255 |
| Other liabilities | 12,102 | 5,988 |
| Members' equity | 107,839 | 108,761 |
| Total liabilities and members equity | \$271,909 | \$264,004 |
| Company's net investment in unconsolidated partnerships | \$32,137 | \$32,367 |

The selected data and results of operations for the unconsolidated partnerships were as follows (in thousands):

| | Years Ended December 31, | | |
|---|--------------------------|-------------|------------|
| | 2013 | 2012 | 2011 |
| Total revenues | \$12,930 | \$8,823 | \$8,567 |
| Total expenses | (21,589) | (19,939) | (19,868) |
| Loss from continuing operations | (8,659) | (11,116) | (11,301) |
| Gain on sale of discontinued operations (1) | — | — | 22,927 |
| Loss from discontinued operations | — | — | (6,677) |
| Net (loss) / income | \$(8,659) | \$(11,116) | \$4,949 |
| Company's equity in net loss of unconsolidated partnerships | \$(905) | \$(1,389) | \$(2,489) |
| Fees earned by the Company (2) | \$260 | \$90 | \$1,117 |

During the year ended December 31, 2011, PREI I LLC recorded a gain on sale of discontinued operations upon sale of certain properties to the Company. In accordance with the equity method of accounting, the Company's (1) share of the equity in net income in PREI I LLC excludes any gain on sale since such gain was generated upon sale of the properties to the Company. The Company recorded a gain on revaluation of the acquired unconsolidated partnership.

The Company acts as the operating member or partner, as applicable, and day-to-day manager for the partnerships. (2) The Company is entitled to receive fees for providing construction and development services (as applicable) and management services to the PREI joint ventures, which are reflected in tenant recoveries and other income in the consolidated statements of operations.

9. Derivatives and Other Financial Instruments

The Company is exposed to the effect of changes in interest rates on the Operating Partnership's U.S. dollar-LIBOR-based and GBP-LIBOR-based debt. The Company limits this risk by following established risk management policies and procedures including the use of derivatives. The Company's objectives in using interest rate

derivatives are to add stability to interest expense and to manage its exposure to interest rate movements related to the Operating Partnership's LIBOR-based debt. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. The interest rate swaps hedge the Company's exposure to the variability on expected cash flows attributable to changes in interest rates. These interest rate swaps are currently intended to hedge interest payments associated with the Operating Partnership's Term Loan due 2017 and Term Loan due 2018.

Table of Contents

On March 30, 2012, the Company entered into four interest rate swaps with an aggregate notional amount of \$200.0 million under which at each monthly settlement date the Company either (1) receives the difference between a fixed interest rate (the “USD Strike Rate”) and one-month U.S. dollar-LIBOR if the USD Strike Rate is less than one-month U.S. dollar-LIBOR or (2) pays such difference if the USD Strike Rate is greater than one-month U.S. dollar-LIBOR. The interest rate swaps hedge the Company’s exposure to the variability on expected cash flows attributable to changes in interest rates on the first interest payments, due on the date that is on or closest after each swap’s settlement date, associated with the amount of one-month U.S. dollar-LIBOR-based debt equal to each swap’s notional amount. These interest rate swaps, with a notional amount of \$200.0 million, are currently intended to hedge interest payments associated with the Operating Partnership’s Term Loan due 2017 - U.S. Dollar. No initial investment was made to enter into the interest rate swap agreements.

On August 2, 2012, in connection with the conversion of a portion of the outstanding borrowings under the Term Loan due 2017 into GBP (for further discussion, see Note 5 above), the Company entered into two interest rate swaps with an aggregate notional amount of £100.0 million under which at each monthly settlement date the Company either (1) receives the difference between a fixed interest rate (the “GBP Strike Rate”) and one-month GBP-LIBOR if the GBP Strike Rate is less than one-month GBP-LIBOR or (2) pays such difference if the GBP Strike Rate is greater than one-month GBP-LIBOR. The interest rate swaps hedge the Company’s exposure to the variability on expected cash flows attributable to changes in interest rates on the first interest payments, due on the date that is on or closest after each swap’s settlement date, associated with the amount of one-month GBP-LIBOR-based debt equal to each swap’s notional amount. These interest rate swaps, with a notional amount of £100.0 million, are currently intended to hedge interest payments associated with the Operating Partnership’s Term Loan due 2017 - GBP. No initial investment was made to enter into the interest rate swap agreements.

On September 25, 2013, the Operating Partnership entered into three interest rate swaps with an aggregate notional amount of \$200.0 million under which at each monthly settlement date the Company either (1) receives the difference between a fixed interest rate (the “Strike Rate”) and one-month U.S. dollar-LIBOR if the Strike Rate is less than one-month U.S. dollar-LIBOR or (2) pays such difference if the Strike Rate is greater than one-month U.S. dollar-LIBOR. The interest rate swaps hedge the Company’s exposure to the variability on expected cash flows attributable to changes in interest rates on the first interest payment, due date on or after each swap’s settlement date, associated with the amount of one-month U.S. dollar-LIBOR-based debt equal to each swap’s notional amount. These interest rate swaps, with a notional amount of \$200.0 million, are currently intended to hedge interest payments associated with the Operating Partnership’s Term Loan due 2018 for three years. No initial investment was made to enter into the interest rate swap agreements.

As of December 31, 2013, the Company had deferred interest costs of approximately \$35.4 million in accumulated other comprehensive loss related to forward starting swaps, which were settled with the corresponding counterparties in 2009. The forward starting swaps were entered into to mitigate the Company’s exposure to the variability in expected future cash flows attributable to changes in future interest rates associated with a forecasted issuance of fixed-rate debt, with interest payments for a minimum of ten years. The deferred interest costs will be amortized as additional interest expense over a remaining period of approximately five years.

The following is a summary of the terms of the interest rate swaps and their respective fair-values (dollars in thousands):

| | Notional Amount | Strike Rate | Effective Date | Expiration Date | Fair-Value(1) | |
|---------------------|--------------------|-------------|----------------|-----------------|----------------------|----------------------|
| | | | | | December 31, 2013 | December 31, 2012 |
| Interest rate swaps | \$200,000 | 1.1630 % | March 30, 2012 | March 30, 2017 | \$(1,876) | \$(4,826) |
| Interest rate swaps | 200,000 | 0.7010 % | | | (288) | — |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | October 1, 2013 | October 1, 2016 | | |
|---------------------------|-----------|--------|---|--------------------|--------------------|-------|-------------|
| Interest rate swaps(2) | 82,595 | 0.7310 | % | August 2, 2012 | March 30, 2017 | 1,545 | (216) |
| Interest rate swaps(2) | 82,595 | 0.7425 | % | August 2, 2012 | March 30, 2017 | 1,519 | (243) |
| Total interest rate swaps | \$565,190 | | | | | \$900 | \$ (5,285) |

(1) Fair-value of derivative instruments does not include any related accrued interest payable, which is included in accrued expenses on the accompanying consolidated balance sheets. Derivative valuations are classified in Level 2 of the fair-value hierarchy. Assets are included in other assets and liabilities are included in accounts payable, accrued expenses and other liabilities on the accompanying consolidated balance sheets.

(2) Translation to U.S. dollars is based on exchange rates of \$1.65 to £1.00 and \$1.62 to £1.00 at December 31, 2013 and December 31, 2012, respectively.

Table of Contents

For derivatives designated as cash flow hedges, the effective portion of changes in the fair-value of the derivative is initially reported in other comprehensive income (outside of earnings) and subsequently reclassified to earnings in the period in which the hedged forecasted transaction affects earnings. During the years ended December 31, 2013, 2012 and 2011, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt. The ineffective portion of the change in fair-value of the derivatives is recognized directly in earnings. No portion of the derivatives designated as cash flow hedges were classified as ineffective during the years ended December 31, 2013 and 2012.

The Company's use of proceeds from its March 2011 unsecured debt offering to repay a portion of the outstanding indebtedness on its unsecured line of credit caused the amount of variable-rate indebtedness to fall below the combined notional value of the outstanding interest rate swaps on March 30, 2011, causing the Company to be overhedged. As a result, the Company re-performed tests to assess the effectiveness of its interest rate swaps. Although the interest rate swaps with an aggregate notional amount of \$150.0 million passed the assessment tests and the \$115.0 million swap continued to qualify for hedge accounting, the \$35.0 million swap no longer qualified for hedge accounting due to the lack of variable rate debt expected to be outstanding during the remaining term of the swap. As a result, the Company accelerated the reclassification of amounts deferred in accumulated other comprehensive loss to earnings related to the hedged forecasted transactions that became probable of not occurring during the period in which the Company was overhedged. This resulted in a cumulative charge to earnings for the year ended December 31, 2011 of approximately \$1.0 million. From the date that hedge accounting was discontinued on the \$35.0 million swap, changes in the fair-value associated with this interest rate swap were recorded directly to earnings, resulting in the recognition of a gain of approximately \$12,000 for the year ended December 31, 2011, which is included as a component of other expense. These swaps expired in August 2011.

During the year ended December 31, 2013, the Company recorded a total gain on derivative instruments of \$416,000, primarily related to changes in the fair-value of other derivative instruments. During the year ended December 31, 2012, the Company recorded a total loss on derivative instruments of \$9,000, primarily related to changes in the fair-value of other derivative instruments. During the year ended December 31, 2011, the Company recorded total loss on derivative instruments of \$544,000, primarily related to the reduction in the amount of the variable-rate indebtedness relating to the \$150.0 million interest rate swaps, hedge ineffectiveness on cash flow hedges due to mismatches in maturity dates and interest rate reset dates between the interest rate swaps and corresponding debt and changes in the fair-value of other derivative instruments. Gains and losses on derivative instruments are included in other expense within the consolidated statement of operations.

Amounts reported in accumulated other comprehensive loss related to derivatives will be reclassified to earnings during the period in which the hedged forecasted transaction affects earnings. The change in net unrealized gain / (loss) on derivative instruments includes reclassifications of net unrealized losses from accumulated other comprehensive loss as (1) an increase to interest expense of \$9.5 million, \$8.5 million and \$10.4 million for the years ended December 31, 2013, 2012, and 2011, respectively, and (2) a gain on derivative instruments of \$416,000, and losses of \$9,000 and \$544,000 for the years ended December 31, 2013, 2012, and 2011, respectively. During the next twelve months, the Company estimates that an additional \$9.9 million will be reclassified from accumulated other comprehensive loss as an increase to interest expense. In addition, for the years ended December 31, 2013, 2012, and 2011, approximately \$326,000, \$118,000 and \$236,000, respectively, of settlement payments on interest rate swaps have been deferred in accumulated other comprehensive loss and will be amortized over the useful lives of the related development or redevelopment projects.

The following is a summary of the amount of gain / (loss) recognized in other comprehensive income related to the derivative instruments (in thousands):

Table of Contents

| | Year Ended December 31, | | |
|--|----------------------------|-----------|------------|
| | 2013 | 2012 | 2011 |
| Amount of gain / (loss) recognized in other comprehensive income (effective portion): | | | |
| Cash flow hedges | | | |
| Interest rate swaps | \$3,497 | \$(6,863) | \$(104) |
| Amount of loss reclassified from accumulated other comprehensive loss to income (effective portion): | | | |
| Cash flow hedges | | | |
| Interest rate swaps (1) | \$(2,619) | \$(1,578) | \$(3,385) |
| Forward starting swaps (2) | (6,832) | (6,933) | (7,027) |
| Total interest rate swaps | \$(9,451) | \$(8,511) | \$(10,412) |
| Amount of gain / (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing): | | | |
| Cash flow hedges | | | |
| Interest rate swaps | \$— | \$— | (544) |
| Total interest rate swaps | — | — | \$(544) |
| Other derivative instruments | 416 | (9) | — |
| Total gain / (loss) on derivative instruments | \$416 | \$(9) | \$(544) |

Amount represents payments made to swap counterparties for the effective portion of interest rate swaps that were (1) recognized as an increase to interest expense for the periods presented (the amount was recorded as an increase and corresponding decrease to accumulated other comprehensive loss in the same accounting period).

(2) Amount represents reclassifications of deferred interest costs from accumulated other comprehensive loss to interest expense related to the Company's previously settled forward starting swaps.

10. Fair-Value of Financial Instruments

The Company's disclosures of estimated fair-value of financial instruments at December 31, 2013 and December 31, 2012 were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair-value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair-value amounts.

The carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and other liabilities approximate fair-value due to the short-term nature of these instruments.

The Company utilizes quoted market prices to estimate the fair-value of its fixed-rate and variable-rate debt, when available. If quoted market prices are not available, the Company calculates the fair-value of its mortgage notes payable and other fixed-rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed-rate debt, a market credit spread is added to the quoted yields on federal government treasury securities with similar terms to debt. In determining the current market rate for variable-rate debt, a market credit spread is added to the current effective interest rate. The carrying values of interest rate swaps are reflected at their fair-values.

At December 31, 2013 and December 31, 2012, the aggregate fair-value and the carrying value of the Company's financial instruments were as follows (in thousands):

Table of Contents

| | December 31, 2013 | | December 31, 2012 | |
|----------------------------------|-------------------|----------------|-------------------|----------------|
| | Fair-Value (1) | Carrying Value | Fair-Value (1) | Carrying Value |
| Mortgage notes payable, net | \$730,394 | \$709,324 | \$605,948 | \$571,652 |
| Exchangeable Senior Notes | 202,626 | 180,000 | 209,484 | 180,000 |
| Notes due 2016, net | 417,040 | 398,787 | 421,400 | 398,289 |
| Notes due 2020, net | 275,600 | 248,210 | 292,725 | 247,984 |
| Notes due 2022, net | 240,400 | 248,086 | 261,750 | 247,904 |
| Term Loan due 2017 - U.S. dollar | 244,751 | 243,596 | 243,596 | 243,596 |
| Term Loan due 2017 - GBP (2) | 165,969 | 165,190 | 161,860 | 161,860 |
| Term Loan due 2018 | 350,000 | 350,000 | — | — |
| Unsecured line of credit | 128,000 | 128,000 | 118,000 | 118,000 |
| Derivative instruments (3) | (1,316 |) (1,316 |) 5,285 | 5,285 |
| Available-for-sale securities | 19,566 | 19,566 | 390 | 390 |

(1) Fair-values of debt and derivative instruments are classified in Level 2 of the fair-value hierarchy. Fair-value of available-for-sale securities are classified in Level 1 of the fair-value hierarchy.

(2) The principal balance represents the U.S. dollar amount based on the exchange rate of \$1.65 to £1.00 and \$1.62 to £1.00 at December 31, 2013 and December 31, 2012, respectively.

(3) The Company's derivative instruments are reflected in other assets and in accounts payable, accrued expenses and other liabilities on the accompanying consolidated balance sheets based on their respective balances (see Note 9).

11. Acquisitions

The Company acquired the following properties during the year ended December 31, 2013. The table below reflects the purchase price allocation for these acquisitions, excluding the merger with Wexford, which is discussed below, and the purchase of properties with approximately 274,000 and 300,000 square feet of pre-development and development potential, respectively, for approximately \$13.4 million recorded as investments in real estate (in thousands):

| Property | Acquisition Date | Investments in Real Estate | In-Place Lease | Management Agreement | Below Market Lease | Acquisition Date Fair- Value |
|---|-------------------|----------------------------------|-------------------|-------------------------|--------------------------|------------------------------------|
| Woodside Technology Park | February 28, 2013 | \$78,681 | \$8,162 | \$865 | \$(708 |) \$87,000 |
| The Campus at Lincoln Centre | March 20, 2013 | 37,000 | — | — | — | 37,000 |
| 320 Charles Street | June 18, 2013 | 47,018 | 4,578 | — | (2,078 |) 49,518 |
| Total | | \$162,699 | \$12,740 | \$865 | \$(2,786 |) \$173,518 |
| Weighted average intangible amortization life (in months) | | | 61 | 108 | 18 | |

Wexford Merger

On May 31, 2013, the Company completed a merger with Wexford. The purchase price allocations of the fair-value of assets acquired, liabilities assumed and consideration paid in the Wexford merger are presented below (in thousands):

Table of Contents

| | At Acquisition |
|---|----------------|
| Assets: | |
| Investments in real estate | \$659,517 |
| Cash and cash equivalents | 5,182 |
| Accounts receivable, net | 1,537 |
| Deferred leasing costs (1) | 52,670 |
| Other assets (2) | 89,631 |
| Total assets | \$808,537 |
| Liabilities: | |
| Mortgage notes payable (3) | 254,735 |
| Other liabilities (4) | 69,270 |
| Total liabilities | \$324,005 |
| Fair value of net assets acquired | \$484,532 |
| Cash consideration paid for Wexford | \$345,268 |
| Equity consideration paid for Wexford (5) | 123,596 |
| Contingent consideration in merger with Wexford (6) | 15,668 |
| Total consideration for Wexford | \$484,532 |

- (1) \$52.7 million of acquired in-place leases with a weighted-average lease term of approximately 10.9 years are included in deferred leasing costs.
- \$9.6 million of acquired above-market leases with a weighted-average lease term of approximately 11.6 years and
- (2) \$11.0 million of acquired below-market ground leases with a weighted-average lease term of approximately 51.7 years are included in other assets.
- \$8.7 million of debt premiums with a weighted-average term of approximately 9.2 years are included in mortgage
- (3) notes payable, net.
- \$31.4 million of acquired below-market leases with a weighted-average lease term of approximately 13.4 years and
- (4) \$2.5 million of acquired above-market ground leases with a weighted-average lease term of approximately 64.0 years are included in other liabilities.
- (5) Consists of 5,568,227 shares of the Parent Company's common stock and 336,960 operating partnership units.
- (6) Includes potential additional consideration to be paid to the seller upon the achievement of certain pipeline development milestones.

Wexford - Variable Interest Entities

Wexford is a party to certain contractual arrangements with tax credit investors ("TCIs") that were established to enable the TCIs to receive the benefits of historic tax credits ("HTCs") and/or new market tax credits ("NMTCs") for certain properties owned by Wexford. At May 31, 2013, Wexford owned seven properties that had syndicated HTCs or NMTCs, or both, to TCIs. At December 31, 2013, Wexford owned nine properties that had syndicated HTCs or NMTCs, or both, to TCIs.

Historic Tax Credits and New Market Tax Credits

Capital contributions are made by TCIs into special purpose entities that ultimately invest these funds in the entity that owns the subject property that generates the tax credits. The TCIs are allocated substantially all of the tax credits and hold only a noncontrolling interest in the economic risk and rewards of the special purpose entities. HTCs are delivered to the TCI upon substantial completion of the project. NMTCs are allowed for up to 39% of a qualified investment and are delivered to the TCI after the investment has been funded and spent on a qualified business. HTCs

are subject to 20% recapture per year beginning one year after the completion of the historic rehabilitation of the subject property. NMTCs are subject to 100% recapture until the end of the seventh year following the qualifying investment. The Company has provided the TCIs with certain guarantees which protect the TCIs from loss should a tax credit recapture event occur. The contractual arrangements with the TCIs include a put/call provision whereby the Company may be obligated or entitled to repurchase the ownership interest of the TCIs in the special purpose entities at the end of the tax credit recapture period. The Company anticipates that either the TCIs will exercise their put rights or the Company will exercise its call rights; however, the Company believes that the put rights are more likely to be exercised.

115

Table of Contents

The Company has determined that the special purpose entities are VIEs, since there is insufficient capital to finance their activities without further subordinated financial support. The Company has determined that it is the primary beneficiary of these VIEs, because it has the authority to direct the activities which most significantly impact their economic performance.

The portion of the TCI's capital contribution that is attributed to the put is recorded at fair-value at inception and is accreted to the expected put price as interest expense in the consolidated statement of operations. At December 31, 2013, approximately \$4.3 million of put liabilities were included in other liabilities in the consolidated balance sheets. The remaining balance of the TCI's capital contribution is initially recorded in other liabilities in the consolidated balance sheets and will be relieved, upon delivery of the tax credit to the TCI, as a reduction in the carrying value of the subject property, net of allocated expenses. During the year ended December 31, 2013, \$34.4 million of tax credits, net of costs and estimated put payments, were contributed by TCIs which were recorded as other liabilities in the consolidated balance sheets, of which \$22.4 million of tax credits have been delivered to the TCIs and were reclassified as a reduction of the carrying value of the subject property. Direct and incremental costs incurred in structuring the transaction are deferred and will be recognized as an increase in the cost basis of the subject property upon the recognition of the related tax credit as discussed above.

The Company has determined that certain special purpose entities owning properties under development are VIEs, since there is insufficient capital to finance the remaining development activities without further subordinated financial support. The Company has determined it is the primary beneficiary of these VIEs, because it has the authority to direct the activities which most significantly impact their economic performance. Selected financial data of the VIEs at December 31, 2013 consisted of the following (in thousands):

| | |
|--------------------------------|----------------------|
| | December 31, 2013 |
| Investment in real estate, net | \$177,901 |
| Total assets | 198,968 |
| Total liabilities | 60,197 |

Pro Forma Results of the Parent Company

The unaudited pro forma revenues and operating income of the Parent Company, including the acquisitions that occurred in 2013 as if they had taken place on January 1, 2012, are as follows (in thousands, except per share amounts):

| | | |
|--|-------------------------|-----------|
| | Year Ended December 31, | |
| | 2013 | 2012 |
| Total revenues | \$666,904 | \$590,415 |
| Net income / (loss) available to common stockholders | 36,981 | (19,493) |
| Net income / (loss) per share available to common stockholders - basic and diluted | \$0.20 | \$(0.13) |

Pro forma data may not be indicative of the results that would have been reported had the acquisitions actually occurred as of January 1, 2012, nor is it intended to be a projection of future results.

Pro Forma Results of the Operating Partnership

The unaudited pro forma revenues and operating income of the Operating Partnership, including the acquisitions that occurred in 2013 as if they had taken place on January 1, 2012, are as follows (in thousands, except per unit amounts):

Year Ended December 31,

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | 2013 | 2012 |
|---|-----------|-----------|
| Total revenues | \$666,904 | \$590,415 |
| Net income / (loss) available to unitholders | 37,800 | (19,547) |
| Net income / (loss) per unit available to unitholders - basic and diluted | \$0.20 | \$(0.13) |

Pro forma data may not be indicative of the results that would have been reported had the acquisitions actually occurred as of January 1, 2012, nor is it intended to be a projection of future results.

Table of Contents

Revenues of approximately \$45.3 million and net loss of approximately \$2.6 million associated with properties acquired in 2013 listed above are included in the consolidated statements of operations for the year ended December 31, 2013 for both the Parent Company and the Operating Partnership.

12. Discontinued Operations

In April 2012, the Company completed the exchange of an operating property on Forbes Boulevard in South San Francisco for an office property located in Redwood City, California. As a result, during the year ended December 31, 2012, the Company reclassified the Forbes Boulevard property as a discontinued operation. The table below reflects the details of the property and the exchange (in thousands):

| Property | Date of Sale | Original Acquisition Date | Sales Price (1) | Impairment loss |
|------------------|----------------|---------------------------|--------------------|--------------------|
| Forbes Boulevard | April 27, 2012 | September 5, 2007 | \$28,000 | \$(4,552) |

(1) The sales price was equal to the fair-value of the office property received as consideration in the exchange with the independent third party.

The results of operations of the Forbes Boulevard property are reported as discontinued operations for all periods presented in the accompanying consolidated financial statements. The following table summarizes the revenue and expense components that comprise income / (loss) from discontinued operations (in thousands):

| | Year Ended December 31, | | |
|--|----------------------------|------------|---------|
| | 2013 | 2012 | 2011 |
| Total revenues | \$— | \$454 | \$1,499 |
| Total expenses | — | 272 | 1,025 |
| Income from discontinued operations before impairment loss | — | 182 | 474 |
| Impairment loss | — | (4,552) | — |
| (Loss) / income from discontinued operations | \$— | \$(4,370) | \$474 |

Discontinued operations have not been segregated in the consolidated statements of cash flows. Therefore, amounts for certain captions will not agree with respective data in the consolidated statements of operations.

13. Incentive Award Plan

The Company has adopted the 2013 Amendment and Restatement of the BioMed Realty Trust, Inc. and BioMed Realty, L.P. 2004 Incentive Award Plan (the "Plan"). The Plan provides for grants to directors, employees and consultants of the Company and the Operating Partnership (and their respective subsidiaries) of stock options, restricted stock, LTIP units, stock appreciation rights, dividend equivalents, and other incentive awards. The Company has reserved 10,740,000 shares of common stock for issuance pursuant to the Plan, subject to adjustments as set forth in the Plan. As of December 31, 2013, 6,896,224 shares of common stock or awards convertible into or exchangeable for common stock remained available for future issuance under the Plan. Each LTIP unit and each Performance Unit issued will count as one share of common stock for purposes of calculating the limit on shares that may be issued. Compensation cost for these incentive awards is measured based on the fair-value of the award on the grant date (fair-value is calculated based on the closing price of the Company's common stock on the date of grant) and is recognized as expense over the respective vesting period, which for restricted stock awards and LTIP units is generally four to five years. Fully vested incentive awards may be settled for either cash or stock depending on the Company's election and the type of award granted. Participants are entitled to cash dividends and may vote such awarded shares, but the sale or transfer of such shares is limited during the restricted or vesting period. The restricted

stock grants may only be settled for stock whereas the LTIP units may be redeemed for either cash or common stock, at the Company's election.

The Parent Company has awarded Performance Units to certain of its executive officers, which represent the maximum number of Performance Units that may vest. Each Performance Unit represents a contingent right to receive one share of the Parent Company's common stock if vesting conditions are satisfied. Performance Units vest at the end of designated time periods (each, a "Performance Period") based upon the Parent Company's total stockholder return relative to its peer group (the "Market Conditions"). The grant date fair-value of the Performance Units was estimated using a Monte Carlo simulation which considered the likelihood of achieving the Market Conditions. The Monte Carlo simulation uses a statistical formula underlying the Black-

Table of Contents

Scholes and binomial formulas, and such simulation was run approximately 100,000 times. For each simulation, the value of the payoff was calculated at the end of the respective Performance Period and was then discounted to the grant date at a risk-free interest rate. The expected value of the Performance Units on the grant date was determined by simulating the total shareholder return for the Company and the peer group considering the stock price variance for each of the peer group companies, compared to each other and the Company's stock estimating the rank of the Company's stock. The valuation was performed in a risk-neutral framework, so no assumption was made with respect to an equity risk premium. Other significant assumptions used in the valuation included an expected term of 24 and 36 months, an average risk-free interest rate of 0.35%, and an average dividend yield of 4.41%. No dividends will be paid or accrued on the Performance Units, and shares of the Parent Company's common stock will not be issued until vesting of the Performance Units occurs.

A summary of the Company's unvested restricted stock and LTIP units is presented below:

| | Unvested Restricted Shares/LTIP Units | Weighted Average Grant-Date Fair-Value |
|------------------------------|---|---|
| Balance at December 31, 2010 | 1,588,060 | \$15.15 |
| Granted | 630,337 | 18.38 |
| Vested | (467,120) | 16.03 |
| Forfeited | (30,215) | 16.17 |
| Balance at December 31, 2011 | 1,721,062 | 16.09 |
| Granted | 395,350 | 18.46 |
| Vested | (520,258) | 15.17 |
| Forfeited | (35,642) | 15.97 |
| Balance at December 31, 2012 | 1,560,512 | 17.00 |
| Granted | 657,106 | 20.33 |
| Vested | (665,808) | 15.91 |
| Forfeited | (39,805) | 18.15 |
| Balance at December 31, 2013 | 1,512,005 | \$18.91 |

Selected data of the Company's incentive award plan is presented below (in thousands, except share and period amounts):

| | Years Ended December 31, | | |
|--|--------------------------|---------|----------|
| | 2013 | 2012 | 2011 |
| Aggregate value of restricted stock/LTIP Units granted | \$13,234 | \$7,300 | \$11,612 |
| Aggregate value of Performance Units granted | \$4,973 | \$3,329 | \$— |
| Fair-value of stock/LTIP Units vested | \$13,321 | \$9,502 | \$8,547 |
| Stock-based compensation expense recognized in general and administrative expenses and rental operations expense - restricted stock/LTIP Units | \$10,134 | \$9,556 | \$7,582 |
| Stock-based compensation expense recognized in general and administrative expenses - Performance Units | \$2,445 | \$1,974 | \$— |
| Shares surrendered to the Company and retired in lieu of cash payments for taxes due on the vesting of restricted stock | 253,671 | 178,915 | 129,342 |
| Data at period end: | | | |
| Total compensation to be expensed related to unvested awards in future periods - restricted stock | \$17,145 | | |
| Weighted-average expense period (in years) - restricted stock | 2.6 | | |
| Total compensation to be expensed related to unvested awards in future periods - Performance Units | \$2,528 | | |

Weighted-average expense period (in years) - Performance Units 1.5

14. Commitments and Contingencies

Concentration of Credit Risk

118

Table of Contents

Life science entities comprise the vast majority of the Company's tenant base. Because of the dependence on a single industry, adverse conditions affecting that industry will more adversely affect our business. Two of the Company's tenants, Human Genome Sciences, Inc., a wholly owned subsidiary of GlaxoSmithKline plc, and Vertex Pharmaceuticals Incorporated, comprised 10.8% and 7.7%, or \$48.0 million and \$34.5 million, respectively, of rental revenues for the year ended December 31, 2013; 12.2% and 8.5%, or \$48.0 million and \$33.4 million, respectively, of rental revenues for the year ended December 31, 2012; and 14.5% and 10.0%, or \$48.0 million and \$33.2 million, respectively, of rental revenues for the year ended December 31, 2011. These tenants are located in the Company's Maryland, and Boston and San Diego markets, respectively. The inability of these tenants to make lease payments could materially adversely affect the Company's business.

The Company generally does not require collateral or other security from our tenants, other than security deposits or letters of credit in select cases.

Construction and Other Related Commitments

As of December 31, 2013, the Company had approximately \$415.8 million outstanding in commitments related to the funding of the construction loan, tenant improvements, leasing commissions, and construction-related capital expenditures, with approximately \$350.5 million expected to be paid in 2014, approximately \$64.2 million expected to be paid in 2015 and 2016, and approximately \$1.2 million expected to be paid in 2017 and 2018.

Ground Leases

As of December 31, 2013, the Company had approximately \$513.2 million outstanding in commitments related to ground leases with approximately \$4.5 million expected to be paid in 2014, approximately \$9.6 million expected to be paid in 2015 and 2016, approximately \$10.3 million expected to be paid in 2017 and 2018 and approximately \$488.8 million expected to be paid thereafter.

Insurance

The Company carries insurance coverage on its properties with policy specifications and insured limits that it believes are adequate given the relative risk of loss, cost of the coverage and standard industry practice. However, certain types of losses (such as from the perils of earthquakes, windstorms, terrorism and floods) may be either uninsurable or not economically insurable. Further, certain of the properties are located in areas that are subject to earthquake activity, windstorms and floods. Should a property sustain damage as a result of an earthquake, windstorm or flood, the Company may incur losses due to insurance deductibles, co-payments on insured losses or uninsured losses. Should an uninsured loss occur, the Company could lose some or all of its capital investment, cash flow and anticipated profits related to one or more properties.

Environmental Matters

The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. The Company is not aware of any environmental liability with respect to the properties that would have a material adverse effect on the Company's business, assets or results of operations. There can be no assurance that such a material environmental liability does not exist. The existence of any such material environmental liability could have an adverse effect on the Company's results of operations and cash flow. The Company carries environmental remediation insurance for its properties. This insurance, subject to certain exclusions and deductibles, covers the cost to remediate environmental damage caused by future spills or the historic presence of previously undiscovered hazardous substances, as well as third-party bodily injury and property damage claims related to the release of hazardous substances.

Tax Indemnification Agreements and Minimum Debt Requirements

As a result of the contribution of properties to the Operating Partnership, the Company has indemnified the contributors of the properties against adverse tax consequences if it directly or indirectly sells, exchanges or otherwise disposes of the properties in a taxable transaction before August 11, 2014, the ten-year anniversary of the completion of the Company's initial public offering. The Company also has agreed to use its reasonable best efforts to maintain at least \$8.0 million of debt, some of which must be property specific, for the same period to enable certain contributors to guarantee the debt in order to defer potential taxable gain they may incur if the Operating Partnership repays the existing debt.

Legal Proceedings

119

Table of Contents

Although the Company is involved in legal proceedings arising in the ordinary course of business, as of December 31, 2013, the Company is not currently a party to any legal proceedings nor, to its knowledge, is any legal proceeding threatened against it that it believes would have a material adverse effect on its financial position, results of operations or liquidity.

15. Quarterly Financial Information of the Parent Company (unaudited)

The Company's selected quarterly information for the years ended December 31, 2013 and 2012 (in thousands, except per share data) was as follows.

| | 2013 Quarter Ended(1) | | | |
|---|-----------------------|--------------|-----------|-----------|
| | December 31 | September 30 | June 30 | March 31 |
| Total revenues | \$157,993 | \$159,232 | \$159,639 | \$160,450 |
| Net income | 10,576 | 4,136 | 15,037 | 17,458 |
| Net (income) / loss attributable to noncontrolling interests | (297 |) 111 | (234 |) (146 |
| Preferred stock dividends | — | — | — | (2,393 |
| Net income available to common stockholders | \$10,279 | \$4,247 | \$14,803 | \$8,388 |
| Net income per share available to common stockholders - basic and diluted | \$0.05 | \$0.02 | \$0.08 | \$0.05 |

| | 2012 Quarter Ended(1) | | | |
|---|-----------------------|--------------|-----------|------------|
| | December 31 | September 30 | June 30 | March 31 |
| Total revenues | \$138,771 | \$134,537 | \$124,848 | \$120,012 |
| Income / (loss) from continuing operations | 8,260 | 6,455 | (5,283 |) 6,702 |
| Income / (loss) from discontinued operations | — | — | 49 | (4,420 |
| Net income / (loss) | 8,260 | 6,455 | (5,234 |) 2,282 |
| Net (income) / loss attributable to noncontrolling interests | (93 |) (46 |) 172 | 30 |
| Preferred stock dividends | (3,651 |) (3,651 |) (3,651 |) (3,651 |
| Net income / (loss) available to common stockholders | \$4,516 | \$2,758 | \$(8,713 |) \$(1,339 |
| Income / (loss) from continuing operations per share available to common stockholders - basic and diluted | \$0.03 | \$0.02 | \$(0.06 |) \$0.02 |
| Net income / (loss) per share available to common stockholders - basic and diluted | \$0.03 | \$0.02 | \$(0.06 |) \$(0.01 |

(1)The sum of quarterly financial data may vary from the annual data due to rounding.

16. Quarterly Financial Information of the Operating Partnership (unaudited)

The Company's selected quarterly information for the years ended December 31, 2013 and 2012 (in thousands, except per share data) was as follows.

| | 2013 Quarter Ended(1) | | | |
|--|-----------------------|--------------|-----------|-----------|
| | December 31 | September 30 | June 30 | March 31 |
| Total revenues | \$157,993 | \$159,232 | \$159,639 | \$160,450 |
| Net income | 10,576 | 4,136 | 15,037 | 17,458 |
| Net (income) / loss attributable to noncontrolling interests | (12 |) 229 | 29 | 8 |
| Preferred unit distributions | — | — | — | (2,393 |
| Net income available to unitholders | \$10,564 | \$4,365 | \$15,066 | \$8,542 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | |
|--|--------|--------|--------|--------|
| Net income per unit available to unitholders - basic and diluted | \$0.05 | \$0.02 | \$0.08 | \$0.05 |
|--|--------|--------|--------|--------|

120

Table of Contents

| | 2012 Quarter Ended(1) | | | |
|---|-----------------------|-----------------|-----------|--------------|
| | December 31 | September 30 | June 30 | March 31 |
| Total revenues | \$138,771 | \$134,537 | \$124,848 | \$120,012 |
| Income / (loss) from continuing operations | 8,260 | 6,455 | (5,283 |) 6,702 |
| Income / (loss) from discontinued operations | — | — | 49 | (4,420) |
| Net income / (loss) | 8,260 | 6,455 | (5,234 |) 2,282 |
| Net (income) / loss attributable to noncontrolling interests | (7 |) 7 | 6 | 4 |
| Preferred unit distributions | (3,651 |) (3,651 |) (3,651 |) (3,651) |
| Net income / (loss) available to unitholders | \$4,602 | \$2,811 | \$(8,879 |) \$(1,365) |
| Income / (loss) from continuing operations per unit available to unitholders - basic and diluted | \$0.03 | \$0.02 | \$(0.06 |) \$0.02 |
| Net income / (loss) per unit available to unitholders - basic and diluted | \$0.03 | \$0.02 | \$(0.06 |) \$(0.01) |

(1)The sum of quarterly financial data may vary from the annual data due to rounding.

BIOMED REALTY TRUST, INC. AND BIOMED REALTY, L.P.
SCHEDULE III - REAL ESTATE AND ACCUMULATED DEPRECIATION
As of December 31, 2013
(In thousands)

Table of Contents

| Property | Year Built/Renovated | Encumbrances (1) | Initial Cost | | Building and Improvements | Costs Subsequent to Acquisition | Gross amount carried at December 31, 2013 | | Total Accumulated Depreciation (2) (3) | Net | |
|---|----------------------|---------------------|--------------|---------------------------------|------------------------------|--|--|---------------------------------|---|----------|-----------|
| | | | Land | Building and Improvements | | | Land | Building and Improvements | | | |
| Albany Street | 1922/1998 | \$ — | \$ 1,942 | \$ — | \$ 31,293 | \$ 1,169 | \$ 1,942 | \$ 32,462 | 34,406 | (6,788) | \$ 27,616 |
| Ardentech Court | 1997/2008 | — | 2,742 | — | 5,379 | 9,406 | 2,742 | 14,785 | 17,523 | (2,891) | 11,636 |
| Ardenwood Venture | 1985 | — | 3,550 | — | 10,603 | 5,376 | 3,550 | 15,979 | 19,529 | (1,453) | 15,076 |
| Ardsley Park (4) | 1956/2000 | — | 6,581 | — | 9,479 | 27,559 | 6,581 | 37,038 | 43,613 | (635) | 39,984 |
| Balboa Avenue | 1968/2000 | — | 1,316 | — | 9,493 | 967 | 1,316 | 10,460 | 11,725 | (635) | 9,241 |
| Bayshore Boulevard | 2000 | — | 3,667 | — | 22,593 | 7,486 | 3,667 | 30,079 | 33,746 | (6,937) | 22,809 |
| Beckley Street | 1999 | — | 1,480 | — | 17,590 | — | 1,480 | 17,590 | 19,079 | (976) | 15,094 |
| Bernardo Center Drive | 1974/2008 | — | 2,580 | — | 13,714 | 284 | 2,580 | 13,998 | 16,578 | (896) | 13,482 |
| 9900 Belward Campus | 2001 | 10,631 | 2,038 | — | 8,274 | 8 | 2,038 | 8,282 | 10,326 | (263) | 9,867 |
| 9901 Belward Campus | 2001 | 13,091 | 2,362 | — | 12,185 | — | 2,362 | 12,185 | 14,547 | (1) | 13,926 |
| 9911 Belward Campus Drive | 2005 | — | 4,160 | — | 196,814 | — | 4,160 | 196,814 | 200,983 | (883) | 162,091 |
| 9920 Belward Campus Drive | 2000 | — | 3,935 | — | 11,206 | — | 3,935 | 11,206 | 15,127 | (1271) | 12,870 |
| 320 Bent Street | 2003 | — | — | — | 88,254 | 7,420 | — | 95,674 | 95,697 | (460) | 85,914 |
| 301 Binney Street | 2007 | — | — | — | 217,073 | 5,760 | — | 222,833 | 222,853 | (3610) | 197,223 |
| 301 Binney Street Garage | 2007 | — | — | — | 15,805 | 113 | — | 15,918 | 15,985 | (85) | 15,063 |
| BRDG Park at Danforth Plant Science Center | 2009 | — | — | — | 31,139 | — | — | 31,139 | 31,189 | (6) | 30,283 |
| Bridgeview Technology Park I | 1977/2002 | — | 2,494 | — | 14,716 | 18,895 | 2,494 | 33,611 | 36,105 | (5,692) | 24,413 |
| Bridgeview Technology Park II | 1977/2002 | — | 1,522 | — | 13,066 | 27 | 1,522 | 13,093 | 14,613 | (383) | 11,732 |
| 210 Broadway | 2000 | — | 6,917 | — | 16,272 | 5,442 | 6,917 | 21,714 | 28,631 | (3,803) | 27,328 |
| 550 Broadway | 1967/2006 | — | 3,700 | — | 24,300 | — | 3,700 | 24,300 | 28,008 | (382) | 26,118 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | | | | | | | |
|-------------------------|-----------|-------------|--------|---------|---------|--------|---------|-------------|---|---------|
| Center for Life Science | 2008 | 334,440,000 | — | 407,747 | 257,664 | 60,000 | 665,411 | 725,416,658 |) | 608,753 |
| Charles Street | 1911/1986 | — | 5,000 | 7,033 | 57 | 5,000 | 7,090 | 12,094,59 |) | 10,631 |
| 320 Charles Street | 1952/2007 | — | 14,020 | 32,998 | — | 14,020 | 32,998 | 47,018,74 |) | 45,844 |
| Chesterfield | — | — | 1,350 | 6,853 | 63 | 1,350 | 6,916 | 8,266 |) | 8,266 |
| Coast 9 | 1974-1984 | — | 13,455 | 12,786 | 20,654 | 13,455 | 33,440 | 46,895,11 |) | 42,284 |
| Coolidge Avenue | 1962/1999 | — | 2,760 | 7,102 | 3,873 | 2,760 | 10,975 | 13,715,05 |) | 11,830 |
| Dumbarton Circle | 1990 | — | 2,723 | 5,097 | 495 | 2,723 | 5,592 | 8,313,244 |) | 5,071 |
| Eccles Avenue (5) | 1965/1995 | — | 21,257 | 608 | 9,896 | 21,257 | 10,504 | 31,7608 |) | 31,153 |
| Elliott Avenue | 1925/2004 | — | 10,124 | 38,911 | 62,964 | 10,124 | 101,875 | 111,099,592 |) | 98,407 |
| 21 Erie Street | 1925/2004 | — | 3,366 | 18,372 | 148 | 3,366 | 18,520 | 21,880,94 |) | 17,892 |
| 40 Erie Street | 1996 | — | 7,593 | 33,765 | 3,931 | 7,593 | 37,696 | 45,287,44 |) | 37,545 |

Table of Contents

| | | | | | | | | | | | |
|---|-----------|--------|---------|---|---------|--------|---------|---------|---------|----------|---------|
| 4570 Executive Drive | 1999 | — | 7,685 | — | 48,693 | 328 | 7,685 | 49,021 | 56,706 | (8,211) | 48,495 |
| 4775 / 4785 Executive Drive | 2009 | — | 10,180 | — | 17,100 | 8,137 | 10,180 | 25,237 | 35,417 | (570) | 34,847 |
| 500 Fairview Avenue | 1959/1991 | — | — | — | 3,285 | 3,529 | — | 6,814 | 6,814 | (3,298) | 3,516 |
| 530 Fairview Avenue | 2008 | — | 2,703 | — | 694 | 46,268 | 2,703 | 46,962 | 49,665 | (11,306) | 38,359 |
| Faraday Avenue | 1986 | — | 1,370 | — | 7,201 | — | 1,370 | 7,201 | 8,571 | (1,505) | 7,066 |
| 4320 Forest Park Avenue | 2005 | 21,000 | — | — | 26,105 | 142 | — | 26,247 | 26,247 | (699) | 25,548 |
| Fresh Pond Research Park | 1948/2002 | — | 3,500 | — | 18,322 | 23,523 | 3,500 | 41,845 | 45,345 | (6,895) | 38,450 |
| Gateway Business Park | 1991-1998 | — | 116,851 | — | 10,981 | 7,043 | 116,851 | 18,024 | 134,875 | (9,226) | 125,649 |
| Gazelle Court | 2011 | — | 10,100 | — | 1,769 | 55,893 | 10,100 | 57,662 | 67,762 | (6,604) | 61,158 |
| George Patterson Boulevard | 1996/2005 | — | 1,575 | — | 11,029 | 2,044 | 1,575 | 13,073 | 14,648 | (2,609) | 12,039 |
| Granta Park | 1999/2010 | — | 34,589 | — | 152,797 | — | 34,589 | 152,797 | 187,386 | (6,802) | 180,584 |
| Graphics Drive | 1992/2007 | — | 800 | — | 6,577 | 6,941 | 800 | 13,518 | 14,318 | (5,768) | 8,550 |
| 50 Hampshire Street | 1999 | — | 19,537 | — | 58,205 | 185 | 19,537 | 58,390 | 77,927 | (3,445) | 74,482 |
| 60 Hampshire Street | 1900/2009 | — | 4,164 | — | 78 | 1,410 | 4,164 | 1,488 | 5,652 | (78) | 5,574 |
| Heritage @ 4240 Hershey Center for Applied Research | 1948/2013 | — | — | — | 12,966 | 18,365 | — | 31,331 | 31,331 | (50) | 31,281 |
| Industrial Road Innovation | 2007 | — | — | — | 16,736 | — | — | 16,736 | 16,736 | (494) | 16,242 |
| Research Park at ODU I | 2001/2005 | — | 12,000 | — | 41,718 | 16,286 | 12,000 | 58,004 | 70,004 | (22,701) | 47,303 |
| Innovation Research Park at ODU II | 2007 | — | — | — | 26,426 | — | — | 26,426 | 26,426 | (778) | 25,648 |
| Research Park at ODU II | 2009 | — | — | — | 25,297 | 22 | — | 25,319 | 25,319 | (585) | 24,734 |
| 3525 John Hopkins Court | 1991 | — | 3,993 | — | 18,183 | 298 | 3,993 | 18,481 | 22,474 | (1,780) | 20,694 |
| 3545-3575 John Hopkins Court | 1991/2008 | — | 3,560 | — | 19,495 | 20,046 | 3,560 | 39,541 | 43,101 | (7,302) | 35,799 |
| Kaiser Drive | 1990 | — | 3,430 | — | 6,093 | 10,391 | 3,430 | 16,484 | 19,914 | (4,298) | 15,616 |
| 450 Kendall Street (Kendall G) (4) | — | — | — | — | 8,259 | 5,614 | — | 13,873 | 13,873 | — | 13,873 |
| 500 Kendall Street (Kendall D) | 2002 | 57,927 | 3,572 | — | 166,308 | 627 | 3,572 | 166,935 | 170,507 | (36,039) | 134,468 |
| Kendall Crossing Apartments | 2003 | — | — | — | 6,665 | 577 | — | 7,242 | 7,242 | (502) | 6,740 |
| King of Prussia | 1954/2004 | — | 12,813 | — | 66,152 | 1,900 | 12,813 | 68,052 | 80,865 | (22,573) | 58,292 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | | | | | | | | |
|-------------------------------|-----------|---|--------|--------|--------|---------|--------|---------|---------|----------|---------|
| Landmark at Eastview (4)(6) | 1958/2008 | — | — | 14,210 | 55,250 | 249,407 | 16,943 | 304,657 | 321,600 | (54,027) | 267,573 |
| The Campus at Lincoln Center | — | — | 37,000 | — | — | 1,281 | 37,000 | 1,281 | 38,281 | — | 38,281 |
| 3711 Market Street | 2008 | — | — | — | 85,357 | 879 | — | 86,236 | 86,236 | (2,008) | 84,228 |
| 3737 Market Street (4) | — | — | — | — | 24,588 | 31,338 | — | 55,926 | 55,926 | — | 55,926 |
| Medical Center Drive | 1995 | — | 9,620 | — | 43,561 | 14,676 | 9,620 | 58,237 | 67,857 | (5,506) | 62,351 |
| Monte Villa Parkway 6114-6154 | 1996/2002 | — | 1,020 | — | 5,759 | 8,766 | 1,020 | 14,525 | 15,545 | (2,787) | 12,758 |
| Nancy Ridge Drive | 1994 | — | 10,100 | — | 28,611 | 16,378 | 10,100 | 44,989 | 55,089 | (7,010) | 48,079 |
| 6122-6126 Nancy Ridge | 1987/2003 | — | 2,344 | — | 9,611 | 1,787 | 2,344 | 11,398 | 13,742 | (2,878) | 10,864 |

Table of Contents

| | | | | | | | | | | | |
|------------------------------------|-----------|---------|--------|---|---------|---------|--------|---------|---------|----------|---------|
| 6828 Nancy Ridge Drive | 1983/2010 | — | 4,174 | — | 10,592 | — | 4,174 | 10,592 | 14,766 | (654) | 14,112 |
| Science Center at Oyster Point | 2008-2009 | — | 19,464 | — | 89,762 | 5,122 | 19,464 | 94,884 | 114,348 | (9,700) | 104,648 |
| One Research Way | 1980/2008 | — | 1,813 | — | 6,454 | 6,171 | 1,813 | 12,625 | 14,438 | (1,905) | 12,533 |
| Pacific Center Boulevard | 1991/2008 | — | 5,400 | — | 11,493 | 3,395 | 5,400 | 14,888 | 20,288 | (3,571) | 16,717 |
| Pacific Research Center | 2000/2008 | — | 74,147 | — | 142,437 | 151,438 | 74,147 | 293,875 | 368,022 | (55,555) | 312,467 |
| Paramount Parkway | 1999 | — | 1,080 | — | 14,535 | 26 | 1,080 | 14,561 | 15,641 | (1,826) | 13,815 |
| Patriot Drive | 1984/2001 | — | 848 | — | 6,906 | 449 | 848 | 7,355 | 8,203 | (1,023) | 7,180 |
| Phoenixville Pike | 1989/2008 | — | 1,204 | — | 10,880 | 13,418 | 1,204 | 24,298 | 25,502 | (8,048) | 17,454 |
| Piedmont Triad Research - Wake 90 | 1927/2013 | — | 2,160 | — | 41,632 | 48,231 | 2,160 | 89,862 | 92,022 | (115) | 91,907 |
| 1701 / 1711 Research Boulevard (4) | 1970/2004 | — | 7,492 | — | 8,834 | 14,315 | 7,492 | 23,149 | 30,641 | (267) | 30,374 |
| Road to the Cure | 1977/2007 | — | 4,430 | — | 19,128 | 12,039 | 4,430 | 31,167 | 35,597 | (6,017) | 29,580 |
| San Diego Science Center | 1973/2002 | — | 3,871 | — | 21,875 | 2,640 | 3,871 | 24,515 | 28,386 | (6,073) | 22,313 |
| 10240 Science Center Drive | 2002 | — | 4,079 | — | 12,124 | 22 | 4,079 | 12,146 | 16,225 | (1,443) | 14,782 |
| 10255 Science Center Drive | 1995 | — | 2,630 | — | 16,029 | 21 | 2,630 | 16,050 | 18,680 | (3,761) | 14,919 |
| Shady Grove Road | 2003 | 143,067 | 28,895 | — | 197,548 | 3,339 | 28,895 | 200,887 | 229,782 | (39,629) | 190,153 |
| Sidney Street | 2000 | — | 7,579 | — | 50,459 | 170 | 7,579 | 50,629 | 58,208 | (10,874) | 47,334 |
| Sorrento Plaza | 1978/2003 | — | 2,364 | — | 5,946 | 498 | 2,364 | 6,444 | 8,808 | (945) | 7,863 |
| 11388 Sorrento Valley Road | 2000 | — | 2,366 | — | 8,514 | 321 | 2,366 | 8,835 | 11,201 | (1,133) | 10,068 |
| Sorrento Valley Boulevard | 1982 | — | 4,140 | — | 2,606 | 13,926 | 4,140 | 16,532 | 20,672 | (2,606) | 18,066 |
| 311 South Sarah | 1913 | — | 5,180 | — | — | — | 5,180 | — | 5,180 | — | 5,180 |
| Spring Mill Drive | 1988 | — | 1,074 | — | 7,948 | 928 | 1,074 | 8,876 | 9,950 | (2,149) | 7,801 |
| Summers Ridge | — | — | 47,301 | — | — | — | 47,301 | — | 47,301 | — | 47,301 |
| Trade Centre Avenue | 1997 | — | 3,275 | — | 15,404 | — | 3,275 | 15,404 | 18,679 | (3,507) | 15,172 |
| Torreyana Road | 1980/1997 | — | 7,660 | — | 24,468 | 4,257 | 7,660 | 28,725 | 36,385 | (4,579) | 31,806 |
| 9865 Towne Centre Drive | 2008 | — | 5,738 | — | 2,991 | 20,206 | 5,738 | 23,197 | 28,935 | (4,986) | 23,949 |
| 9885 Towne Centre Drive | 2001/2008 | — | 4,982 | — | 28,513 | — | 4,982 | 28,513 | 33,495 | (6,682) | 26,813 |
| Tributary Street | 1983/1998 | — | 2,060 | — | 10,597 | — | 2,060 | 10,597 | 12,657 | (2,395) | 10,262 |
| 900 Uniqema Boulevard | 2000 | — | 404 | — | 3,692 | 69 | 404 | 3,761 | 4,165 | (931) | 3,234 |
| | 1999 | — | 1,350 | — | 13,229 | 186 | 1,350 | 13,415 | 14,765 | (3,229) | 11,536 |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

| | | | | | | | | | | | |
|---|------|--------|-------|---|--------|-------|-------|--------|--------|---------|--------|
| 1000 Uniqema Boulevard Baltimore Garage, LLC | 2005 | 4,738 | — | — | 16,234 | — | — | 16,234 | 16,234 | (347) | 15,887 |
| University of Maryland BioPark I | 2005 | 79,698 | — | — | 19,783 | 13 | — | 19,796 | 19,796 | (484) | 19,312 |
| University of Maryland BioPark II | 2007 | — | — | — | 94,113 | 5,374 | — | 99,487 | 99,487 | (2,246) | 97,241 |
| University of Maryland BioPark III | — | — | 6,061 | — | 8,481 | — | 6,061 | 8,481 | 14,542 | — | 14,542 |
| University of Miami Life Science & Technology Park | 2011 | 20,000 | 758 | — | 77,693 | 1,930 | 758 | 79,623 | 80,381 | (1,807) | 78,574 |

Table of Contents

| | | | | | | | | | | |
|--|-----------|-----------|-----------|----------|-------------|-------------|-----------|-------------|-------------|-------------|
| University Tech Park at 1959/2006 | — | — | — | 40,174 | 7,908 | — | 48,082 | 48,082 | (680) | |
| IIT Vassar Street | 1950/1998 | — | 2,040 | — | 13,841 | 12,882 | 2,040 | 26,723 | 28,763 | (6,860) |
| Waples Street | 1983/2005 | — | 2,470 | — | 2,907 | 11,464 | 2,470 | 14,371 | 16,841 | (7,677) |
| Wateridge Circle | 2001 | — | 6,536 | — | 34,462 | 4,082 | 6,536 | 38,544 | 45,080 | (3,258) |
| Wake Forest Biotech Place | 1937/2011 | — | 1,266 | — | 87,812 | 93 | 1,266 | 87,910 | 89,176 | (1,533) |
| Walnut Street | 1972/2004 | — | 5,200 | — | 36,067 | — | 5,200 | 36,067 | 41,267 | (8,028) |
| Weston Parkway | 1990 | — | 536 | — | 5,022 | 147 | 536 | 5,169 | 5,705 | (539) |
| 675 West Kendall Street (Kendall A) | 2002 | — | 4,922 | — | 121,182 | 2,258 | 4,922 | 123,440 | 128,362 | (26,376) |
| 50 West Watkins Mill Road | 1988/2005 | — | 1,451 | — | 11,611 | 245 | 1,451 | 11,856 | 13,307 | (1,464) |
| 55 / 65 West Watkins Mill Road | 1999 | — | 2,320 | — | 10,393 | 198 | 2,320 | 10,591 | 12,911 | (1,634) |
| Woodside Technology Park | 1999 | — | 13,350 | — | 65,331 | 283 | 13,350 | 65,614 | 78,964 | (2,920) |
| 217th Place | 1987/2007 | — | 7,125 | — | 3,529 | 14,774 | 7,125 | 18,303 | 25,428 | (4,419) |
| Total | | \$684,599 | \$816,335 | \$14,210 | \$3,803,622 | \$1,366,576 | \$833,278 | \$5,170,202 | \$6,003,480 | \$(785,578) |

(1) Includes mortgage notes secured by various properties but excludes unamortized debt premium of \$11.3 million.

(2) The aggregate gross cost of the Company's rental property for federal income tax purposes approximated \$6.5 billion as of December 31, 2013 (unaudited).

(3) Depreciation of building and improvements is recorded on a straight-line basis over the estimated useful lives ranging from less than one year to 40 years.

(4) The property or a portion of the property was under development or pre-development as of December 31, 2013.

(5) This property represents the potential for ground-up development.

(6) During 2007, the Company acquired a fee simple interest in the land at its Landmark at Eastview property. The balance of \$14.2 million was subsequently reclassified from ground lease to land.

Table of Contents

A reconciliation of historical cost and related accumulated depreciation is as follows (in thousands):

| | Year Ended December 31, | | |
|------------------------------|-------------------------|--------------|--------------|
| | 2013 | 2012 | 2011 |
| Investment in real estate: | | | |
| Balance at beginning of year | \$4,923,166 | \$4,402,720 | \$3,878,092 |
| Property acquisitions | 835,599 | 395,560 | 409,425 |
| Property sales | (4,155) | (33,048) | — |
| Improvements | 244,719 | 157,934 | 115,203 |
| Balance at end of year | \$6,003,480 | \$4,923,166 | \$4,402,720 |
| Accumulated Depreciation: | | | |
| Balance at beginning of year | \$(603,450) | \$(452,474) | \$(341,978) |
| Depreciation expense | (182,129) | (152,506) | (110,496) |
| Property sales | 1,374 | 1,530 | — |
| Balance at end of year | \$(785,578) | \$(603,450) | \$(452,474) |

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Controls and Procedures (BioMed Realty Trust, Inc.)

Evaluation of Disclosure Controls and Procedures

BioMed Realty Trust, Inc. maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to its management, including BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) under the Exchange Act, BioMed Realty Trust, Inc. carried out an evaluation, under the supervision and with the participation of its management, including BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BioMed Realty Trust, Inc.'s disclosure controls and procedures. Based on the foregoing, BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, BioMed Realty Trust, Inc.'s disclosure controls and procedures were effective and were operating at a reasonable assurance level.

Management's Report on Internal Control Over Financial Reporting

Internal control over financial reporting refers to the process designed by, or under the supervision of, BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, and effected by BioMed Realty Trust, Inc.'s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles, and includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the

company's assets that could have a material effect on the financial statements.

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and

126

Table of Contents

is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the company, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of management, including BioMed Realty Trust, Inc.'s Chief Executive Officer and Chief Financial Officer, BioMed Realty Trust, Inc. conducted an evaluation of the effectiveness of its internal control over financial reporting. Management has used the framework set forth in the report entitled "Internal Control — Integrated Framework (1992)" published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of the company's internal control over financial reporting. Based on its evaluation, management has concluded that the company's internal control over financial reporting was effective as of December 31, 2013, the end of the company's most recent fiscal year. The scope of management's assessment of the effectiveness of its internal control over financial reporting included all of its consolidated operations except for the operations of Wexford, which was acquired on May 31, 2013. Wexford's total assets and total revenues constituted approximately 14% and 5%, respectively, of BioMed Realty Trust, Inc.'s consolidated financial statement amounts as of and for the year ended December 31, 2013. During the year ended December 31, 2013, management continued to integrate Wexford into its overall internal control over financial reporting processes.

BioMed Realty Trust, Inc.'s independent registered public accounting firm, KPMG LLP, has issued an attestation report over BioMed Realty Trust, Inc.'s internal control over financial reporting, which report is contained elsewhere in this annual report on Form 10-K.

Changes in Internal Control over Financial Reporting

There has been no change in BioMed Realty Trust, Inc.'s internal control over financial reporting during the quarter ended December 31, 2013 that has materially affected, or is reasonably likely to materially affect, BioMed Realty Trust, Inc.'s internal control over financial reporting.

Controls and Procedures (BioMed Realty, L.P.)

Evaluation of Disclosure Controls and Procedures

The operating partnership maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer of the general partner, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) under the Exchange Act, the operating partnership carried out an evaluation, under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer of the general partner, of the effectiveness of the design and operation of the operating partnership's disclosure controls and procedures. Based on the foregoing, the Chief Executive Officer and Chief Financial Officer of the general partner concluded that, as of the end of the period covered by this report, the operating partnership's disclosure controls and procedures were effective and were operating at a reasonable assurance level.

Management's Report on Internal Control Over Financial Reporting

Internal control over financial reporting refers to the process designed by, or under the supervision of, the Chief Executive Officer and Chief Financial Officer of the general partner, and effected by the general partner's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles, and includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the operating

partnership; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the operating partnership are being made only in accordance with authorizations of management and directors of the general partner of the operating partnership; and (3) provide reasonable assurance regarding prevention or timely

127

Table of Contents

detection of unauthorized acquisition, use or disposition of the operating partnership's assets that could have a material effect on the financial statements.

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining adequate internal control over financial reporting for the operating partnership, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer of the general partner, the operating partnership conducted an evaluation of the effectiveness of its internal control over financial reporting. Management has used the framework set forth in the report entitled "Internal Control — Integrated Framework (1992)" published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of the operating partnership's internal control over financial reporting. Based on its evaluation, management has concluded that the operating partnership's internal control over financial reporting was effective as of December 31, 2013, the end of the operating partnership's most recent fiscal year. The scope of management's assessment of the effectiveness of its internal control over financial reporting included all of its consolidated operations except for the operations of Wexford, which was acquired on May 31, 2013. Wexford's total assets and total revenues constituted approximately 14% and 5%, respectively, of BioMed Realty, L.P.'s consolidated financial statement amounts as of and for the year ended December 31, 2013. During the year ended December 31, 2013, management continued to integrate Wexford into its overall internal control over financial reporting processes.

Changes in Internal Control over Financial Reporting

There has been no change in the operating partnership's internal control over financial reporting during the quarter ended December 31, 2013 that has materially affected, or is reasonably likely to materially affect, the operating partnership's internal control over financial reporting.

Table of Contents

ITEM 9B. OTHER INFORMATION

None

129

Table of Contents

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information concerning our directors, executive officers and corporate governance required by Item 10 will be included in the Proxy Statement to be filed relating to BioMed Realty Trust, Inc.'s 2014 Annual Meeting of Stockholders and is incorporated herein by reference.

Pursuant to instruction G(3) to Form 10-K, information concerning audit committee financial expert disclosure set forth under the heading "Information Regarding the Board — Committees of the Board — Audit Committee" will be included in the Proxy Statement to be filed relating to BioMed Realty Trust, Inc.'s 2014 Annual Meeting of Stockholders and is incorporated herein by reference.

Pursuant to instruction G(3) to Form 10-K, information concerning compliance with Section 16(a) of the Exchange Act concerning our directors and executive officers set forth under the heading entitled "General — Section 16(a) Beneficial Ownership Reporting Compliance" will be included in the Proxy Statement to be filed relating to BioMed Realty Trust, Inc.'s 2014 Annual Meeting of Stockholders and is incorporated herein by reference.

ITEM 11. EXECUTIVE COMPENSATION

The information concerning our executive compensation required by Item 11 will be included in the Proxy Statement to be filed relating to BioMed Realty Trust, Inc.'s 2014 Annual Meeting of Stockholders and is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information concerning the security ownership of certain beneficial owners and management and related stockholder matters required by Item 12 will be included in the Proxy Statement to be filed relating to BioMed Realty Trust, Inc.'s 2014 Annual Meeting of Stockholders and is incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information concerning certain relationships and related transactions and director independence required by Item 13 will be included in the Proxy Statement to be filed relating to BioMed Realty Trust, Inc.'s 2014 Annual Meeting of Stockholders and is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information concerning our principal accountant fees and services required by Item 14 will be included in the Proxy Statement to be filed relating to BioMed Realty Trust, Inc.'s 2014 Annual Meeting of Stockholders and is incorporated herein by reference.

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)(1) and (2) Financial Statements and Schedules:

Please refer to the Index to Consolidated Financial Statements included under Part II, Item 8, Financial Statements and Supplementary Data.

(3) Exhibits

| Exhibit Number | Description of Exhibit |
|----------------|--|
| 2.1 | Agreement and Plan of Merger, dated as of March 26, 2013, by and among BioMed Realty Trust, Inc., BioMed Realty, L.P., Westco Sub LLC, Wexford Science & Technology, LLC and Wexford Equities, LLC.(1) |
| 3.1 | Articles of Amendment and Restatement of BioMed Realty Trust, Inc.(2) |

3.2 Articles of Amendment of BioMed Realty Trust, Inc.(3)

3.3 Articles of Amendment of BioMed Realty Trust, Inc.(4)

130

Table of Contents

| | |
|-------|--|
| 3.4 | Articles of Amendment of BioMed Realty Trust, Inc.(5) |
| 3.5 | Third Amended and Restated Bylaws of BioMed Realty Trust, Inc.(6) |
| 3.6 | Certificate of Limited Partnership of BioMed Realty, L.P.(7) |
| 3.7 | Certificate of Amendment of Certificate of Limited Partnership of BioMed Realty, L.P.(7) |
| 3.8 | Certificate of Amendment of Certificate of Limited Partnership of BioMed Realty, L.P.(8) |
| 4.1 | Form of Certificate for Common Stock of BioMed Realty Trust, Inc.(9) |
| 4.2 | Indenture, dated January 11, 2010, among BioMed Realty, L.P., BioMed Realty Trust, Inc. and U.S. Bank National Association, as trustee, including the form of 3.75% Exchangeable Senior Notes due 2030 and guarantee thereof.(10) |
| 4.3 | Indenture, dated April 29, 2010, among BioMed Realty, L.P., BioMed Realty Trust, Inc. and U.S. Bank National Association, as trustee, including the form of 6.125% Senior Notes due 2020 and guarantee thereof.(11) |
| 4.4 | Indenture, dated March 30, 2011, by and among BioMed Realty, L.P., BioMed Realty Trust, Inc. and U.S. Bank National Association, as trustee.(12) |
| 4.5 | Supplemental Indenture No. 1, dated March 30, 2011, by and among BioMed Realty, L.P., BioMed Realty Trust, Inc. and U.S. Bank National Association, as trustee, including the form of 3.85% Senior Notes due 2016 and guarantee thereof.(12) |
| 4.6 | Supplemental Indenture No. 2, dated June 28, 2012, by and among BioMed Realty, L.P., BioMed Realty Trust, Inc. and U.S. Bank National Association, as trustee, including the form of 4.25% Senior Notes due 2022 and guarantee thereof. (13) |
| 10.1 | Fourth Amended and Restated Agreement of Limited Partnership of BioMed Realty, L.P. dated as of January 18, 2007.(14) |
| 10.2* | Amendment One to the Fourth Amended and Restated Agreement of Limited Partnership of BioMed Realty, L.P. dated as of February 6, 2014. |
| 10.3 | Registration Rights Agreement dated as of August 13, 2004 among BioMed Realty Trust, Inc. and the persons named therein.(2) |
| 10.4 | 2004 Incentive Award Plan of BioMed Realty Trust, Inc. and BioMed Realty, L.P. (as Amended and Restated Effective May 29, 2013).(15) |
| 10.5 | First Amendment to 2004 Incentive Award Plan of BioMed Realty Trust, Inc. and BioMed Realty, L.P. (as Amended and Restated Effective May 29, 2013).(15) |
| 10.6 | Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2004 Incentive Award Plan.(16) |
| 10.7 | Form of Long Term Incentive Plan Unit Award Agreement.(17) |
| 10.8 | Form of Performance Unit Award Grant Notice and Performance Unit Award Agreement under the 2004 Incentive Award Plan.(18) |
| 10.9 | Annual Incentive Bonus Plan.(19) |
| 10.10 | Change in Control and Severance Agreement dated as of January 25, 2012 among BioMed Realty Trust, Inc., BioMed Realty, L.P. and Alan D. Gold.(18) |
| 10.11 | Change in Control and Severance Agreement dated as of January 25, 2012 among BioMed Realty Trust, Inc., BioMed Realty, L.P. and R. Kent Griffin, Jr.(18) |
| 10.12 | Change in Control and Severance Agreement dated as of January 25, 2012 among BioMed Realty Trust, Inc., BioMed Realty, L.P. and Gary A. Kreitzer.(18) |
| 10.13 | Change in Control and Severance Agreement dated as of January 25, 2012 among BioMed Realty Trust, Inc., BioMed Realty, L.P. and Matthew G. McDevitt.(18) |
| 10.14 | Change in Control and Severance Agreement dated as of January 25, 2012 among BioMed Realty Trust, Inc., BioMed Realty, L.P. and Greg N. Lubushkin.(18) |
| 10.15 | Form of Amended and Restated Indemnification Agreement between BioMed Realty Trust, Inc. and each of its directors and officers.(20) |
| 10.16 | BioMed Realty Trust, Inc. Severance Plan, effective August 25, 2010.(21) |

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

- 10.17 Contribution Agreement between Alan D. Gold and BioMed Realty, L.P. dated as of May 4, 2004.(9)
- 10.18 Contribution Agreement between Gary A. Kreitzer and BioMed Realty, L.P. dated as of May 4, 2004.(9)
- 10.19 Contribution Agreement between John F. Wilson, II and BioMed Realty, L.P. dated as of May 4, 2004.(9)
- 10.20 Form of Contribution Agreement between the additional contributors and BioMed Realty, L.P. dated as of May 4, 2004.(9)

131

Table of Contents

| | |
|----------|---|
| 10.21 | Amended and Restated Unsecured Credit Agreement, dated as of September 24, 2013, by and among BioMed Realty, L.P., KeyBank National Association, as Administrative Agent, and certain lenders party thereto.(22) |
| 10.22 | Form of Amended and Restated Line Note under Amended and Restated Unsecured Credit Agreement.(22) |
| 10.23 | Form of Amended and Restated Competitive Bid Note under Amended and Restated Unsecured Credit Agreement.(22) |
| 10.24 | Form of Term Note under Amended and Restated Unsecured Credit Agreement.(22) |
| 10.25 | Form of Amended and Restated Swing Loan Note under Amended and Restated Unsecured Credit Agreement.(22) |
| 10.26 | Unsecured Term Credit Agreement, dated as of March 30, 2012, by and among BioMed Realty, L.P., KeyBank National Association, as Administrative Agent, and certain lenders party thereto. (23) |
| 10.27 | First Amendment to Unsecured Term Credit Agreement, dated as of August 2, 2012, by and among BioMed Realty, L.P., KeyBank National Association, as Administrative Agent, and certain lenders party thereto. (24) |
| 10.28 | Second Amendment to Unsecured Term Credit Agreement, dated as of September 24, 2013, by and among BioMed Realty, L.P., KeyBank National Association, as Administrative Agent, and certain lenders party thereto. (22) |
| 10.29 | Form of Amended and Restated Term Note (Domestic Currency) under Unsecured Term Credit Agreement, as amended. (24) |
| 10.30 | Form of Term Note (Qualified Foreign Currency) under Unsecured Term Credit Agreement, as amended. (24) |
| 10.31 | Lease Agreement, dated as of May 24, 2006, between BMR-Shady Grove Road HQ LLC and Human Genome Sciences, Inc.(25) |
| 10.32 | Registration Rights Agreement, dated January 11, 2010, among BioMed Realty Trust, Inc., BioMed Realty, L.P., Deutsche Bank Securities Inc., Credit Suisse Securities (USA) LLC, Morgan Stanley & Co. Incorporated and UBS Securities LLC.(10) |
| 10.33 | Registration Rights Agreement, dated April 29, 2010, among BioMed Realty, L.P., BioMed Realty Trust, Inc., Wells Fargo Securities, LLC, Credit Suisse Securities (USA) LLC and Deutsche Bank Securities Inc.(11) |
| 10.34 | Director Compensation Policy. (26) |
| 10.35 | Dividend Reinvestment and Stock Purchase Plan.(27) |
| 12.1* | Ratio of Earnings to Fixed Charges. |
| 21.1* | List of Subsidiaries of BioMed Realty Trust, Inc. and BioMed Realty, L.P. |
| 23.1* | Consent of KPMG LLP. |
| 31.1* | Certifications of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certifications of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1* | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS* | XBRL Instance Document. |
| 101.SCH* | XBRL Taxonomy Extension Schema Document. |
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document. |

* Filed herewith.

(1) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 26, 2013.

Edgar Filing: BioMed Realty Trust Inc - Form 10-K

- (2) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 20, 2004.
- (3) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2009.
- (4) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 22, 2010.

Table of Contents

- (5) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2013.
- (6) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 6, 2013.
- (7) Incorporated herein by reference to BioMed Realty Trust, Inc. and BioMed Realty, L.P.'s Registration Statement on Form S-4 (File No. 333-168968), filed with the Securities and Exchange Commission on August 20, 2010.
- (8) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2013.
- (9) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Registration Statement on Form S-11, as amended (File No. 333-115204), filed with the Securities and Exchange Commission on May 5, 2004.
- (10) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2010.
- (11) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 30, 2010.
- (12) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2011.
- (13) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 28, 2012.
- (14) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2007.
- (15) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2013.
- (16) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 12, 2010.
- (17) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 5, 2007.
- (18) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 31, 2012.
- (19) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 9, 2012.
- (20) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2010.
- (21) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 31, 2010.
- (22) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2013.
- (23) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2012.
- (24) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 2, 2012.
- (25) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 26, 2006.
- (26) Incorporated herein by reference to BioMed Realty Trust, Inc.'s and BioMed Realty, L.P.'s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2013.
- (27) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Registration Statement on Form S-3 (File No. 333-143658), filed with the Securities and Exchange Commission on June 11, 2007.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.

BIOMED REALTY TRUST, INC.

BIOMED REALTY, L.P.

By: BioMed Realty Trust, Inc.

Its general partner

/s/ ALAN D. GOLD

Alan D. Gold

Chairman of the Board and

Chief Executive Officer

(Principal Executive Officer)

/s/ ALAN D. GOLD

Alan D. Gold

Chairman of the Board and

Chief Executive Officer

(Principal Executive Officer)

/s/ GREG N. LUBUSHKIN

Greg N. Lubushkin

Chief Financial Officer

(Principal Financial Officer)

/s/ GREG N. LUBUSHKIN

Greg N. Lubushkin

Chief Financial Officer

(Principal Financial Officer)

/s/ STEPHEN A. WILLEY

Stephen A. Willey

Vice President, Chief Accounting Officer

(Principal Accounting Officer)

/s/ STEPHEN A. WILLEY

Stephen A. Willey

Vice President, Chief Accounting Officer

(Principal Accounting Officer)

Dated: February 6, 2014

Dated: February 6, 2014

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrants and in the capacities and on the dates indicated.

Table of Contents

| Signature | Title | Date |
|--|--|------------------|
| /s/ ALAN D. GOLD Alan D. Gold | Chairman of the Board and Chief Executive Officer | February 6, 2014 |
| /s/ DANIEL M. BRADBURY Daniel M. Bradbury | Director | February 6, 2014 |
| /s/ WILLIAM R. BRODY William R. Brody | Director | February 6, 2014 |
| /s/ BARBARA R. CAMBON Barbara R. Cambon | Director | February 6, 2014 |
| /s/ EDWARD A. DENNIS Edward A. Dennis | Director | February 6, 2014 |
| /s/ RICHARD I. GILCHRIST Richard I. Gilchrist | Director | February 6, 2014 |
| /s/ GARY A. KREITZER Gary A. Kreitzer | Executive Vice President and Director | February 6, 2014 |
| /s/ THEODORE D. ROTH Theodore D. Roth | Director | February 6, 2014 |
| /s/ M. FAYE WILSON M. Faye Wilson | Director | February 6, 2014 |